



(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 471/04 (2006.01)
C07D 401/04 (2006.01) C07D 487/04 (2006.01)
C07D 417/04 (2006.01) A61K 31/4427 (2006.01)
C07D 417/14 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2015/024146

(22) International Filing Date:

2 April 2015 (02.04.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/976,880 8 April 2014 (08.04.2014) US
62/019,577 1 July 2014 (01.07.2014) US

(71) Applicant: **RIGEL PHARMACEUTICALS, INC.**
[US/US]; 1180 Veterans Boulevard, South San Francisco,
CA 94080 (US).

(72) Inventors: **SINGH, Rajinder**; 1832 Hillman Avenue, Bel-
mont, CA 94002 (US). **BHAMIDIPATI, Somasekhar**;
878 Andromeda Lane, Foster City, CA 94404 (US). **DING,**

Pingyu; 709 Foster City Boulevard, Foster City, CA 94404
(US). **PAYAN, Donald**; 24 Windsor Drive, Hillsborough,
CA 94010 (US). **GELMAN, Marina**; 248 26th Avenue,
San Francisco, CA 94121 (US). **KINSELLA, Todd**; 1743
Hempstead Place, Redwood City, CA 94061 (US).


(74) Agent: **GREENFIELD, Michael, S.**; McDonnell Boehnen
Hulbert &, Berghoff LLP, 300 South Wacker Drive, Chica-
go, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

[Continued on next page]

(54) Title: 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE



(IV)

(57) Abstract: The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF- β superfamily such as Nodal or Activin.



TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND
METHODS OF USE**BACKGROUND OF THE DISCLOSURE****Field of the disclosure**

[0001] This disclosure relates to pharmaceutically active compounds that inhibit signalling of a member of the TGF- β superfamily of cytokines, such as Nodal and Activin, the disclosure also relates to combination therapies for treatment of cancer comprising administration of a compound that inhibits a member of the TGF- β superfamily of cytokines in conjunction with another therapeutic treatment of the cancer. And the invention also relates to methods of determining and measuring inhibition of a TGF- β superfamily member by a compound disclosed herein and, optionally administering the compound to a subject having cancer in conjunction with another therapeutic treatment of the cancer.

Summary of the Related Art

[0002] Growth and Differentiation Factor-8 (GDF-8), also known as myostatin, and TGF- β 1 are a members of the Transforming Growth Factor-beta (TGF- β) superfamily of structurally related growth factors, all of which possess physiologically important growth-regulatory and morphogenetic properties (Kingsley *et al.* (1994) *Genes Dev.*, 8: 133-46; Hoodless *et al.* (1998) *Curr. Topics Microbiol. Immunol.*, 228: 235-72). For example, activation of TGF- β 1 signaling and expansion of extracellular matrix are early and persistent contributors to the development and progression of fibrotic disorders, such as involved in chronic renal disease and vascular disease. Border W. A., et al, *N. Engl. J. Med.*, 1994; 331(19), 1286-92. GDF-8 is a negative regulator of skeletal muscle mass, and there is considerable interest in identifying factors which regulate its biological activity. For example, GDF-8 is highly expressed in the developing and adult skeletal muscle. The GDF-8 null mutation in transgenic mice is characterized by a marked hypertrophy and hyperplasia of the skeletal muscle (McPherron *et al.* (1997) *Nature*, 387: 83-90). Similar increases in skeletal muscle mass are evident in naturally occurring mutations of GDF-8 in cattle (Ashmore *et al.* (1974) *Growth*, 38: 501-507; Swatland and Kieffer (1994) *J. Anim. Sci.*, 38: 752-757; McPherron and Lee (1997) *Proc. Natl. Acad. Sci. USA*, 94: 12457-12461; and Kambadur *et al.* (1997) *Genome Res.*, 7: 910-915). Since GDF-8 is expressed in both developing and adult muscles, it is not clear whether it regulates muscle mass during development or in adults. Thus, the question of whether or not GDF-8 regulates muscle mass in

adults is important from a scientific and therapeutic perspective. Recent studies have also shown that muscle wasting associated with HIV-infection in humans is accompanied by increases in GDF-8 protein expression (Gonzalez-Cadavid *et al.* (1998) PNAS, 95: 14938-43). In addition, GDF-8 can modulate the production of muscle-specific enzymes (*e.g.*, creatine kinase) and modulate myoblast cell proliferation (WO 00/43781).

[0003] A number of human and animal disorders are associated with loss or functional impairment of muscle tissue, including muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, and cachexia. To date, very few reliable or effective therapies exist for these disorders. However, the terrible symptoms associated with these disorders may be substantially reduced by employing therapies that increase the amount of muscle tissue in patients suffering from the disorders. While not curing the conditions, such therapies would significantly improve the quality of life for these patients and could ameliorate some of the effects of these diseases. Thus, there is a need in the art to identify new therapies that may contribute to an overall increase in muscle tissue in patients suffering from these disorders.

[0004] In addition to its growth-regulatory and morphogenetic properties in skeletal muscle, GDF-8 may also be involved in a number of other physiological processes, including glucose homeostasis in the development of type 2 diabetes and adipose tissue disorders, such as obesity. For example, GDF-8 modulates pre-adipocyte differentiation to adipocytes (Kim *et al.* (2001) BBRC, 281: 902-906).

[0005] There are also a number of conditions associated with a loss of bone, including osteoporosis, especially in the elderly and/or postmenopausal women. Currently available therapies for these conditions work by inhibiting bone resorption. A therapy that promotes new bone formation would be a desirable alternative to or addition to, these therapies.

[0006] Like TGF- β -1, -2, and -3, the GDF-8 protein is synthesized as a precursor protein consisting of an amino-terminal propeptide and a carboxy-terminal mature domain (McPherron and Lee, (1997) Proc. Natl. Acad. Sci. USA, 94: 12457-12461). Before cleavage, the precursor GDF-8 protein forms a homodimer. The amino-terminal propeptide is then cleaved from the mature domain. The cleaved propeptide may remain noncovalently bound to the mature domain dimer, inactivating its biological activity (Miyazono *et al.* (1988) J. Biol. Chem., 263: 6407-6415; Wakefield *et al.* (1988) J. Biol. Chem., 263; 7646-7654; and Brown *et al.* (1990) Growth

Factors, 3: 35-43). It is believed that two GDF-8 propeptides bind to the GDF-8 mature dimer (Thies *et al.* (2001) Growth Factors, 18: 251-259). Due to this inactivating property, the propeptide is known as the “latency-associated peptide” (LAP), and the complex of mature domain and propeptide is commonly referred to as the “small latent complex” (Gentry and Nash (1990) Biochemistry, 29: 6851-6857; Derynck *et al.* (1995) Nature, 316: 701-705; and Massague (1990) Ann. Rev. Cell Biol., 12: 597-641). Other proteins are also known to bind to GDF-8 or structurally related proteins and inhibit their biological activity. Such inhibitory proteins include follistatin, and potentially, follistatin-related proteins (Gamer *et al.* (1999) Dev. Biol., 208: 222-232). The mature domain is believed to be active as a homodimer when the propeptide is removed.

[0007] GDF-8 is highly conserved in sequence and in function across species. The amino acid sequence of murine and human GDF-8 is identical, as is the pattern of mRNA expression (McPherron *et al.* (1997) Nature 387: 83-90; Gonzalez-Cadavid *et al.* (1998) Proc. Natl. Acad. Sci. USA 95: 14938-14943). This conservation of sequence and function suggests that inhibition of GDF-8 in humans is likely to have a similar effect to inhibition of GDF-8 in mice.


[0008] GDF-8 is involved in the regulation of many critical biological processes. Due to its key function in these processes, GDF-8 may be a desirable target for therapeutic intervention.

[0009] For example, US Patent No. 7,320,789, shows that GDF-8 antibodies in mouse models can increase muscle strength (*e.g.*, for treating sarcopenia), increase muscle mass and strength in dystrophic muscle (*e.g.*, for treating Duchenne's muscular dystrophy), increase bone mass and bone density (*e.g.*, for prevention and treatment of osteoporosis), augment bone healing (*e.g.*, for treating an established muscle or bone degenerative disease (*e.g.*, fracture repair and spine fusion, preventing the decline in bone mass, microarchitecture and strength associated with estrogen deficiency, increasing trabecular bone density), and are useful for treatment of metabolic disorders such as type 2 diabetes, impaired glucose tolerance, metabolic syndrome (*e.g.*, syndrome X), insulin resistance induced by trauma (*e.g.*, burns), and adipose tissue disorders (*e.g.*, obesity).

[0010] In particular, therapeutic agents that inhibit the activity of GDF-8 may be used to treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial, particularly muscle and adipose tissue disorders, bone degenerative diseases, neuromuscular disorders, and diabetes, as discussed above.


SUMMARY OF THE DISCLOSURE

[0011] In one aspect, the present disclosure relates to compounds of the formula (III),



(III)

and formula (IV)



and pharmaceutically acceptable salts thereof, wherein the substituents are defined herein.

[0012] In another aspect, the invention comprises combination therapies for the treatment of cancer. In this aspect, the invention comprises a method of treating cancer comprising administering to a subject a compound disclosed herein in conjunction with a therapeutic treatment of cancer. In some embodiments of the invention, the compounds disclosed herein are used in combination with standard of care anti-proliferative treatments of cancer.


[0013] In another aspect, the invention comprised testing and measuring the ability of compounds to inhibit a member of the TGF- β superfamily in a cancerous cell comprising contact the cancerous cell with the compound and measuring for inhibition of a TGF- β superfamily member. Optionally, the method further comprises administering the compound to a subject having cancer of the type of the cancerous cell in conjunction with another therapeutic treatment of the cancer.

[0014] In another aspect, the invention comprises inhibiting growth and/or proliferation of a cancer cell comprising contacting the cancer cell with an effective amount of a compound (including pharmaceutically acceptable salts thereof) disclosed herein. In an embodiment of this aspect, the cancer cell is also contacted (simultaneously or sequentially) with another therapeutic

agent (many examples of which are disclosed hereinbelow). In such embodiment, the cancer cell is inhibited to a greater extent than subjecting the cell to either a compound disclosed herein or the other therapeutic agent alone.

DETAILED DESCRIPTION OF THE DISCLOSURE

[0015] In one aspect, compounds for use in the methods of the invention are of formula (I),



(I)

and pharmaceutically acceptable salts thereof, wherein

X is C(H) or N;

R¹ and R² are each independently hydrogen, halogen, cyano, nitro, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, heterocyclyl, aryl, heteroaryl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR, -SR, -NR^aR^a, -C(O)R, -C(O)OR, -C(O)NR^aR^a, -S(O)₂NR^aR^a, -OC(O)R, -N(R)C(O)R, -OC(O)OR, -O(CH₂)_mC(O)NR^aR^a, -N(R)C(O)OR, -N(R)C(O)NR^aR^a, -N(R)S(O)₂NR^aR^a or -N(R)S(O)₂R;

or when R¹ and R² are attached to adjacent carbon atoms they are optionally taken together with the atoms to which they are attached to form a 5- or 6-membered ring optionally substituted with one or two groups that are each independently halogen, oxo, oxime, imino, C₁₋₆alkyl, C₁₋₆haloalkyl, or -R¹⁰;

each R^a is independently R or, two R^a together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclyl group, optionally including 1-4 additional heteroatoms selected from O, N and S and optionally substituted with 1-4 R groups;

each R^b is independently halogen, cyano, oxo, C₁₋₆alkyl, C₁₋₆haloalkyl, or -OR;

m is 0, 1 or 2;

n is 1, 2, 3 or 4;

R⁵ and R⁶ are each independently hydrogen, halogen, C₁₋₆alkyl optionally substituted with 1-3 R^b, C₁₋₆haloalkyl, C₃₋₈cycloalkyl optionally substituted with one or two

R^b , heteroaryl optionally substituted with one or two R^b , aryl optionally substituted with one or two R^b , heterocyclyl(C_{1-6} alkyl) optionally substituted with one or two R^b , -OR, -SR, -NR^aR^a, -OC(O)R, -C(O)NR^aR^a, -OC(O)NR^aR^a, -C(O)OR, -N(R)C(O)R, -N(R)S(O)₂R, or R^5 and R^6 are optionally taken together with the atoms to which they are attached to form a 5- or 6-membered ring optionally including 1-3 additional heteroatoms selected from O, N and S and optionally substituted with 1-4 R^b ;

Z is (a) a fused bicyclic ring of the formula, , wherein

ring A is a phenyl or 5- or 6-membered heteroaryl,

ring B is a 5- or 6-membered heterocyclyl or 5- or 6-membered heteroaryl;

or (b) pyridinyl or pyrimidinyl,

wherein

Z is optionally substituted by one or two groups that are each independently halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl), $-R^Z$, or $-C_{1-6}$ alkyl- R^Z , wherein the C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), and heteroaryl(C_{1-6} alkyl) are each optionally substituted by one or two groups that are each independently halogen, C_{1-6} alkyl, or $-R^Z$;

and R^Z is cyano, $-CF_3$, -OR, -SR, -NR^aR^a, -C(O)R, -C(O)OR, -C(O)NR^aR^a, -S(O)₂NR^aR^a, -S(O)₂R⁰, -OC(O)R, -N(R)C(O)R, -OC(O)OR, -OC(O)NR^aR^a, -N(R)C(O)OR, -N(R)C(O)NR^aR^a, -N(R)S(O)₂R, or -OP(O)(OR)₂;

or Z is (c) phenyl substituted with 1, 2, 3, 4, or 5 groups that are each independently a halogen;

wherein each R is independently hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroaryl(heteroaryl)-, heterocyclyl(aryl)-, heteroaryl(heterocyclyl)-, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), or heteroaryl(C_{1-6} alkyl), each optionally substituted by 1-5 groups

that are each independently R^b , $-OR^0$, $-SR^0$, $-N(R^0)_2$, $-C(O)R^0$, $-C(O)OR^0$, $-C(O)N(R^0)_2$, $-S(O)_2N(R^0)_2$, $-OC(O)R^0$, $-N(R^0)C(O)R^0$, $-OC(O)OR^0$, $-O(CH_2)_mC(O)N(R^0)_2$, $-N(R^0)C(O)OR^0$, $-N(R^0)C(O)N(R^0)_2$, or $-N(R^0)S(O)_2R^0$; and each R^0 is independently hydrogen, C_{1-6} haloalkyl, C_{1-6} alkyl optionally substituted with 1-3 R^b , C_{3-8} cycloalkyl optionally substituted with one or two R^b or, alternatively two R^0 together with a nitrogen atom to which they are bound (for example when R is $-C(O)N(R^0)_2$) form a 3-8 membered heterocyclyl group, optionally including 1-4 additional heteroatoms selected from O, N and S and optionally substituted with 0-3 R^b and R groups.

[0016] For example, in one embodiment, the disclosure provides pharmaceutically active compounds and pharmaceutically acceptable salts thereof as described above, in which

n is 1;

X is C(H) or N;

R^1 and R^2 are each independently hydrogen, halogen, cyano, nitro, C_{1-6} alkyl,


C_{1-6} haloalkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, heterocyclyl, aryl, heteroaryl, $-R^{10}$, or $-C_{1-6}$ alkyl- R^{10} , wherein R^{10} is $-OR$, $-SR$, $-NR^aR^a$, $-C(O)R$, $-C(O)OR$, $-C(O)NR^aR^a$, $-S(O)_2NR^aR^a$, $-OC(O)R$, $-N(R)C(O)R$, $-OC(O)OR$, $-OC(O)NR^aR^a$, $-N(R)C(O)OR$, $-N(R)C(O)NR^aR^a$, or $-N(R)S(O)_2R$;

or when R^1 and R^2 are attached to adjacent carbon atoms they are optionally taken together with the atoms to which they are attached to form a 5- or 6-membered heteroaryl group optionally substituted with one or two groups that are each independently halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, or $-R^{10}$;

each R^a is independently R or, two R^a together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclyl group, optionally including 1-4 additional heteroatoms selected from O, N and S and optionally substituted with 1-4 R groups;

R^5 and R^6 are each independently hydrogen, halogen, C_{1-6} alkyl, C_{1-6} haloalkyl,

C_{3-8} cycloalkyl, $-OR$, $-SR$, $-NR^aR^a$, $-OC(O)R$, $-N(R)C(O)R$, or $-N(R)S(O)_2R$;

Z is (a) a fused bicyclic ring of the formula, , wherein

ring A is a phenyl or 5- or 6-membered heteroaryl,

ring B is a 5- or 6-membered heterocyclyl or 5- or 6-membered heteroaryl, and wherein

Z is optionally substituted by one or two groups that are each independently halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), heteroaryl(C₁₋₆alkyl), -R^Z, or -C₁₋₆alkyl-R^Z, wherein the C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), and heteroaryl(C₁₋₆alkyl) are each optionally substituted by one or two groups that are each independently halogen, C₁₋₆alkyl, or -R^Z;


and R^Z is -OR, -SR, -NR^aR^a, -C(O)R, -C(O)OR, -C(O)NR^aR^a, -S(O)₂NR^aR^a, -OC(O)R, -N(R)C(O)R, -OC(O)OR, -OC(O)NR^aR^a, -N(R)C(O)OR, -N(R)C(O)NR^aR^a, -N(R)S(O)₂R, or -OP(O)(OR)₂;

or (b) phenyl substituted with 1, 2, 3, 4, or 5 groups that are each independently a halogen;

and each R is independently hydrogen or C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), or heteroaryl(C₁₋₆alkyl), each optionally substituted by one or two groups that are each independently -OR⁰, -SR⁰, -N(R⁰)₂, -C(O)R⁰, -C(O)OR⁰, -C(O)N(R⁰)₂, -S(O)₂N(R⁰)₂, -OC(O)R⁰, -N(R⁰)C(O)R⁰, -OC(O)OR⁰, -OC(O)N(R⁰)₂, -N(R⁰)C(O)OR⁰, -N(R⁰)C(O)N(R⁰)₂, or -N(R⁰)S(O)₂R⁰, wherein each R⁰ is independently hydrogen or C₁₋₆alkyl.

[0017] In other embodiments, the compounds are subgenera of formula (I) in which the substituents are selected as any and all combinations of one or more of structural formula (I), n, R¹, R², R⁵, R⁶, X, Z, R^a, R^b, R^Z, R and R⁰ as defined herein, including without limitation, the following:

[0018] **Structural Formula I is one of formulae (Ia) – (Ih):**



(Id)	(Ie)	(If)
(Ig)	(Ih)	(Ii)
(Ij)	(Ik)	(Il)
(Im)	(In)	(Io)
(Ip)	(Iq)	(Ir)
(Is)	(It)	(Iu)
(Iv)	(Iw)	(Ix)

[0019] X in any of formulae (I), (Ia), and (Ib) is selected from one of the following groups (1a) – (1b):

(1a) X is C(H).

(1b) X is N.

[0020] R¹ in any of formulae (I) and (Ia) - (Ix) is selected from one of the following groups (2a) – (2m):

(2a) R¹ is hydrogen, halogen, cyano, nitro, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, heterocyclyl, aryl, heteroaryl, each optionally substituted with one two or three R, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR, -SR, -NR₂, -C(O)R, -C(O)OR, -C(O)NR₂, -S(O)₂NR₂, -OC(O)R, -N(R)C(O)R, -OC(O)OR, -OC(O)NR₂, -N(R)C(O)OR, -N(R)C(O)NR₂, or -N(R)S(O)₂R.

(2b) R¹ is hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR, -SR, -NR₂, -C(O)R, -C(O)OR, -C(O)NR₂, -S(O)₂NR₂, -OC(O)R, -N(R)C(O)R, or -N(R)S(O)₂R.

(2c) R¹ is hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl.

(2d) R¹ is hydrogen, halogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, -C₁₋₆alkyl-OR¹¹, -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl.

(2e) R¹ is fluoro, cyano, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, isopropoxy, benzyloxy, cyclopropyl, cyclopentyl, cyclopentenyl, phenyl, amino, dimethylamino, methylsulfonylamino, aminocarbonyl, dimethylaminocarbonyl, n-propylaminocarbonyl, aminosulfonyl, or hydroxymethyl.

(2f) R¹ is halogen or C₁₋₆alkyl.

(2g) R¹ is halogen or C₁₋₄alkyl.

(2h) R¹ is halogen or methyl.

(2i) R¹ is fluoro or methyl.

(2j) R¹ is fluoro.

(2k) R¹ is methyl.

(2l) R¹ is hydrogen, halogen, cyano, nitro, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, heterocyclyl, aryl, heteroaryl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR, -SR, -NR₂, -C(O)R, -C(O)OR, -C(O)NR₂, -S(O)₂NR₂, -OC(O)R, -N(R)C(O)R, -OC(O)OR, -OC(O)NR₂, -N(R)C(O)OR, -N(R)C(O)NR₂, or -N(R)S(O)₂R.

(2m) any one of (2a) – (2d) and (2l), where R¹ is not hydrogen.

[0021] **R² in any of formulae (I) and (Ia) - (Ir) is selected from one of the following groups (3a) – (3m):**

(3a) R² is hydrogen, halogen, cyano, nitro, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, heterocyclyl, aryl, heteroaryl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR, -SR, -NR₂, -C(O)R, -C(O)OR, -C(O)NR₂, -S(O)₂NR₂, -OC(O)R, -N(R)C(O)R, -OC(O)OR, -OC(O)NR₂, -N(R)C(O)OR, -N(R)C(O)NR₂, or -N(R)S(O)₂R.

(3b) R² is hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR, -SR, -NR₂, -C(O)R, -C(O)OR, -C(O)NR₂, -S(O)₂NR₂, -OC(O)R, -N(R)C(O)R, or -N(R)S(O)₂R.

(3c) R² is hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl

(3d) R² is hydrogen, halogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, -C₁₋₆alkyl-OR¹¹, -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl.

(3e) R² is fluoro, cyano, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, isopropoxy, benzyloxy, cyclopropyl, cyclopentyl, cyclopentenyl, phenyl, amino, dimethylamino, methylsulfonylamino, aminocarbonyl, dimethylaminocarbonyl, n-propylaminocarbonyl, aminosulfonyl, or hydroxymethyl.

- (3f) R^2 is halogen or C_{1-6} alkyl.
- (3g) R^2 is halogen or C_{1-4} alkyl.
- (3h) R^2 is halogen or methyl.
- (3i) R^2 is fluoro or methyl.
- (3j) R^2 is fluoro.
- (3k) R^2 is methyl.
- (3l) R^2 is hydrogen, halogen, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, heterocyclyl, aryl, heteroaryl, $-R^{10}$, or $-C_{1-6}$ alkyl- R^{10} , wherein R^{10} is $-OR$, $-SR$, $-NR_2$, $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, $-S(O)_2NR_2$, $-OC(O)R$, $-N(R)C(O)R$, $-OC(O)OR$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)NR_2$, or $-N(R)S(O)_2R$.
- (3m) any one of (3a) - (3d) and (3l) where R^2 is not hydrogen.

[0022] **R^1 and R^2 in any of formulae (I) and (Ia) - (Ir) are selected from one of the following groups (4a) - (4i):**

- (4a) R^1 and R^2 are each independently hydrogen, halogen, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, heterocyclyl, aryl, heteroaryl, $-R^{10}$, or $-C_{1-6}$ alkyl- R^{10} , wherein R^{10} is $-OR$, $-SR$, $-NR_2$, $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, $-S(O)_2NR_2$, $-OC(O)R$, $-N(R)C(O)R$, $-OC(O)OR$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)NR_2$, or $-N(R)S(O)_2R$.
- (4b) R^1 and R^2 are each independently hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, $-R^{10}$, or $-C_{1-6}$ alkyl- R^{10} , wherein R^{10} is $-OR$, $-SR$, $-NR_2$, $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, $-S(O)_2NR_2$, $-OC(O)R$, $-N(R)C(O)R$, or $-N(R)S(O)_2R$.
- (4c) R^1 and R^2 are each independently hydrogen, halogen, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, $-R^{10}$, or $-C_{1-6}$ alkyl- R^{10} , wherein R^{10} is $-OR^{11}$, $-N(R^{11})_2$, $-C(O)N(R^{11})_2$, $-S(O)_2N(R^{11})_2$, or $-N(R^{11})S(O)_2R^{11}$, wherein each R^{11} is hydrogen or C_{1-6} alkyl.

- (4d) R^1 and R^2 are each independently hydrogen, halogen, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, $-C_{1-6}$ alkyl-OR¹¹, -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C_{1-6} alkyl.
- (4e) R^1 and R^2 are each independently hydrogen, fluoro, cyano, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, isopropoxy, benzyloxy, cyclopropyl, cyclopentyl, cyclopentenyl, phenyl, amino, dimethylamino, methylsulfonylamino, aminocarbonyl, dimethylaminocarbonyl, n-propylaminocarbonyl, aminosulfonyl, or hydroxymethyl.
- (4f) R^1 and R^2 are each independently hydrogen, halogen, or C_{1-6} alkyl.
- (4g) R^1 is fluoro and R^2 is methyl.
- (4h) any one of (4a) – (4f), where R^1 is not hydrogen.
- (4i) any one of (4a) – (4f), where R^2 is not hydrogen.
- (4j) any one of (4a) – (4f), where neither R^1 nor R^2 is hydrogen.

[0023] R⁵ in any of formulae (I) and (Ia) - (Ix) is selected from one of the following groups (5a) – (5r):

- (5a) R^5 is hydrogen, halogen, C_{1-6} alkyl, -OR, -NR^aR^a, -N(R)C(O)R, or -N(R)S(O)₂R.
- (5b) R^5 is hydrogen, halogen, C_{1-6} alkyl, -OR⁵⁰, -NR⁵⁰R⁵⁰, -N(R⁵⁰)C(O)R⁵⁰, or -N(R⁵⁰)S(O)₂R⁵⁰, wherein each R⁵⁰ is independently hydrogen or C_{1-6} alkyl.
- (5c) R^5 is hydrogen, halogen, C_{1-4} alkyl, -OR⁵⁰, -NR⁵⁰R⁵⁰, -N(R⁵⁰)C(O)R⁵⁰, or -N(R⁵⁰)S(O)₂R⁵⁰, wherein each R⁵⁰ is independently hydrogen or C_{1-4} alkyl.
- (5d) R^5 is hydrogen, fluoro, chloro, methyl, methoxy, ethoxy, amino, acetylamino, or methylsulfonylamino.
- (5e) R^5 is fluoro or chloro.
- (5f) R^5 is fluoro.
- (5g) R^5 is chloro.

- (5h) R⁵ is methyl.
- (5i) R⁵ is methoxy or ethoxy.
- (5j) R⁵ is amino, acetylamino, or methylsulfonylamino.
- (5k) R⁵ is hydrogen.
- (5l) R⁵ is -NR^aR^a.
- (5m) R⁵ is -N(R)CO(R).
- (5n) R⁵ is heteroaryl optionally substituted with one or two R^b or aryl optionally substituted with one or two R^b.
- (5o) R⁵ is C₃₋₈cycloalkyl optionally substituted with one or two R^b or heterocyclyl(C₁₋₆alkyl) optionally substituted with one or two R^b.
- (5p) R⁵ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, -OR, -SR, -NR^aR^a, -OC(O)R, -N(R)C(O)R, or -N(R)S(O)₂R.
- (5q) R⁵ is hydrogen, halogen, C₁₋₆alkyl optionally substituted with 1-3 R^b, C₁₋₆haloalkyl, C₃₋₈cycloalkyl optionally substituted with one or two R^b, heteroaryl optionally substituted with one or two R^b, -OR, -SR, -NR^aR^a, -OC(O)R, -C(O)NR^aR^a, -OC(O)NR^aR^a, -C(O)OR, -N(R)C(O)R, -N(R)S(O)₂R.
- (5r) any one of (5a) – (5d), (5p) and (5q), where R⁵ is not hydrogen.

[0024] **R⁶ in any of formulae (I) and (Ia) - (Ix) is selected from one of the following groups (6a) – (6n):**

- (6a) R⁶ is hydrogen, halogen, C₁₋₆alkyl, -OR, -NR^aR^a, -N(R)C(O)R, or -N(R)S(O)₂R.
- (6b) R⁶ is hydrogen, halogen, C₁₋₆alkyl, -OR⁶⁰, -NR⁶⁰R⁶⁰, -N(R⁶⁰)C(O)R⁶⁰, or -N(R⁶⁰)S(O)₂R⁶⁰, wherein each R⁶⁰ is independently hydrogen or C₁₋₆alkyl.
- (6c) R⁶ is hydrogen, halogen, C₁₋₄alkyl, -OR⁶⁰, -NR⁶⁰R⁶⁰, -N(R⁶⁰)C(O)R⁶⁰, or -N(R⁶⁰)S(O)₂R⁶⁰, wherein each R⁶⁰ is independently hydrogen or C₁₋₄alkyl.
- (6d) R⁶ is hydrogen, fluoro, chloro, methyl, methoxy, ethoxy, amino, acetylamino, or methylsulfonylamino.

- (6e) R⁶ is fluoro or chloro.
- (6f) R⁶ is fluoro.
- (6g) R⁶ is chloro.
- (6h) R⁶ is methyl.
- (6i) R⁶ is methoxy or ethoxy.
- (6j) R⁶ is amino, acetylamino, or methylsulfonylamino.
- (6k) R⁶ is hydrogen.
- (6l) R⁶ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, -OR, -SR, -NR^aR^a, -OC(O)R, -N(R)C(O)R, or -N(R)S(O)₂R.
- (6m) R⁶ is hydrogen, halogen, C₁₋₆alkyl optionally substituted with 1-3 R^b, C₁₋₆haloalkyl, C₃₋₈cycloalkyl optionally substituted with one or two R^b, heteroaryl optionally substituted with one or two R^b, -OR, -SR, -NR^aR^a, -OC(O)R, -C(O)NR^aR^a, -OC(O)NR^aR^a, -C(O)OR, -N(R)C(O)R, -N(R)S(O)₂R.
- (6n) any one of (6a) – (6d), (6l) and (6m), where R⁶ is not hydrogen.

[0025] **R⁵ and R⁶ in any of formulae (I) and (Ia) - (Ix) are selected from one of the following groups (7a) – (7u):**

- (7a) R⁵ and R⁶ are each independently hydrogen, halogen, C₁₋₆alkyl, -OR, -NR^aR^a, -N(R)C(O)R, or -N(R)S(O)₂R.
- (7b) one of R⁵ and R⁶ is hydrogen, and the other is halogen, C₁₋₆alkyl, -OR, -NR^aR^a, -N(R)C(O)R, or -N(R)S(O)₂R.
- (7c) R⁵ and R⁶ are each independently hydrogen, halogen, C₁₋₆alkyl, -OR⁷, -NR⁷R⁷, -N(R⁷)C(O)R⁷, or -N(R⁷)S(O)₂R⁷, wherein each R⁷ is independently hydrogen or C₁₋₆alkyl.
- (7d) one of R⁵ and R⁶ is hydrogen, and the other is halogen, C₁₋₆alkyl, -OR⁷, -NR⁷R⁷, -N(R⁷)C(O)R⁷, or -N(R⁷)S(O)₂R⁷, wherein each R⁷ is independently hydrogen or C₁₋₆alkyl.

- (7e) R^5 and R^6 are each independently hydrogen, halogen, C_{1-4} alkyl, $-OR^7$, $-NR^7R^7$, $-N(R^7)C(O)R^7$, or $-N(R^7)S(O)_2R^7$, wherein each R^7 is independently hydrogen or C_{1-4} alkyl.
- (7f) one of R^5 and R^6 is hydrogen, and the other is halogen, C_{1-4} alkyl, $-OR^7$, $-NR^7R^7$, $-N(R^7)C(O)R^7$, or $-N(R^7)S(O)_2R^7$, wherein each R^7 is independently hydrogen or C_{1-4} alkyl.
- (7g) R^5 and R^6 are each independently hydrogen, fluoro, chloro, methyl, methoxy, ethoxy, amino, acetylamino, or methylsulfonylamino.
- (7h) one of R^5 and R^6 is hydrogen, and the other is fluoro, chloro, methyl, methoxy, ethoxy, amino, acetylamino, or methylsulfonylamino.
- (7i) any one of (7a) – (7h), where one of R^5 and R^6 is not hydrogen.
- (7j) R^5 and R^6 are each hydrogen.
- (7k) one of R^5 and R^6 is hydrogen, and the other is fluoro, or chloro.
- (7l) one of R^5 and R^6 is hydrogen, and the other is methyl.
- (7m) one of R^5 and R^6 is hydrogen, and the other is methoxy or ethoxy.
- (7n) one of R^5 and R^6 is hydrogen, and the other is amino, acetylamino, or methylsulfonylamino.
- (7o) one of R^5 and R^6 is hydrogen, and the other is amino.
- (7p) one of R^5 and R^6 is hydrogen, and the other is acetylamino.
- (7q) one of R^5 and R^6 is hydrogen, and the other is methylsulfonylamino.
- (7r) R^5 and R^6 are each independently hydrogen, halogen, C_{1-6} alkyl optionally substituted with 1-3 R^b , C_{1-6} haloalkyl, C_{3-8} cycloalkyl optionally substituted with one or two R^b , heteroaryl optionally substituted with one or two R^b , $-OR$, $-SR$, $-NR^aR^a$, $-OC(O)R$, $-C(O)NR^aR^a$, $-OC(O)NR^aR^a$, $-C(O)OR$, $-N(R)C(O)R$, $-N(R)S(O)_2R$, or R^5 and R^6 are optionally taken together with the atoms to which they are attached to form a 5- or

6-membered ring optionally including 1-3 additional heteroatoms selected from O, N and S and optionally substituted with 1-4 R^b.

(7s) R⁵ and R⁶ are taken together with the atoms to which they are attached to form a 5- or 6-membered ring optionally including 1-3 additional heteroatoms selected from O, N and S and optionally substituted with 1-4 R^b.

(7t) R⁵ and R⁶ are each independently hydrogen, halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, -OR, -SR, -NR^aR^a, -OC(O)R, -N(R)C(O)R, or -N(R)S(O)₂R.

(7u) any one of (7r) and (7t), where one of R⁵ and R⁶ is not hydrogen.

[0026] Z in any of formulae (I) and (Ia) - (Ix) is selected from one of the following groups (8a) - (8tt):



(8a) Z is a fused bicyclic ring of the formula, , wherein ring A is a phenyl or pyridyl ring; and ring B is a 5- or 6-membered heterocyclyl or 5- or 6-membered heteroaryl, wherein Z is optionally substituted as in formula (I).

(8b) Z is as in (8a), wherein ring B is a 5- or 6-membered heterocyclyl.

(8c) Z is as in (8a), wherein ring B is a 5-membered heterocyclyl.

(8d) Z is as in (8a), wherein ring B is a 6-membered heterocyclyl.

(8e) Z is as in (8a), wherein ring B is a 5- or 6-membered heteroaryl.

(8f) Z is as in (8a), wherein ring B is a 5-membered heteroaryl.

(8g) Z is as in (8a), wherein ring B is a thienyl, pyrrolyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, or oxazolyl ring.


(8h) Z is as in (8a), wherein ring B is a 6-membered heteroaryl.

(8i) Z is as in (8a), wherein ring B is a pyridyl, pyrimidinyl, or pyrazinyl ring.

(8j) Z is as in any one of (8a) - (8i), wherein ring A is a phenyl ring.


(8k) Z is as in any one of (8a) - (8i), wherein ring A is a pyridyl ring.

(8l) Z is of the formula,




wherein each is optionally substituted by one or two groups that are each independently halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), heteroaryl(C₁₋₆alkyl), -R^Z, or -C₁₋₆alkyl-R^Z, wherein the C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), and heteroaryl(C₁₋₆alkyl) are each optionally substituted by one to four groups that are each independently C₁₋₆alkyl or -R^Z.

(8m) Z is of the formula,




wherein each is optionally substituted by one or two groups that are each independently halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), heteroaryl(C₁₋₆alkyl), -R^Z, or -C₁₋₆alkyl-R^Z, wherein the C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), and heteroaryl(C₁₋₆alkyl) are each optionally substituted by one to four groups that are each independently C₁₋₆alkyl or -R^Z.

(8n) Z is of the formula,



wherein R^{Z1} is hydrogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl or -C₁₋₆alkyl-R^Z; and
 R^{Z2} is hydrogen, halogen, C₁₋₆haloalkyl, C₃₋₈cycloalkyl or C₁₋₆alkyl, wherein the C₃₋₈cycloalkyl for R^{Z1} and R^{Z2} are optionally substituted with one or two halogen, C₁₋₆alkyl, or -R^Z.

(8o) Z is of the formula,




wherein

Q is $-O-$, $-S-$, or $-N(R^{Z1})-$; and


R^{Z1} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, or $-C_{1-6}$ alkyl- R^Z ; and

R^{Z2} is hydrogen, halogen, or C_{1-6} alkyl.


(8p) As in (8o), where Z is of the formula,




(8q) As in (8o), where Z is of the formula,




(8r) As in (8o), where Z is of the formula,




(8s) As in (8o), where Z is of the formula,







(8t) As in (8o), where Z is of the formula,




(8u) As in (8o), where Z is of the formula,




(8v) As in (8o), where Z is of the formula,



(8w) As in (8o), where Z is of the formula,



(8x) As in (8o), where Z is of the formula,



(8y) As in (8o), where Z is of the formula,

(8z) As in any one of (8n), (8r) – (8t), and (8y), where R^{Z1} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl), $-R^{Z3}$, $-C_{1-6}$ alkyl- R^{Z3} , or $-C_{1-6}$ alkyl- R^{Z4} , wherein R^{Z3} is $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, or $-S(O)_2NR_2$; and R^{Z4} is $-OR$, $-SR$, $-NR_2$, $-OC(O)R$, $-N(R)C(O)R$, $-OC(O)OR$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)NR_2$, $-N(R)S(O)_2R$, or $-OP(O)(OR)_2$.

(8aa) As in any one of (8n), (8r) – (8t), and (8y), where R^{Z1} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl), $-R^{Z3}$, $-C_{1-6}$ alkyl- R^{Z3} , or $-C_{1-6}$ alkyl- R^{Z4} , wherein R^{Z3} is $-C(O)R^{Z6}$, $-C(O)OR^{Z6}$, $-C(O)NR^{Z6}_2$, or $-S(O)_2NR^{Z5}_2$; and R^{Z4} is $-OR^{Z5}$, $-SR^{Z5}$, $-NR^{Z5}_2$, $-OC(O)R^{Z5}$, $-N(R^{Z5})C(O)R^{Z5}$, $-OC(O)OR^{Z5}$, $-OC(O)NR^{Z5}_2$,

$-\text{N}(\text{R}^{\text{Z5}})\text{C}(\text{O})\text{OR}^{\text{Z5}}$, $-\text{N}(\text{R}^{\text{Z5}})\text{C}(\text{O})\text{NR}^{\text{Z5}}_2$, $-\text{N}(\text{R}^{\text{Z5}})\text{S}(\text{O})_2\text{R}^{\text{Z5}}$, or $-\text{OP}(\text{O})(\text{OR}^{\text{Z5}})_2$, and wherein each R^{Z5} is independently hydrogen or C_{1-6} alkyl; and each R^{Z6} is independently hydrogen or C_{1-6} alkyl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), or heteroaryl(C_{1-6} alkyl), each optionally substituted by one or two groups that are each independently $-\text{OR}^0$, $-\text{SR}^0$, $-\text{N}(\text{R}^0)_2$, $-\text{C}(\text{O})\text{R}^0$, $-\text{C}(\text{O})\text{OR}^0$, $-\text{C}(\text{O})\text{N}(\text{R}^0)_2$, $-\text{S}(\text{O})_2\text{N}(\text{R}^0)_2$, $-\text{OC}(\text{O})\text{R}^0$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{R}^0$, $-\text{OC}(\text{O})\text{OR}^0$, $-\text{OC}(\text{O})\text{N}(\text{R}^0)_2$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{OR}^0$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{N}(\text{R}^0)_2$, or $-\text{N}(\text{R}^0)\text{S}(\text{O})_2\text{R}^0$, wherein each R^0 is independently hydrogen or C_{1-6} alkyl.

(8bb) As in any one of (8n), (8r) – (8t), and (8y), where R^{Z1} is hydrogen, C_{1-6} alkyl, heterocyclyl, heterocyclyl(C_{1-6} alkyl), $-\text{C}_{1-6}$ alkyl- R^{Z4} , or $-\text{C}(\text{O})\text{OR}^{\text{Z6}}$, wherein R^{Z4} is $-\text{OR}^{\text{Z5}}$, $-\text{SR}^{\text{Z5}}$, $-\text{NR}^{\text{Z5}}_2$, $-\text{OC}(\text{O})\text{R}^{\text{Z5}}$, $-\text{N}(\text{R}^{\text{Z5}})\text{C}(\text{O})\text{R}^{\text{Z5}}$, $-\text{OC}(\text{O})\text{OR}^{\text{Z5}}$, $-\text{OC}(\text{O})\text{NR}^{\text{Z5}}_2$, $-\text{N}(\text{R}^{\text{Z5}})\text{C}(\text{O})\text{OR}^{\text{Z5}}$, $-\text{N}(\text{R}^{\text{Z5}})\text{C}(\text{O})\text{NR}^{\text{Z5}}_2$, $-\text{N}(\text{R}^{\text{Z5}})\text{S}(\text{O})_2\text{R}^{\text{Z5}}$, or $-\text{OP}(\text{O})(\text{OR}^{\text{Z5}})_2$, wherein the heterocyclyl and heterocyclyl(C_{1-6} alkyl) are each optionally substituted by one or two groups that are each independently halogen or C_{1-6} alkyl; and wherein each R^{Z5} is independently hydrogen or C_{1-6} alkyl; and each R^{Z6} is independently hydrogen or C_{1-6} alkyl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), or heteroaryl(C_{1-6} alkyl), each optionally substituted by $-\text{OR}^0$, $-\text{SR}^0$, $-\text{N}(\text{R}^0)_2$, $-\text{C}(\text{O})\text{R}^0$, $-\text{C}(\text{O})\text{OR}^0$, or $-\text{C}(\text{O})\text{N}(\text{R}^0)_2$, wherein each R^0 is independently hydrogen or C_{1-6} alkyl.

(8cc) As in any one of (8n), (8r) – (8t), and (8y), where R^{Z1} is hydrogen, C_{1-6} alkyl, heterocyclyl, heterocyclyl(C_{1-6} alkyl), $-\text{C}_{1-6}$ alkyl- OR^{Z5} , $-\text{C}_{1-6}$ alkyl- $\text{OP}(\text{O})(\text{OR}^{\text{Z5}})_2$, or $-\text{C}(\text{O})\text{OR}^{\text{Z6}}$, wherein the heterocyclyl and heterocyclyl(C_{1-6} alkyl) are each optionally substituted by one or two C_{1-6} alkyl groups; and wherein each R^{Z5} is independently hydrogen or C_{1-6} alkyl; each R^{Z6} is independently hydrogen or C_{1-6} alkyl or heteroaryl(C_{1-6} alkyl), each optionally substituted by $-\text{OR}^0$, or $-\text{N}(\text{R}^0)_2$, wherein each R^0 is independently hydrogen or C_{1-6} alkyl.

(8dd) As in any one of (8n), (8r) – (8t), and (8y), where R^{Z1} is hydrogen, methyl, ethyl, isopropyl, 2-(morpholin-4-yl)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-hydroxypropyl, 3-ethoxypropyl, 4-tetrahydropyranyl, N-methylpiperidin-4-yl, $-\text{CH}_2\text{-OP}(\text{O})(\text{OH})_2$, or 3-(indol-3-yl)-2-aminopropylloxycarbonyl.

(8ee) As in any one of (8n) - (8dd), where R^{Z2} is hydrogen or halogen.

(8ff) As in any one of (8n) - (8dd), where R^{Z2} is hydrogen or C_{1-6} alkyl.

(8gg) As in any one of (8n) - (8dd), where R^{Z2} is hydrogen or methyl.





(8hh) As in any one of (8n) - (8dd), where R^{Z2} is hydrogen.

(8ii) Z is halophenyl (e.g., 4-halophenyl).

(8jj) Z is dihalophenyl.

(8kk) Z is fluorophenyl.


(8ll) Z is 4-fluorophenyl.



. In any one of (8nn) and (8oo), R^{Z1} independently is for each occurrence hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl or $-C_{1-6}$ alkyl- R^Z , wherein the C_{3-8} cycloalkyl are optionally substituted by one or two halogen, C_{1-6} alkyl, or $-R^Z$.


(8pp) In any one of (8nn) – (8pp), R^{Z2} independently is for each occurrence hydrogen, halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, $-R^Z$, or $-C_{1-6}$ alkyl- R^Z , wherein the C_{3-8} cycloalkyl are optionally substituted by one or two halogen, C_{1-6} alkyl, or $-R^Z$.

(8qq) Z is of the formula,



wherein each is optionally substituted by one or two groups that are each independently halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), heteroaryl(C₁₋₆alkyl), -R^Z, or -C₁₋₆alkyl-R^Z, wherein the C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), and heteroaryl(C₁₋₆alkyl) are each optionally substituted by one to four groups that are each independently C₁₋₆alkyl or -R^Z.

(8rr) Z is of the formula,



wherein R^{Z1} is hydrogen, C₁₋₆alkyl, C₁₋₆haloalkyl, or -C₁₋₆alkyl-R^Z; and R^{Z2} is hydrogen, halogen, or C₁₋₆alkyl.

(8ss) Z is pyridinyl.

(8tt) Z is pyrimidinyl, optionally substituted by one or two groups that are each independently halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), heteroaryl(C₁₋₆alkyl), -R^Z, or -C₁₋₆alkyl-R^Z, wherein the C₃₋₈cycloalkyl, heterocyclyl, aryl, heteroaryl, C₃₋₈cycloalkyl(C₁₋₆alkyl), heterocyclyl(C₁₋₆alkyl), aryl(C₁₋₆alkyl), and heteroaryl(C₁₋₆alkyl) are each optionally substituted by one or two groups that are each independently halogen, C₁₋₆alkyl, or -R^Z; and R^Z is cyano, -CF₃, -OR, -SR, -NR^aR^a, -C(O)R, -C(O)OR, -C(O)NR^aR^a, -S(O)₂NR^aR^a, -S(O)₂R⁰, -OC(O)R, -N(R)C(O)R, -OC(O)OR, -OC(O)NR^aR^a, -N(R)C(O)OR, -N(R)C(O)NR^aR^a, -N(R)S(O)₂R, or -OP(O)(OR)₂.

[0027] In in any of formulae (I) and (Ia) - (If) is selected from one of the following definitions (9a) – (9c):

(9a) n is 1.

(9b) n is 1, 2 or 3.

(9c) n is 1 or 2.

[0028] The compounds of formulae (I),(Ia) - (Ix) described above and (III) and (IV) (described below) are useful as kinase inhibitors and/or inhibitors of cytokine signaling. Exemplary kinases inhibited by the presently disclosed compounds formulae I and (Ia) – (Ix) include, without limitation, ACVR1; ACVR1B (ALK-4); ACVR1C; ACVR2A; ACVR2B; ACVRL1; BMPR1A; BMPR1B; BMPR2; TGFBR1 (ALK-5), PI3K and MAP4K4 (HGK). Exemplary cytokines, the signaling of which is inhibited by the present compounds of formulae (I), include, without limitation, TGF- β superfamily, including Activin, Nodal, TGF- β 1, and GDF-8. In one aspect the present compounds are selective for one or more kinase and/or cytokine signaling pathway. For example, exemplary compounds inhibit TGF- β 1 signaling, GDF-8 signaling, or both. In one aspect the present compounds inhibit GDF-8 signaling preferentially to TGF- β 1 signaling, such that GDF8 signaling is inhibited at least about 1.5-fold more potently or from about 1.1-fold to about 25-fold more potently. In one embodiment certain compounds inhibit GDF8 signaling at least about 5-fold more potently, such as from about 8-fold to about 50-fold, or at least about 10-fold more potently, such as from about 15-fold to about 300-fold more potently.

[0029] Exemplary compounds of formulae I and (Ia - Ix) (e.g., Compounds 63, 389, 448, 456, 460, 494 and 818) inhibit MAP4K4 with an IC₅₀ of less than about 500 nM. Such compounds are particularly useful in muscle disorders, such as cachexia and sarcopenia as MAP4K4 acts as a suppressor of skeletal muscle differentiation. See, Wang M, Amano SU, Flach RJ, Chawla A, Aouadi M, Czech P. Molecular and cellular biology. 2013 Feb;33(4):678-87.

[0030] In particular the present compounds can be use to treat disorders, such as pulmonary hypertension, chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, kidney fibrosis, lung fibrosis, including idiopathic pulmonary fibrosis, and

liver fibrosis, hepatitis B, hepatitis C, alcohol-induced hepatitis, cancer, haemochromatosis, primary biliary cirrhosis, restenosis, retroperitoneal fibrosis, mesenteric fibrosis, endometriosis, keloids, cancer, abnormal bone function, inflammatory disorders, scarring and photaging of the skin.

[0031] Particular proliferative diseases that can be treated with the present compounds include those selected from a benign or malignant tumor, carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina or thyroid, sarcoma, glioblastomas, multiple myeloma or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma or a tumor of the neck and head, an epidermal hyperproliferation, melanoma, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of epithelial character, leukemias and lymphomas, a mammary carcinoma or a leukemia. Other diseases include Cowden syndrome, Lhermitte-Duclos disease and Bannayan-Zonana syndrome, or diseases in which the PI3K/PKB pathway is aberrantly activated.

[0032] In an aspect, the disclosure provides a method of treating a disease mediated by GDF-8, the method comprising administering to a subject having a disease mediated by GDF-8 a therapeutically effective amount of a compound as disclosed herein. In a particular embodiment, the disease is small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, pancreatic cancer, multiple myeloma, T-acute lymphoblastic leukemia or AML.

[0033] In another aspect the disclosure provides the compounds disclosed herein for use in treating a disease mediated by GDF-8. In a particular embodiment, the disease is small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, pancreatic cancer, multiple myeloma, T-acute lymphoblastic leukemia or AML.

[0034] In another aspect, the disclosure provides the use of the compounds disclosed herein for the preparation of a medicament for treating a disease mediated by GDF-8. In an embodiment of this aspect, the disease is small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, pancreatic cancer, multiple myeloma, T-acute lymphoblastic leukemia or AML.

[0035] The compounds of Formula (I) described herein also include isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass

conventionally found in nature. Examples of isotopes that may be incorporated into the compounds disclosed herein include, but are not limited to, ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{18}F etc. Thus, the disclosed compounds may be enriched in one or more of these isotopes relative to the natural abundance of such isotope. As is known to those of skill in the art, such isotopically enriched compounds are useful for a variety of purposes. For example, substitution with heavier isotopes such as deuterium (^2H) may afford certain therapeutic advantages that result from greater metabolic stability. Substitution with positron emitting isotopes, such as ^{18}F can be useful in Positron Emission Tomography (PET) studies. By way of example, deuterium (^2H) has a natural abundance of about 0.015%. Accordingly, for approximately every 6,500 hydrogen atoms occurring in nature, there is one deuterium atom. Specifically contemplated herein are compounds enriched in deuterium at one or more positions. Thus, deuterium containing compounds of the disclosure have deuterium at one or more positions (as the case may be) in an abundance of greater than 0.015%.

Particular subgenera of compounds of any one of the Formula (I) for use in the methods of the invention, include compounds as defined in each of the following rows, wherein each entry is a group number as defined above (e.g., (1b) refers to X is N), and a dash “-” indicates that the variable is as defined for formula (I) or defined according to any one of the applicable variable definitions (1a)-(8II) [e.g., when X is a dash, it can be either as defined for Formula (I) or any one of definitions (1a)-(1b)]:

Formula (I)	R ¹ & R ²	R ⁵ & R ⁶	Z
(Id)	(4a)	(7a)	(8a)
(Id)	(4a)	(7a)	(8n)
(Id)	(4a)	(7a)	(8rr)
(Id)	(4a)	(7a)	(8o)
(Id)	(4a)	(7g)	(8a)
(Id)	(4a)	(7g)	(8n)
(Id)	(4a)	(7g)	(8rr)
(Id)	(4a)	(7g)	(8o)
(Id)	(4a)	(7i)	(8a)
(Id)	(4a)	(7i)	(8n)
(Id)	(4a)	(7i)	(8rr)
(Id)	(4a)	(7i)	(8o)

Formula (I)	R ¹ & R ²	R ⁵ & R ⁶	Z
(Id)	(4d)	(7a)	(8a)
(Id)	(4d)	(7a)	(8n)
(Id)	(4d)	(7a)	(8rr)
(Id)	(4d)	(7a)	(8o)
(Id)	(4d)	(7g)	(8a)
(Id)	(4d)	(7g)	(8n)
(Id)	(4d)	(7g)	(8rr)
(Id)	(4d)	(7g)	(8o)
(Id)	(4d)	(7i)	(8a)
(Id)	(4d)	(7i)	(8n)
(Id)	(4d)	(7i)	(8rr)
(Id)	(4d)	(7i)	(8o)

Formula (I)	R ¹ & R ²	R ⁵ & R ⁶	Z
(Ie)	(4d)	(7g)	(8a)
(Ie)	(4d)	(7g)	(8n)
(Ie)	(4d)	(7g)	(8rr)
(Ie)	(4d)	(7g)	(8o)
(Ie)	(4d)	(7i)	(8a)
(Ie)	(4d)	(7i)	(8n)
(Ie)	(4d)	(7i)	(8rr)
(Ie)	(4d)	(7i)	(8o)
(Ie)	(4e)	(7a)	(8a)
(Ie)	(4e)	(7a)	(8n)
(Ie)	(4e)	(7a)	(8rr)
(Ie)	(4e)	(7a)	(8o)
(Ie)	(4e)	(7g)	(8a)
(Ie)	(4e)	(7g)	(8n)
(Ie)	(4e)	(7g)	(8n)
(Ie)	(4e)	(7g)	(8o)
(Ie)	(4e)	(7i)	(8a)
(Ie)	(4e)	(7i)	(8n)
(Ie)	(4e)	(7g)	(8rr)
(Ie)	(4e)	(7i)	(8o)
(Ie)	(4f)	(7a)	(8a)
(Ie)	(4f)	(7a)	(8n)
(Ie)	(4f)	(7a)	(8rr)
(Ie)	(4f)	(7a)	(8o)
(Ie)	(4f)	(7g)	(8a)
(Ie)	(4f)	(7g)	(8n)
(Ie)	(4f)	(7g)	(8rr)
(Ie)	(4f)	(7g)	(8o)
(Ie)	(4f)	(7i)	(8a)
(Ie)	(4f)	(7i)	(8n)
(Ie)	(4f)	(7i)	(8rr)
(Ie)	(4f)	(7i)	(8o)


Formula (I)	R ¹ & R ²	R ⁵ & R ⁶	Z
(Ie)	(4g)	(7a)	(8a)
(Ie)	(4g)	(7a)	(8n)
(Ie)	(4g)	(7a)	(8rr)
(Ie)	(4g)	(7a)	(8o)
(Ie)	(4g)	(7g)	(8a)
(Ie)	(4g)	(7g)	(8n)
(Ie)	(4g)	(7g)	(8rr)
(Ie)	(4g)	(7g)	(8o)
(Ie)	(4g)	(7i)	(8a)
(Ie)	(4g)	(7i)	(8n)
(Ie)	(4g)	(7i)	(8rr)
(Ie)	(4g)	(7i)	(8o)
(Ie)	(2j), (3k)	(7a)	(8a)
(Ie)	(2j), (3k)	(7a)	(8n)
(Ie)	(2j), (3k)	(7a)	(8rr)
(Ie)	(2j), (3k)	(7a)	(8o)
(Ie)	(2j), (3k)	(7g)	(8a)
(Ie)	(2j), (3k)	(7g)	(8n)
(Ie)	(2j), (3k)	(7g)	(8rr)
(Ie)	(2j), (3k)	(7g)	(8o)
(Ie)	(2j), (3k)	(7i)	(8a)
(Ie)	(2j), (3k)	(7i)	(8n)
(Ie)	(2j), (3k)	(7i)	(8rr)
(Ie)	(2j), (3k)	(7i)	(8o)
(If)	(4a)	-	(8a)
(If)	(4a)	-	(8n)
(If)	(4a)	-	(8rr)
(If)	(4a)	-	(8o)
(If)	(4d)	-	(8a)
(If)	(4d)	-	(8n)
(If)	(4d)	-	(8rr)
(If)	(4d)	-	(8o)

Formula (I)	R ¹ & R ²	R ⁵ & R ⁶	Z
(If)	(4e)	-	(8a)
(If)	(4e)	-	(8n)
(If)	(4e)	-	(8rr)
(If)	(4e)	-	(8o)
(If)	(4f)	-	(8a)
(If)	(4f)	-	(8n)
(If)	(4f)	-	(8rr)
(If)	(4f)	-	(8o)
(If)	(4g)	-	(8a)
(If)	(4g)	-	(8n)
(If)	(4g)	-	(8rr)
(If)	(4g)	-	(8o)
(If)	(2j), (3k)	-	(8a)
(If)	(2j), (3k)	-	(8n)
(If)	(2j), (3k)	-	(8rr)
(If)	(2j), (3k)	-	(8o)
(Ir)	(4a)	-	(8a)
(Ir)	(4a)	-	(8n)
(Ir)	(4a)	-	(8rr)
(Ir)	(4a)	-	(8o)

Formula (I)	R ¹ & R ²	R ⁵ & R ⁶	Z
(Ir)	(4d)	-	(8a)
(Ir)	(4d)	-	(8n)
(Ir)	(4d)	-	(8rr)
(Ir)	(4d)	-	(8o)
(Ir)	(4e)	-	(8a)
(Ir)	(4e)	-	(8n)
(Ir)	(4e)	-	(8rr)
(Ir)	(4e)	-	(8o)
(Ir)	(4f)	-	(8a)
(Ir)	(4f)	-	(8n)
(Ir)	(4f)	-	(8rr)
(Ir)	(4f)	-	(8o)
(Ir)	(4g)	-	(8a)
(Ir)	(4g)	-	(8n)
(Ir)	(4g)	-	(8rr)
(Ir)	(4g)	-	(8o)
(Ir)	(2j), (3k)	-	(8a)
(Ir)	(2j), (3k)	-	(8n)
(Ir)	(2j), (3k)	-	(8rr)
(Ir)	(2j), (3k)	-	(8o)

[0036] In certain of such embodiments, n is 1.

[0037] In one particular embodiment, the methods employ compounds of formula (I) according to the formula,



(II)

or pharmaceutically acceptable salts thereof, wherein

R^1 and R^2 are each independently hydrogen, halogen, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, heterocyclyl, aryl, heteroaryl, $-R^{10}$, or $-C_{1-6}$ alkyl- R^{10} , wherein R^{10} is $-OR$, $-SR$, $-NR_2$, $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, $-S(O)_2NR_2$, $-OC(O)R$, $-N(R)C(O)R$, $-OC(O)OR$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)NR_2$, or $-N(R)S(O)_2R$;

R^5 and R^6 are each independently hydrogen, halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, $-OR$, $-SR$, $-NR_2$, $-OC(O)R$, $-N(R)C(O)R$, or $-N(R)S(O)_2R$;

R^{Z1} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl), $-R^{Z3}$, $-C_{1-6}$ alkyl- R^{Z3} , or $-C_{1-6}$ alkyl- R^{Z4} , wherein the C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), and heteroaryl(C_{1-6} alkyl) are each optionally substituted by one or two groups that are each independently halogen, C_{1-6} alkyl, $-R^{Z3}$, or $-R^{Z4}$, wherein

R^{Z3} is $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, or $-S(O)_2NR_2$; and

R^{Z4} is $-OR$, $-SR$, $-NR_2$, $-OC(O)R$, $-N(R)C(O)R$, $-OC(O)OR$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)NR_2$, $-N(R)S(O)_2R$, or $-OP(O)(OR)_2$;

R^{Z2} is hydrogen, halogen, or C_{1-6} alkyl;

and each R is independently hydrogen or C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), or heteroaryl(C_{1-6} alkyl), each optionally substituted by one or two groups that are each independently $-OR^0$, $-SR^0$, $-N(R^0)_2$, $-C(O)R^0$, $-C(O)OR^0$, $-C(O)N(R^0)_2$, $-S(O)_2N(R^0)_2$, $-OC(O)R^0$, $-N(R^0)C(O)R^0$, $-OC(O)OR^0$, $-OC(O)N(R^0)_2$, $-N(R^0)C(O)OR^0$, $-N(R^0)C(O)N(R^0)_2$, or $-N(R^0)S(O)_2R^0$, wherein each R^0 is independently hydrogen or C_{1-6} alkyl.

[0038] The disclosure further comprises the methods of the invention employing subgenera of formula (II) in which the substituents are selected as any and all combinations of one or more of R^1 , R^2 , R^5 , R^6 , R^{Z1} , and R^{Z2} as defined herein, including without limitation, the following:

[0039] R¹ is selected from one of the following groups (9a) – (9k):

- (9a)** R¹ is hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR, -SR, -NR₂, -C(O)R, -C(O)OR, -C(O)NR₂, -S(O)₂NR₂, -OC(O)R, -N(R)C(O)R, or -N(R)S(O)₂R.
- (9b)** R¹ is hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl.
- (9c)** R¹ is hydrogen, halogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, -C₁₋₆alkyl-OR¹¹, -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl.
- (9d)** R¹ is fluoro, cyano, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, isopropoxy, benzyloxy, cyclopropyl, cyclopentyl, cyclopentenyl, phenyl, amino, dimethylamino, methylsulfonylamino, aminocarbonyl, dimethylaminocarbonyl, n-propylaminocarbonyl, aminosulfonyl, or hydroxymethyl.
- (9e)** R¹ is halogen or C₁₋₆alkyl.
- (9f)** R¹ is halogen or C₁₋₄alkyl.
- (9g)** R¹ is halogen or methyl.
- (9h)** R¹ is fluoro or methyl.
- (9i)** R¹ is fluoro.
- (9j)** R¹ is methyl.
- (9k)** any one of (9a) – (9c), where R¹ is not hydrogen.

[0040] R² is selected from one of the following groups (10a) – (10k):

- (10a)** R² is hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR, -SR, -NR₂, -C(O)R, -C(O)OR, -C(O)NR₂, -S(O)₂NR₂, -OC(O)R, -N(R)C(O)R, or -N(R)S(O)₂R.
- (10b)** R² is hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl.
- (10c)** R² is hydrogen, halogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, -C₁₋₆alkyl-OR¹¹, -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl.

- (10d) R² is fluoro, cyano, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, isopropoxy, benzyloxy, cyclopropyl, cyclopentyl, cyclopentenyl, phenyl, amino, dimethylamino, methylsulfonylamino, aminocarbonyl, dimethylaminocarbonyl, n-propylaminocarbonyl, aminosulfonyl, or hydroxymethyl.
- (10e) R² is halogen or C₁₋₆alkyl.
- (10f) R² is halogen or C₁₋₄alkyl.
- (10g) R² is halogen or methyl.
- (10h) R² is fluoro or methyl.
- (10i) R² is fluoro.
- (10j) R² is methyl.
- (10k) As in any of (10a) - (10c), in which R² is not hydrogen.

[0041] **R¹ and R² are selected from one of the following groups (11a) – (11i):**

- (11a) R¹ and R² are each independently hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR, -SR, -NR₂, -C(O)R, -C(O)OR, -C(O)NR₂, -S(O)₂NR₂, -OC(O)R, -N(R)C(O)R, or -N(R)S(O)₂R.
- (11b) R¹ and R² are each independently hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, -R¹⁰, or -C₁₋₆alkyl-R¹⁰, wherein R¹⁰ is -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl.
- (11c) R¹ and R² are each independently hydrogen, halogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, -C₁₋₆alkyl-OR¹¹, -OR¹¹, -N(R¹¹)₂, -C(O)N(R¹¹)₂, -S(O)₂N(R¹¹)₂, or -N(R¹¹)S(O)₂R¹¹, wherein each R¹¹ is hydrogen or C₁₋₆alkyl.
- (11d) R¹ and R² are each independently hydrogen, fluoro, cyano, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, isopropoxy, benzyloxy, cyclopropyl, cyclopentyl, cyclopentenyl, phenyl, amino, dimethylamino, methylsulfonylamino, aminocarbonyl, dimethylaminocarbonyl, n-propylaminocarbonyl, aminosulfonyl, or hydroxymethyl.
- (11e) R¹ and R² are each independently hydrogen, halogen, or C₁₋₆alkyl.
- (11f) R¹ is fluoro and R² is methyl.
- (11g) any one of (11a) – (11e), where R¹ is not hydrogen.
- (11h) any one of (11a) - (11e), where R² is not hydrogen.

(11i) any one of (11a) – (11e), where neither R^1 nor R^2 is hydrogen.

[0042] **R^5 is selected from one of the following groups (12a) – (12k):**

(12a) R^5 is hydrogen, halogen, C_{1-6} alkyl, $-OR^{50}$, $-NR^{50}R^{50}$, $-N(R^{50})C(O)R^{50}$, or $-N(R^{50})S(O)_2R^{50}$, wherein each R^{50} is independently hydrogen or C_{1-6} alkyl.

(12b) R^5 is hydrogen, halogen, C_{1-4} alkyl, $-OR^{50}$, $-NR^{50}R^{50}$, $-N(R^{50})C(O)R^{50}$, or $-N(R^{50})S(O)_2R^{50}$, wherein each R^{50} is independently hydrogen or C_{1-4} alkyl.

(12c) R^5 is hydrogen, fluoro, chloro, methyl, methoxy, ethoxy, amino, acetylamino, or methylsulfonylamino

(12d) R^5 is fluoro or chloro

(12e) R^5 is fluoro

(12f) R^5 is chloro

(12g) R^5 is methyl

(12h) R^5 is methoxy or ethoxy

(12i) R^5 is amino, acetylamino, or methylsulfonylamino

(12j) R^5 is hydrogen.

(12k) any one of (12a) – (12i), where R^5 is not hydrogen.

[0043] **R^6 is selected from one of the following groups (13a) – (13k):**

(13a) R^6 is hydrogen, halogen, C_{1-6} alkyl, $-OR^{60}$, $-NR^{60}R^{60}$, $-N(R^{60})C(O)R^{60}$, or $-N(R^{60})S(O)_2R^{60}$, wherein each R^{60} is independently hydrogen or C_{1-6} alkyl.

(13b) R^6 is hydrogen, halogen, C_{1-4} alkyl, $-OR^{60}$, $-NR^{60}R^{60}$, $-N(R^{60})C(O)R^{60}$, or $-N(R^{60})S(O)_2R^{60}$, wherein each R^{60} is independently hydrogen or C_{1-4} alkyl.

(13c) R^6 is hydrogen, fluoro, chloro, methyl, methoxy, ethoxy, amino, acetylamino, or methylsulfonylamino

(13d) R^6 is fluoro or chloro

(13e) R^6 is fluoro

(13f) R^6 is chloro

(13g) R^6 is methyl

(13h) R^6 is methoxy or ethoxy

(13i) R^6 is amino, acetylamino, or methylsulfonylamino

(13j) R^6 is hydrogen.

(13k) any one of (13a) – (13j), where R⁶ is not hydrogen.

[0044] R⁵ and R⁶ are selected from one of the following groups (14a) – (14o):

- (14a) R⁵ and R⁶ are each independently hydrogen, halogen, C₁₋₆alkyl, -OR⁷, -NR⁷R⁷, -N(R⁷)C(O)R⁷, or -N(R⁷)S(O)₂R⁷, wherein each R⁷ is independently hydrogen or C₁₋₆alkyl.
- (14b) one of R⁵ and R⁶ is hydrogen, and the other is halogen, C₁₋₆alkyl, -OR⁷, -NR⁷R⁷, -N(R⁷)C(O)R⁷, or -N(R⁷)S(O)₂R⁷, wherein each R⁷ is independently hydrogen or C₁₋₆alkyl.
- (14c) R⁵ and R⁶ are each independently hydrogen, halogen, C₁₋₄alkyl, -OR⁷, -NR⁷R⁷, -N(R⁷)C(O)R⁷, or -N(R⁷)S(O)₂R⁷, wherein each R⁷ is independently hydrogen or C₁₋₄alkyl.
- (14d) one of R⁵ and R⁶ is hydrogen, and the other is halogen, C₁₋₄alkyl, -OR⁷, -NR⁷R⁷, -N(R⁷)C(O)R⁷, or -N(R⁷)S(O)₂R⁷, wherein each R⁷ is independently hydrogen or C₁₋₄alkyl.
- (14e) R⁵ and R⁶ are each independently hydrogen, fluoro, chloro, methyl, methoxy, ethoxy, amino, acetylamino, or methylsulfonylamino
- (14f) one of R⁵ and R⁶ is hydrogen, and the other is fluoro, chloro, methyl, methoxy, ethoxy, amino, acetylamino, or methylsulfonylamino
- (14g) any one of (14a) – (14f), where one of R⁵ and R⁶ is not hydrogen.
- (14h) R⁵ and R⁶ are each hydrogen
- (14i) one of R⁵ and R⁶ is hydrogen, and the other is fluoro, or chloro
- (14j) one of R⁵ and R⁶ is hydrogen, and the other is methyl
- (14k) one of R⁵ and R⁶ is hydrogen, and the other is methoxy or ethoxy
- (14l) one of R⁵ and R⁶ is hydrogen, and the other is amino, acetylamino, or methylsulfonylamino
- (14m) one of R⁵ and R⁶ is hydrogen, and the other is amino
- (14n) one of R⁵ and R⁶ is hydrogen, and the other is acetylamino
- (14o) one of R⁵ and R⁶ is hydrogen, and the other is methylsulfonylamino

[0045] R^{Z1} is selected from one of the following groups (15a) – (15j):

- (15a)** R^{Z1} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl), $-R^{Z3}$, $-C_{1-6}$ alkyl- R^{Z3} , or $-C_{1-6}$ alkyl- R^{Z4} , wherein R^{Z3} is $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, or $-S(O)_2NR_2$; and R^{Z4} is $-OR$, $-SR$, $-NR_2$, $-OC(O)R$, $-N(R)C(O)R$, $-OC(O)OR$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)NR_2$, $-N(R)S(O)_2R$, or $-OP(O)(OR)_2$.
- (15b)** R^{Z1} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl), $-R^{Z3}$, $-C_{1-6}$ alkyl- R^{Z3} , or $-C_{1-6}$ alkyl- R^{Z4} , wherein R^{Z3} is $-C(O)R^{Z6}$, $-C(O)OR^{Z6}$, $-C(O)NR^{Z6}_2$, or $-S(O)_2NR^{Z5}_2$; and R^{Z4} is $-OR^{Z5}$, $-SR^{Z5}$, $-NR^{Z5}_2$, $-OC(O)R^{Z5}$, $-N(R^{Z5})C(O)R^{Z5}$, $-OC(O)OR^{Z5}$, $-OC(O)NR^{Z5}_2$, $-N(R^{Z5})C(O)OR^{Z5}$, $-N(R^{Z5})C(O)NR^{Z5}_2$, $-N(R^{Z5})S(O)_2R^{Z5}$, or $-OP(O)(OR^{Z5})_2$, and wherein each R^{Z5} is independently hydrogen or C_{1-6} alkyl; and each R^{Z6} is independently hydrogen or C_{1-6} alkyl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), or heteroaryl(C_{1-6} alkyl), each optionally substituted by one or two groups that are each independently $-OR^0$, $-SR^0$, $-N(R^0)_2$, $-C(O)R^0$, $-C(O)OR^0$, $-C(O)N(R^0)_2$, $-S(O)_2N(R^0)_2$, $-OC(O)R^0$, $-N(R^0)C(O)R^0$, $-OC(O)OR^0$, $-OC(O)N(R^0)_2$, $-N(R^0)C(O)OR^0$, $-N(R^0)C(O)N(R^0)_2$, or $-N(R^0)S(O)_2R^0$, wherein each R^0 is independently hydrogen or C_{1-6} alkyl.
- (15c)** R^{Z1} is hydrogen, C_{1-6} alkyl, heterocyclyl, heterocyclyl(C_{1-6} alkyl), $-C_{1-6}$ alkyl- R^{Z4} , or $-C(O)OR^{Z6}$, wherein R^{Z4} is $-OR^{Z5}$, $-SR^{Z5}$, $-NR^{Z5}_2$, $-OC(O)R^{Z5}$, $-N(R^{Z5})C(O)R^{Z5}$, $-OC(O)OR^{Z5}$, $-OC(O)NR^{Z5}_2$, $-N(R^{Z5})C(O)OR^{Z5}$, $-N(R^{Z5})C(O)NR^{Z5}_2$, $-N(R^{Z5})S(O)_2R^{Z5}$, or $-OP(O)(OR^{Z5})_2$, wherein the heterocyclyl and heterocyclyl(C_{1-6} alkyl) are each optionally substituted by one or two groups that are each independently halogen or C_{1-6} alkyl; and wherein each R^{Z5} is independently hydrogen or C_{1-6} alkyl; and each R^{Z6} is independently hydrogen or C_{1-6} alkyl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), or heteroaryl(C_{1-6} alkyl), each optionally substituted by $-OR^0$, $-SR^0$, $-N(R^0)_2$, $-C(O)R^0$, $-C(O)OR^0$, or $-C(O)N(R^0)_2$, wherein each R^0 is independently hydrogen or C_{1-6} alkyl.
- (15d)** R^{Z1} is hydrogen, C_{1-6} alkyl, heterocyclyl, heterocyclyl(C_{1-6} alkyl), $-C_{1-6}$ alkyl- OR^{Z5} , or $-C_{1-6}$ alkyl- $OP(O)(OR^{Z5})_2$, or $-C(O)OR^{Z6}$, wherein the heterocyclyl and heterocyclyl(C_{1-6} alkyl) are each optionally substituted by one or two C_{1-6} alkyl groups;

and wherein each R^{Z5} is independently hydrogen or C_{1-6} alkyl; each R^{Z6} is independently hydrogen or C_{1-6} alkyl or heteroaryl(C_{1-6} alkyl), each optionally substituted by $-OR^0$, or $-N(R^0)_2$, wherein each R^0 is independently hydrogen or C_{1-6} alkyl.

(15e) R^{Z1} is hydrogen, methyl, ethyl, isopropyl, 2-(morpholin-4-yl)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-hydroxypropyl, 3-ethoxypropyl, 4-tetrahydropyranyl, N-methylpiperidin-4-yl, $-CH_2-OP(O)(OH)_2$, or 3-(indol-3-yl)-2-aminopropylloxycarbonyl.

(15f) R^{Z1} is hydrogen, methyl, or 3-(indol-3-yl)-2-aminopropylloxycarbonyl.

(15g) R^{Z1} is hydrogen or methyl.

(15h) R^{Z1} is hydrogen.

(15i) R^{Z1} is methyl.

(15j) R^{Z1} is 3-(indol-3-yl)-2-aminopropylloxycarbonyl.

[0046] R^{Z2} is selected from one of the following groups (16a) – (16d):

(16a) R^{Z2} is hydrogen or halogen

(16b) R^{Z2} is hydrogen or C_{1-6} alkyl;

(16c) R^{Z2} is hydrogen or methyl;

(16d) R^{Z2} is hydrogen

[0047] Particular embodiments of this aspect of the disclosure include compounds of any one of the Formula (II), each as defined in each of the following rows, wherein each entry is a group number as defined above, and a dash “-“ indicates that the variable is as defined for formula (II) or defined according to any one of the applicable variable definitions **(9a)-(16d)** [e.g., when R^{Z1} is a dash, it can be either as defined for Formula (II) or any one of definitions **(15a)-(15j)**]:

$R^1 \& R^2$	$R^5 \& R^6$	R^{Z1}	R^{Z2}
(11d)	(14e)	(15e)	(16a)
(11d)	(14e)	(15e)	(16b)
(11d)	(14e)	(15g)	(16a)
(11d)	(14e)	(15g)	(16b)
(11d)	(14f)	(15e)	(16a)
(11d)	(14f)	(15e)	(16b)
(11d)	(14f)	(15g)	(16a)
(11d)	(14f)	(15g)	(16b)

$R^1 \& R^2$	$R^5 \& R^6$	R^{Z1}	R^{Z2}
(11d)	(14h)	(15e)	(16a)
(11d)	(14h)	(15e)	(16b)
(11d)	(14h)	(15g)	(16a)
(11d)	(14h)	(15g)	(16b)
(11d)	(14i)	(15e)	(16a)
(11d)	(14i)	(15e)	(16b)
(11d)	(14i)	(15g)	(16a)
(11d)	(14i)	(15g)	(16b)

R ¹ & R ²	R ⁵ & R ⁶	R ^{Z1}	R ^{Z2}
(11e)	(14e)	(15e)	(16a)
(11e)	(14e)	(15e)	(16b)
(11e)	(14e)	(15g)	(16a)
(11e)	(14e)	(15g)	(16b)
(11e)	(14f)	(15e)	(16a)
(11e)	(14f)	(15e)	(16b)
(11e)	(14f)	(15g)	(16a)
(11e)	(14f)	(15g)	(16b)
(11e)	(14h)	(15e)	(16a)
(11e)	(14h)	(15e)	(16b)
(11e)	(14h)	(15g)	(16a)
(11e)	(14h)	(15g)	(16b)
(11e)	(14i)	(15e)	(16a)
(11e)	(14i)	(15e)	(16b)
(11e)	(14i)	(15g)	(16a)
(11e)	(14i)	(15g)	(16b)

R ¹ & R ²	R ⁵ & R ⁶	R ^{Z1}	R ^{Z2}
(11f)	(14e)	(15e)	(16a)
(11f)	(14e)	(15e)	(16b)
(11f)	(14e)	(15g)	(16a)
(11f)	(14e)	(15g)	(16b)
(11f)	(14f)	(15e)	(16a)
(11f)	(14f)	(15e)	(16b)
(11f)	(14f)	(15g)	(16a)
(11f)	(14f)	(15g)	(16b)
(11f)	(14h)	(15e)	(16a)
(11f)	(14h)	(15e)	(16b)
(11f)	(14h)	(15g)	(16a)
(11f)	(14h)	(15g)	(16b)
(11f)	(14i)	(15e)	(16a)
(11f)	(14i)	(15e)	(16b)
(11f)	(14i)	(15g)	(16a)
(11f)	(14i)	(15g)	(16b)

[0048] In certain embodiments of the compounds as described throughout this disclosure, Z is optionally substituted by one or two groups that are each independently halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, -R^Z, or -C₁₋₆alkyl-R^Z, wherein each and R^Z is cyano, -CF₃, -OR, -SR, -NR^aR^a, -C(O)R, -C(O)OR, -C(O)NR^aR^a, -S(O)₂NR^aR^a, -S(O)₂R⁰, -OC(O)R, -N(R)C(O)R, -OC(O)OR, -OC(O)NR^aR^a, -N(R)C(O)OR, -N(R)C(O)NR^aR^a, -N(R)S(O)₂R, or -OP(O)(OR)₂. In certain such embodiments, each R is independently hydrogen, C₁₋₆alkyl, or C₁₋₆haloalkyl, each optionally substituted by 1-3 groups that are each independently R^b, -OR⁰, -SR⁰, -N(R⁰)₂, -C(O)R⁰, -C(O)OR⁰, -C(O)N(R⁰)₂, -S(O)₂N(R⁰)₂, -OC(O)R⁰, -N(R⁰)C(O)R⁰, -OC(O)OR⁰, -O(CH₂)_mC(O)N(R⁰)₂, -N(R⁰)C(O)OR⁰, -N(R⁰)C(O)N(R⁰)₂, or -N(R⁰)S(O)₂R⁰, in which each R^b is independently halogen, cyano, oxo, C₁₋₆alkyl, C₁₋₆haloalkyl or -OR¹³, in which R¹³ is hydrogen, C₁₋₆alkyl or C₁₋₆haloalkyl, each optionally substituted by 1-3 groups that are each independently halogen, cyano, oxo, C₁₋₆alkyl, C₁₋₆haloalkyl, -OR⁰, -SR⁰, -N(R⁰)₂, -C(O)R⁰, -C(O)OR⁰, -C(O)N(R⁰)₂, -S(O)₂N(R⁰)₂, -OC(O)R⁰, -N(R⁰)C(O)R⁰,

$-\text{OC}(\text{O})\text{OR}^0$, $-\text{O}(\text{CH}_2)_m\text{C}(\text{O})\text{N}(\text{R}^0)_2$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{OR}^0$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{N}(\text{R}^0)_2$, or $-\text{N}(\text{R}^0)\text{S}(\text{O})_2\text{R}^0$, in which each R^0 is independently hydrogen, C_{1-6} haloalkyl or C_{1-6} alkyl optionally substituted with 1-3 $\text{R}^{\text{b}0}$, in which each $\text{R}^{\text{b}0}$ is independently halogen, cyano or oxo.

[0049] In certain embodiments of the compounds as described throughout this disclosure, each R^{a} is independently hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl, each optionally substituted by 1-3 groups that are each independently R^{b} , $-\text{OR}^0$, $-\text{SR}^0$, $-\text{N}(\text{R}^0)_2$, $-\text{C}(\text{O})\text{R}^0$, $-\text{C}(\text{O})\text{OR}^0$, $-\text{C}(\text{O})\text{N}(\text{R}^0)_2$, $-\text{S}(\text{O})_2\text{N}(\text{R}^0)_2$, $-\text{OC}(\text{O})\text{R}^0$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{R}^0$, $-\text{OC}(\text{O})\text{OR}^0$, $-\text{O}(\text{CH}_2)_m\text{C}(\text{O})\text{N}(\text{R}^0)_2$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{OR}^0$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{N}(\text{R}^0)_2$, or $-\text{N}(\text{R}^0)\text{S}(\text{O})_2\text{R}^0$, or two R^{a} together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclyl group, optionally including 1-4 additional heteroatoms selected from O, N and S and optionally substituted with 1-4 R groups.

[0050] In certain embodiments of the compounds as described throughout this disclosure, each R^{b} is independently halogen, cyano, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl or $-\text{OR}^{11}$, in which R^{12} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), or heteroaryl(C_{1-6} alkyl), each optionally substituted by 1-3 groups that are each independently halogen, cyano, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl, $-\text{OR}^0$, $-\text{SR}^0$, $-\text{N}(\text{R}^0)_2$, $-\text{C}(\text{O})\text{R}^0$, $-\text{C}(\text{O})\text{OR}^0$, $-\text{C}(\text{O})\text{N}(\text{R}^0)_2$, $-\text{S}(\text{O})_2\text{N}(\text{R}^0)_2$, $-\text{OC}(\text{O})\text{R}^0$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{R}^0$, $-\text{OC}(\text{O})\text{OR}^0$, $-\text{O}(\text{CH}_2)_m\text{C}(\text{O})\text{N}(\text{R}^0)_2$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{OR}^0$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{N}(\text{R}^0)_2$, or $-\text{N}(\text{R}^0)\text{S}(\text{O})_2\text{R}^0$, in which each R^0 is independently hydrogen, C_{1-6} haloalkyl, C_{1-6} alkyl optionally substituted with 1-3 $\text{R}^{\text{b}0}$, C_{3-8} cycloalkyl optionally substituted with one or two $\text{R}^{\text{b}0}$ or, alternatively two R^0 together with a nitrogen atom to which they are bound (for example when R is $-\text{C}(\text{O})\text{N}(\text{R}^0)_2$) form a 3-8 membered heterocyclyl group, optionally including 1-4 additional heteroatoms selected from O, N and S and optionally substituted with 0-3 $\text{R}^{\text{b}0}$, in which each $\text{R}^{\text{b}0}$ is independently halogen, cyano or oxo.

[0051] In certain embodiments of the compounds as described throughout this disclosure, each R^{b} is independently halogen, cyano, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl or $-\text{OR}^{13}$, in which R^{13} is hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl, each optionally substituted by 1-3 groups that are each independently halogen, cyano, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl, $-\text{OR}^0$, $-\text{SR}^0$, $-\text{N}(\text{R}^0)_2$, $-\text{C}(\text{O})\text{R}^0$, $-\text{C}(\text{O})\text{OR}^0$, $-\text{C}(\text{O})\text{N}(\text{R}^0)_2$, $-\text{S}(\text{O})_2\text{N}(\text{R}^0)_2$, $-\text{OC}(\text{O})\text{R}^0$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{R}^0$, $-\text{OC}(\text{O})\text{OR}^0$, $-\text{O}(\text{CH}_2)_m\text{C}(\text{O})\text{N}(\text{R}^0)_2$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{OR}^0$, $-\text{N}(\text{R}^0)\text{C}(\text{O})\text{N}(\text{R}^0)_2$, or $-\text{N}(\text{R}^0)\text{S}(\text{O})_2\text{R}^0$, in which each R^0 is independently hydrogen, C_{1-6} haloalkyl or C_{1-6} alkyl

optionally substituted with 1-3 R^{b0} , in which each R^{b0} is independently halogen, cyano or oxo.

[0052] In certain embodiments of the compounds as described throughout this disclosure, each R is independently hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, heterocyclyl, aryl, heteroaryl, C_{3-8} cycloalkyl(C_{1-6} alkyl), heterocyclyl(C_{1-6} alkyl), aryl(C_{1-6} alkyl), or heteroaryl(C_{1-6} alkyl), each optionally substituted by 1-3 groups that are each independently R^b , $-OR^0$, $-SR^0$, $-N(R^0)_2$, $-C(O)R^0$, $-C(O)OR^0$, $-C(O)N(R^0)_2$, $-S(O)_2N(R^0)_2$, $-OC(O)R^0$, $-N(R^0)C(O)R^0$, $-OC(O)OR^0$, $-O(CH_2)_mC(O)N(R^0)_2$, $-N(R^0)C(O)OR^0$, $-N(R^0)C(O)N(R^0)_2$, or $-N(R^0)S(O)_2R^0$. In certain such embodiments, each R^0 is hydrogen, C_{1-6} haloalkyl or C_{1-6} alkyl.

[0053] In certain embodiments of the compounds as described throughout this disclosure, each R is independently hydrogen, C_{1-6} alkyl, or C_{1-6} haloalkyl, each optionally substituted by 1-3 groups that are each independently R^b , $-OR^0$, $-SR^0$, $-N(R^0)_2$, $-C(O)R^0$, $-C(O)OR^0$, $-C(O)N(R^0)_2$, $-S(O)_2N(R^0)_2$, $-OC(O)R^0$, $-N(R^0)C(O)R^0$, $-OC(O)OR^0$, $-O(CH_2)_mC(O)N(R^0)_2$, $-N(R^0)C(O)OR^0$, $-N(R^0)C(O)N(R^0)_2$, or $-N(R^0)S(O)_2R^0$, in which each R^b is independently halogen, cyano, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl or $-OR^{13}$, in which R^{13} is hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl, each optionally substituted by 1-3 groups that are each independently halogen, cyano, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl, $-OR^0$, $-SR^0$, $-N(R^0)_2$, $-C(O)R^0$, $-C(O)OR^0$, $-C(O)N(R^0)_2$, $-S(O)_2N(R^0)_2$, $-OC(O)R^0$, $-N(R^0)C(O)R^0$, $-OC(O)OR^0$, $-O(CH_2)_mC(O)N(R^0)_2$, $-N(R^0)C(O)OR^0$, $-N(R^0)C(O)N(R^0)_2$, or $-N(R^0)S(O)_2R^0$, in which each R^0 is independently hydrogen, C_{1-6} haloalkyl or C_{1-6} alkyl optionally substituted with 1-3 R^{b0} , in which each R^{b0} is independently halogen, cyano or oxo.







[0054] In certain embodiments of the compounds as described throughout this disclosure, R^0 is independently hydrogen, C_{1-6} haloalkyl, or C_{1-6} alkyl optionally substituted with 1-3 R^{b0} , in which each R^{b0} is independently halogen, cyano or oxo.






[0055] In certain embodiments of the compounds as described throughout this disclosure, each C_{1-6} (halo)alkyl is a C_{1-3} (halo)alkyl. In other embodiments of the compounds as described throughout this disclosure, each C_{1-6} (halo)alkyl is a C_{1-2} (halo)alkyl.

[0056] In certain embodiments of the compounds as described throughout this disclosure, when R^1 and R^2 are attached to adjacent carbon atoms they are optionally taken together with the atoms to which they are attached to form a 5- or 6-membered ring optionally substituted with one or two groups that are each independently halogen, oxo, oxime, imino, C_{1-6} alkyl, C_{1-6} haloalkyl,

or -R¹⁰. The ring can be for example, an aryl ring (e.g., a benzo) or a 5- or 6-membered heteroaryl ring (e.g. a pyrido or a thieno). When the ring is a heteroaryl ring, it can include 1 or 2 heteroatoms selected from N, O and S. In other embodiments, the ring is a cycloalkylene (e.g., 5 or 6 membered), or a heterocyclyl ring (e.g., 5 or 6 membered) including 1 or 2 heteroatoms selected from N, O and S.

[0057] In certain embodiments, the compound of formula (I) is one of the compounds of **Table 1**, optionally provided as a salt (e.g., the salt indicated in the Table):

Cpd #	Structure	Salt
1		TFA(2)
2		TFA(2)
3		Formic Acid(2)
4		Formic Acid(2)
5		Formic Acid(2)
6		TFA(2)

Cpd #	Structure	Salt
7		TFA(2)
8		Formic Acid(2)
9		TFA(2)
10		TFA(2)
11		TFA(2)
12		TFA(2)

Cpd #	Structure	Salt
13		TFA(2)
14		TFA(2)
15		TFA(3)
16		TFA(3)
17		Formic Acid(3)
18		TFA(3)
19		TFA(3)
20		TFA(3)

Cpd #	Structure	Salt
21		TFA(3)
22		TFA(3)
23		TFA(3)
24		TFA(2)
25		TFA(2)
26		TFA(2)
27		TFA(3)
28		TFA(3)

Cpd #	Structure	Salt
29		TFA(3)
30		TFA(2)
31		TFA(2)
32		TFA(2)
33		Parent
34		Parent
35		Parent
36		Parent

Cpd #	Structure	Salt
37		Parent
38		Parent
39		Parent
40		Parent
41		Parent
42		Parent
43		Parent

Cpd #	Structure	Salt
44		Parent
45		Parent
46		Parent
47		Parent
48		Parent
49		Parent
50		Parent







Cpd #	Structure	Salt
51		Parent
52		Parent
53		Parent
54		Parent
55		Parent
56		Parent
57		Parent
58		Parent










Cpd #	Structure	Salt
59		Parent
60		Parent
61		Parent
62		Parent
63		Parent
64		Parent
65		Parent
66		Parent
67		Parent

Cpd #	Structure	Salt
68		Parent
69		Parent
70		Parent
71		Parent
72		Parent
73		Parent
74		Parent
75		Parent
76		Parent

Cpd #	Structure	Salt
77		Parent
78		Parent
79		Parent
80		Parent
81		Parent
82		Parent
83		Parent
84		Parent
85		Parent

Cpd #	Structure	Salt
86		Parent
87		Parent
88		Parent
89		Parent
90		Parent
91		Parent
92		Parent
93		Parent
94		Parent

Cpd #	Structure	Salt
95		Parent
96		Parent
97		Parent
98		Parent
99		Parent
100		Parent
101		Parent
102		Parent
103		Parent










Cpd #	Structure	Salt
104		Parent
105		Parent
106		Parent
107		Parent
108		Parent
109		Parent
110		Parent
111		Parent
112		Parent










Cpd #	Structure	Salt
113		Parent
114		Parent
115		Parent
116		Parent
117		Parent
118		Parent
119		Parent
120		Parent
121		Parent

Cpd #	Structure	Salt
122		Parent
123		Parent
124		Parent
125		Parent
126		Parent
127		Parent
128		Parent
129		Parent
130		Parent

Cpd #	Structure	Salt
131		Parent
132		Parent
133		Parent
134		Parent
135		Parent
136		Parent
137		Parent
138		Parent
139		Parent
140		Parent

Cpd #	Structure	Salt
141		Parent
142		Parent
143		Parent
144		Parent
145		Parent
146		Parent
147		Parent
148		Parent
149		Parent

Cpd #	Structure	Salt
150		Parent
151		Parent
152		Parent
153		Parent
154		Parent
155		Parent
156		Parent
157		Parent
158		Parent

Cpd #	Structure	Salt
159		Parent
160		Parent
161		Parent
162		Parent
163		Parent
164		Parent
165		Parent
166		Parent
167		Parent

Cpd #	Structure	Salt
168		Parent
169		Parent
170		Parent
171		Parent
172		Parent
173		Parent
174		Parent
175		Parent
176		Parent

Cpd #	Structure	Salt
177		Parent
178		Parent
179		TFA
180		Parent
181		Parent
182		Parent
183		Parent
184		Parent
185		Parent

Cpd #	Structure	Salt
186		Parent
187		Parent
188		Parent
189		Parent
190		Parent
191		Parent
192		Parent
193		Parent
194		Parent










Cpd #	Structure	Salt
195		Parent
196		Parent
197		Parent
198		Parent
199		Parent
200		Parent
201		Parent
202		Parent
203		Parent








Cpd #	Structure	Salt
204		Parent
205		Parent
206		Parent
207		Parent
208		Parent
209		Parent
210		Parent
211		TFA(3)
212		TFA(3)







Cpd #	Structure	Salt
213		TFA(2)
214		TFA(2)
215		TFA(2)
216		TFA(2)
217		TFA(2)
218		TFA(3)
219		TFA(3)
220		TFA(3)
221		TFA(3)







Cpd #	Structure	Salt
222		Parent
223		TFA(3)
224		TFA(3)
225		TFA(2)
226		TFA(3)
227		Parent
228		TFA(3)
229		TFA
230		TFA(3)







Cpd #	Structure	Salt
231		TFA
232		TFA(2)
233		TFA(3)
234		TFA
235		TFA(2)
236		TFA
237		TFA(2)
238		TFA(2)







Cpd #	Structure	Salt
239		TFA(2)
240		TFA(3)
241		TFA(2)
242		TFA(2)
243		TFA(2)
244		TFA(3)
245		TFA(3)
246		TFA(3)
247		TFA(3)








Cpd #	Structure	Salt
248		Parent
249		Parent
250		Parent
251		Parent
252		Parent
253		Parent
254		Parent









Cpd #	Structure	Salt
255		Parent
256		Parent
257		Parent
258		Parent
259		Parent
260		Parent

Cpd #	Structure	Salt
261		Parent
262		Parent
263		Parent
264		Parent
265		Parent
266		Parent

Cpd #	Structure	Salt
267		Parent
268		Parent
269		Parent
270		Parent
271		Parent
272		Parent

Cpd #	Structure	Salt
273		Parent
274		Parent
275		Parent
276		Parent
277		Parent
278		Parent

Cpd #	Structure	Salt
279		Parent
280		Parent
281		Parent
282		Parent
283		Parent
284		Parent
285		Parent

Cpd #	Structure	Salt
286		Parent
287		Parent
288		Parent
289		Parent
290		Parent
291		Parent
292		Parent
296		Parent

Cpd #	Structure	Salt
294		Parent
295		Parent
296		Parent
297		Parent
298		Parent
299		Parent
300		Parent

Cpd #	Structure	Salt
301		Parent
302		Parent
303		Parent
304		Parent
305		Parent
306		TFA(3)
307		Parent
308		Formic Acid(2)
309		Formic Acid(2)

Cpd #	Structure	Salt
310		TFA(2)
311		Formic Acid(3)
312		Formic Acid(2)
313		Formic Acid(1)
314		Formic Acid(2)
315		Formic Acid(2)
316		Formic Acid(2)
317		Formic Acid(2)

Cpd #	Structure	Salt
318		Formic Acid(2)
319		Formic Acid(3)
320		Formic Acid(3)
321		TFA(3)
322		Formic Acid(3)
323		Formic Acid(3)
324		Formic Acid(3)
325		Formic Acid(3)

Cpd #	Structure	Salt
326		Formic Acid(3)
327		Formic Acid(3)
328		TFA(3)
329		Formic Acid(3)
330		Formic Acid(3)
331		Formic Acid(3)
332		Formic Acid(3)
333		Formic Acid(2)

Cpd #	Structure	Salt
334		Formic Acid(2)
335		Formic Acid(3)
336		Formic Acid(3)
337		Formic Acid(3)
338		Formic Acid(3)
339		Formic Acid(3)
340		Formic Acid(2)
341		Formic Acid(2)

Cpd #	Structure	Salt
342		Formic Acid(2)
343		TFA(2)
344		TFA(2)
345		TFA(3)
346		Formic Acid(2)
347		Formic Acid(3)
348		TFA(2)
349		TFA(2)

Cpd #	Structure	Salt
350		TFA(2)
351		Formic Acid(3)
352		Formic Acid(3)
353		Formic Acid(3)
354		Formic Acid(3)
355		Formic Acid(3)
356		Formic Acid(3)
357		Formic Acid(3)
358		Formic Acid(3)

Cpd #	Structure	Salt
359		Formic Acid(3)
360		TFA(3)
361		Formic Acid(2)
362		Formic Acid(2)
363		TFA(3)
364		TFA(3)
365		TFA(3)
366		Formic Acid(3)
367		Formic Acid(3)

Cpd #	Structure	Salt
368		Formic Acid(3)
369		Formic Acid(3)
370		Formic Acid(3)
371		Formic Acid(3)
372		Formic Acid(3)
373		Formic Acid(3)
374		Formic Acid(3)
375		Formic Acid(2)
376		Formic Acid(2)

Cpd #	Structure	Salt
377		Formic Acid(2)
378		Formic Acid(2)
379		Formic Acid(2)
380		Formic Acid(2)
381		Formic Acid(2)
382		Formic Acid(2)
383		Formic Acid(3)
384		Formic Acid(3)
385		TFA(3)

Cpd #	Structure	Salt
386		TFA(3)
387		TFA(3)
388		Parent
389		Parent
390		TFA(2)
391		TFA(2)
392		Formic Acid(3)
393		Formic Acid(3)

Cpd #	Structure	Salt
394		Formic Acid(3)
395		Formic Acid(2)
396		Formic Acid(2)
397		Formic Acid(3)
398		Formic Acid(3)
399		Formic Acid(3)
400		Formic Acid(3)
401		Formic Acid(3)
402		Formic Acid(3)

Cpd #	Structure	Salt
403		Formic Acid(3)
404		Formic Acid(3)
405		Formic Acid(3)
406		Formic Acid(3)
407		Formic Acid(3)
408		Formic Acid(3)
409		Formic Acid(2)
410		Formic Acid(2)
411		Formic Acid(3)

Cpd #	Structure	Salt
412		Formic Acid(3)
413		Formic Acid(3)
414		Formic Acid(3)
415		Formic Acid(3)
416		Formic Acid(3)
417		Formic Acid(3)
418		Formic Acid(2)
419		Formic Acid(2)
420		Formic Acid(2)

Cpd #	Structure	Salt
421		Formic Acid(3)
422		Formic Acid(3)
423		TFA(3)
424		TFA(3)
425		Formic Acid(3)
426		Formic Acid(2)
427		Formic Acid(2)
428		Formic Acid(2)
429		Formic Acid(3)

Cpd #	Structure	Salt
430		Formic Acid(3)
431		Formic Acid(2)
432		Formic Acid(3)
433		Formic Acid(3)
434		Formic Acid(3)
435		Formic Acid(3)
436		Formic Acid(3)
437		Formic Acid(3)
438		Formic Acid(3)

Cpd #	Structure	Salt
439		Formic Acid(3)
440		Formic Acid(2)
441		Formic Acid(2)
442		Formic Acid(3)
443		Formic Acid(3)
444		Formic Acid(3)
445		Formic Acid(3)
446		Formic Acid(3)
447		Formic Acid(3)

Cpd #	Structure	Salt
448		Parent
449		TFA(3)
450		TFA(3)
451		TFA(3)
452		TFA(3)
453		TFA(3)
454		TFA(3)
455		TFA(3)
456		TFA(3)

Cpd #	Structure	Salt
457		TFA(3)
458		Formic Acid(3)
459		Formic Acid(3)
460		Formic Acid(3)
461		Formic Acid(3)
462		Formic Acid(3)
463		Formic Acid(3)
464		Formic Acid(3)
465		Formic Acid(3)

Cpd #	Structure	Salt
466		Formic Acid(3)
467		Formic Acid(3)
468		Formic Acid(3)
469		Formic Acid(3)
470		Formic Acid(3)
471		Formic Acid(3)
472		Formic Acid(3)
473		Formic Acid(3)
474		Formic Acid(3)

Cpd #	Structure	Salt
475		Formic Acid(3)
476		Formic Acid(3)
477		Formic Acid(3)
478		Formic Acid(3)
479		Formic Acid(3)
480		Formic Acid(3)
481		Formic Acid(3)
482		Formic Acid(3)
483		Formic Acid(3)

Cpd #	Structure	Salt
484		Formic Acid(3)
485		Formic Acid(3)
486		Formic Acid(3)
487		Formic Acid(3)
488		Formic Acid(3)
489		Formic Acid(3)
490		Formic Acid(3)
491		Parent

Cpd #	Structure	Salt
492		Formic Acid(3)
493		Formic Acid(3)
494		Formic Acid(3)
495		Formic Acid(3)
496		Parent
497		Formic Acid(3)
498		Formic Acid(3)
499		Formic Acid(3)
500		Formic Acid(3)

Cpd #	Structure	Salt
501		Formic Acid(3)
502		Formic Acid(3)
503		Formic Acid(3)
504		Formic Acid(3)
505		Formic Acid(3)
506		Formic Acid(2)
507		TFA(2)
508		Parent
509		TFA(3)
510		Parent

Cpd #	Structure	Salt
511		Parent
512		Parent
513		Parent
514		Parent
515		Parent
516		Parent
517		Parent
518		Parent
519		Parent

Cpd #	Structure	Salt
520		Parent
521		Parent
522		Parent
523		Parent
524		Parent
525		Parent
526		Parent
527		Parent

Cpd #	Structure	Salt
528		Parent
529		Parent
530		Parent
531		Parent
532		Parent
533		Parent
534		Parent
535		Parent

Cpd #	Structure	Salt
536		Parent
537		Parent
538		Parent
539		Parent
540		Parent
541		Parent
542		Parent
543		Parent

Cpd #	Structure	Salt
544		Parent
545		Parent
546		Parent
547		Parent
548		Parent
549		Parent
550		Parent

Cpd #	Structure	Salt
551		Parent
552		Parent
553		Parent
554		Parent
555		Parent
556		Parent
557		Parent
558		Parent

Cpd #	Structure	Salt
559		Parent
560		Parent
561		Parent
562		Parent
563		Parent
564		Parent
565		Parent
566		Parent

Cpd #	Structure	Salt
567		Parent
568		Parent
569		Parent
570		Parent
571		Parent
572		Parent
573		Parent








Cpd #	Structure	Salt
574		Parent
575		Parent
576		Parent
577		Parent
578		Parent






Cpd #	Structure	Salt
579		Parent
580		Parent
581		Parent
582		Parent
583		Parent

Cpd #	Structure	Salt
584		Parent
585		Parent
586		Parent
587		Parent
588		Parent
589		Parent

Cpd #	Structure	Salt
590		Parent
591		Parent
592		Parent
593		Parent
594		Parent

Cpd #	Structure	Salt
595		Parent
596		Parent
597		Parent
598		Parent
599		Parent
600		Parent
601		Parent
602		Parent

Cpd #	Structure	Salt
603		Parent
604		Parent
605		Parent
606		Parent
607		Parent
608		Parent
609		Parent

Cpd #	Structure	Salt
610		Parent
611		Parent
612		Parent
613		Parent
614		Parent

Cpd #	Structure	Salt
615		Formic Acid(1)
616		Parent
617		Parent
618		Parent
619		Parent
620		Formic Acid(1)
621		Parent

Cpd #	Structure	Salt
622		Parent
623		Parent
624		Parent
625		Parent
626		Parent
627		Parent
628		Parent
629		TFA

Cpd #	Structure	Salt
630		Parent
631		Parent
632		Parent
633		Parent
634		Parent
635		Parent

Cpd #	Structure	Salt
636		Parent
637		Parent
638		Parent
639		Parent
640		Parent
641		Parent

Cpd #	Structure	Salt
642		Parent
643		Parent
644		Parent
645		Formic Acid(1)
646		Formic Acid(1)
647		Formic Acid(1)

Cpd #	Structure	Salt
648		Parent
649		HCl
650		HCl
651		Parent
652		Parent
653		Parent

Cpd #	Structure	Salt
654		Parent
655		Parent
656		Parent
657		Parent
658		Parent
659		Parent
660		Parent

Cpd #	Structure	Salt
661		Parent
662		Parent
663		Parent
664		Parent
665		Parent
666		Parent
667		Parent

Cpd #	Structure	Salt
668		Parent
669		Parent
670		Parent
671		Parent
672		Parent
673		Parent






Cpd #	Structure	Salt
674		Parent
675		Parent
676		Parent
677		Parent
678		Parent






Cpd #	Structure	Salt
679		Parent
680		Parent
681		Parent
682		Parent
683		Parent
684		Parent

Cpd #	Structure	Salt
685		Parent
686		Parent
687		Parent
688		Parent
689		Parent
690		Parent
691		Parent

Cpd #	Structure	Salt
692		Parent
693		Parent
694		Parent
695		Parent
696		Parent
697		Parent
698		Parent
699		Parent

Cpd #	Structure	Salt
700		Parent
701		Parent
702		Parent
703		Parent
704		Parent

Cpd #	Structure	Salt
705		Parent
706		Parent
707		Parent
708		Parent
709		Parent

Cpd #	Structure	Salt
710		Parent
711		Parent
712		Parent
713		Parent
714		Parent

Cpd #	Structure	Salt
715		Parent
716		Parent
717		Parent
718		Parent
719		Parent
720		Parent
721		Parent

Cpd #	Structure	Salt
722		Parent
723		Parent
724		Parent
725		Parent
726		Parent

Cpd #	Structure	Salt
727		Parent
728		Parent
729		Parent
730		Parent
731		Parent
732		Parent

Cpd #	Structure	Salt
733		Parent
734		Parent
735		Parent
736		Parent
737		Parent
738		Parent
739		Parent
740		Parent

Cpd #	Structure	Salt
741		Parent
742		Parent
743		Parent
744		Parent
745		Parent
746		Parent
747		Parent

Cpd #	Structure	Salt
748		Parent
749		Parent
750		Parent
751		Parent
752		Parent
753		Parent
754		Parent

Cpd #	Structure	Salt
755		Parent
756		Parent
757		Parent
758		Parent
759		Parent
760		Parent
761		Parent
762		Parent

Cpd #	Structure	Salt
763		Parent
764		Parent
765		Parent
766		Parent
767		Parent
768		Parent
769		Parent
770		Parent

Cpd #	Structure	Salt
771		Parent
772		Parent
773		Parent
774		Parent
775		Parent
776		Parent
777		Parent
778		Parent







Cpd #	Structure	Salt
779		Parent
780		Parent
781		Parent
782		Parent
783		Parent
784		Parent
785		Parent
786		Parent









Cpd #	Structure	Salt
787		Parent
788		Parent
789		Parent
790		Parent
791		Parent
792		Parent

Cpd #	Structure	Salt
793		Parent
794		Parent
795		Parent
796		Parent
797		Parent
798		Parent
799		Parent
800		Parent

Cpd #	Structure	Salt
801		Parent
802		Parent
803		Parent
804		Parent
805		Parent
806		Parent

Cpd #	Structure	Salt
807		Parent
808		Parent
809		Parent
810		Parent
811		Parent
812		Parent
813		Parent
814		Parent

Cpd #	Structure	Salt
815		Parent
816		Parent
817		Parent
818		Parent
819		Parent
820		Parent

Cpd #	Structure	Salt
821		Parent
822		Parent
823		Parent
824		Parent
825		Parent
826		Parent
827		Parent
828		Parent

Cpd #	Structure	Salt
829		Parent
830		Parent
831		Parent
832		Parent
833		Parent
834		Parent
835		Parent

Cpd #	Structure	Salt
836		Parent
837		Parent
838		Parent
839		Parent
840		Parent
841		Parent
842		Parent
843		Parent

Cpd #	Structure	Salt
844		Parent
845		Parent
846		Parent
847		Parent
848		Parent
849		Parent
850		Parent

Cpd #	Structure	Salt
851		Parent
852		Parent
853		Parent
854		Parent
855		Parent
856		Parent
857		Parent

Cpd #	Structure	Salt
858		Parent
859		Parent
860		Parent
861		Parent
862		Parent
863		Parent
864		Parent

Cpd #	Structure	Salt
865		Parent
866		Parent
867		Parent
868		Parent
869		Parent
870		Parent
871		Parent
872		Parent

Cpd #	Structure	Salt
873		Parent
874		Parent
875		Parent
876		Parent
877		Parent
878		Parent
879		Parent
880		Parent

Cpd #	Structure	Salt
881		Parent
882		Parent
883		Parent
884		Parent
885		Parent
886		Parent
887		Parent
888		Parent

Cpd #	Structure	Salt
889		Parent
890		Parent
891		Parent
892		Parent
893		Parent
894		Parent
895		Parent
896		TFA(3)

Cpd #	Structure	Salt
897		Parent
898		Parent
899		Parent
900		Parent
901		Parent
902		Parent
903		Parent

Cpd #	Structure	Salt
904		Parent
905		Parent
906		Parent
907		Parent
908		Parent

Cpd #	Structure	Salt
909		Parent
910		Parent
911		Parent
912		Parent
913		Parent
914		Parent
915		Parent

Cpd #	Structure	Salt
916		Parent
917		Parent
918		Parent
919		Parent
920		Parent
921		Parent
922		Parent
923		Parent

Cpd #	Structure	Salt
924		Parent
925		Parent
926		Parent
927		Parent
928		Parent
929		Parent
930		Parent
931		Parent

Cpd #	Structure	Salt
932		Parent
933		Parent
934		Parent
935		Parent
936		Parent
937		Parent
938		Parent
939		Parent


Cpd #	Structure	Salt
940		Parent
941		Parent
942		Parent
943		Parent
944		Parent
945		Parent
946		Parent
947		Parent

Cpd #	Structure	Salt
948		Parent
949		Parent
950		Parent
951		Parent
952		Parent
953		Parent
954		Parent
955		Parent

Cpd #	Structure	Salt
956		Parent
957		Parent
958		Parent
959		Parent
960		Parent
961		Parent
962		Parent
963		Parent
964		Parent

Cpd #	Structure	Salt	Cpd #	Structure	Salt
965		Parent	971		Parent
966		Parent	972		Parent
967		Parent	973		Parent
968		Parent	974		Parent
969		Parent	TFA = trifluoroacetate salt (2) = bis(acid) salt (3) = tris(acid) salt Parent = free base compound		
970		Parent			

[0058] In another aspect, the invention comprises compounds of formula (IV) (which are also useful in the methods of the invention):



(IV)

or a pharmaceutically acceptable salt thereof, wherein

Cy¹ is phenyl optionally substituted with 1, 2, 3, or 4 moieties independently selected from halo; C₁₋₃alkyl optionally substituted with 1, 2, or 3 halo, ethynyl, or (trimethylsilyl)ethynyl; -O-C₁₋₃alkyl optionally substituted with 1-3 halo; benzofuranyl; 2,3-dihydrobenzofuranyl; and phenylethenyl; or, when there is a single substituent on

Cy¹, it is one of the foregoing substituents of the phenyl, -O-(C₀₋₃alkyl)R^{IIIe}, or -C(O)N(R^x)₂;

wherein R^{IIIe} is phenyl; heteroaryl (*e.g.*, pyridinyl); or heterocycloalkyl (*e.g.*, oxetane); and each R^x is independently H or C₁₋₃alkyl;

Cy² is pyrazolo[1,5-a]pyrimidinyl; benzo[d]thiazolyl; imidazo[1,2-a]pyridinyl optionally substituted with phenyl-S(O)₂-; [1,2,4]triazolo[1,5-a]pyridinyl; pyridinyl; quinazolinyl; 1H-pyrrolo[2,3-b]pyridinyl; pyrido[3,2-d]pyrimidinyl optionally substituted with amino, methylamino, or methoxy; or pyrido[3,2-d]pyrimidin-4(3H)-one,

wherein the quinazolinyl is optionally substituted with 1 or 2 substituents independently selected from -N(R^{IIIa})₂; R^{IIIc}; C₁₋₃alkyl optionally substituted with 1-3 halo; halo; methoxy; and -N(H)(C₁₋₃alkyl)R^{IV}

each R^{IIIa} is independently H; C₁₋₆alkyl optionally substituted with -C(O)OH, -C(O)O(C₁₋₃alkyl), or -CONH₂; or heteroaryl optionally substituted with C₁₋₃alkyl;


R^{IIIc} is H or C₁₋₃alkyl optionally substituted with 1-3 halo;

R^{IV} is H, C₁₋₃alkyl, -pyrrolidonyl, 4-methylpiperzinyll, -N(C₁₋₂alkyl)(C₁₋₂alkyl), or morpholinyl;

and

R^{IIIc} is H, halo, -OH, C₁₋₃alkyl optionally substituted with 1-3 halo, or -O-C₁₋₃alkyl optionally substituted with 1-3 halo.

[0059] In another aspect, the invention comprises compounds of formula (III) (which are also useful in the methods of the invention):



(III)

or a pharmaceutically acceptable salt thereof, wherein

each R^{IIIa} is independently H, C₁₋₆alkyl optionally substituted with -C(O)OH, -C(O)O(C₁₋₃alkyl), -CONH₂, or heteroaryl (*e.g.*, pyrazolyl) optionally substituted with C₁₋₃alkyl;

x is 0, 1, 2, or 3;


each R^{IIIb} is independently selected from halo, -OH, C₁₋₃alkyl optionally substituted with 1-3 halo, -O-C₁₋₃alkyl optionally substituted with 1-3 halo, or, when x is 1, R^{IIIb} also selected from -O-(C₀₋₃alkyl)R^{IIIe} and -C(O)N(R^x)₂

wherein R^{IIIe} is phenyl, heteroaryl (*e.g.*, pyrrolyl, pyridinyl), or heterocycloalkyl (*e.g.*, oxetane, furan) and each R^x is independently H or C₁₋₃alkyl;

R^{IIIc} is H, halo, -OH, C₁₋₃alkyl optionally substituted with 1-3 halo, or -O-C₁₋₃alkyl optionally substituted with 1-3 halo; and

R^{III d} is H or C₁₋₃alkyl optionally substituted with 1-3 halo.

[0060] In another aspect, the invention comprises compounds of formula (IV) of formula (IIIa) (which are also useful in the methods of the invention):



IIIa

or a pharmaceutically acceptable salt thereof, wherein

each R^{IIIa} is independently H; C₁₋₆alkyl optionally substituted with -C(O)OH, -C(O)O(C₁₋₃alkyl), or -CONH₂; or heteroaryl (*e.g.*, pyrazolyl) optionally substituted with C₁₋₃alkyl;

x is 0, 1, 2, or 3;

each R^{IIIb} is independently selected from halo; -OH; C₁₋₃alkyl optionally substituted with 1-3 halo; or -O-C₁₋₃alkyl optionally substituted with 1-3 halo; or, when x is 1, R^{IIIb} is also selected from -O-(C₀₋₃alkyl)R^{IIIe} and -C(O)N(R^x)₂

wherein R^{IIIe} is phenyl, heteroaryl (*e.g.*, pyrrolyl, pyridinyl), or heterocycloalkyl (*e.g.*, oxetane, furan) and each R^x is independently H or -C₁₋₃alkyl;

R^{IIIc} is H, halo, -OH, C₁₋₃alkyl optionally substituted with 1-3 halo, or -O-C₁₋₃alkyl optionally substituted with 1-3 halo; and

R^{IIIId} is H or C₁₋₃alkyl optionally substituted with 1-3 halo.

[0061] In certain embodiments of the compounds for formulae III and IIIa,

r) both R^{IIIa} are H,

s) R^{IIIId} and R^{IIIc} are each H,

t) x is 1, 2, or 3 and each R^{IIIb} is independently selected from halo, methyl, methoxy, and hydroxy,

u) both R^{IIIa} are H and R^{IIIId} and R^{IIIc} are each H, or

v) both R^{IIIa} are H, R^{IIIId} and R^{IIIc} are each H, and x is 1, 2, or 3 and each R^{IIIb} is independently selected from halo, methyl, methoxy, -difluoromethyl, and hydroxy, or

w) x is 1, 2, or 3 and at least one R^{IIIb} is difluoromethyl.

[0062] In certain embodiments, the compound of formula III and IIIa is one of the compounds in the following table or a pharmaceutically acceptable salt thereof:

#	Structure
975	
976	

#	Structure
977	
978	

#	Structure
979	
980	

#	Structure
981	
982	
983	
984	
985	
986	

#	Structure
987	
988	
989	
990	
991	
992	

#	Structure
993	
994	
995	
996	
997	
998	

#	Structure
999	
1000	
1001	
1002	
1003	
1004	

#	Structure
1005	
1006	
1007	
1008	
1009	
1010	
1011	


#	Structure
1012	
1013	
1014	
1015	
1016	
1017	
1018	

#	Structure
1019	
1020	
1021	
1022	
1023	
1024	
1025	

#	Structure
1026	
1027	
1028	
1029	
1030	
1031	

#	Structure
1032	
1033	
1034	
1035	
1036	

[0063] In another aspect, the invention comprises compounds of formula (IV) of formula (IVa) (which are also useful in the methods of the invention):



(IVa)

or a pharmaceutically acceptable salt thereof, wherein

Cy¹ is phenyl optionally substituted with 1, 2, 3, or 4 moieties independently selected from halo, C₁₋₃alkyl optionally substituted with 1, 2, or 3 halo, ethynyl, and (trimethylsilyl)ethynyl, benzofuranyl, 2,3-dihydrobenzofuranyl, phenylethenyl, and

Cy² is pyrazolo[1,5-a]pyrimidinyl, benzo[d]thiazolyl, imidazo[1,2-a]pyridinyl optionally substituted with phenyl-S(O)₂-, [1,2,4]triazolo[1,5-a]pyridinyl, pyridinyl, quinazolinyl optionally substituted with halo, methoxy, and -N(H)(C₁₋₃alkyl)R^{IV}, 1H-pyrrolo[2,3-b]pyridinyl, pyrido[3,2-d]pyrimidinyl optionally substituted with amino, methylamino, or methoxy, pyrido[3,2-d]pyrimidin-4(3H)-one,

wherein R^{IV} is H, C₁₋₃alkyl, -pyrrolidonyl, 4-methylpiperzinyl,

-N(C₁₋₂alkyl)(C₁₋₂alkyl), morpholinyl.

[0064] In some embodiments of the compounds of formula IVa,

(IV)(i) Cy¹ is phenyl optionally substituted with 1, 2, or 3 moieties independently selected from F, Cl, methyl, and -CF₂H;

(IV)(ii) Cy¹ is phenyl optionally substituted with (trimethylsilyl)ethynyl

(IV)(iii) Cy¹ is phenyl optionally substituted with ethynyl;

(IV)(iv) Cy¹ is benzofuranyl or 2,3-dihydrobenzofuranyl;

(IV)(v) Cy² is quinazolin-6-yl optionally substituted with F, Cl, methoxy, amino, methylamino,

(IV)(vi) Cy² is pyridin-4-yl or benzo[d]thiazol-6-yl.

[0065] In this aspect the invention also comprises one of the following compounds and pharmaceutically acceptable salts thereof.

#	Structure
1037	
1038	
1039	
1040	
1041	
1042	
1043	
1044	
1045	

#	Structure
1046	
1047	
1048	
1049	
1050	
1051	
1052	
1053	

#	Structure
1054	
1055	
1056	
1057	
1058	
1059	
1060	
1061	
1062	

#	Structure
1063	
1064	
1065	
1066	
1067	
1068	
1069	
1070	
1071	


#	Structure
1072	
1073	
1074	
1075	
1076	
1077	
1078	
1079	
1080	

#	Structure
1081	
1082	
1083	
1084	
1085	
1086	
1087	
1088	
1089	

#	Structure	#	Structure	#	Structure
1090		1094		1098	
1091		1095		1099	
1092		1096		1100	
1093		1097			

[0066] In another embodiment, the invention comprises the genera of compounds described by structures (III) and (IV), above, except that compounds 1-974 otherwise falling within the scope of these genera are expressly excluded.

[0067] In another embodiment, the disclosure provides a compound of formula,













or a pharmaceutically acceptable salt thereof, wherein

X is CH and each R^Z is independently -OH, -C₁₋₃alkyl optionally substituted with one or more halo, or C₁₋₃alkoxy optionally substituted with one or more halo, or

X is N and each R^Z is independently halo, -OH, -C₁₋₃alkyl optionally substituted with one or more halo, or C₁₋₃alkoxy optionally substituted with one or more halo, and

a is 1, 2, or 3,

provided the compound is not one of the following compounds:

			
411	451	452	456
			
462	478	480	484
	or		
495		964	

[0068] Compounds of formula IV in which Cy¹ is halo are useful intermediates for making the compounds of formula IV.

[0069] In another aspect, the invention comprises combination therapies for the treatment of cancer, including both pre-malignant and malignant neoplasms. In this aspect, the invention comprises a method of treating cancer comprising administering to a subject a compound disclosed herein in conjunction with a therapeutic treatment of cancer. In some embodiments of the invention, the compounds disclosed herein are used in combination of standard of care anti-proliferative treatments of cancer. The amount of a compound disclosed herein for use in the combination therapy is an amount sufficient to inhibit signaling by members of the TGF- β superfamily, such as Nodal and Activin, which promote the survival and/or differentiation of cancer stem cells and thereby enhance the efficacy of the therapeutic treatment. Treatment with the present compounds thus blocks the ability of cancer stem cells to recapitulate a tumor destroyed by treatment with standard of care. Efficacy of treatment can be determined by any art recognized method generally employed for the particular cancer being treated and includes, for example, retardation, inhibition, or regression of tumor growth.

[0070] Reference to “combination therapy” and treatment with a compound disclosed herein “in conjunction with” another therapeutic treatment means that the compound and other

therapeutic treatment can be administered simultaneously or sequentially such that the resultant treatment is more efficacious than either treatment alone.

[0071] One embodiment of treating cancer in a subject comprises administering to a subject in need thereof an amount described above of a compound disclosed herein in combination with the administration of a therapeutically effective amount of one or more chemotherapeutic agents, wherein the one or more chemotherapeutic agents is selected from the group consisting of antimetabolites, alkylating agents, coordination compounds, platinum complexes, DNA cross-linking compounds, inhibitors of transcription enzymes, tyrosine kinase inhibitors, protein kinase inhibitors, topoisomerase inhibitors, DNA minor-groove binding compounds, vinca alkaloids, taxanes, antitumor antibiotics, hormones, aromatase inhibitors, enzymes, growth factor receptors antibodies, cytokines, cell surface markers antibodies, HDAC inhibitors, HSP 90 inhibitors, BCL-2 inhibitors, B-raf inhibitors, MEK inhibitors, mTOR inhibitors, proteasome inhibitors and monoclonal antibodies.

[0072] Among the BCL-2 inhibitors useful in the invention is ABT-199.

[0073] Another embodiment of methods for treating a subject comprises administering to the subject an amount (as described above) of a compound disclosed herein in combination with the administration of a therapeutically effective amount of one or more chemotherapeutic agents, the one or more chemotherapeutic agents being independently selected from the group consisting of mechlorothamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, ethyleneimines, methylmelamines, procarbazine, dacarbazine, temozolomide, busulfan, carmustine, lomustine, methotrexate, fluorouracil, capecitabine, cytarabine, gemcitabine, cytosine arabinoside, mecaptopurine, fludarabine, cladribine, thioguanine, azathioprine, vinblastine, vincristine, paclitaxel, docetaxel, colchicine, actinomycin D, daunorubicin, bleomycin, L-asparaginase, cisplatin, carboplatin, oxaliplatin, prednisone, dexamethasone, amino glutethimide, formestane, anastrozole, hydroxyprogesterone caproate, medroxyprogesterone, tamoxifen, amsacrine, mitoxantrone, topotecan, irinotecan, camptothecin, afatinib, axitinib, bosutinib, bortezomib, carfilzomib, cabozantinib, cediranib, crizotinib, dasatinib, dabrafenib, evorolimus, ibrutinib, LDK378, LGX818, MEK162, regorafenib, ruxolitinib, selumetinib, sorafenib, trametinib, vemurafenib, erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, nilotinib, palbociclib, pazopanib, pomatinib, semaxanib, sirolimus, sunitinib, temsirolimus, vatalanib, vandetanib, anti Her2 antibodies, interferon- α , interferon- γ , interleukin 2, GM-CSF, anti CTLA 4 antibodies,

rituximab, anti CD33 antibodies, MGCD0103, vorinostat, 17-AAG, thalidomide, lenalidomide, rapamycin, CCI-779, doxorubicine, gemcitabine, melphalan, NPI052, gemtuzumab, alemtuzumab, cetuximab, ibritumomab tiuxetan, tositumomab, iodine-131 tositumomab, trastuzumab, ado-trastuzumab emtansine, obinutuzumab, bevacizumab, rituximab, and anti-TRAIL death receptor antibodies.

[0074] Among the CTLA 4 antibodies that can be used in the present invention is ipilimumab, marketed as YERVOY® by Bristol-Myers Squibb.

[0075] Other chemotherapeutic agents include checkpoint pathway inhibitors, *e.g.*, PD-1 inhibitors, such as nivolumab and lambrolizumab, and PD-L1 inhibitors, such as pembrolizumab, MEDI-4736 and MPDL3280A/RG7446. Additional checkpoint inhibitors for combination with the compounds disclosed herein include, Anti-LAG-3 agents, such as BMS-986016 (MDX-1408).

[0076] Further chemotherapeutic agents for combination with the presently disclosed TGF- β signalling inhibitors include Anti-SLAMF7 agents, such as the humanized monoclonal antibody elotuzumab (BMS-901608), anti-KIR agents, such as the anti-KIR monoclonal antibody lirilumab (BMS-986015), and anti-CD137 agents, such as the fully human monoclonal antibody urelumab (BMS-663513).

[0077] The following table displays exemplary cancers treatable in the combination therapies of the invention and the therapeutic drug and/or other treatment for use with the compounds disclosed herein:

Cancer	Drug or Treatment
Glioma	lomustine, temozolide and/or radiation
hepatocellular carcinoma	Sorafenib and/or regorafenib
myelodysplastic syndromes	decitabine and/or azacytidine
pancreatic cancer	Gemcitabine
ovarian cancer, such as epithelial ovarian carcinoma	carboplatin, cisplatin, doxorubicin, gemcitabine, and/or paclitaxel
breast cancer	Trastuzumab
basal and squamous skin carcinomas	5-fluorouracil, imiquimod, and/or photodynamic therapy (<i>e.g.</i> with 5-aminolevulinic acid),
head and neck carcinoma	bleomycin, cisplatin, cetuximab, docetaxel,

Cancer	Drug or Treatment
	fluorouracil, and/or methotrexate
triple negative breast cancer	Paclitaxel
Prostate	abiraterone and/or enzalutamide

[0078] In another aspect, the invention comprises a method of determining and measuring the ability of the compounds disclosed herein to inhibit signaling by members of the TGF- β superfamily, such as Nodal and Activin, in order to identify cancers and, more specifically, tumors. In one embodiment, neoplasms susceptible to such combination therapy can be identified by testing for Nodal and Activin signaling activity using techniques known to those skilled in the art, including, for example, assays described in Lonardo, E. et al. (2011) Cell Stem Cell 9, 433-446 (which is hereby incorporated by reference in its entirety). Optionally in this embodiment, where the tested compound is found to inhibit signalling of a member of the TGF- β superfamily, such as Nodal and Activin, in the tested neoplasm, the compound is subsequently used in a combination therapy for treatment of the neoplasm, as described herein.

General Synthetic Methodologies

[0079] Many general references providing commonly known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds are available (see, e.g., Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001; or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978).


[0080] Compounds as described herein can be purified by any of the means known in the art, including chromatographic means, such as HPLC, preparative thin layer chromatography, flash column chromatography and ion exchange chromatography. Any suitable stationary phase can be used, including normal and reversed phases as well as ionic resins. Most typically the disclosed compounds are purified via silica gel and/or alumina chromatography. See, e.g., Introduction to Modern Liquid Chromatography, 2nd Edition, ed. L. R. Snyder and J. J. Kirkland, John Wiley and Sons, 1979; and Thin Layer Chromatography, ed E. Stahl, Springer-Verlag, New York, 1969.

[0081] During any of the processes for preparation of the subject compounds, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules


concerned. This may be achieved by means of conventional protecting groups as described in standard works, such as J. F. W. McOmie, "Protective Groups in Organic Chemistry," Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," Third edition, Wiley, New York 1999, in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in "Methoden der organischen Chemie," Houben-Weyl, 4th edition, Vol. 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, "Aminosäuren, Peptide, Proteine," Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and/or in Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide and Derivate," Georg Thieme Verlag, Stuttgart 1974. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

[0082] The compounds disclosed herein can be made using procedures familiar to the person of ordinary skill in the art and as described herein. For example, compounds of structural formula (I) can be prepared according to Schemes 1-49, or analogous synthetic schemes.


[0083] As is known to those of skill in the art of organic synthesis, esters and amides can be formed from the corresponding acids, alcohols and amines by conventional techniques. By way of example, organic acids can be converted to the corresponding acid chloride by reaction with oxalyl chloride. Acid chlorides can then be reacted with alcohols or amines to form the desired ester or amide, as shown in Schemes 1-4. Alternatively, activating reagents like HATU, TBTU or HBTU can be used in to condense an amine can be condensed with an organic acid to form the corresponding amide, as shown in Scheme 5.




Scheme 8



Scheme 9




Scheme 10




[0087] Pyrimidinyl compounds can be made via the reaction sequence shown in Scheme 11.

Scheme 11




[0088] Various additional compounds of the disclosure can be made using the reactions shown in Schemes 12-27.


Scheme 12




Scheme 13




Scheme 14




Scheme 15




Scheme 16




Scheme 17




Scheme 18




Scheme 19




Scheme 20




Scheme 21




Scheme 22




Scheme 23




Scheme 24




Scheme 25



Scheme 26




Scheme 27



[0089] The conditions for boronate cross-coupling to form Compound 448 were ineffective when the corresponding bromopyrido[3,2-d]pyrimidine was used. Scheme 28 provides an alternative route to the pyrido[3,2-d]pyrimidine products.

Scheme 28



[0090] One of skill in the art can adapt the reaction sequences of Schemes 1-28 to fit the desired target molecule. Of course, in certain situations one of skill in the art will use different reagents to affect one or more of the individual steps or to use protected versions of certain of the substituents. Additionally, one skilled in the art would recognize that the compounds described herein can be synthesized using different routes altogether.

2-Chloro-3-(hetero)arylpiperidine compounds

[0091] In another aspect, the present disclosure includes novel intermediates useful to prepare the present kinase inhibitors as well as other pharmaceutically effective compounds as is readily apparent to those of skill in the art of medicinal chemistry. For example, the 2-chloro-3-(hetero)arylpiperidine compounds described herein are suitable for cross coupling, by for example, palladium mediated chemistry, such as a Suzuki reaction, to form the kinase inhibitors disclosed herein as well as other novel biologically active compounds. 2-Chloro-3-(hetero)arylpiperidine compounds according to this aspect of the disclosure are described throughout the present specification.

Methods of Treating Disease

[0092] The compounds of the present disclosure are useful to prevent, diagnose, and treat various medical disorders in humans or animals. The compounds are used to inhibit or reduce one or more activities associated with the GDF protein, relative to a GDF protein not bound by

the same compounds. Optionally, the compounds inhibit or reduce one or more of the activities of mature GDF-8 (regardless of whether in monomeric form, active dimeric form, or complexed in a GDF-8 latent complex) relative to a mature GDF-8 protein that is not bound by the same compounds. In an embodiment, the activity of the mature GDF-8 protein, when bound by one or more of the presently disclosed compounds, is inhibited at least 50%, optionally at least 60, 62, 64, 66, 68, 70, 72, 72, 76, 78, 80, 82, 84, 86, or 88%, optionally at least 90, 91, 92, 93, or 94%, and optionally at least 95% to 100% relative to a mature GDF-8 protein that is not bound by one or more of the presently disclosed compounds.

[0093] The medical disorder being diagnosed, treated, or prevented by the presently disclosed compounds is optionally a muscle and neuromuscular disorder; an adipose tissue disorder such as obesity; type 2 diabetes, impaired glucose tolerance, metabolic syndromes (*e.g.*, syndrome X), insulin resistance induced by trauma such as burns; or bone degenerative disease such as osteoporosis. The medical condition is optionally a muscle or neuromuscular disorder, such as muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia and disorders associated with a loss of bone, which include osteoporosis, especially in the elderly and/or postmenopausal women, glucocorticoid-induced osteoporosis, osteopenia, and osteoporosis-related fractures. Other target metabolic bone diseases and disorders amendable to treatment with GDF-8 inhibitors of the disclosure include low bone mass due to chronic glucocorticoid therapy, premature gonadal failure, androgen suppression, vitamin D deficiency, secondary hyperparathyroidism, nutritional deficiencies, and anorexia nervosa. The antibodies are optionally used to prevent, diagnose, or treat such medical disorders in mammals, optionally in humans.

[0094] The compounds or compositions of the present disclosure are administered in therapeutically effective amounts. As used herein, an “effective amount” of the antibody is a dosage which is sufficient to reduce the activity of GDF proteins to achieve a desired biological outcome (*e.g.*, increasing muscle mass or strength). Generally, a therapeutically effective amount may vary with the subject's age, condition, and sex, as well as the severity of the medical condition in the subject. The dosage may be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. Generally, the compositions are administered so that compounds are given at a dose between 1 $\mu\text{g}/\text{kg}$ and 20 mg/kg . Optionally, the

compounds are given as a bolus dose, to maximize the circulating levels of compounds for the greatest length of time after the dose. Continuous infusion may also be used after the bolus dose.

[0095] The methods of treating, diagnosing, or preventing the above medical conditions with the presently disclosed compounds can also be used on other proteins in the TGF- β superfamily. Many of these proteins, *e.g.*, BMP-11, are related in structure to GDF-8. Accordingly, in another embodiment, the disclosure comprises methods of treating the aforementioned disorders by administering to a subject a compound capable of inhibiting BMP-11 or Activin, either alone or in combination with other TGF- β inhibitors, such as a neutralizing antibody against GDF-8.

[0096] Accordingly, in one aspect, the disclosure provides methods for inhibiting GDF-8 in a cell comprising contacting the cell with an effective amount of a compound or pharmaceutically acceptable salt of formula (I) or (II) or any embodiment thereof, or a pharmaceutical composition comprising the same. In another aspect, the disclosure comprises methods for treating a patient suffering from a disease or disorder, wherein the patient would therapeutically benefit from an increase in mass or strength of muscle tissue, comprising administering to a patient a therapeutically effective amount of a compound or pharmaceutically acceptable salt of formula (I) or (II) or any embodiment thereof, or a pharmaceutical composition comprising the same. The disease or disorder can be a muscular disorder, adipose tissue disorder, neuromuscular disorders, metabolic disorder, diabetes, or bone degenerative disorder. In certain embodiments, the disease or disorder is a muscular disorder, such as, but not limited to, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia. In certain other embodiments, the disease or disorder is muscular dystrophy. In other embodiments, the disease or disorder is obesity, type 2 diabetes, impaired glucose tolerance, syndrome X, insulin resistance induced by trauma, or osteoporosis. In particular embodiments, the disease or disorder is osteoporosis.

[0097] In yet other embodiments, the disease or disorder is low bone mass due to chronic glucocorticoid therapy, premature gonadal failure, androgen suppression, vitamin D deficiency, secondary hyperparathyroidism, nutritional deficiencies, and anorexia nervosa.

[0098] In another aspect, the disclosure comprises methods for increasing muscle mass in a mammal comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of formula (I) or (II) or any embodiment thereof, or a pharmaceutical composition comprising the same. In another aspect, the disclosure comprises

methods for increasing muscle strength in a mammal comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of formula (I) or (II) or any embodiment thereof, or a pharmaceutical composition comprising the same. In another aspect, the disclosure comprises methods for increasing trabecular bone density in a patient in need thereof, comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of formula (I) or (II) or any embodiment thereof, or a pharmaceutical composition comprising the same. In any of the preceding methods and embodiments, thereof, the subject can be a mammal. As used herein, the terms “individual” or “patient” or “subject” are used interchangeably, and refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.

[0099] *Pharmaceutical Formulations and Dosage Forms*

[0100] The pharmaceutical compositions described herein generally comprise a combination of a compound described herein and a pharmaceutically acceptable carrier, diluent, or excipient. Such compositions are substantially free of non-pharmaceutically acceptable components, *i.e.*, contain amounts of non-pharmaceutically acceptable components lower than permitted by US regulatory requirements at the time of filing this application. In some embodiments of this aspect, if the compound is dissolved or suspended in water, the composition further optionally comprises an additional pharmaceutically acceptable carrier, diluent, or excipient. In other embodiments, the pharmaceutical compositions described herein are solid pharmaceutical compositions (*e.g.*, tablet, capsules, *etc.*).

[0101] These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (*e.g.*, by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, *e.g.*,

intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

[0102] Also, pharmaceutical compositions can contain, as the active ingredient, one or more of the compounds described herein above in combination with one or more pharmaceutically acceptable carriers. In making the compositions described herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

[0103] In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, *e.g.* about 40 mesh.

[0104] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

[0105] The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

[0106] The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[0107] For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound described herein. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of a compound described herein.

[0108] The tablets or pills can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

[0109] The liquid forms in which the compounds and compositions can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous

or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

[0110] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described *supra*. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.

[0111] The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.

[0112] The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

[0113] The therapeutic dosage of the compounds can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound described herein in a pharmaceutical composition can

vary depending upon a number of factors including dosage, chemical characteristics (*e.g.*, hydrophobicity), and the route of administration. For example, the compounds described herein can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 µg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

[0114] The compounds described herein can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like.

Definitions

[0115] As is understood by those of skill in the art, compounds of the formulae presented herein, such as but not limited to formula I above, may have asymmetric centers and accordingly include stereoisomeric forms (*e.g.*, enantiomers, diastereomers, etc.) of compounds. And in addition compounds of the formulae presented herein encompass pharmaceutically acceptable salts, solvates, for example hydrates, and the like having such formulae. Likewise, the term “compound” as used herein is understood to include pharmaceutically acceptable salts, solvates, hydrates and the like of such compounds.

[0116] Terms used herein may be preceded and/or followed by a single dash, “-,” or a double dash, “=,” to indicate the bond order of the bond between the named substituent and its parent moiety; a single dash indicates a single bond and a double dash indicates a double bond or a pair of single bonds in the case of a spiro-substituent. In the absence of a single or double dash it is understood that a single bond is formed between the substituent and its parent moiety; further, substituents are intended to be read “left to right” unless a dash indicates otherwise. For example, C₁-C₆alkoxycarbonyloxy and -OC(O)C₁-C₆alkyl indicate the same functionality; similarly arylalkyl, arylalkyl-, and -alkylaryl indicate the same functionality.

[0117] Further, certain terms herein may be used as both monovalent and divalent linking radicals as would be familiar to those skilled in the art, and by their presentation linking between two other moieties. For example, an alkyl group can be both a monovalent radical or divalent radical; in the latter case, it would be apparent to one skilled in the art that an additional hydrogen atom is removed from a monovalent alkyl radical to provide a suitable divalent moiety.

[0118] The term “alkenyl” as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons, unless otherwise specified, and containing at least one carbon-carbon double bond. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, 3-decenyl, and 3,7-dimethylocta-2,6-dienyl.

[0119] The term “alkoxy” as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.

[0120] The term “alkyl” as used herein, means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms, unless otherwise specified. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. When an “alkyl” group is a linking group between two other moieties, then it may also be a straight or branched chain; examples include, but are not limited to -CH₂-, -CH₂CH₂-, -CH₂CH₂CHC(CH₃)-, -CH₂CH(CH₂CH₃)CH₂-.

[0121] The term “aryl,” as used herein, means a phenyl (*i.e.*, monocyclic aryl), or a bicyclic ring system containing at least one phenyl ring or an aromatic bicyclic ring containing only carbon atoms in the aromatic bicyclic ring system. The bicyclic aryl can be azulenyl, naphthyl, or a phenyl fused to a monocyclic cycloalkyl, a monocyclic cycloalkenyl, or a monocyclic heterocyclyl. The bicyclic aryl is attached to the parent molecular moiety through any carbon atom contained within the phenyl portion of the bicyclic system, or any carbon atom with the naphthyl or azulenyl ring. The fused monocyclic cycloalkyl or monocyclic heterocyclyl portions of the bicyclic aryl are optionally substituted with one or two oxo and/or thia groups. Representative examples of the bicyclic aryls include, but are not limited to, azulenyl, naphthyl, dihydroinden-1-yl, dihydroinden-2-yl, dihydroinden-3-yl, dihydroinden-4-yl,

2,3-dihydroindol-4-yl, 2,3-dihydroindol-5-yl, 2,3-dihydroindol-6-yl, 2,3-dihydroindol-7-yl, inden-1-yl, inden-2-yl, inden-3-yl, inden-4-yl, dihydronaphthalen-2-yl, dihydronaphthalen-3-yl, dihydronaphthalen-4-yl, dihydronaphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-2-yl, 2,3-dihydrobenzofuran-4-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, 2,3-dihydrobenzofuran-7-yl, benzo[d][1,3]dioxol-4-yl, benzo[d][1,3]dioxol-5-yl, 2H-chromen-2-on-5-yl, 2H-chromen-2-on-6-yl, 2H-chromen-2-on-7-yl, 2H-chromen-2-on-8-yl, isoindoline-1,3-dion-4-yl, isoindoline-1,3-dion-5-yl, inden-1-on-4-yl, inden-1-on-5-yl, inden-1-on-6-yl, inden-1-on-7-yl, 2,3-dihydrobenzo[b][1,4]dioxan-5-yl, 2,3-dihydrobenzo[b][1,4]dioxan-6-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-5-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-6-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-7-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-8-yl, benzo[d]oxazin-2(3H)-on-5-yl, benzo[d]oxazin-2(3H)-on-6-yl, benzo[d]oxazin-2(3H)-on-7-yl, benzo[d]oxazin-2(3H)-on-8-yl, quinazolin-4(3H)-on-5-yl, quinazolin-4(3H)-on-6-yl, quinazolin-4(3H)-on-7-yl, quinazolin-4(3H)-on-8-yl, quinoxalin-2(1H)-on-5-yl, quinoxalin-2(1H)-on-6-yl, quinoxalin-2(1H)-on-7-yl, quinoxalin-2(1H)-on-8-yl, benzo[d]thiazol-2(3H)-on-4-yl, benzo[d]thiazol-2(3H)-on-5-yl, benzo[d]thiazol-2(3H)-on-6-yl, and, benzo[d]thiazol-2(3H)-on-7-yl. In certain embodiments, the bicyclic aryl is (i) naphthyl or (ii) a phenyl ring fused to either a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, or a 5 or 6 membered monocyclic heterocyclyl, wherein the fused cycloalkyl, cycloalkenyl, and heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia.

[0122] The term “arylalkyl,” “-alkylaryl,” and “arylalkyl-” as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.

[0123] The terms “cyano” and “nitrile” as used herein, mean a -CN group.

[0124] The term “cycloalkyl” as used herein, means a monocyclic or a bicyclic cycloalkyl ring system. Monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturated or unsaturated, but not aromatic. In certain embodiments, cycloalkyl groups are fully saturated. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and

cyclooctyl. Bicyclic cycloalkyl ring systems are bridged monocyclic rings or fused bicyclic rings. Bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (*i.e.*, a bridging group of the form $-(\text{CH}_2)_w-$, where w is 1, 2, or 3). Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Fused bicyclic cycloalkyl ring systems contain a monocyclic cycloalkyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The bridged or fused bicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkyl ring. Cycloalkyl groups are optionally substituted with one or two groups which are independently oxo or thia. In certain embodiments, the fused bicyclic cycloalkyl is a 5 or 6 membered monocyclic cycloalkyl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted by one or two groups which are independently oxo or thia.

[0125] “Cycloalkenyl” as used herein refers to a monocyclic or a bicyclic cycloalkenyl ring system. Monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups are unsaturated (*i.e.*, containing at least one annular carbon-carbon double bond), but not aromatic. Examples of monocyclic ring systems include cyclopentenyl and cyclohexenyl. Bicyclic cycloalkenyl rings are bridged monocyclic rings or a fused bicyclic rings. Bridged monocyclic rings contain a monocyclic cycloalkenyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (*i.e.*, a bridging group of the form $-(\text{CH}_2)_w-$, where w is 1, 2, or 3). Representative examples of bicyclic cycloalkenyls include, but are not limited to, norbornenyl and bicyclo[2.2.2]oct-2-enyl. Fused bicyclic cycloalkenyl ring systems contain a monocyclic cycloalkenyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The bridged or fused bicyclic cycloalkenyl is attached to the parent molecular moiety through any carbon atom contained

within the monocyclic cycloalkenyl ring. Cycloalkenyl groups are optionally substituted with one or two groups which are independently oxo or thia.

[0126] The term “halo” or “halogen” as used herein, means -Cl, -Br, -I or -F.

[0127] The term “haloalkyl” as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. In certain examples, a haloalkyl can comprise one to five halogen atoms, or one to three halogen atoms. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.

[0128] The term “heteroaryl,” as used herein, means a monocyclic heteroaryl or a bicyclic ring system containing at least one heteroaromatic ring wherein the heteroatom(s) are selected from O, N, and S. The monocyclic heteroaryl can be a 5 or 6 membered ring. The 5 membered ring consists of two double bonds and one, two, three or four nitrogen atoms and optionally one oxygen or sulfur atom. The 6 membered ring consists of three double bonds and one, two, three or four nitrogen atoms. The 5 or 6 membered heteroaryl is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heteroaryl. Representative examples of monocyclic heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and triazinyl. The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The fused cycloalkyl or heterocyclyl portion of the bicyclic heteroaryl group is optionally substituted with one or two groups which are independently oxo or thia. When the bicyclic heteroaryl contains a fused cycloalkyl, cycloalkenyl, or heterocyclyl ring, then the bicyclic heteroaryl group is connected to the parent molecular moiety through any carbon or nitrogen atom contained within the monocyclic heteroaryl portion of the bicyclic ring system. When the bicyclic heteroaryl is a monocyclic heteroaryl fused to a phenyl ring or a monocyclic heteroaryl, then the bicyclic heteroaryl group is connected to the parent molecular moiety through any carbon atom or nitrogen atom within the bicyclic ring system. Representative examples of bicyclic heteroaryl include, but are not limited to, benzimidazolyl, benzofuranyl, benzothienyl, benzoxadiazolyl, benzoxathiadiazolyl, benzothiazolyl, cinnolinyl, 5,6-dihydroquinolin-2-yl, 5,6-dihydroisoquinolin-1-yl, furopyridinyl, indazolyl, indolyl, isoquinolinyl, naphthyridinyl,

quinolinyl, purinyl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6,7,8-tetrahydroquinolin-3-yl, 5,6,7,8-tetrahydroquinolin-4-yl, 5,6,7,8-tetrahydroisoquinolin-1-yl, thienopyridinyl, 4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazolyl, and 6,7-dihydrobenzo[c][1,2,5]oxadiazol-4(5H)-onyl. In certain embodiments, the fused bicyclic heteroaryl is a 5 or 6 membered monocyclic heteroaryl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused cycloalkyl, cycloalkenyl, and heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia.

[0129] The term “heteroarylalkyl” and “-alkylheteroaryl” as used herein, means a heteroaryl, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Such groups are indicated herein subgenerically for example by “heteroaryl(C₁₋₆alkyl) to indicate a heteroaryl moiety linked to the parent molecule through a C₁₋₆alkyl group, such as a methylene, ethylene, propylene moiety or the like. Representative examples of heteroarylalkyl include, but are not limited to, fur-3-ylmethyl, 1H-imidazol-2-ylmethyl, 1H-imidazol-4-ylmethyl, 1-(pyridin-4-yl)ethyl, pyridin-3-ylmethyl, pyridin-4-ylmethyl, pyrimidin-5-ylmethyl, 2-(pyrimidin-2-yl)propyl, thien-2-ylmethyl, and thien-3-ylmethyl.

[0130] The term “heterocyclyl” as used herein, means a monocyclic heterocycle or a bicyclic heterocycle. The monocyclic heterocycle is a 3, 4, 5, 6 or 7 membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S where the ring is saturated or unsaturated, but not aromatic. The 3 or 4 membered ring contains 1 heteroatom selected from the group consisting of O, N and S. The 5 membered ring can contain zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The 6 or 7 membered ring contains zero, one or two double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S. The monocyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle. Representative examples of monocyclic heterocycle include, but are not limited to, azetidiny, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazoliny, imidazolidiny, isothiazoliny, isothiazolidiny, isoxazoliny, isoxazolidiny, morpholiny, oxadiazoliny, oxadiazolidiny, oxazoliny, oxazolidiny, piperaziny, piperidinyl, pyranyl, pyrazoliny,

pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidithiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. The bicyclic heterocycle is a monocyclic heterocycle fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocycle, or a monocyclic heteroaryl. The bicyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle portion of the bicyclic ring system. Representative examples of bicyclic heterocyclyls include, but are not limited to, 2,3-dihydrobenzofuran-2-yl, 2,3-dihydrobenzofuran-3-yl, indolin-1-yl, indolin-2-yl, indolin-3-yl, 2,3-dihydrobenzothien-2-yl, decahydroquinolinyl, decahydroisoquinolinyl, octahydro-1H-indolyl, and octahydrobenzofuranyl. Heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia. In certain embodiments, the bicyclic heterocyclyl is a 5 or 6 membered monocyclic heterocyclyl ring fused to phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the bicyclic heterocyclyl is optionally substituted by one or two groups which are independently oxo or thia.

[0131] The term “hydroxy” as used herein, means an -OH group.

[0132] The term “nitro” as used herein, means a -NO₂ group.

[0133] The term “oxo” as used herein means a =O group.

[0134] The term “saturated” as used herein means the referenced chemical structure does not contain any multiple carbon-carbon bonds. For example, a saturated cycloalkyl group as defined herein includes cyclohexyl, cyclopropyl, and the like.

[0135] The term “thia” as used herein means a =S group.

[0136] The term “unsaturated” as used herein means the referenced chemical structure contains at least one multiple carbon-carbon bond, but is not aromatic. For example, a unsaturated cycloalkyl group as defined herein includes cyclohexenyl, cyclopentenyl, cyclohexadienyl, and the like.

[0137] As used herein, the term “cell” is meant to refer to a cell that is *in vitro*, *ex vivo* or *in vivo*. In some embodiments, an *ex vivo* cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an *in vitro* cell can be a cell in a cell culture. In some embodiments, an *in vivo* cell is a cell living in an organism such as a mammal.

[0138] As used herein, the term “contacting” refers to the bringing together of indicated moieties in an *in vitro* system or an *in vivo* system. For example, “contacting” a kinase with a compound includes the administration of a compound described herein to an individual or patient, such as a human, having the kinase (such as Alk4 or Alk5), as well as, for example, introducing a compound into a sample containing a cellular or purified preparation containing the kinase.

[0139] As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.

[0140] In certain embodiments, a therapeutically effective amount can be an amount suitable for (1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; (2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder; or (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (*i.e.*, reversing the pathology and/or symptomatology) such as decreasing the severity of disease.

[0141] As used here, the terms “treatment” and “treating” means (i) ameliorating the referenced disease state, for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (*i.e.*, reversing or improving the pathology and/or symptomatology) such as decreasing the severity of disease; (ii) eliciting the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician; or (iii) inhibiting the referenced disease state; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder.

[0142] As used herein, the phrase “pharmaceutically acceptable salt” refers to both pharmaceutically acceptable acid and base addition salts and solvates. Such pharmaceutically acceptable salts include salts of inorganic and organic acids. Examples of inorganic salts include,

without limitation, those formed from hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic and hydroiodic acids. Examples of organic acids suitable for the formation of pharmaceutically acceptable salts of the presently disclosed compounds include acetic, formic, fumaric, glutaric, glycolic, trifluoroacetic, benzenesulfonic, ethanesulfonic, toluenesulfonic, methanesulfonic, nitric, benzoic, camphor sulfonic, citric, cinnamic, oxalic, tartaric, maleic, malonic, mandelic, pantoic, propionic, pyruvic and xinafoic acids, and the like. Non-toxic pharmaceutical base addition salts include salts formed from bases with inorganic and organic counterions. By way of example suitable inorganic counterions include sodium, potassium, calcium, ammonium, sulfate and the like. Pharmaceutically acceptable organic bases for the formation of base addition salts include, without limitation, arginine, choline, ethylenediamine, histidine, lysine, methylglucamine, piperazine, triethanolamine and tris(hydroxymethyl)aminomethane (tris). Those skilled in the art will recognize a wide variety of non-toxic pharmaceutically acceptable addition salts. For additional pharmaceutically acceptable salts, see, M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;66:1-19 which is incorporated herein by reference.

EXAMPLES


[0143] The following abbreviations and/or acronyms are used within the examples:

Ph	Phenyl
aq.	Aqueous
MW	microwave
LC/MS or LCMS	Liquid chromatograph, mass spectrometry
TFA	Trifluoroacetic acid
EtOAc	Ethyl acetate
MeOH	Methanol
DMSO	Dimethylsulfoxide
Et	Ethyl
TLC	Thin layer chromatography
THF	Tetrahydrofuran
rt	Room temperature
DMF	N,N-dimethylformamide

dppf	1,1'-Bis(diphenylphosphino)- ferrocene
HPLC	High-performance liquid chromatography
DMA	N,N-dimethylacetamide
EtOH	Ethanol
dba	dibenzylideneacetone
Me	Methyl
Ac ₂ O	Acetic anhydride
OAc	acetate
HBTU	O-Benzotriazole-N,N,N',N'- tetramethyl-uronium- hexafluoro-phosphate
t-BuOMe	Tert-butyl methyl ether

AcOH	Acetic acid
DMAP	4-dimethylaminopyridine


iPr ₂ NEt	di(isopropyl)ethylamine
NBS	N-bromosuccinimide

Example 1 General Synthetic Scheme A**Example 2** General LC/MS Methods

[0144] LC/MS: room temperature (A or B)

[0145] Method A: Column: Luna 5 μ C8 (100 X 4.6 mm), Flow rate 1.0 ml/min, Mobile phase: A: H₂O 0.05% TFA, B: CH₃CN 0.05% TFA

[0146] Method B: Column: Gemini 5 μ C18 (100 X 4.6 mm), Flow rate 1.5 ml/min, Mobile phase: A: H₂O 0.05% HCOOH, B: CH₃CN 0.05% HCOOH


Example 3 5-(2-Chloropyridin-3-yl)-1H-indazole

[0147] A single necked round bottom flask equipped with a magnetic stir bar was charged with 1-Boc-indazole-5-boronic acid pinacol ester (3.0 g, 8.7 mmol), 3-bromo-2-chloropyridine (2.0 g, 10.4 mmol), Pd(PPh₃)₄ (1 g, 0.86 mmol) and 2M aq. Na₂CO₃ (10 mL, 20 mmol) and 1,4-dioxane under nitrogen atmosphere. The reaction flask was fitted with a reflux condenser containing three-way stopcock equipped with argon filled balloon. The reaction contents were stirred and air was removed from the closed reaction system by vacuum and back filled with argon. Following three cycles of degassing, the reaction mixture was heated at 100 °C (oil-bath) under argon. Initial clear heterogeneous reaction mixture turned to clear biphasic off-yellow solution. After 12 h with no additional change in the proportion of the product, as analyzed by

LC/MS, the reaction mixture was cooled to room temperature. Upon concentration of the reaction mixture, EtOAc/water (200 mL / 100 mL) was transferred to the concentrate and stirred for 30 min. The organic layer was separated and the aqueous layer extracted with EtOAc (2 X 75 mL).

[0148] MgSO₄ and Celite[®] were added to combined organic layers, stirred for 20 min and the contents suction filtered. The filter cake was washed with EtOAc (100 mL) and the combined filtrates concentrated by rotary evaporator under vacuum. The crude concentrate was dissolved in 1% MeOH/CH₂Cl₂ and absorbed on silica gel (20 g) by evaporating the solvent followed by drying. Subsequent purification by flash silica gel column purification of the dry powder (CombiFlash[®] companion system[®] with RediSep[®] silica gel column 120 g, 30-70%EtOAc/hexanes eluting solvent) provided 5-(2-chloropyridin-3-yl)-1H-indazole (1.0 g, 50%) as a white crystalline solid after concentration of the desired product fractions. ¹H NMR (DMSO-d₆): δ 13.2 (s, 1H), 8.41 (dd, 1H, J = 1.8 and 4.7 Hz), 8.13 (s, 1H), 7.90 (dd, 1H, J = 1.7 and 4.7 Hz), 7.84 (s, 1H), 7.62 (d, 1H, J = 8.8 Hz), 7.51 (dd, 1H, J = 4.7 and 7.3 Hz), 7.42 (dd, 1H, J = 1.4 and 8.5 Hz). LCMS: 95 %, MS (m/e) 230 (MH⁺).


Example 4 *tert*-Butyl 5-bromo-1H-indazole-1-carboxylate



[0149] A single necked round bottom flask containing a with a magnetic stir bar was charged with 5-bromo-1H-indazole (3.0 g, 15.2 mmol), di-*tert*-butyl dicarbonate (4.2 g, 19.2 mmol) and acetonitrile (30 mL) under a mild stream of nitrogen at room temperature. Triethylamine (1.8 g, 2.5 mL, 17.7 mmol) was added in one portion to the above stirred homogeneous solution followed by portions-wise addition of 4-(dimethylamino)pyridine (2.2 g, 18 mmol) over a period of 15 min. The homogenous off-brown clear reaction mixture was stirred at room temperature under nitrogen and the progress of reaction monitored by TLC (50% EtOAc/hexanes). Stirring was discontinued after 3h and the reaction mixture concentrated by rotary evaporator under vacuum. A clear viscous liquid was obtained and dissolved in EtOAc/hexanes (7:3, 200 mL), and

diluted with water (75 mL). Organic layer was separated and the aqueous layer extracted with EtOAc/hexanes (1:1, 125 mL). The combined organic layers were washed with water (100 mL) followed by 1N aq. HCl (2 x 75 mL) to remove 4-(dimethylamino)pyridine. The combined organic layers were washed with water (2 X 75 mL), saturated aq. NaHCO₃ (2 X 75 mL) and saturated aqueous NaCl. Separated organic layers were dried over anhydrous MgSO₄, filtered, concentrated and dried under vacuum to provide *tert*-butyl 5-bromo-1H-indazole-carboxylate (4.5 g, purity 97%) as a pale yellow viscous liquid which was used without further purification. ¹H NMR (DMSO-d₆): δ 8.36 (d, 1H, J = 0.8 Hz), 8.11 (app d, 1H, J = 0.8 Hz), 8.00 (d, 1H, J = 8.8 Hz), 7.71 (app dd, 1H, J = 0.8 and 8.8 Hz), 1.62 (s, 9H). LCMS: 97 %, MS (m/e) 241 (MH⁺-*t*-Bu).


Example 5 5-(2-Chloropyridin-3-yl)-1H-indazole



[0150] A single necked round bottom flask (250 mL) equipped with a magnetic stir bar was charged with *tert*-butyl 5-bromo-1H-indazole-carboxylate (4.0 g, 13.4 mmol) dissolved in 1,4-dioxane (130 mL), 2-chloro-3-pyridine boronic acid pinacol ester (4 g, 16.7 mmol), Pd(PPh₃)₄ (1.5 g, 1.3 mmol) and 2M aq. Na₂CO₃ (20 mL, 40 mmol) under nitrogen atmosphere. The rubber septum was replaced with reflux condenser containing three-way stopcock equipped with argon filled balloon. The reaction contents were stirred and air was removed from the closed reaction system by vacuum and back filled with argon. Following three cycles of degassing, the reaction mixture was heated at 100 °C (oil-bath) under argon. Inflated argon balloon was emptied, refilled with argon and remounted in the course of reaction. The initial pale yellow heterogeneous reaction mixture turned to clear biphasic off-brown solution. After 18 h with no additional change in the proportion of the product (62%) as analyzed by LC/MS, the reaction mixture was cooled to room temperature. Upon concentration of the reaction mixture, EtOAc/water (200 mL / 75 mL) was transferred to the concentrate and stirred for 30 min. The organic layer was separated and the aqueous layer extracted with EtOAc (100 mL X 2). MgSO₄ (20 g) and Celite®

(20 g) were added to combined organic layers and the contents suction filtered after stirring for 1 h. The filter cake was washed with EtOAc (300 mL) and the combined filtrates concentrated by rotary evaporator under vacuum. The crude concentrate was dissolved in in 1% MeOH/CH₂Cl₂ and absorbed on silica gel (20 g) by evaporating the solvent followed by drying. Subsequent purification by flash silica gel column purification of the dry powder (Combiflash® companion system® with RediSep® silica gel column 120 g, 30-70%EtOAc/hexanes eluting solvent) provided 5-(2-chloropyridin-3-yl)-1H-indazole (1.5 g, 47%) as a white crystalline solid after concentration of the desired product fractions. ¹H NMR (DMSO-d₆): 13.2 (s, 1H), 8.41 (dd, 1H, J = 1.8 and 4.7 Hz), 8.13 (s, 1H), 7.90 (dd, 1H, J = 1.7 and 4.7 Hz), 7.84 (s, 1H), 7.62 (d, 1H, J = 8.8 Hz), 7.51 (dd, 1H, J = 4.7 and 7.3 Hz), 7.42 (dd, 1H, J = 1.4 and 8.5 Hz). LCMS: 95 %, MS (m/e) 230 (MH⁺).


Example 6 *tert*-Butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate




[0151] A single necked round bottom flask equipped with a magnetic stir bar was charged with 5-bromo-1H-pyrazolo[3,4-b]pyridine (1.0 g, 5 mmol), di-*tert*-butyl dicarbonate (1.4 g, 6.4 mmol) and acetonitrile (10 mL) under a mild stream of nitrogen at room temperature. Triethylamine (0.72 g, 1.0 mL, 7.1 mmol) was added in one portion to the above stirred homogeneous solution followed by portions-wise addition of 4-(dimethylamino)pyridine (0.74 g, 6.05 mmol) over a period of 15 min. The homogenous reaction mixture was stirred at room temperature and the progress of reaction was monitored by TLC (50% EtOAc/hexanes). Stirring was discontinued after 3h, the reaction mixture concentrated and diluted with water (25 mL). The resultant off-brown solid was filtered and suction dried to provide the desired *tert*-butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate (1.4 g, 93%). The material obtained was used in the next step without further purification. ¹H NMR (DMSO-d₆): δ 8.77 (d, 1H, J = 2.0 Hz), 8.62 (d, 1H, J = 2.0 Hz), 8.39 (s, 1H), 1.60 (s, 9H), (dd, 1H, J = 1.8 and 4.7 Hz), 8.13 (s, 1H), 7.90 (dd,

1H, J = 1.7 and 4.7 Hz), 7.84 (s, 1H), 7.62 (d, 1H, J = 8.8 Hz), 7.51 (dd, 1H, J = 4.7 and 7.3 Hz), 7.42 (dd, 1H, J = 1.4 and 8.5 Hz). LCMS: 97 %, MS (m/e) 226 (MH⁺-*t*-Bu).


Example 7 5-(2-Chloropyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine



[0152] 5-(2-chloropyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine was prepared in the similar to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole by heating the mixture of *tert*-butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate (2.0 g, 6.7 mmol), 2-chloro-3-pyridineboronic acid pinacol ester (1.9 g, 8.0 mmol), Pd(PPh₃)₄ (770 mg, 67 mmol), 1,4-dioxane (40 mL) and 2M aq. Na₂CO₃ (9 mL, 18 mmol) under argon atmosphere. After 12 h, the reaction mixture was cooled to room temperature and concentrated. The crude concentrate was diluted with EtOAc/water (200 mL / 100 mL), allowed to stir for 30 min and the heterogeneous solution was filtered. The filter cake was washed with EtOAc (200 mL) and water (75 mL) successively. The filter cake thus obtained was analyzed as the desired product (0.55 g) and dissolved in a mixture of THF/MeOH (2:1, 50 mL). The homogeneous solution was passed through a pad of Celite[®] and the filtrate concentrated to provide desired product as a crystalline solid (0.45 g). Organic layer from combined filtrates was separated, stirred with MgSO₄/Celite[®] for 20 min and filtered. The filtrate was concentrated and subjected to flash silica gel column purification (Combiflash[®] companion system[®] with RediSep[®] silica gel column 12g, 30-50-90EtOAc/hexanes eluting solvent gradient upon dry loading the sample by absorbing on silica gel) to obtain another 0.4 g of 5-(2-chloropyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine. Total yield: 52%. ¹H NMR (DMSO-d₆): δ 13.83 (s, 1H), 8.59 (d, 1H, J = 2.0 Hz), 8.45 (dd, 1H, J = 1.7 and 4.7 Hz), 8.36 (d, 1H, J = 2.0 Hz), 8.21 (s, 1H), 8.00 (dd, 1H, J = 1.7 and 7.7 Hz), 7.59 (dd, 1H, J = 4.7 and 7.7 Hz). LCMS: rt 5.20 min (A), purity 94 %, MS (m/e) 231 (MH⁺).

Example 8 2-Chloro-3-(4-fluorophenyl)pyridine


[0153] 2-Chloro-3-(4-fluorophenyl)pyridine was synthesized analogous to the reaction conditions used in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole by heating the mixture of 4-fluorophenyl boronic acid (3.0 g, 21.4 mmol), 3-bromo-2-chloropyridine (4.9 g, 25.7 mmol), Pd(PPh₃)₄ (1.6 g, 1.3 mmol) and 2M aq. Na₂CO₃ (25 mL, 50 mmol) in 1,4-dioxane (125 mL) under argon atmosphere for 12 h. LC/MS indicated three products with MH⁺ 208, 254 and 268. Upon work-up of the reaction mixture, as discussed in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, the crude concentrated was purified by flash silica gel column chromatography [Combiflash[®] companion system[®] with RediSep[®] silica gel column 120 g, 10-50%EtOAc/hexanes eluting solvent gradient upon liquid loading on to column]. Two fractions containing the desired product were identified and concentrated. 2-Chloro-3-(4-fluorophenyl)pyridine was isolated as a crystalline solid (888 mg, 16%) from the fraction containing 2, 3-bis(4-fluorophenyl)pyridine by suspending the semi solid fraction mixture in 10% EtOAc/hexanes and filtered. ¹H NMR (DMSO-d₆): δ 8.41 (dd, 1H, J = 1.8 and 4.7 Hz), 7.86 (dd, 1H, J = 2.0 and 7.6 Hz), 7.54-7.48 (m, 3H), 7.34-7.31 (m, 2H). ¹⁹F NMR (DMSO-d₆): δ -114.06 (s). LCMS: rt 7.50 min (A), purity 99 %, MS (m/e) 208 (MH⁺).

Example 9 *tert*-Butyl 6-bromo-1H-indazole-1-carboxylate


[0154] Analogous to the preparation and work-up procedure of *tert*-butyl 5-bromo-1H-indazole-carboxylate, *tert*-butyl 6-bromo-1H-indazole-carboxylate was obtained by the reaction

of 6-bromo-1H-indazole (5.0 g, 25.4 mmol), di-*tert*-butyl dicarbonate (7.2 g, 32.9 mmol), triethylamine (3.6 g, 1.0 mL, 35.7 mmol) and 4-(dimethylamino)pyridine (3.1 g, 25 mmol) in acetonitrile (40 mL) under a mild stream of nitrogen at room temperature. *tert*-butyl 6-bromo-1H-indazole-carboxylate (7.5 g, 97%) as a pale yellow viscous liquid which was used without further purification. ¹H NMR (DMSO-d₆): δ 8.36 (d, 1H, J = 0.8 Hz), 8.11 (app d, 1H, J = 0.8 Hz), 8.00 (d, 1H, J = 8.8 Hz), 7.71 (app dd, 1H, J = 0.8 and 8.8 Hz), 1.62 (s, 9H). LCMS: 97 %, MS (m/e) 241 (MH⁺-*t*-Bu).


Example 10 6-(2-Chloropyridin-3-yl)-1H-indazole




[0155] Analogous to the reaction conditions and work-up procedures used in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 5-(2-chloropyridin-3-yl)-1H-indazole was obtained by heating the mixture of *tert*-butyl 6-bromo-1H-indazole-carboxylate (7.3 g, 24.6 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (7.0 g, 29.5 mmol), Pd(PPh₃)₄ (2 g, 1.7 mmol) and aq. Na₂CO₃ (44 mL, 88 mmol) in 1,4-dioxane (200 mL) under argon atmosphere. The crude concentrate that was obtained after the extractive work-up dissolved in CH₂Cl₂, adsorbed on to silica gel and dried. Subsequent purification by flash silica gel column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 120 g, 30-70%EtOAc/hexanes eluting solvent gradient upon dry powder loading) provided 5-(2-chloropyridin-3-yl)-1H-indazole as a white solid (4.2 g, 74%). ¹H NMR (DMSO-d₆): δ 13.21 (s, 1H), 8.43 (dd, 1H, J = 1.7 and 4.7 Hz), 8.12 (s, 1H), 7.93 (dd, 1H, J = 1.7 and 7.6 Hz), 7.84 (d, 1H, J = 8.5 Hz), 7.59 (s, 1H), 7.52 (dd, 1H, J = 4.7 and 7.6 Hz), 7.17 (d, 1H, J = 8.5 Hz). LCMS: rt 6.17 min (A), purity 98 %, MS (m/e) 230 (MH⁺).

Example 11 1-Trityl-6-bromo-2-benzoxazolinone


[0156] Triethylamine (0.72 g, 1.0 mL, 7.1 mmol) was added to a stirring a mixture of 6-bromo-2benzoxazolinone (0.89 g, 4.2 mmol) and tritylchloride (1.21 g, 4.4 mmol) in CH_2Cl_2 (10 mL) for a period of 10 min. The reaction was monitored by TLC (silica gel) and concentrated after 1h. The concentrate was diluted with water and sonicated to form a heterogeneous solution. The resulting off-white solid was suction filtered and dried to provide 1-trityl-6-bromo-2-benzoxazolinone (2.0 g). LCMS: rt 9.45 min (A), purity 96 %, MS (m/e) 456 (MH^+).

Example 12 6-(2-chloropyridin-3-yl)benzo[d]oxazol-2(3H)-one

[0157] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 6-(2-chloropyridin-3-yl)benzo[d]oxazol-2(3H)-one was prepared by heating the mixture of 1-trityl-6-bromo-2-benzoxazolinone (2.0 g, 4.4 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.3 g, 5.4 mmol), $\text{Pd(PPh}_3)_4$ (0.5 g, 0.43 mmol) and 2M aq. Na_2CO_3 (8 mL, 16 mmol) in 1,4-dioxane (75 mL) under argon atmosphere for 12 h. LC/MS indicated three products with MH^+ 489, 245 and 566. Extractive work-up followed by flash silica gel column purification (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g, 20-70%EtOAc/hexanes eluting solvent gradient upon dry loading the concentrate absorbed on silica gel) provided 6-(2-chloropyridin-3-yl)benzo[d]oxazol-2(3H)-one (0.44 g, 38%) as an off-white solid after concentration of the respective product fractions. LCMS: rt 5.85 min (A), purity 94 %, MS (m/e) 247 (MH^+).

Example 13 3-(Benzo[d][1,3]dioxol-6-yl)-2-chloropyridine


[0158] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 3-(benzo[d][1,3]dioxol-6-yl)-2-chloropyridine was prepared by heating the mixture of 3,4-(methylenedioxy)phenyl boronic acid (3.0 g, 18.1 mmol), 3-bromo-2-chloropyridine (4.2 g, 1.8 mmol), $\text{Pd(PPh}_3)_4$ (1.2 g, 1.0 mmol) and 2M aq. Na_2CO_3 (27 mL, 54 mmol) in 1,4-dioxane (125 mL) under argon atmosphere for 12 h. LC/MS indicated three products. The crude concentrate that was obtained after the extractive work-up dissolved in CH_2Cl_2 , adsorbed on to silica gel and dried. Subsequent purification by flash silica gel column chromatography (CombiFlash[®] companion system[®] with RediSep[®] silica gel column 120 g, 30-70% EtOAc/hexanes eluting solvent gradient upon dry powder loading) provided 3-(benzo[d][1,3]dioxol-6-yl)-2-chloropyridine as a white solid 2.3 g, (38%). ¹H NMR (DMSO-*d*₆): δ 8.38 (dd, 1H, *J* = 1.7 and 4.7 Hz), 7.82 (dd, 1H, *J* = 2.0 and 7.6 Hz), 7.47 (dd, 1H, *J* = 4.7 and 7.6 Hz), 7.05 (d, 1H, *J* = 1.7 Hz), 7.01 (d, 1H, *J* = 7.9 Hz), 6.90 (dd, 1H, *J* = 1.7 and 7.9 Hz), 6.07 (s, 2H). LCMS: *rt* 7.27 min (A), purity 96 %, MS (*m/e*) 234 (MH^+).

Example 14 6-(2-Chloropyridin-3-yl)-1-methyl-1H-indazole

[0159] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 6-(2-chloropyridin-3-yl)-1-methyl-1H-indazole was prepared by heating the mixture of 6-bromo-1-methyl-1H-indazole (2.0 g, 9.5 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (2.2 g, 9.4


mmol), Pd(PPh₃)₄ (0.54 g, 0.46 mmol) and 2M aq. Na₂CO₃ (14 mL, 28 mmol) in 1,4-dioxane (75 mL) under argon atmosphere for 12 h. Upon extractive work-up as discussed in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole with CH₂Cl₂ and purification of the concentrate by flash silica gel column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g, 30-50%EtOAc/hexanes eluting solvent gradient upon dry loading the concentrate absorbed on silica gel) provided 6-(2-chloropyridin-3-yl)-1-methyl-1H-indazole as a white solid (1.8 g, 77%). ¹H NMR (DMSO-d₆): δ 8.45 (dd, 1H, J = 1.7 and 4.7 Hz), 8.09 (s, 1H), 7.94 (dd, 1H, J = 2.0 and 7.6 Hz), 7.82 (d, 1H, J = 8.5 Hz), 7.74 (s, 1H), 7.54 (dd, 1H, J = 4.7 and 7.6 Hz), 7.22 (d, 1H, J = 8.5 Hz), 4.06 (s, 3H). LCMS: rt 6.80 min (A), purity 97 %, MS (m/e) 244 (MH⁺).

Example 15 *tert*-Butyl 6-bromo-1H-pyrazolo[4,3-b]pyridine-1-carboxylate




[0160] Analogous to the preparation of *tert*-butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate, 6-bromo-1H-pyrazolo[4,3-b]pyridine (2.0 g, 10.10 mmol) was reacted with di-*tert*-butyl dicarbonate (2.8 g, 13.10 mmol), NEt₃ (1.44 g, 2.0 mL, 14 mmol) and 4-(dimethylamino)pyridine in acetonitrile (20 mL) for 3h. Work-up as discussed previously in the preparation of *tert*-butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate provided desired product of *tert*-butyl 6-bromo-1H-pyrazolo[4,3-b]pyridine-1-carboxylate as a brown solid (2.8 g, 93%).

Example 16 6-(2-Chloropyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine




[0161] 6-(2-Chloropyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine was synthesized in the similar manner to the preparation of 5-(2-chloropyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine by heating the mixture of *tert*-butyl 6-bromo-1H-pyrazolo[4,3-b]pyridine-1-carboxylate (2.5 g, 8.4 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (2.2 g, 9.2 mmol), Pd(PPh₃)₄ (610 mg, 0.52 mmol) and 2M aq. Na₂CO₃ (12 mL, 24 mmol) in 1,4-dioxane (40 mL). Upon work-up of the reaction mixture similar to 5-(2-chloropyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine provided 6-(2-chloropyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine as an off-white crystalline solid. ¹H NMR (DMSO-d₆): δ 13.50 (s, 1H), 8.57 (app s, 1H), 8.48 (dd, 1H, J = 1.7 and 4.7 Hz), 8.35 (s, 1H), 8.12 (s, 1H), 8.02 (dd, 1H, J = 1.7 and 7.6 Hz), 7.60 (dd, 1H, J = 4.7 and 7.7 Hz). LCMS: rt 4.50 min (A), purity 94 %, MS (m/e) 231 (MH⁺).


Example 17 6-(2-Chloropyridin-3-yl)-1-methyl-1H-indazole



[0162] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 5-(2-chloropyridin-3-yl)-1-methyl-1H-indazole was prepared by heating the mixture of 5-bromo-1-methyl-1H-indazole (1.0 g, 4.7 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.2 g, 5.2 mmol), Pd(PPh₃)₄ (270 mg, 0.23 mmol) and 2M aq. Na₂CO₃ (6 mL, 12 mmol) in 1,4-dioxane (75 mL) under argon atmosphere for 12 h. Upon work-up as discussed in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole and purification of the concentrate by flash silica gel column chromatography [CombiFlash[®] companion system[®] with RediSep[®] silica gel column 40 g, 30-50%EtOAc/hexanes eluting solvent gradient upon dry loading the concentrate absorbed on silica gel] provided 5-(2-chloropyridin-3-yl)-1-methyl-1H-indazole as white solid (0.84 g, 73%). ¹H NMR (DMSO-d₆): δ 8.41 (dd, 1H, J = 1.7 and 4.7 Hz), 8.10 (s, 1H), 7.90 (dd, 1H, J = 1.7 and 7.6 Hz), 7.83 (app t, 1H, J = 0.6 Hz), 7.72 (dd, 1H, J = 0.6 and 8.8 Hz), 7.51 (dd, 1H, J = 4.7 and 7.6 Hz), 7.48 (dd, 1H, J = 1.7 and 8.8 Hz), 4.07 (s, 3H). LCMS: rt 6.73 min (A), purity 99 %, MS (m/e) 244 (MH⁺).

Example 18 *tert*-Butyl 5-bromo-3-methyl-1H-indazole-1-carboxylate


[0163] Analogous to the preparation *tert*-butyl 5-bromo-1H-pyrazolo[3,4-*b*]pyridine-1-carboxylate, *tert*-butyl 5-bromo-3-methyl-1H-indazole-1-carboxylate was prepared by reacting 5-bromo-3-methyl-1H-indazole (1.0g, 4.7 mmol), di-*tert*-butyl dicarbonate (1.2 g, 6.4 mmol), NEt₃ (0.72g, 1.0 mL, 7.1 mmol) and 4-(dimethylamino)pyridine (0.57 g, 4.7 mmol). The reaction mixture was concentrated and diluted with water. The resultant solid was collected by filtration and suction dried to provide *tert*-butyl 5-bromo-3-methyl-1H-indazole-1-carboxylate (1.5 g, 97%) as a white solid. ¹H NMR (DMSO-*d*₆): δ 8.10 (d, 1H, J = 1.8 Hz), 7.96 (d, 1H, J = 9.1 Hz), 7.71 (dd, 1H, J = 1.8 and 9.1 Hz), 2.49 (s, 3H), 1.61 (s, 9H). LCMS: 97 %, MS (*m/e*) 254 (MH⁺-*t*-Bu).

Example 19 5-(2-Chloropyridin-3-yl)-3-methyl-1H-indazole


[0164] 5-(2-Chloropyridin-3-yl)-3-methyl-1H-indazole was synthesized in the similar manner to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole by heating the mixture of *tert*-butyl 5-bromo-3-methyl-1H-indazole-1-carboxylate (1.5 g, 4.8 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.3 g, 5.3 mmol), Pd(PPh₃)₄ (390 mg, 0.33 mmol) and 2M aq. Na₂CO₃ (7 mL, 14 mmol) in 1,4-dioxane (40 mL). Upon work-up and purification procedure used in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole provided 5-(2-chloropyridin-3-yl)-3-methyl-1H-indazole (0.52, 43%) as a white crystalline solid. ¹H NMR (DMSO-*d*₆): δ 12.75 (s, 1H), 8.41 (dd, 1H, J = 1.7 and 4.7 Hz), 7.91 (dd, 1H, J = 1.7 and 7.6 Hz), 7.77 (s, 1H), 7.52

(d, 1H, J = 8.5 Hz), 7.51 (dd, 1H, J = 4.7 and 7.6 Hz), 7.41 (dd, 1H, J = 1.4 and 8.5 Hz), 2.49 (s, 3H). LCMS: rt 6.28 min (A), purity 97 %, MS (m/e) 244.


Example 20 6-(2-Chloropyridin-3-yl)benzo[d]thiazole



[0165] 6-(2-Chloropyridin-3-yl)benzo[d]thiazole was prepared analogous to 5-(2-chloropyridin-3-yl)-1H-indazole by heating the mixture of 6-bromobenzo[d]thiazole (2.0 g, 9.3 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (2.7 g, 11.2 mmol), Pd(PPh₃)₄ (500 mg, 0.43 mmol) and 2M aq. Na₂CO₃ (14 mL, 28 mmol) in 1,4-dioxane (100 mL). The reaction mixture was concentrated at the completion of the reaction (12h) and diluted with CH₂Cl₂ (200 mL/100 mL). Mixed organic layers were stirred with MgSO₄ and Celite[®] for 30min. The slurry was suction filtered and concentrated by rotary evaporator under vacuum. The crude concentrate was dissolved in CH₂Cl₂, adsorbed on silica gel and dried. The dry powder thus obtained was purified by silica gel flash column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g, 30-70% EtOAC/hexanes eluting solvent gradient). 6-(2-chloropyridin-3-yl)benzo[d]thiazole (1.9 g, 82%) was obtained as a white solid upon concentration of the product fractions. ¹H NMR (DMSO-d₆): δ 9.46 (s, 1H), 8.46 (dd, 1H, J = 1.7 and 4.7 Hz), 8.30 (d, 1H, J = 1.4 Hz), 8.17 (d, 1H, J = 8.2 Hz), 7.96 (dd, 1H, J = 1.7 and 7.6 Hz), 7.63 (dd, 1H, J = 1.4 and 8.5 Hz), 7.53 (dd, 1H, J = 4.7 and 7.6 Hz). LCMS: rt 6.71 min (A), purity 99 %, MS (m/e) 247.

Example 21 5-(2-Chloropyridin-3-yl)benzo[d]thiazole


[0166] 5-(2-chloropyridin-3-yl)benzo[d]thiazole was prepared in the similar manner of 6-(2-chloropyridin-3-yl)benzo[d]thiazole by heating the mixture of 5-bromobenzo[d]thiazole (1.0 g, 4.67 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.34 g, 5.6 mmol), $\text{Pd(PPh}_3)_4$ (250 mg, 0.22 mmol) and 2M aq. Na_2CO_3 (7 mL, 14 mmol) in 1,4-dioxane (50 mL). Upon work-up and purification protocol used in the preparation of 6-(2-chloropyridin-3-yl)benzo[d]thiazole provided 5-(2-chloropyridin-3-yl)benzo[d]thiazole as a white solid (820 mg, 70%). $^1\text{H NMR}$ (DMSO- d_6): δ 9.46 (s, 1H), 8.45 (dd, 1H, $J = 2.0$ and 4.9 Hz), 8.27 (d, 1H, $J = 8.5$ Hz), 8.17 (app s, 1H), 7.97 (dd, 1H, $J = 1.7$ and 7.6 Hz), 7.58 (d, 1H, $J = 8.5$ Hz), 7.53 (dd, 1H, $J = 4.7$ and 7.6 Hz), LCMS: rt 6.73 min (A), purity 99 %, MS (m/e) 247.

Example 22 6-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine

[0167] 6-(2-chloropyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine was synthesized in the similar to 6-(2-chloropyridin-3-yl)benzo[d]thiazole from 6-bromo[1,2,4]triazolo[4,3a]pyridine (1.0 g, 5.0 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.45 g, 6.0 mmol), $\text{Pd(PPh}_3)_4$ (300 mg, 0.26 mmol) and 2M aq. Na_2CO_3 (8mL, 16 mmol) in 1,4-dioxane (50 mL). Workup of the reaction mixture was carried out by sequential steps of concentrating the reaction mixture, extraction with CH_2Cl_2 , drying over $\text{MgSO}_4/\text{Celite}^\text{®}$, filtration and concentration. Thus obtained crude residue was dissolved in CH_2Cl_2 (10 mL) and the homogeneous solution stirred with 50%


EtOAc/hexanes (40 mL). The resulting off-white precipitate was collected by filtration and dried to provide 6-(2-chloropyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine (0.68 g, 58%). ¹H NMR (DMSO-d₆): δ 8.29 (s, 1H), 8.74 (s, 1H), 8.50 (dd, 1H, J = 1.7 and 4.7 Hz), 8.01 (dd, 1H, J = 1.7 and 7.6 Hz), 7.87 (d, 1H, J = 9.7 Hz), 7.58 (dd, 1H, J = 4.7 and 7.6 Hz), 7.51 (dd, 1H, J = 1.4 and 9.7 Hz). LCMS: rt 3.90 min (A), purity 99 %, MS (m/e) 231 (MH⁺).

Example 23 6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridine




[0168] 6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridine was synthesized in the similar to 6-(2-chloropyridin-3-yl)benzo[d]thiazole from 6-iodo-imidazo[1,2-a]pyridine (1.0 g, 4.1 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.2 g, 5.0 mmol), Pd(PPh₃)₄ (250 mg, 0.22 mmol) and 2M aq. Na₂CO₃ (7 mL, 12 mmol) in 1,4-dioxane (50 mL). Workup of the reaction mixture was carried out by sequential steps of concentrating the reaction mixture, extraction with CH₂Cl₂, drying over MgSO₄/ Celite[®], filtration and concentration. The crude residue was stirred in 50% EtOAc/hexanes (40 mL). The resulting white precipitate was filtered and dried to provide 6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine (0.52 g, 55%). ¹H NMR (DMSO-d₆): δ 8.73 (dd, 1H, J = 0.8 and 1.8 Hz), 8.47 (dd, 1H, J = 2.0 and 4.7 Hz), 8.00 (dd, 1H, J = 2.0 and 7.6 Hz), 7.98 (s, 1H), 7.64 (d, 1H, J = 8.8 Hz), 7.63 (s, 1H), 7.56 (dd, 1H, J = 4.7 and 7.6 Hz), 7.33 (dd, 1H, J = 1.8 and 8.8 Hz). LCMS: rt 3.16 min (A), purity 99 %, MS (m/e) 230 (MH⁺).

Example 24 *tert*-Butyl 5-bromo-6-methyl-1H-indazole-1-carboxylate




[0169] Analogous to the preparation *tert*-butyl 5-bromo-3-methyl-1H-indazole-1-carboxylate, *tert*-Butyl 5-bromo-6-methyl-1H-indazole-1-carboxylate was prepared by reacting 5-bromo-6-methyl-1H-indazole (1.0 g, 4.7 mmol), di-*tert*-butyl dicarbonate (1.2 g, 6.4 mmol), NEt₃ (0.72 g, 1.0 mL, 7.2 mmol) and 4-(dimethylamino)pyridine (0.57 g, 4.7 mmol). The reaction mixture was concentrated and diluted with water. The resultant precipitate was collected by filtration to obtain the desired product (1.4 g, 95%). ¹H LCMS: 97 %, MS (m/e) (MH⁺-*t*-Bu).


Example 25 5-(2-Chloropyridin-3-yl)-6-methyl-1H-indazole




[0170] 5-(2-Chloropyridin-3-yl)-6-methyl-1H-indazole was synthesized in the similar manner to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole by heating the mixture of *tert*-butyl 5-bromo-6-methyl-1H-indazole-1-carboxylate (1.4 g, 4.5 mmol), 2-chloro-3-pyridineboronic acid pinacol ester (1.4 g, 5.9 mmol), Pd(PPh₃)₄ (370 mg, 0.32 mmol) and 2M aq. Na₂CO₃ (7 mL, 14 mmol) in 1,4-dioxane (40 mL). Upon work-up and purification procedure used in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole provided 5-(2-chloropyridin-3-yl)-6-methyl-1H-indazole as a white solid (780 mg, 67%). ¹H NMR (DMSO-d₆): δ 13.02 (s, 1H), 8.44 (dt, 1H, J = 1.7 and 4.7 Hz), 8.01 (s, 1H), 7.81 (dt, 1H, J = 1.7 and 7.6 Hz), 7.53 (s, 1H), 7.51-7.48 (m, 1H), 7.45 (s, 1H), 2.12 (s, 3H). LCMS: rt 6.30 min (A), purity 98 %, MS (m/e) 244.

Example 26 *tert*-Butyl 5-bromo-7-methyl-1H-indazole-1-carboxylate



Example 28 6-(2-Chloropyridin-3-yl)-1H-benzimidazole


[0172] 6-(2-Chloropyridin-3-yl)-1H-benzimidazole was synthesized in the similar manner to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole by heating the mixture of 3-bromo-2-chloropyridine (0.70 g, 3.63 mmol), 1H-benzimidazole-5-boronic acid pinacol ester (0.8 g, 3.27 mmole), Pd(PPh₃)₄ (330 mg, 0.28 mmol) and 2M aq. Na₂CO₃ (4mL, 8 mmol) in 1,4-dioxane (30 mL). Upon extractive work-up with CH₂Cl₂ and purification of the concentrate by flash silica gel column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 24 g, 3% MeOH/EtOAc as a eluting solvent upon dry loading the concentrate absorbed on silica gel) provided 6-(2-chloropyridin-3-yl)-1H-benzimidazole (200 mg, 26%). ¹H NMR (DMSO-d₆): δ 12.57 (s, 1H), 8.95 (dd, 1H, J = 1.7 and 4.9 Hz), 8.28 (s, 1H), 7.90 (dd, 1H, J = 1.7 and 7.6 Hz), 7.70-7.62 (m, 2H), 7.58 (dd, 1H, J = 4.9 and 7.6 Hz), 7.29-7.27 (app s, 1H). LCMS: rt 3.71 min (A), purity 96 %, MS (m/e) 230 (MH⁺).

Example 29 6-(2-Chloropyridin-3-yl)-1-methyl-1H-benzimidazole

[0173] 6-(2-Chloropyridin-3-yl)-1-methyl-1H-benzimidazole was synthesized in the similar manner to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole by heating the mixture of 6-bromo-1-methyl-1H-benzimidazole (1.0 g, 4.7 mmole), 2-chloro-3-pyridine boronic acid pinacol ester (1.4 g, 5.8 mmol), Pd(PPh₃)₄ (330 mg, 0.28 mmol) and 2M aq. Na₂CO₃ (7mL, 14 mmol) in 1,4-dioxane (60 mL). Upon extractive work-up with CH₂Cl₂ and purification (Combiflash[®]


companion system[®] with RediSep[®] silica gel column 24 g, 3% MeOH/EtOAc as a eluting solvent) provided off-white solid of 6-(2-chloropyridin-3-yl)-1H-benzimidazole (430 mg, 36%). ¹H NMR (DMSO-d₆): δ 8.42 (dd, 1H, J = 1.7 and 4.7 Hz), 8.24 (s, 1H), 7.91 (dd, 1H, J = 1.7 and 7.6 Hz), 7.60 (d, 1H, J = 8.8 Hz), 7.67 (app d, 1H, J = 0.7 Hz), 7.53 (dd, 1H, J = J = 4.7 and 7.6 Hz), 7.29 (dd, 1H, J = 1.7 and 8.8 Hz), 3.86 (s, 3H) LCMS: rt 3.85 min (A), purity 94 %, MS (m/e) 244 (MH⁺)

Example 30 5-(2-Chloropyridin-3-yl)-1H-benzimidazole



[0174] 5-(2-Chloropyridin-3-yl)-1-methyl-1H-benzimidazole was synthesized in the similar manner to the preparation of 6-(2-Chloropyridin-3-yl)-1-methyl-1H-benzimidazole. ¹H NMR (DMSO-d₆): δ 8.41 (dd, 1H, J = 1.7 and 4.7 Hz), 8.25 (s, 1H), 7.89 (dd, 1H, J = 1.7 and 7.6 Hz), 7.71 (app d, 1H, J = 0.7 Hz), 7.65 (d, 1H, J = 8.5 Hz), 7.51 (dd, 1H, J = J = 4.7 and 7.6 Hz), 7.35 (dd, 1H, J = 1.4 and 8.5 Hz), 3.86 (s, 3H). LCMS: rt 3.86 min (A), purity 93 %, MS (m/e) 244 (MH⁺)


Example 31 6-(2-Chloropyridin-3-yl)benzoxazole



[0175] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 6-(2-chloropyridin-3-yl)benzoxazole was prepared by heating the mixture of 6-bromo-benzoxazole (1.0 g, 5.1 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.5 g, 6.6 mmol), Pd(PPh₃)₄


(400 mg, 0.34 mmol) and 2M aq. Na_2CO_3 (8 mL, 16 mmol) in 1,4-dioxane (40 mL). Upon extractive work-up with CH_2Cl_2 and purification (Combiflash[®] companion system[®] with RediSep[®] silica gel column 24 g, 30-50% EtOAc/hexanes as a eluting solvent) provided off-white solid of 6-(2-chloropyridin-3-yl)benzoxazole (440 mg, 37%). ¹H NMR (DMSO- d_6): δ 8.82 (s, 1H), 8.45 (dd, 1H, $J = 1.7$ and 4.7 Hz), 7.95-7.92 (m, 2H), 7.89 (d, 1H, $J = 8.5$ Hz), 7.55 (dd, 1H, $J = 4.7$ and 7.6 Hz), 7.49 (d, 1H, $J = 8.5$ Hz). LCMS: rt 5.93 min (B), purity 99 %, MS (m/e) 231 (MH^+)

Example 32 5-(2-Chloropyridin-3-yl)benzoxazole



[0176] 5-(2-Chloropyridin-3-yl)benzoxazole (310 mg, 25%) was prepared in the identical manner to the preparation of 6-(2-chloropyridin-3-yl)benzoxazole. ¹H NMR (DMSO- d_6): δ 8.82 (s, 1H), 8.44 (dd, 1H, $J = 1.7$ and 4.7 Hz), 7.95-7.90 (m, 2H), 7.87 (d, 1H, $J = 8.5$ Hz), 7.55-7.50 (m, 2H). LCMS: rt 5.96 min (A), purity 94 %, MS (m/e) 231 (MH^+).


Example 33 Preparation of 5-bromo-1-ethyl-1H-indazole and 5-bromo-2-ethyl-2H-indazole



[0177] A stirred mixture of 5-bromo-1H-indazole (2.0 g, 10.1 mmol), iodoethane (2.0, 12.8 mmol), Cs_2CO_3 (4.0 g, 12.27 mmol) was heated in dry DMF at 40 °C for 12h under argon. The reaction mixture was cooled, diluted with water and EtOAc. Aqueous layer was discarded and the organic layer was washed with water and aq. NaCl successively. Collected organic layer was stirred with MgSO_4 for 10 min, filtered and concentrated. The well separated (on TLC) regio-isomers were isolated by flash silica gel column chromatography (combiflash 0-30-50%


EtOAc/hexanes, 80 g). 5-Bromo-1-ethyl-1H-indazole (1.2 g, liquid, 52%). LCMS: rt 7.58 min (A), purity 99 %, MS (m/e) 231 (MH⁺). 5-bromo-2-ethyl-2H-indazole (900 mg, liquid, 39%). LCMS: rt 6.98 min (A), purity 97 %, MS (m/e) 227 (MH⁺).

Example 34 5-(2-Chloropyridin-3-yl)-2-ethyl-2H-indazole



[0178] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 5-(2-chloropyridin-3-yl)-2-ethyl-2H-indazole was prepared by the heating the mixture of 5-bromo-2-ethyl-2H-indazole (0.90 g, 3.98 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.1 g, 4.60 mmol), Pd(PPh₃)₄ (300 mg, 0.34 mmol) and 2M aq. Na₂CO₃ (5 mL, 10 mmol) in 1,4-dioxane (40 mL). 5-(2-chloropyridin-3-yl)-2-ethyl-2H-indazole (732 mg, 70%) was isolated as an off-white solid after the workup and purification by flash silica gel purification. ¹H NMR (DMSO-d₆): δ 8.45 (s, 1H), 8.40 (dd, 1H, J = 1.7 and 4.7 Hz), 7.89 (dd, 1H, J = 1.7 and 7.6 Hz), 7.76 (s, 1H), 7.67 (d, 1H, J = 9.1 Hz), 7.49 (dd, 1H, J = 4.9 and 7.5 Hz), 7.29 (d, 1H, J = 9.1 Hz), 4.46 (qt, 2H, J = 7.3 Hz), 1.40 (t, 3H, J = 7.3 Hz). LCMS: rt 6.51 min (A), purity 98 %, MS (m/e) 258 (MH⁺).


Example 35 5-(2-Chloropyridin-3-yl)-1-ethyl-2H-indazole




[0179] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 5-(2-chloropyridin-3-yl)-1-ethyl-2H-indazole was prepared by heating the mixture of 5-bromo-1-

ethyl-1H-indazole (0.90 g, 3.98 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.1 g, 4.60 mmol), Pd(PPh₃)₄ (300 mg, 0.34 mmol) and 2M aq. Na₂CO₃ (5mL, 10 mmol) in 1,4-dioxane (40 mL). 5-(2-chloropyridin-3-yl)-1-ethyl-1H-indazole (842 mg, 82%) was isolated as an off-white solid after the workup and flash silica gel purification. ¹H NMR (DMSO-d₆): δ 8.41 (dd, 1H, J = 1.7 and 4.7 Hz), 8.11 (s, 1H), 7.92 (dd, 1H, J = 1.7 and 7.6 Hz), 7.83 (app t, 1H, J = 0.6 Hz), 7.73 (dd, 1H, J = 0.6 and 8.8 Hz), 7.51 (dd, 1H, J = 4.7 and 7.6 Hz), 7.46 (dd, 1H, J = 1.7 and 8.8 Hz), 4.46 (qt, 2H, J = 7.3 Hz), 1.40 (t, 3H, J = 7.3 Hz). LCMS: rt 5.46 min (B), purity 97 %, MS (m/e) 258 (MH⁺).


Example 36 6-(2-Chloropyridin-3-yl)quinoline



[0180] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 6-(2-chloropyridin-3-yl)quinoline was prepared by heating the mixture of 6-bromoquinoline (1.0 g, 4.8 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.5 g, 6.20 mmol), Pd(PPh₃)₄ (330 mg, 0.28 mmol) and 2M aq. Na₂CO₃ (7 mL, 14 mmol) in 1,4-dioxane (40 mL). 6-(2-Chloropyridin-3-yl)quinoline was isolated as a white solid (670 mg,) following the extractive work-up with CH₂Cl₂ and purification by flash silica gel purification. ¹H NMR (DMSO-d₆): δ 8.95 (dd, 1H, J = 1.2 and 4.4 Hz), 8.49 (dd, 1H, J = 1.7 and 4.7 Hz), 8.43 (d, 1H, J = 8.5 Hz), 8.11-8.09 (app m, 2H), 8.01 (dd, 1H, J = 1.7 and 7.6 Hz), 7.86 (dd, 1H, J = 1.4 and 8.8 Hz), 7.61-7.55 (m, 2H). LCMS: rt 4.13 min (A), purity 99 %, MS (m/e) 241 (MH⁺).

Example 37 6-(2-Chloropyridin-3-yl)isoquinoline


[0181] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 6-(2-chloropyridin-3-yl)quinoline was prepared by heating the mixture of 6-bromoisoquinoline (1.0 g, 4.8 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.5 g, 6.2 mmol), $\text{Pd}(\text{PPh}_3)_4$ (330 mg, 0.28 mmol) and 2M aq. Na_2CO_3 (7 mL, 14 mmol) in 1,4-dioxane (40 mL). 6-(2-Chloropyridin-3-yl)quinoline was isolated as a white solid (670 mg, 57%) upon work-up and purification by flash silica gel column purification. ^1H NMR (DMSO- d_6): δ 9.37 (s, 1H), 8.55 (dd, 1H, $J = 1.4$ and 5.5 Hz), 8.50-8.48 (m, 1H), 8.22 (d, 1H, $J = 8.5$ Hz), 8.07 (s, 1H), 8.01 (dt, 1H, $J = 1.2$ and 7.6 Hz), 7.88 (d, 1H, $J = 5.8$ Hz), 7.78 (dd, 1H, $J = 0.4$ and 8.5 Hz), 7.58 (dd, 1H, $J = 4.7$ and 7.3 Hz). LCMS: rt 4.01 min (A), purity 97 %, MS (m/e) 241 (MH^+).

Example 38 7-(2-Chloropyridin-3-yl)isoquinoline

[0182] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, 7-(2-chloropyridin-3-yl)isoquinoline was prepared by heating the mixture of 7-bromoisoquinoline (1.0 g, 4.8 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.5 g, 6.20 mmol), $\text{Pd}(\text{PPh}_3)_4$ (330 mg, 0.28 mmol) and 2M aq. Na_2CO_3 (7 mL, 14 mmol) in 1,4-dioxane (40 mL). 7-(2-Chloropyridin-3-yl)isoquinoline was isolated as a white solid (820 mg, 70%) after the CH_2Cl_2 work-up and silica gel flash column purification. ^1H NMR (DMSO- d_6): δ 9.37 (s, 1H), 8.55 (d,


1H, J = 5.8 Hz), 8.49 (dd, 1H, J = 1.7 and 4.7 Hz), 8.23 (s, 1H), 8.07 (d, 1H, J = 7.5 Hz), 8.02 (dd, 1H, J = 1.7 and 7.6 Hz), 7.91-7.88 (m, 2H), 7.58 (dd, 1H, J = 4.7 and 7.6 Hz). LCMS: rt 3.96 min (A), purity 95 %, MS (m/e) 241 (MH⁺).

Example 39 6-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine




[0183] 6-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine was synthesized in the similar to 6-(2-chloropyridin-3-yl)benzo[d]thiazole from 6-bromo[1,2,4]triazolo[1,5-a]pyridine (1.0 g, 5.0 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.45 g, 6.0 mmol), Pd(PPh₃)₄ (300 mg, 0.26 mmol) and 2M aq. Na₂CO₃ (8mL, 16 mmol) in 1,4-dioxane (50 mL). Upon workup, the crude residue was dissolved in CH₂Cl₂ (10 mL) and stirred with 50% EtOAc/hexanes (40 mL). The resulting off-white precipitate was filtered and dried to provide 6-(2-chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (0.68 g, 58%). ¹H NMR (DMSO-d₆): δ 9.18 (dd, 1H, J = 0.86 and 1.7 Hz), 8.57 (s, 1H), 8.50 (dd, 1H, J = 1.7 and 4.9 Hz), 8.05 (dd, 1H, J = 2.0 and 7.8 Hz), 7.94 (dd, 1H, J = 0.9 and 9.1 Hz), 7.80 (dd, 1H, J = 1.7 and 9.1 Hz), 7.59 (dd, 1H, J = 4.7 and 7.6 Hz). LCMS: rt 5.00 min (A), purity 97 %, MS (m/e) 231.

Example 40 3-Chloro-2-(4-fluoro-3-methylphenyl)pyridine




[0184] 3-Chloro-2-(4-fluoro-3-methylphenyl)pyridine was synthesized analogous to the reaction conditions used in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole by heating the mixture of 4-fluoro-3-methylphenyl boronic acid (1.0 g, 6.5 mmol), 2-bromo-3-chloropyridine (1.4 g, 7.1 mmol), Pd(PPh₃)₄ (0.45 g, 0.38 mmol) and 2M aq. Na₂CO₃ (8 mL, 16 mmol) in 1,4-dioxane (125 mL) under argon atmosphere for 3 h. Upon work-up of the reaction mixture, as discussed in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, the crude concentrate was purified by flash silica gel column chromatography [Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g, 10-30%EtOAc/hexanes eluting solvent gradient upon liquid loading on to column] to obtain 3-chloro-2-(4-fluoro-3-methylphenyl)pyridine as a white solid (790 mg, 54%). ¹H NMR (DMSO-d₆): δ 8.60 (dd, 1H, J = 1.4 and 4.7 Hz), 8.02 (dd, 1H, J = 1.4 and 8.2 Hz), 7.57 (app d, 1H, J = 7.3 Hz), 7.54-7.49 (m, 1H), 7.42 (dd, 1H, J = 4.7 and 8.2 Hz), 7.23 (t, 1H, J = 8.8 Hz), 2.28 (s, 3H). LCMS: 97 %, MS (m/e) 222.

Example 41 3-Chloro-2-(3-methylphenyl)pyridine



[0185] 3-Chloro-2-(3-methylphenyl)pyridine was synthesized analogous to the reaction conditions used in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole by heating the mixture of 3-methylphenyl boronic acid (1.76 g, 12.9 mmol), 2-bromo-3-chloropyridine (2.7 g, 14.2 mmol), Pd(PPh₃)₄ (0.9 g, 0.77 mmol) and 2M aq. Na₂CO₃ (16 mL, 32 mmol) in 1,4-dioxane (125 mL) under argon atmosphere for 3 h. Upon work-up of the reaction mixture, as discussed in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, the crude concentrate was purified by flash silica gel column chromatography [Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g, 10-30%EtOAc/hexanes eluting solvent gradient upon liquid loading on to column] to obtain 3-chloro-2-(3-methylphenyl)pyridine (1.62 g, 61%) as a clear liquid. ¹H NMR (DMSO-d₆): δ 8.60 (dd, 1H, J = 1.4 and 4.7 Hz), 8.00 (dd, 1H, J = 1.4 and 8.2 Hz), 7.44-7.37 (m, 3H), 7.25 (app d, 1H, J = 8.2 Hz), 2.36 (s, 3H). LCMS: 97 %, MS (m/e) 204.

Example 42 1-methyl-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole (Compound 186)

[0186] 1,4-Dioxane (3 mL) was transferred to a microwave vial (Smith Creator[®]) containing 3-chloro-2-(3-methylphenyl)pyridine (100 mg, 0.49 mmol), 1-methyl-1H-benzimidazole boronic acid (95 mg, 0.54 mmol), $\text{PdCl}_2(\text{dppf})_2 \cdot \text{CH}_2\text{Cl}_2$ (35 mg, 0.042 mmol) and 2M aq. Na_2CO_3 (0.6 mL, 1.2 mmol). Slow stream of argon was bubbled through the heterogeneous red solution while stirring the reaction mixture. The vial was capped and heated in a microwave at 150 °C for 50 min. Progress of the reaction was analyzed by LC/MS. The reaction mixture was passed through a pad of Celite[®] and washed the pad with EtOAc (10 mL). The filtrate was concentrated and purified by preparative HPLC. Subsequently, product fractions were concentrated, diluted with water, neutralized with aq. NaHCO_3 and extracted with EtOAc. Organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated. The concentrate was dissolved in acetonitrile/water (1:1, 15 mL) and allowed to freeze by external cooling in dry ice/acetone. Lyophilization of the frozen residue resulted in an off-white solid of 1-methyl-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole. ¹H NMR (DMSO-d₆): δ 8.64 (dd, 1H, J = 1.7 and 4.7 Hz), 8.16 (s, 1H), 7.87 (dd, 1H, J = 1.7 and 7.6 Hz), 7.51 (d, 1H, J = 1.5 Hz), 7.47-7.43 (m, 2H), 7.27 (s, 1H), 7.03-6.97 (m, 2H), 6.90 (app d, 1H, J = 6.7 Hz), 6.85 (dd, 1H, J = 8.5 Hz), 3.76 (s, 3H), 2.19 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -114.29 (s). LCMS: rt 3.16 min (A), purity 97 %, MS (m/e) 300 (MH⁺).

Example 43

[0187] The following analogs are prepared by the reaction of respective 3-chloro-2-arylpyridine and benzimidazole boronic acids by identical reaction conditions and followed by compound purification procedure as discussed with the previous reaction.


[0188] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 187). ¹H NMR (DMSO-d₆): δ 8.63 (dd, 1H, J = 1.7 and 4.7 Hz), 8.17 (s, 1H), 7.86 (dd, 1H, J = 1.7 and 7.6 Hz), 7.53 (s, 1H), 7.48 (d, 1H, J = 8.2 Hz), 7.46 (dd, 1H, J = 4.7 and 7.9

Hz), 7.38 (d, 1H, J = 7.9 Hz), 6.92-6.83 (m, 3H), 3.77 (s, 3H), 2.12 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.91 (s). LCMS: rt 3.51 min (A), purity 97 %, MS (m/e) 318 (MH⁺).

[0189] 1-Methyl-5-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole (Compound 188). ¹H NMR (DMSO-d₆): δ 8.62 (dd, 1H, J = 1.4 and 4.7 Hz), 8.15 (s, 1H), 7.82 (dd, 1H, J = 1.4 and 7.6 Hz), 7.48-7.40 (m, 3H), 7.28 (s, 1H), 7.02-6.98 (m, 3H), 6.88 (d, 1H, J = 7.2 Hz), 3.79 (s, 3H), 2.19 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.91 (s). LCMS: rt 3.26 min (A), purity 97 %, MS (m/e) 300 (MH⁺).

[0190] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 189). ¹H NMR (DMSO-d₆): δ 8.62 (dd, 1H, J = 1.7 and 4.7 Hz), 8.16 (s, 1H), 7.82 (dd, 1H, J = 1.7 and 7.6 Hz), 7.49-7.37 (m, 4H), 7.00 (dd, 1H, J = 1.4 and 8.5 Hz), 6.91-6.83 (m, 2H), 3.80 (s, 3H), 2.13 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -119.03 (s). LCMS: rt 3.68 min (A), MS (m/e) 318 (MH⁺).

Example 44 General synthetic method B:



[0191] 1,4-Dioxane (3 mL) was transferred to a microwave vial (Smith Creator[®]) containing 2-chloro-3-arylpyridine (1eq), respective arylboronic acid/or pinacol ester (1.2-1.3 eq). PdCl₂(PPh₃)₂ (0.1 eq), and 2M aq. Na₂CO₃ (2.2 eq). Slow stream of argon was bubbled through the heterogeneous solution while stirring the reaction mixture. The vial was capped and heated in a microwave at 150 °C for 50 min. Progress of the reaction was analyzed by LC/MS. At the end of the microwave heating, the reaction mixture was passed through a pad of Celite[®] and washed the pad with EtOAc (10 mL). The filtrate was concentrated and purified by preparative HPLC. Subsequently, product fractions were concentrated, diluted with water, neutralized with aq. NaHCO₃ and extracted with EtOAc. Organic layer was dried over anhydrous Na₂SO₄, polish filtered and concentrated. The concentrate was dissolved in acetonitrile/water (1:1, 15 mL) and allowed to freeze by external cooling in dry ice/acetone. Lyophilization of the frozen residue provided respective analogs for further characterization.

[0192] The following compounds were prepared as described in Example 44 by use of the appropriate arylboronic acid/or pinacol ester:

[0193] 5-(5-Ethoxy-2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 1). ¹H NMR (CD₃OD, 300 MHz): 8.43 (s, 1H), 8.06 (s, 1H), 8.00 (m, 1H), 7.77 (bs, 1H), 7.47 (m, 1H), 7.35 (m, 1H), 7.15-7.05 (m, 2H), 6.99 (m, 1H), 4.34 (q, 2H), 2.17 (s, 3H), 1.51 (t, 3H); MS (ES) 348.32 (M+H);

[0194] 5-(5-Ethoxy-2-(2-fluorophenyl)pyridin-3-yl)-1H-indazole (Compound 2). ¹H NMR (CD₃OD, 300 MHz): 8.12 (s, 1H), 8.05 (bs, 1H), 7.87 (s, 1H), 7.67-7.44 (m, 7H), 6.99 (m, 1H), 4.17 (q, 2H), 1.43 (t, 3H); MS (ES) 334.32 (M+H);

[0195] 5-(5-Ethoxy-2-m-tolylpyridin-3-yl)-1H-indazole (Compound 3). ¹H NMR (CD₃OD, 300 MHz): 8.41 (s, 1H), 8.03 (s, 1H), 8.01 (m, 1H), 7.73 (s, 1H), 7.45 (m, 1H), 7.32- 7.08 (m, 4H), 7.02 (m, 1H), 4.38 (q, 2H), 2.13 (s, 3H), 1.48 (t, 3H); MS (ES) 330.33 (M+H);

[0196] 5-(5-Ethoxy-2-(4-fluoro-2-isopropoxyphenyl)pyridin-3-yl)-1H-indazole (Compound 4). ¹H NMR (CD₃OD, 300 MHz): 8.13 (s, 1H), 8.08 (s, 1H), 8.01 (m, 1H), 7.77 (bs, 1H), 7.49 (m, 1H), 7.36 (m, 1H), 7.11-7.02 (m, 3H), 4.34 (q, 2H), 4.23 (t, 1H), 1.48 (t, 3H), 1.41 (d, 6H); MS (ES) 392.36 (M+H);

[0197] 5-(5-Ethoxy-2-(3-fluorophenyl)pyridin-3-yl)-1H-indazole (Compound 5). ¹H NMR (CD₃OD, 300 MHz): 8.29 (m, 1H), 8.01 (s, 1H), 7.68 (s, 1H), 7.46 (m, 2H), 7.17 (m, 2H), 6.99-6.94 (m, 3H), 4.22 (q, 2H), 1.46 (t, 3H); MS (ES) 334.34 (M+H);

[0198] 5-(5-Ethoxy-2-(4-fluorophenyl)pyridin-3-yl)-1H-indazole (Compound 6). ¹H NMR (CD₃OD, 300 MHz): 8.40 (m, 1H), 8.06 (s, 1H), 8.01 (m, 1H), 7.82 (bs, 1H), 7.44(m, 1H), 7.26 (m, 2H), 7.12 (m, 2H), 7.03 (m, 1H), 4.34 (q, 2H), 1.51 (t, 3H); MS (ES) 334.33 (M+H);

[0199] 5-(5-Ethoxy-2-(3, 4-difluorophenyl)pyridin-3-yl)-1H-indazole (Compound 7). ¹H NMR (CD₃OD, 300 MHz): 8.53 (s, 1H), 8.02 (s, 1H), 7.96 (m, 1H), 7.77 (bs, 1H), 7.43 (m, 1H), 7.38 (m, 1H), 7.12 (m, 2H), 7.02 (m, 1H), 4.36 (q, 2H), 1.49 (t, 3H); MS (ES) 352.31 (M+H);

[0200] 5-(2-(4-Fluoro-3-methylphenyl)-5-methoxypyridin-3-yl)-1H-indazole (Compound 8). ¹H NMR (CD₃OD, 300 MHz): 8.28 (bs, 1H), 8.02 (s, 1H), 7.64-7.39 (m, 3H), 7.18 (m, 1H), 7.09 (m, 1H), 6.96 (m, 1H), 6.80 (m, 1H), 3.95 (s, 3H), 2.11 (s, 3H); MS (ES) 334.46 (M+H);

[0201] 5-(5-Chloro-2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 9). ¹H NMR (CD₃OD, 300 MHz): 8.59 (bs, 1H), 8.02 (m, 1H), 7.94 (m, 1H), 7.70 (s, 1H), 7.59 (m,

1H), 7.25 (m, 1H), 7.12 (m, 1H), 7.02 (m, 1H), 6.84 (m, 1H), 2.12 (s, 3H); MS (ES) 338.29 (M+H);

[0202] 5-(5-Fluoro-2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 10). ¹H NMR (CD₃OD, 300 MHz): 8.50 (bs, 1H), 8.03 (s, 1H), 7.76 (m, 1H), 7.70 (m, 1H), 7.41 (m, 1H), 7.20 (m, 1H), 7.12 (m, 1H), 7.01 (m, 1H), 6.84 (m, 1H), 2.12 (s, 3H); MS (ES) 322.31 (M+H);

[0203] 5-(2-(4-Fluoro-3-methylphenyl)-5-methylpyridin-3-yl)-1H-indazole (Compound 11). ¹H NMR (CD₃OD, 300 MHz): 8.67 (bs, 1H), 8.53 (s, 1H), 8.07 (s, 1H), 7.79 (m, 1H), 7.51 (m, 1H), 7.36 (m, 1H), 7.17 (m, 2H), 7.02 (m, 1H), 2.65 (s, 3H), 2.20 (s, 3H); MS (ES) 318.36 (M+H);

[0204] 5-(2-(4-Fluoro-3-methylphenyl)-6-methylpyridin-3-yl)-1H-indazole (Compound 12). ¹H NMR (CD₃OD, 300 MHz): 8.53 (m, 1H), 8.06 (s, 1H), 7.90 (m, 1H), 7.75 (bs, 1H), 7.49 (m, 1H), 7.41 (m, 1H), 7.19-7.02 (m, 3H), 2.86 (s, 3H), 2.22 (s, 3H); MS (ES) 318.30 (M+H);

[0205] 5-(2-(4-Cyclopropylphenyl)-6-methylpyridin-3-yl)-1H-indazole (Compound 13). ¹H NMR (CD₃OD, 300 MHz): 8.49 (m, 1H), 8.04 (s, 1H), 7.89 (m, 1H), 7.74 (s, 1H), 7.47 (m, 1H), 7.28 (m, 2H), 7.10 (m, 3H), 2.86 (s, 3H), 1.92 (m, 1H), 1.03 (m, 2H), 0.69 (m, 2H); MS (ES) 326.28 (M+H);

[0206] 5-(2-(3-Isopropylphenyl)-6-methylpyridin-3-yl)-1H-indazole (Compound 14). ¹H NMR (CD₃OD, 300 MHz): 8.55 (m, 1H), 8.03 (s, 1H), 7.92 (m, 1H), 7.72 (s, 1H), 7.47-7.35 (m, 4H), 7.13 (m, 2H), 2.87 (s, 3H), 2.75 (t, 1H), 0.98 (3H), 0.96 (3H); MS (ES) 328.31 (M+H);

[0207] 6-(3-Cyclopropylphenyl)-5-(1H-indazol-5-yl)pyridin-3-amine (Compound 15). ¹H NMR (CD₃OD, 300 MHz): 8.01 (m, 2H), 7.60 (s, 1H), 7.36 (m, 1H), 7.25 (m, 1H), 7.06-6.93 (m, 4H), 6.76 (s, 1H), 1.69 (m, 1H), 0.73 (m, 2H), 0.27 (m, 2H); MS (ES) 327.27 (M+H);

[0208] 5-(1H-Indazol-5-yl)-6-(3-isopropylphenyl)pyridin-3-amine (Compound 16). ¹H NMR (CD₃OD, 300 MHz): 8.03 (m, 1H), 8.00 (s, 1H), 7.80 (m, 1H), 7.71 (m, 1H), 7.47 (m, 1H), 7.32-7.10 (m, 4H), 7.00 (s, 1H), 2.65 (t, 1H), 0.94 (d, 6H); MS (ES) 329.29 (M+H);

[0209] 6-(4-Fluoro-3-methylphenyl)-5-(1H-indazol-5-yl)pyridin-3-amine (Compound 17). ¹H NMR (CD₃OD, 300 MHz): 8.82 (m, 1H), 8.41 (s, 1H), 8.20 (m, 1H), 8.01 (m, 2H), 7.62 (m, 1H), 7.32 (m, 1H), 7.05-6.82 (m, 2H), 2.12 (s, 3H); MS (ES) 319.12 (M+H);

- [0210] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-amine (Compound 18). ¹H NMR (CD₃OD, 300 MHz): 9.21 (s, 1H), 8.05 (s, 1H), 7.92 (m, 2H), 7.62 (m, 1H), 7.29 (m, 1H), 7.26-7.17 (m, 1H), 6.88 (m, 1H), 6.77 (m, 1H), 2.12 (s, 3H); MS (ES) 336.25 (M+H);
- [0211] 5-(Benzo[d]thiazol-6-yl)-6-(3-cyclopropylphenyl)pyridin-3-amine (Compound 19). ¹H NMR (CD₃OD, 300 MHz): 9.21 (s, 1H), 8.05 (m, 1H), 7.91 (m, 1H), 7.84 (s, 1H), 7.29 (m, 1H), 7.25 (m, 1H), 7.08-6.93 (m, 3H), 6.75 (s, 1H), 1.70 (m, 1H), 0.73 (m, 2H), 0.27 (m, 2H); MS (ES) 344.28 (M+H);
- [0212] 5-(Benzo[d]thiazol-6-yl)-6-m-tolylpyridin-3-amine (Compound 20). ¹H NMR (CD₃OD, 300 MHz): 9.21 (s, 1H), 8.06 (s, 1H), 7.91 (s, 1H), 8.84 (m, 1H), 7.29-7.01 (m, 5H), 6.90 (m, 1H), 2.19 (s, 3H); MS (ES) 318.28 (M+H);
- [0213] 6-(4-Fluoro-3-methylphenyl)-5-(1H-indazol-5-yl)pyridin-2-amine (Compound 21). ¹H NMR (CD₃OD, 300 MHz): 8.10 (m, 1H), 8.01 (s, 1H), 7.66 (s, 1H), 7.42 (m, 1H), 7.31 (m, 1H), 7.13-7.00 (m, 3H), 6.96 (m, 1H), 2.19 (s, 3H); MS (ES) 319.25 (M+H);
- [0214] 6-(3-Cyclopropylphenyl)-5-(1H-indazol-5-yl)pyridin-2-amine (Compound 22). ¹H NMR (CD₃OD, 300 MHz): 8.09 (m, 1H), 8.00 (s, 1H), 7.63 (s, 1H), 7.44 (m, 1H), 7.27-7.11 (m, 5H), 6.95 (s, 1H), 1.80 (m, 1H), 0.84 (m, 2H), 0.37 (m, 2H); MS (ES) 327.28 (M+H);
- [0215] 5-(1H-Indazol-5-yl)-6-m-tolylpyridin-2-amine (Compound 23). ¹H NMR (CD₃OD, 300 MHz): 8.10 (m, 1H), 8.07 (s, 1H), 7.65 (s, 1H), 7.42 (m, 1H), 7.24 (m, 3H), 7.08 (m, 3H), 2.27 (s, 3H); MS (ES) 301.26 (M+H);
- [0216] N-(6-(4-Fluoro-3-methylphenyl)-5-(1H-indazol-5-yl)pyridin-3-yl)acetamide (Compound 24). ¹H NMR (CD₃OD, 300 MHz): 9.21 (s, 1H), 8.38 (m, 1H), 8.07 (s, 1H), 7.76 (s, 1H), 7.50 (m, 1H), 7.32 (m, 1H), 7.11 (m, 2H), 6.98 (m, 1H), 2.25 (s, 3H), 2.18 (s, 3H); MS (ES) 361.21 (M+H);
- [0217] N-(6-(3-Cyclopropylphenyl)-5-(1H-indazol-5-yl)pyridin-3-yl)acetamide (Compound 25). ¹H NMR (CD₃OD, 300 MHz): 9.24 (s, 1H), 8.38 (m, 1H), 8.06 (s, 1H), 7.74 (m, 1H), 7.49 (m, 1H), 7.26-7.11 (m, 3H), 6.95 (s, 1H), 2.25 (s, 3H), 1.82 (m, 1H), 0.85 (m, 2H), 0.37 (m, 2H); MS (ES) 369.27 (M+H);
- [0218] N-(5-(1H-Indazol-5-yl)-6-m-tolylpyridin-3-yl)acetamide (Compound 26). ¹H NMR (CD₃OD, 300 MHz): 9.25 (s, 1H), 8.40 (m, 1H), 8.05 (s, 1H), 7.74 (s, 1H), 7.48 (m, 1H), 7.24-7.06 (m, 4H), 2.26 (s, 3H), 2.25 (s, 3H); MS (ES) 343.27 (M+H);

- [0219] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-2-amine (Compound 27). ¹H NMR (CD₃OD, 300 MHz): 9.26 (s, 1H), 8.11(m, 1H), 8.08 (s, 1H), 7.95 (m, 1H), 7.35 (m, 2H), 7.11 (m, 2H), 7.01 (m, 1H), 2.20 (s, 3H); MS (ES) 336.26 (M+H);
- [0220] 5-(Benzo[d]thiazol-6-yl)-6-(3-cyclopropylphenyl)pyridin-2-amine (Compound 28). ¹H NMR (CD₃OD, 300 MHz): 9.26 (s, 1H), 8.12 (m, 1H), 8.09 (m, 1H), 7.92 (s, 1H), 7.30-7.10 (m, 4H), 6.97 (s, 1H), 1.81 (m, 1H), 0.85 (m, 2H), 0.38 (m, 2H); MS (ES) 344.33 (M+H);
- [0221] 5-(Benzo[d]thiazol-6-yl)-6-m-tolylpyridin-2-amine (Compound 29). ¹H NMR (CD₃OD, 300 MHz): 9.25 (s, 1H), 8.12 (m, 1H), 7.95 (m, 2H), 7.31-7.10 (m, 3H), 7.08 (m, 2H), 2.28 (s, 3H); MS (ES) 318.31 (M+H);
- [0222] N-(6-(4-Fluoro-3-methylphenyl)-5-(1H-indazol-5-yl)pyridin-3-yl)methanesulfonamide (Compound 30). ¹H NMR (CD₃OD, 300 MHz): 8.57 (s, 1H), 8.06 (s, 1H), 8.02 (m, 1H), 7.74 (m, 1H), 7.48 (m, 2H), 7.29 (m, 1H), 7.11 (m, 1H), 6.93 (m, 1H), 3.19 (s, 3H), 2.16 (s, 3H); MS (ES) 397.21 (M+H);
- [0223] N-(6-(3-Cyclopropylphenyl)-5-(1H-indazol-5-yl)pyridin-3-yl) methanesulfonamide (Compound 31). ¹H NMR (CD₃OD, 300 MHz): 8.58 (s, 1H), 8.08 (m, 2H), 7.72 (s, 1H), 7.47 (m, 1H), 7.21-7.10 (m, 4H), 6.92 (s, 1H), 3.20 (s, 3H), 1.77 (m, 1H), 0.81 (m, 2H), 0.34 (m, 2H); MS (ES) 405.26 (M+H);
- [0224] N-(5-(1H-Indazol-5-yl)-6-m-tolylpyridin-3-yl) methanesulfonamide (Compound 32). ¹H NMR (CD₃OD, 300 MHz): 8.61 (s, 1H), 8.15 (m, 1H), 8.05 (s, 1H), 7.74 (s, 1H), 7.48 (m, 1H), 7.44 (m, 1H), 7.23-7.05 (m, 4H), 3.23 (s, 3H), 2.26 (s, 3H); MS (ES) 379.25 (M+H).
- [0225] 6-(2-*m*-Tolylpyridin-3-yl)isoquinoline (Compound 33). ¹H NMR (DMSO-d₆): δ 9.77 (s, 1H), 9.03 – 8.73 (m, 1H), 8.65 (d, *J* = 6.4 Hz, 1H), 8.34 (dd, *J* = 18.1, 8.1 Hz, 3H), 8.22 – 8.03 (m, 1H), 7.67 (ddd, *J* = 7.8, 5.0, 1.2 Hz, 1H), 7.58 (dd, *J* = 8.6, 1.4 Hz, 1H), 7.27 (s, 1H), 7.07 (dt, *J* = 15.0, 7.5 Hz, 2H), 6.95 (d, *J* = 7.5 Hz, 1H), 2.17 (s, 3H). MS (m/e): 297 (MH⁺).
- [0226] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)isoquinoline (Compound 34). ¹H NMR (DMSO-d₆): δ 9.79 (s, 1H), 8.83 – 8.72 (m, 1H), 8.66 (d, *J* = 6.4 Hz, 1H), 8.45 – 8.22 (m, 3H), 8.09 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.71 – 7.51 (m, 2H), 7.38 (d, *J* = 7.4 Hz, 1H), 6.97 – 6.88 (m, 2H), 2.09 (s, 3H). MS (m/e): 315 (MH⁺).
- [0227] 6-(2-(3-Fluorophenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine (Compound 59). ¹H NMR (DMSO-d₆): δ 9.05 – 8.98 (m, 1H), 8.79 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.37 – 8.30 (m, 1H), 8.20 (d,

$J = 2.1$ Hz, 1H), 8.02 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.85 (d, $J = 9.3$ Hz, 1H), 7.67 – 7.47 (m, 2H), 7.42 – 7.23 (m, 2H), 7.23 – 7.07 (m, 2H). MS (m/e): 290 (MH⁺).

[0228] N-(3-(3-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)phenyl)methylsulphonamide (Compound 58). ¹H NMR (DMSO-d₆): δ 9.63 (s, 1H), 9.02 (s, 1H), 8.79 (dd, $J = 4.8, 1.2$ Hz, 1H), 8.33 (d, $J = 2.0$ Hz, 1H), 8.19 (d, $J = 2.0$ Hz, 1H), 8.01 (dd, $J = 7.8, 1.3$ Hz, 1H), 7.85 (d, $J = 9.4$ Hz, 1H), 7.60 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.46 (dd, $J = 9.3, 1.2$ Hz, 1H), 7.33 (d, $J = 5.9$ Hz, 2H), 7.12 (dd, $J = 10.0, 6.8$ Hz, 2H), 2.71 (s, 3H). MS (m/e): 366 (MH⁺).

[0229] 3-(3-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)benzenamine (Compound 56). ¹H NMR (DMSO-d₆): δ 9.04 (d, $J = 3.5$ Hz, 1H), 8.80 (dd, $J = 4.8, 0.7$ Hz, 1H), 8.34 (d, $J = 2.1$ Hz, 1H), 8.24 – 8.16 (m, 1H), 8.03 (dd, $J = 7.8, 0.9$ Hz, 1H), 7.85 (d, $J = 9.3$ Hz, 1H), 7.62 (dd, $J = 7.5, 5.1$ Hz, 1H), 7.47 (dd, $J = 9.3, 0.9$ Hz, 1H), 7.39 – 7.09 (m, 4H). MS (m/e): 287 (MH⁺).

[0230] 6-(2-(3,5-Difluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 55). ¹H NMR (DMSO-d₆): δ 9.04 – 8.96 (m, 1H), 8.78 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.35 (d, $J = 2.0$ Hz, 1H), 8.21 (d, $J = 2.1$ Hz, 1H), 8.03 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.88 (d, $J = 9.3$ Hz, 1H), 7.60 (ddd, $J = 11.0, 8.6, 3.2$ Hz, 2H), 7.27 – 6.96 (m, 3H). MS (m/e): 308 (MH⁺).

[0231] 6-(2-(4-Trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 57). ¹H NMR (DMSO-d₆): δ 9.04 (s, 1H), 8.82 (dd, $J = 4.7, 1.1$ Hz, 1H), 8.34 (s, 1H), 8.20 (d, $J = 2.0$ Hz, 1H), 8.04 (dd, $J = 7.8, 1.1$ Hz, 1H), 7.85 (d, $J = 9.3$ Hz, 1H), 7.72 – 7.54 (m, 5H), 7.50 (d, $J = 9.3$ Hz, 1H). MS (m/e): 340 (MH⁺).

[0232] 6-(2-(4-Methoxyphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 54). ¹H NMR (DMSO-d₆): δ 9.03 (s, 1H), 8.79 (dd, $J = 4.9, 1.5$ Hz, 1H), 8.35 (d, $J = 1.5$ Hz, 1H), 8.20 (d, $J = 2.0$ Hz, 1H), 8.08 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.85 (d, $J = 9.3$ Hz, 1H), 7.64 (dd, $J = 7.8, 5.0$ Hz, 1H), 7.48 (dd, $J = 9.3, 1.5$ Hz, 1H), 7.40 – 7.30 (m, 2H), 6.86 (d, $J = 8.8$ Hz, 2H), 3.72 (s, 3H). MS (m/e): 302 (MH⁺).

[0233] 6-(2-(3-Methoxyphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 52). ¹H NMR (DMSO-d₆): δ 8.98 (s, 1H), 8.78 (d, $J = 4.8$ Hz, 1H), 8.30 (s, 1H), 8.17 (d, $J = 1.0$ Hz, 1H), 8.05 (d, $J = 7.2$ Hz, 1H), 7.81 (d, $J = 9.3$ Hz, 1H), 7.63 (dd, $J = 7.8, 4.9$ Hz, 1H), 7.50 (d, $J = 9.4$ Hz, 1H), 7.16 (t, $J = 7.9$ Hz, 1H), 7.02 (s, 1H), 6.94 – 6.77 (m, 3H), 3.64 (s, 3H). MS (m/e): 302 (MH⁺).

[0234] 3-(3-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)benzotrile (Compound 51). ¹H NMR (DMSO-d₆): δ 9.01 (s, 1H), 8.81 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.33 (d, $J = 2.0$ Hz, 1H), 8.20 (d, $J =$

2.1 Hz, 1H), 8.03 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.91 (d, $J = 1.6$ Hz, 1H), 7.88 – 7.74 (m, 2H), 7.66 – 7.60 (m, 2H), 7.56 – 7.37 (m, 2H). MS (m/e): 297

[0235] 6-(2-(4-Fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 53). ^1H NMR (DMSO- d_6): δ 9.01 (s, 1H), 8.78 (dd, $J = 4.8, 1.5$ Hz, 1H), 8.37 – 8.30 (m, 1H), 8.20 (d, $J = 1.2$ Hz, 1H), 8.02 (d, $J = 7.7$ Hz, 1H), 7.84 (d, $J = 9.4$ Hz, 1H), 7.60 (dd, $J = 7.8, 4.9$ Hz, 1H), 7.54 – 7.38 (m, 3H), 7.11 (t, $J = 8.7$ Hz, 2H). MS (m/e): 290 (MH^+).

[0236] 5-(2-(2-Fluorophenyl)pyridin-3-yl)-1H-indazole (Compound 61). ^1H NMR (DMSO- d_6): δ 13.05 (s, 1H), 8.66 (dd, 1H, $J = 1.4$ and 4.7 Hz), 7.98 (s, 1H), 7.90 (dd, 1H, $J = 1.4$ and 7.6 Hz), 7.56 (app s, 1H), 7.51 (dd, 1H, $J = 4.7$ and 7.9 Hz), 7.44-7.32 (m, 2H), 7.31-7.27 (m, 1H), 7.16 (dt, 1H, $J = 0.8$ and 7.6 Hz), 7.01 (dd, 1H, $J = 1.4$ and 8.5 Hz), 6.96 (app t, 1H, $J = 8.5$ Hz). ^{19}F NMR (DMSO- d_6): δ -118.91. LCMS: rt 4.65 min (A), purity 97 %, MS (m/e) 290 (MH^+).

[0237] 5-(2-(3,4-Difluorophenyl)pyridin-3-yl)-1H-indazole (Compound 62). LCMS: rt 5.20 min (A), purity 98 %, MS (m/e) 308 (MH^+).

[0238] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 63). ^1H NMR (DMSO- d_6): δ 13.05 (s, 1H), 8.62 (dd, 1H, $J = 0.5$ and 4.7 Hz), 8.04 (s, 1H), 7.83 (d, 1H, $J = 7.6$ Hz), 7.66 (s, 1H), 7.45-7.34 (app m, 3H), 7.02 (d, 1H, $J = 8.5$ Hz), 6.96-6.85 (m, 2H), 2.11 (s, 3H). ^{19}F NMR (DMSO- d_6): δ -118.91. LCMS: rt 4.87 min (A), purity 99 % MS (m/e) 304 (MH^+).

[0239] 5-(3-(1H-Indazol-5-yl)pyridin-2-yl)-1H-indazole (Compound 64). ^1H NMR (DMSO- d_6): δ 13.04 (s, 1H), 12.99 (s, 1H), 8.66 (dd, 1H, $J = 1.2$ and 4.7 Hz), 8.01 (s, 1H), 7.95 (s, 1H), 7.85 (dd, 1H, $J = 1.2$ and 7.9 Hz), 7.74 (s, 1H), 7.69 (s, 1H), 7.44 (dd, 1H, $J = 4.7$ and 7.9 Hz), 7.34 (d, 1H, $J = 8.8$ Hz), 7.30 (d, 1H, $J = 8.8$ Hz), 7.22 (dd, 1H, $J = 1.4$ and 8.8 Hz), 7.01 (d, 1H, $J = 8.8$ Hz). LCMS: rt 3.87 min (A), purity 97 %, MS (m/e) 312 (MH^+).

[0240] 5-[2-(3-Fluorophenyl)pyridin-3-yl]-1H-indazole (Compound 65). ^1H NMR (DMSO- d_6): δ 13.10 (s, 1H), 8.68 (dd, 1H, $J = 1.4$ and 4.4 Hz), 8.05 (s, 1H), 7.92 (dd, 1H, $J = 1.4$ and 7.9 Hz), 7.67 (s, 1H), 7.53 (dd, 1H, $J = 4.9$ and 7.6 Hz), 7.43 (d, 1H, $J = 8.5$ Hz), 7.26-7.13 (m, 1H), 7.14-7.02 (m, 4H). ^{19}F NMR (DMSO- d_6): δ -113.58 (qt, $J = 8.6$ Hz) (s). LCMS: rt 4.73 min (A), purity 99 %, MS (m/e) 290 (MH^+).

[0241] 5-[2-(4-Fluorophenyl)pyridin-3-yl]-1H-indazole (Compound 66). ^1H NMR (DMSO- d_6): δ 13.12 (s, 1H), 8.65 (dd, 1H, $J = 1.7$ and 4.7 Hz), 8.04 (s, 1H), 7.89 (dd, 1H, $J = 1.7$ and 7.9

Hz), 7.66 (s, 1H), 7.48 (dd, 1H, J = 4.7 and 7.6 Hz), 7.41 (d, 1H, J = 8.2 Hz), 7.34-7.29 (m, 2H), 7.07-6.99 (m, 3H). ¹⁹F NMR (DMSO-d₆): δ -114.12 (qt, J = 8.6 Hz) (s). LCMS: rt 4.53 min (A), purity 97 %, MS (m/e) 290 (MH⁺).

[0242] 5-[2-(3,5-Difluorophenyl)pyridin-3-yl]-1H-indazole (Compound 67). ¹H NMR (DMSO-d₆): δ 13.12 (s, 1H), 8.65 (dd, 1H, J = 1.7 and 4.7 Hz), 8.07 (s, 1H), 7.89 (dd, 1H, J = 1.7 and 7.6 Hz), 7.68 (s, 1H), 7.54 (dd, 1H, J = 4.7 and 7.6 Hz), 7.46 (d, 1H, J = 8.2 Hz), 7.14-7.04 (m, 2H), 6.94-6.90 (m, 2H). ¹⁹F NMR (DMSO-d₆): δ -110.30 (t, J = 7.8 Hz) . LCMS: rt 5.62 min (A), purity 97 %, MS (m/e) 308 (MH⁺).

[0243] 5-(2-*m*-Tolylpyridin-3-yl)-1H-indazole (Compound 68). ¹H NMR (DMSO-d₆): δ 13.12 (s, 1H), 8.70 (dd, 1H, J = 1.7 and 4.7 Hz), 8.06-8.03 (m, 2H), 7.67 (s, 1H), 7.60 (dd, 1H, J = 4.7 and 7.6 Hz), 7.42 (d, 1H, J = 7.8 Hz), 7.28 (s, 1H), 7.08-6.94 (m, 4H), 2.19 (s, 3H). LCMS: rt 4.62 min (A), purity 97 %, MS (m/e) 286 (MH⁺).

[0244] 5-(2-*p*-Tolylpyridin-3-yl)-1H-indazole (Compound 69). ¹H NMR (DMSO-d₆): δ 13.38 (s, 1H), 8.64 (dd, 1H, J = 1.7 and 4.9 Hz), 8.03 (s, 1H), 7.86 (dd, 1H, J = 1.4 and 7.6 Hz), 7.65 (s, 1H), 7.46 (dd, 1H, J = 4.9 and 7.6 Hz), 7.39 (d, 1H, J = 8.8 Hz), 7.18 (d, 2H, J = 8.2 Hz), 7.03-6.99 (m, 3H), 2.21 (s, 3H). LCMS: rt 4.65 min (A), purity 97 %, MS (m/e) 286 (MH⁺).

[0245] 5-[2-(2,4-Difluorophenyl)pyridin-3-yl]-1H-indazole (Compound 70). ¹H NMR (DMSO-d₆): δ 13.28 (s, 1H), 8.67 (dd, 1H, J = 1.4 and 4.8 Hz), 8.01 (s, 1H), 7.94 (dd, 1H, J = 1.4 and 7.9 Hz), 7.58-7.44 (m, 3H), 7.40 (d, 1H, J = 8.5 Hz), 7.10-7.00 (app m, 3 H). ¹⁹F NMR (DMSO-d₆): δ -110.06 (q, J = 8.6 Hz), -110.56 (qt, J = 8.6 Hz) LCMS: rt 5.07 min (A), purity 97 %, MS (m/e) 308 (MH⁺).

[0246] 5-[2-(3,5-Dimethylphenyl)pyridin-3-yl]-1H-indazole (Compound 71). ¹H NMR (DMSO-d₆): δ 13.38 (s, 1H), 8.73 (dd, 1H, J = 1.4 and 4.9 Hz), 8.15 (dd, 1H, J = 1.7 and 7.9 Hz), 8.06 (s, 1H), 7.69 (app t, 2H, J = 6.7 Hz), 7.86 (dd, 1H, J = 1.4 and 7.6 Hz), 7.43 (d, 1H, J = 8.5 Hz), 7.03 (dd, 1H, J = 1.7 and 8.8 Hz), 6.94 (s, 3H), 2.09 (s, 6H). LCMS: rt 4.93 min (A), purity 97 %, MS (m/e) 300 (MH⁺).

[0247] 5-(2-(3-Fluoro-4-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 72). ¹H NMR (DMSO-d₆): δ 8.72 (dd, 1H, J = 1.4 and 4.9 Hz), 8.07 (d, 1H, J = 0.8 Hz), 8.06 (dd, 1H, J = 1.4 and 7.9 Hz), 7.69 (app d, 1H, J = 0.8 Hz), 7.62 (dd, 1H, J = 4.9 and 7.9 Hz), 7.44 (d, 1H, J = 8.8Hz), 7.15-7.09 (m, 2H), 7.04 (dd, 1H, J = 1.7 and 8.5 Hz), 6.97 (dd, 1H, J = 1.7 and 7.9 Hz), 2.19 (s, 3H). LCMS: rt 4.98 min (A), purity 97 %, MS (m/e) 304 (MH⁺).

[0248] 5-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 73). ¹H NMR (DMSO-d₆): δ 13.28 (s, 1H), 8.72 (dd, 1H, J = 1.4 and 4.7 Hz), 8.05 (dd, 1H, J = 1.4 and 7.9 Hz), 8.01 (s, 1H), 7.64 (dd, 1H, J = 4.9 and 7.9 Hz), 7.60 (s, 1H), 7.39 (d, 1H, J = 8.8 Hz), 7.32 (d, 1H, J = 1.8 and 8.8 Hz), 7.17-7.14 (m, 1H), 7.07 (dd, 1H, J = 1.7 and 8.5 Hz), 6.86 (app t, 1H, J = 7.6 Hz), 2.25 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -119.68. LCMS: rt 4.95 min (A), purity 97 %, MS (m/e) 304 (MH⁺).

[0249] 5-(2-(2-Fluoro-4-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 74). ¹H NMR (DMSO-d₆): δ 13.43 (s, 1H), 8.73 (dd, 1H, J = 1.4 and 4.9 Hz), 8.11 (dd, 1H, J = 1.4 and 7.9 Hz), 8.02 (s, 1H), 7.69 (dd, 1H, J = 4.9 and 7.9 Hz), 7.61 (s, 1H), 7.40 (d, 1H, J = 8.8 Hz), 7.33 (t, 1H, J = 7.6 Hz), 7.06 (dd, 1H, J = 1.4 and 8.5 Hz), 7.01 (d, 1H, J = 7.6 Hz), 6.86 (d, 1H, J = 11 Hz), 2.25 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -115.46 (dd, J = 7.6 and 11 Hz). LCMS: rt 4.88 min (A), purity 97 %, MS (m/e) 304 (MH⁺).

[0250] 5-(2-(3-Aminophenyl)pyridin-3-yl)-1H-indazole (Compound 75). LCMS: rt 3.43 min (A), purity 97 %, MS (m/e) 287 (MH⁺).

[0251] 5-(2-(3-Methylsulfonylamino)phenyl)pyridin-3-yl)-1H-indazole (Compound 76). ¹H NMR (DMSO-d₆): δ 9.67 (s, 1H), 8.72 (dd, 1H, J = 1.4 and 4.9 Hz), 8.06 (d, 1H, J = 7.9 Hz), 8.05 (s, 1H), 7.67 (s, 1H), 7.64 (dd, 1H, J = 4.9 and 7.6 Hz), 7.42 (d, 1H, J = 8.5 Hz), 7.21 (d, 1H, J = 7.9 Hz), 7.18 (s, 1H), 7.10-7.02 (m, 3H), 2.56 (s, 3H). LCMS: rt 3.97 min (A), purity 97 %, MS (m/e) 365 (MH⁺).

[0252] 5-(2-(3,4-Difluorophenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 77). ¹H NMR (DMSO-d₆): δ 13.65 (s, 1H), 8.70 (d, 1H, J = 4.7 Hz), 8.22 (s, 1H), 8.14 (s, 2H), 7.96 (d, 1H, J = 7.6 Hz), 7.53 (dd, 1H, J = 4.7 and 7.9 Hz), 7.39 (app t, 1H, J = 9.7 Hz), 7.29 (qt, 1H, J = 8.6 Hz), 7.03-6.98 (m, 1H). ¹⁹F NMR (DMSO-d₆): δ -138.69-138.84 (app m), -139.47-139.55 (app m). LCMS: rt 4.26 min (B), purity 97 %, MS (m/e) 309 (MH⁺).

[0253] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 78). ¹H NMR (DMSO-d₆): δ 13.65 (s, 1H), 8.67 (d, 1H, J = 4.7 Hz), 8.18 (d, 1H, J = 2.0 Hz), 8.12 (d, 2H, J = 2.0 Hz), 7.92 (d, 1H, J = 7.6 Hz), 7.49 (dd, 1H, J = 4.7 and 7.6 Hz), 7.35 (d, 1H, J = 7.6 Hz), 6.93 (d, 2H, J = 7.9 Hz), 2.12 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.53 (s). LCMS: rt 3.81 min (B), purity 97 %, MS (m/e) 305 (MH⁺).

[0254] 5-(2-*m*-Tolylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 79). ¹H NMR (DMSO-d₆): δ 13.65 (s, 1H), 8.67 (d, 1H, J = 4.7 Hz), 8.16 (s, 1H), 8.11 (s, 2H), 7.92 (d, 1H, J =

6.7 Hz), 7.49 (dd, 1H, J = 4.7 and 7.6 Hz), 7.23 (s, 1H), 7.05 (s, 1H), 7.04 (s, 1H), 6.91 (app d, 1H, J = 6.7 Hz), 2.19 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.91 (s). LCMS: rt 3.29 min (B), purity 97 %, MS (m/e) 287 (MH⁺).

[0255] 5-(2-(4-Fluorophenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 80). ¹H NMR (DMSO-d₆): δ 13.65 (s, 1H), 8.65 (dd, 1H, J = 1.4 and 4.7 Hz), 8.17 (s, 1H), 8.12 (s, 2H), 7.93 (dd, 1H, J = 1.4 and 7.6 Hz), 7.51 (dd, 1H, J = 4.7 and 7.9 Hz), 7.30 (app d, 1H, J = 4.7 and 8.8 Hz), 7.07 (app t, 2H, J = 8.8 Hz). ¹⁹F NMR (DMSO-d₆): δ -114.06 (s). LCMS: rt 3.42 min (B), purity 97 %, MS (m/e) 291 (MH⁺).

[0256] 5-(2-(3-Fluoro-4-methylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 81). LCMS: rt 4.17 min (B), purity 97 %, MS (m/e) 305 (MH⁺).

[0257] 5-(2-(2-Fluoro-4-methylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 82). LCMS: rt 4.07 min (B), purity 97 %, MS (m/e) 305 (MH⁺).

[0258] 2-(2-Fluorophenyl)-3-(4-fluorophenyl)pyridine (Compound 83). LCMS: rt 5.89 min (B), purity 97 %, MS (m/e) 268 (MH⁺).

[0259] 2-(3,4-Difluorophenyl)-3-(4-fluorophenyl)pyridine (Compound 84). LCMS: rt 6.52 min (B), purity 97 %, MS (m/e) 286 (MH⁺).

[0260] 2-(4-Fluoro-3-methylphenyl)-3-(4-fluorophenyl)pyridine (Compound 85). ¹H NMR (DMSO-d₆): δ 8.77 (dd, 1H, J = 1.4 and 5.3 Hz), 8.19 (d, 1H, J = 7.6 Hz), 7.77 (dd, 1H, J = 5.3 and 7.6 Hz), 7.36 (d, 1H, J = 7.2 Hz), 7.26-7.15 (m, 4H), 7.08 (app d, 2H, J = 8.5 Hz), 2.16 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -113.94 (s), -116.31 (s). LCMS: 6.10 min (B), purity 97 %, MS (m/e) 282 (MH⁺).

[0261] 2-(3-Fluorophenyl)-3-(4-fluorophenyl)pyridine (Compound 86). LCMS: rt 6.11 min (B), purity 97 %, MS (m/e) 268 (MH⁺).

[0262] 2,3-Bis-(4-fluorophenyl)pyridine (Compound 87). LCMS: rt 5.70 min (B), purity 97 %, MS (m/e) 268 (MH⁺).

[0263] 3-(4-Fluorophenyl)-2-*m*-tolylpyridine (Compound 88). LCMS: rt 5.70 min (B), purity 97 %, MS (m/e) 264 (MH⁺).

[0264] (5-(3-(1H-Indazol-5-yl)pyridin-2-yl)-2-fluorophenyl)methanol (Compound 89). ¹H NMR (DMSO-d₆): δ 8.64 (dd, 1H, J = 1.4 and 4.7 Hz), 8.04 (s, 1H), 7.84 (dd, 1H, J = 1.4 and 7.6 Hz), 7.67-7.64 (app m, 2H), 7.44 (d, 1H, J = 4.7 and 7.6 Hz), 7.42 (d, 1H, J = 8.8 Hz), 7.01 (dd, 1H, J = 1.4 and 8.8 Hz), 6.98-6.93 (m, 1H), 6.87 (t, 1H, J = 8.8 Hz), 5.20 (t, 1H, J = 5.5 Hz),

4.45 (d, 2H, J = 5.5 Hz). ¹⁹F NMR (DMSO-d₆): δ -118.91 (s). LCMS: rt 2.87 min (B), purity 97 %, MS (m/e) 320 (MH⁺).

[0265] 4-(3-(1H-Indazol-5-yl)pyridin-2-yl)-2-methylbenzenamine (Compound 90). LCMS: rt 2.22 min (B), purity 97 %, MS (m/e) 301(MH⁺).

[0266] [3-(3-(1H-Indazol-5-yl)pyridin-2-yl)phenyl]methanol (Compound 91). ¹H NMR (DMSO-d₆): δ 13.1 (s, 1H), 8.63 (dd, 1H, J = 1.4 and 4.7 Hz), 8.02 (s, 1H), 7.83 (dd, 1H, J = 1.7 and 7.9 Hz), 7.65 (s, 1H), 7.46-7.37 (m, 3H), 7.16 (d, 1H, J = 7.6 Hz), 7.04 (d, 1H, J = 7.9 Hz), 7.01 (dd, 1H, J = 1.4 and 7.9 Hz), 6.95 (d, 1H, J = 7.6 Hz), 5.13 (bs, 1H), 4.38 (s, 2H). LCMS: rt 2.54 min (B), purity 97 %, MS (m/e) 302 (MH⁺).

[0267] 4-(3-(1H-Indazol-5-yl)pyridin-2-yl)-N,N,2-trimethylbenzenamine (Compound 92). ¹H NMR (DMSO-d₆): δ 13.01 (s, 1H), 8.58 (dd, 1H, J = 0.4 and 4.4 Hz), 8.04 (s, 1H), 7.77 (d, 1H, J = 7.6 Hz), 7.67 (s, 1H), 7.41 (app d, 1H, J = 7.6 Hz), 7.37 (dd, 1H, J = 4.8 and 7.6 Hz), 7.25 (s, 1H), 7.03 (d, 1H, J = 8.5 Hz), 6.90 (app d 1H, J = 7.6 Hz), 6.72 (d, 1H, J = 8.5 Hz), 2.55 (s, 6H), 2.11 (s, 3H). LCMS: rt 2.39 min (B), purity 97 %, MS (m/e) 329 (MH⁺).

[0268] 5-(2-(4-Fluoro-3-(trifluoromethyl)phenyl)pyridin-3-yl)-1H-indazole (Compound 93). ¹H NMR (DMSO-d₆): δ 13.1 (s, 1H), 8.70 (dd, 1H, J = 1.4 and 4.7 Hz), 8.06 (s, 1H), 7.94 (dd, 1H, J = 1.7 and 7.9 Hz), 7.70 (app s, 2H), 7.56 (d, 1H, J = 7.9 Hz), 7.54 (d, 1H, J = 7.9 Hz), 7.45 (d, 1H, j = 8.8 Hz), 7.33 (app t, 1H, J = 8.8 Hz), 7.05 (dd, 1H, J 1.5 and 8.5 Hz). ¹⁹F NMR (DMSO-d₆): δ -117.12 (app m), -60.34 (d, 1H, J = 15 Hz). LCMS: rt 6.22 min (A), purity 97 %, MS (m/e) 358 (MH⁺).

[0269] 2-Fluoro-5-(3-(1H-indazol-5-yl)pyridin-2-yl)benzamide (Compound 94). LCMS: rt 3.07 min (A), purity 97 %, MS (m/e) 333 (MH⁺).

[0270] 2-Fluoro-5-(3-(1H-indazol-5-yl)pyridin-2-yl)-N,N-dimethylbenzamide (Compound 95). LCMS: rt 3.42 min (A), purity 97 %, MS (m/e) 361 (MH⁺).

[0271] 5-(3-(1H-Indazol-5-yl)pyridin-2-yl)-2-fluoro-N-propylbenzamide (Compound 96). LCMS: rt 4.06 min (A), purity 97 %, MS (m/e) 375 (MH⁺).

[0272] 6-(2-(2-Fluorophenyl)pyridin-3-yl)-1H-indazole (Compound 97). LCMS: rt 4.50 min (A), purity 97 %, MS (m/e) 290 (MH⁺).

[0273] 6-(2-(3,4-Difluorophenyl)pyridin-3-yl)-1H-indazole (Compound 98). LCMS: rt 5.53 min (A), purity 97 %, MS (m/e) 308 (MH⁺).

- [0274] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 99). ¹H NMR (DMSO-d₆): δ 13.02 (s, 1H), 8.65 (d, 1H, J = 4.7 Hz), 8.03 (d, 1H, J = 0.5 Hz), 7.87 (d, 1H, J = 7.6 Hz), 7.64 (d, 1H, J = 8.2 Hz), 7.46 (dd, 1H, J = 4.7 and 7.6 Hz), 7.38 (app s, 2H), 6.95-6.93 (m, 1H), 6.90 (d, 1H, J = 8.2 Hz), 6.83 (d, 1H, J = 8.5 Hz), 2.11 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.78 (s). LCMS: rt 4.60 min (A), purity 97 %, MS (m/e) 304 (MH⁺).
- [0275] 6-(2-(3-Fluorophenyl)pyridin-3-yl)-1H-indazole (Compound 100). LCMS: rt 4.70 min (A), purity 97 %, MS (m/e) 290 (MH⁺).
- [0276] 6-(2-(4-Fluorophenyl)pyridin-3-yl)-1H-indazole (Compound 101). ¹H NMR (DMSO-d₆): δ 13.10 (s, 1H), 8.67 (dd, 1H, J = 1.7 and 4.7 Hz), 8.03 (s, 1H), 7.88 (dd, 1H, J = 1.4 and 7.6 Hz), 7.64 (d, 1H, J = 7.2 Hz), 7.48 (dd, 1H, J = 4.9 and 7.9 Hz), 7.38 (s, 1H), 7.34-7.30 (m, 2H), 7.04 (app t, 2H, J = 8.8 Hz), 6.83 (d, 1H, J = 8.5 Hz). ¹⁹F NMR (DMSO-d₆): δ -114.29 (s). LCMS: rt 4.27 min, purity 97 %, MS (m/e) 290 (MH⁺).
- [0277] 6-(2-*m*-Tolylpyridin-3-yl)-1H-indazole (Compound 102). LCMS: rt 4.00 min (A), purity 97 %, MS (m/e) 286 (MH⁺).
- [0278] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)benzo[d]oxazol-2(3H)-one (Compound 103). LCMS: rt 4.68 min (A), purity 97 %, MS (m/e) 321 (MH⁺).
- [0279] 3-(Benzo[d][1,3]dioxol-6-yl)-2-(2-fluorophenyl)pyridine (Compound 104). LCMS: rt 5.39 min (B), purity 97 %, MS (m/e) 294 (MH⁺).
- [0280] 3-(Benzo[d][1,3]dioxol-6-yl)-2-(3,4-difluorophenyl)pyridine (Compound 105). LCMS: rt 6.10 min (B), purity 97 %, MS (m/e) 312 (MH⁺).
- [0281] 3-(Benzo[d][1,3]dioxol-6-yl)-2-(4-fluoro-3-methylphenyl)pyridine (Compound 106). ¹H NMR (DMSO-d₆): δ 8.71 (dd, 1H, J = 1.4 and 4.9 Hz), 8.05 (d, 1H, J = 7.6 Hz), 7.65 (dd, 1H, J = 4.9 and 7.9 Hz), 7.39 (d, 1H, J = 7.6 Hz), 7.07 (d, 2H, J = 7.6 Hz), 6.87 (d, 1H, J = 8.2 Hz), 6.76 (d, 1H, J = 1.4 Hz), 6.63 (dd, 1H, J = 1.4 and 8.2 Hz), 6.01 (s, 2H), 2.19 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -114.29 (s). LCMS: rt 5.43 min (B), purity 97 %, MS (m/e) 308 (MH⁺).
- [0282] 3-(Benzo[d][1,3]dioxol-6-yl)-2-(3-fluorophenyl)pyridine (Compound 107). LCMS: rt 5.61 min (B), purity 97 %, MS (m/e) 294 (MH⁺).
- [0283] 3-(Benzo[d][1,3]dioxol-6-yl)-2-(4-fluorophenyl)pyridine (Compound 108). LCMS: rt 5.10 min (B), purity 97 %, MS (m/e) 294 (MH⁺).
- [0284] 3-(Benzo[d][1,3]dioxol-6-yl)-2-*m*-tolylpyridine (Compound 109). LCMS: rt 4.78 min (B), purity 97 %, MS (m/e) 290 (MH⁺).

- [0285] 3-(Benzo[d][1,3]dioxol-6-yl)-2-(2-fluoro-5-methylphenyl)pyridine (Compound 110). LCMS: rt 5.79 min (B), purity 97 %, MS (m/e) 308 (MH⁺).
- [0286] 2-(3-(1H-Indazol-5-yl)pyridin-2-yl)benzotrile (Compound 111). LCMS: rt 4.28 min (B), purity 97 %, MS (m/e) 297 (MH⁺).
- [0287] 3-(3-(1H-Indazol-5-yl)pyridin-2-yl)benzotrile (Compound 112). LCMS: rt 4.42min (B), purity 97 %, MS (m/e) 297 (MH⁺).
- [0288] 4-(3-(1H-Indazol-5-yl)pyridin-2-yl)benzotrile (Compound 113). LCMS: rt4.50 min (B), purity 97 %, MS (m/e) 297 (MH⁺).
- [0289] 4-(3-(1H-Indazol-5-yl)pyridin-2-yl)-2-fluorobenzotrile (Compound 114). LCMS: rt5.11 min (B), purity 97 %, MS (m/e) 315 (MH⁺).
- [0290] 5-(2-(4-(Trifluoromethyl)phenyl)pyridin-3-yl)-1H-indazole (Compound 115). ¹H NMR (DMSO-d₆): δ 133.18 (s, 1H), 8.69 (dd, 1H, J = 1.4 and 4.7 Hz), 8.04 (s, 1H), 7.90 (dd, 1H, J = 1.4 and 7.9 Hz), 7.68 (s, 1H), 7.59-7.47 (m, 5H), 7.42 (d, 1H, J = 8.8 Hz), 7.02 (dd, 1H, J = 1.4 and 8.8 Hz). LCMS: rt 5.47 min (B), purity 97%, MS (m/e) 340 (MH⁺).
- [0291] 5-(2-(3-Methoxyphenyl)pyridin-3-yl)-1H-indazole (Compound 117). ¹H NMR (DMSO-d₆): δ 13.02 (s, 1H), 8.64 (dd, 1H, J = 1.4 and 4.8 Hz), 8.03 (s, 1H), 7.84 (d, 1H, J = 7.9 Hz), 7.65 (s, 1H), 7.45 (dd, 1H, J = 4.7 and 7.6 Hz), 7.40 (d, 1H, J = 8.5 Hz)7.08 (t, 1H, J = 7.9 Hz), 7.03 (d, 1H, J = 8.5 Hz), 6.86 (m, 3H), 3.68 (s, 3H). LCMS: rt 3.49 min (B), purity 97%, MS (m/e) 302 (MH⁺).
- [0292] 5-(2-(4-Methoxyphenyl)pyridin-3-yl)-1H-indazole (Compound 118). LCMS: rt 2.99 min (B), purity 97%, MS (m/e) 302 (MH⁺).
- [0293] 5-(2-(3,4-Dimethoxyphenyl)pyridin-3-yl)-1H-indazole (Compound 119). LCMS: rt 2.85 min (B), purity 97%, MS (m/e) 332 (MH⁺).
- [0294] 3-(3-(1H-Indazol-5-yl)pyridin-2-yl)phenol (Compound 120). ¹H NMR (DMSO-d₆): δ 13.10 (s, 1H), 8.61 (dd, 1H, J = 1.7 and 4.7 Hz), 8.03 (s, 1H), 7.82 (dd, 1H, J = 1.7 and 7.6 Hz), 7.65 (s, 1H), 7.43 (dd, 1H, J = 4.7 and 7.6 Hz), 7.39 (d, 1H, J = 8.2 Hz), 7.02 (dd, 1H, J = 1.4 and 8.5 Hz), 6.94 (t, 1H, J = 7.6 Hz), 6.77 (s, 1H), 6.59 (dd, 2H, J = 2.0 and 7.6 Hz). LCMS: rt 2.63 min (B), purity 97%, MS (m/e) 288 (MH⁺).
- [0295] 4-(3-(1H-Indazol-5-yl)pyridin-2-yl)phenol (Compound 121). LCMS: rt 2.27 min (B), purity 97%, MS (m/e) 288 (MH⁺).

[0296] 4-(3-(1H-Indazol-5-yl)pyridin-2-yl)-2-methylphenol (Compound 122). LCMS: rt 2.42 min (B), purity 97%, MS (m/e) 302 (MH⁺).

[0297] 5-(2-(3,5-dimethoxyphenyl)pyridin-3-yl)-1H-indazole (Compound 123). LCMS: rt 3.79 min (B), purity 97%, MS (m/e) 332 (MH⁺).

[0298] 5-(2-(4-Fluoro-3-methoxyphenyl)pyridin-3-yl)-1H-indazole (Compound 124). ¹H NMR (DMSO-d₆): δ 13.01 (s, 1H), 8.65 (dd, 1H, J = 4.4 Hz), 8.04 (s, 1H), 7.85 (dd, 1H, J = 1.7 and 7.9 Hz), 7.67 (s, 1H), 7.45 (dd, 1H, J = 4.7 and 7.9 Hz), 7.44 (d, 1H, J = 8.2 Hz), 7.07-6.97 (m, 3H), 6.82-6.77 (m, 1H), 3.49 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -117.70 (q, H = 4.2 Hz). LCMS: rt 3.95 min (B), purity 97%, MS (m/e) 320 (MH⁺).

[0299] 5-(2-(3-Methoxy-4-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 125). LCMS: rt 4.86 min (B), purity 97%, MS (m/e) 316 (MH⁺).

[0300] 5-(2-(4-(Benzyloxy)-3-methoxyphenyl)pyridin-3-yl)-1H-indazole (Compound 126). ¹H NMR (DMSO-d₆): δ 13.01 (s, 1H), 8.61 (d, 1H, J = 4.7 Hz), 8.05 (s, 1H), 7.79 (d, 1H, J = 7.9 Hz), 7.67 (s, 1H), 7.43-7.29 (m, 7H), 7.04 (d, 1H, J = 9.1 Hz), 6.91 (s, 1H), 6.87 (d, 1H, J = 7.9 Hz), 6.78 (d, 1H, J = 9.1 Hz), 4.98 (s, 2H), 3.49 (s, 3H). LCMS: rt 4.51 min (B), purity 97%, MS (m/e) 408 (MH⁺).

[0301] 5-(2-(4-Aminosulfonylphenyl)pyridin-3-yl)-1H-indazole (Compound 127). LCMS: rt 3.40 min (B), purity 97%, MS (m/e) 351 (MH⁺).

[0302] 5-(2-(3-Aminosulfonylphenyl)pyridin-3-yl)-1H-indazole (Compound 128). LCMS: rt 3.36 min (B), purity 97%, MS (m/e) 351 (MH⁺).

[0303] 6-(2-(3,4-Difluorophenyl)pyridin-3-yl)-1-methyl-1H-indazole (Compound 129). LCMS: rt 6.10min (A), purity 97 %, MS (m/e) 322 (MH⁺).

[0304] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-methyl-1H-indazole (Compound 130). ¹H NMR (DMSO-d₆): δ 8.72(dd, 1H, J = 1.4 and 4.9 Hz), 8.04 (dd, 1H, J = 1.4 and 7.9 Hz), 8.01 (s, 1H), 7.67 (s, 1H), 7.60 (dd, 2H, J = 4.8 and 7.9 Hz), 7.41 (d, 1H, J = 7.6 Hz), 7.01-6.99 (m, 2H), 6.74 (d, 1H, J = 8.2 Hz), 4.00 (s, 3H), 2.13 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -117.88 (s). LCMS: rt 5.55 min (A), purity 97 %, MS (m/e) 318 (MH⁺).

[0305] 1-Methyl-6-(2-m-tolylpyridin-3-yl)-1H-indazole (Compound 131). LCMS: rt 5.25 min (A), purity 97 %, MS (m/e) 300 (MH⁺).

[0306] 6-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)-1-methyl-1H-indazole (Compound 132). LCMS: rt 5.78 min (A), purity 97 %, MS (m/e) 318 (MH⁺).

- [0307] 3-(3-(1-Methyl-1H-indazol-6-yl)pyridin-2-yl)benzotrile (Compound 133). LCMS: rt 5.86 min (A), purity 97 %, MS (m/e) 311 (MH⁺).
- [0308] 6-(2-(3-methoxyphenyl)pyridin-3-yl)-1-methyl-1H-indazole (Compound 134). LCMS: rt 5.10 min (A), purity 97 %, MS (m/e) 316 (MH⁺).
- [0309] 6-(2-(4-Fluoro-3-methoxyphenyl)pyridin-3-yl)-1-methyl-1H-indazole (Compound 135). LCMS: rt 5.41 min (A), purity 97 %, MS (m/e) 334 (MH⁺).
- [0310] 3-(3-(1-Methyl-1H-indazol-6-yl)pyridin-2-yl)phenol (Compound 136). LCMS: rt 4.41 min (A), purity 97 %, MS (m/e) 302 (MH⁺).
- [0311] 6-(2-(3,4-Difluorophenyl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine (Compound 137). LCMS: rt 4.83 min (A), purity 97 %, MS (m/e) 309 (MH⁺).
- [0312] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine (Compound 138). ¹H NMR (DMSO-d₆): δ 8.75 (dd, 1H, J = 1.5 and 5.1 Hz), 8.27 (app s 1H), 8.19 (d, 1H, J = 4.8 Hz), 8.09 (dd, 1H, J = 1.5 and 4.8 Hz), 7.93 (t, 1H, J = 0.79 Hz), 7.62 (dd, 1H, J = 4.8 and 8.1 Hz), 7.39 (d, 1H, J = 0.79 Hz), 7.62 (dd, 1H, J = 4.8 and 8.1 Hz), 6.98 -6.92 (m, 2H), 2.13 (s, 3H). LCMS: rt 4.35 min (A), purity 97 %, MS (m/e) 305 (MH⁺).
- [0313] 6-(2-*m*-Tolylpyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine (Compound 139). LCMS: rt 4.00 min (A), purity 97 %, MS (m/e) 287 (MH⁺).
- [0314] 6-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine (Compound 140). LCMS: rt 4.60 min (A), purity 97 %, MS (m/e) 305 (MH⁺).
- [0315] 3-(3-(1H-Pyrazolo[4,3-b]pyridin-6-yl)pyridin-2-yl)benzotrile (Compound 141). LCMS: rt 4.48 min, purity 97 %, MS (m/e) 298 (MH⁺).
- [0316] 6-(2-(3-Methoxyphenyl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine (Compound 142). LCMS: rt 3.90 min (A), purity 97 %, MS (m/e) 303 (MH⁺).
- [0317] 6-(2-(4-Fluoro-3-methoxyphenyl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine (Compound 143). LCMS: rt 4.21 min (A), purity 97 %, MS (m/e) 321 (MH⁺).
- [0318] 3-(3-(1H-Pyrazolo[4,3-b]pyridin-6-yl)pyridin-2-yl)phenol (Compound 144). LCMS: rt 3.11 min (A), purity 97 %, MS (m/e) 289 (MH⁺).
- [0319] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-methyl-1H-indazole (Compound 145). ¹H NMR (DMSO-d₆): δ 8.71 (dd, 1H, J = 0.4 and 4.9 Hz), 8.06 (dd, 1H, J = 1.4 and 7.9 Hz), 8.03 (s, 1H), 7.68 (s, 1H), 7.63 (dd, 1H, J = 4.9 and 7.9 Hz), 7.53 (d, 1H, J = 8.8 Hz), 7.41 (d, 1H, J = 7.9 Hz), 7.07 (dd, 1H, J = 1.4 and 8.8 Hz), 6.97-6.95 (m, 2H), 4.01 (s, 3H), 2.14 (s,

3H). ^{19}F NMR (DMSO- d_6): δ -118.70 (s). LCMS: rt 5.36 min (A), purity 97 %, MS (m/e) 318 (MH^+).

[0320] 1-Methyl-5-(2-m-tolylpyridin-3-yl)-1H-indazole (Compound 146). LCMS: rt 5.11 min (A), purity 97 %, MS (m/e) 300 (MH^+).

[0321] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-methyl-1H-indazole (Compound 147). ^1H NMR (DMSO- d_6): δ 8.69 (dd, 1H, $J = 1.4$ and 4.7 Hz), 8.07 (dd, 1H, $J = 1.7$ and 7.9 Hz), 7.68 (s, 1H), 7.63-7.58 (m, 1H), 7.38 (d, 1H, $J = 7.3$ Hz), 7.30 (d, 1H, $J = 8.8$ Hz), 6.99-6.91 (m, 3H), 2.44 (s, 3H), 2.13 (s, 3H). ^{19}F NMR (DMSO- d_6): δ -117.70 (s). LCMS: rt 5.01 min (A), purity 97 %, MS (m/e) 318 (MH^+).

[0322] 3-Methyl-5-(2-m-tolylpyridin-3-yl)-1H-indazole (Compound 148). LCMS: rt 4.78 min (A), purity 97 %, MS (m/e) 300 (MH^+).

[0323] 5-(2-(3-Ethylphenyl)pyridin-3-yl)-1H-indazole (Compound 149). ^1H NMR (DMSO- d_6): δ 8.64 (dd, 1H, $J = 1.4$ and 4.7 Hz), 8.02 (s, 1H), 7.84 (dd, 1H, $J = 1.4$ and 7.6 Hz), 7.63 (s, 1H), 7.44 (dd, 1H, $J = 4.9$ and 8.7 Hz), 7.39 (d, 1H, $J = 8.8$ Hz), 7.10 (s, 1H), 7.09 (s, 1H), 7.06-7.04 (m, 1H), 7.01 (dd, 1H, $J = 1.4$ and 8.7 Hz), 2.42 (qt, 2H, $J = 7.6$ Hz), 0.86 (t, 3H, $J = 7.6$ Hz). LCMS: rt 4.93 min (A), purity 97 %, MS (m/e) 300 (MH^+).

[0324] 5-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-1H-indazole (Compound 150). ^1H NMR (DMSO- d_6): δ 13.02 (s, 1H), 8.63 (dd, 1H, $J = 1.4$ and 4.8 Hz), 8.03 (s, 1H), 7.82 (dd, 1H, $J = 7.6$ Hz), 7.62 (s, 1H), 7.43 (dd, 1H, $J = 4.8$ and 7.6 Hz), 7.40 (d, 1H, $J = 7.9$ Hz), 7.07 (s, 1H), 7.05 (s, 1H), 7.02-6.94 (m, 2H), 6.86 (s, 1H), 1.76-1.67 (m, 1H), 0.76-0.68 (m, 2H), 0.24-0.19 (m, 2H). LCMS: rt 4.96 min (A), purity 97 %, MS (m/e) 312 (MH^+).

[0325] 5-(2-(3-Ethylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 151). ^1H NMR (DMSO- d_6): δ 13.58 (s, 1H), 8.69 (dd, 1H, $J = 1.4$ and 4.7 Hz), 8.15 (dd, 1H, $J = 0.5$ and 2.0 Hz), 7.93 (dd, 1H, $J = 1.4$ and 7.9 Hz), 7.50 (d, 1H, $J = 4.8$ and 7.9 Hz), 7.16-7.05 (m, 4H), 2.41 (qt, 2H, $J = 7.3$ Hz), 0.86 (t, 3H, $J = 7.3$ Hz). LCMS: rt 4.48 min (A), purity 97 %, MS (m/e) 301 (MH^+).

[0326] 5-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 152). ^1H NMR (DMSO- d_6): δ 13.6 (s, 1H), 8.75 (dd, 1H, $J = 1.4$ and 4.7 Hz), 8.19 (d, 1H, $J = 7.9$ Hz), 8.17 (d, 1H, $J = 5.3$ Hz), 7.98 (d, 1H, $J = 7.6$ Hz), 7.56 (dd, 1H, $J = 4.8$ and 7.9 Hz), 7.18-7.04 (m, 3H), 6.92 (s, 1H), 1.85-1.78 (m, 2H), 0.84-0.78 (m, 2H), 0.33-0.12 (m, 2H). LCMS: rt 4.56 min, purity 97 %, MS (m/e) 313 (MH^+).

[0327] 5-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 153). ¹H NMR (DMSO-d₆): δ 13.6 (s, 1H), 8.70 (dd, 1H, J = 1.4 and 4.7 Hz), 8.22 (d, 1H, J = 1.7 Hz), 8.08 (d, 1H, J = 1.2 Hz), 8.03 (d, 1H, J = 1.4 Hz), 7.96 (dd, 1H, J = 1.4 and 7.9 Hz), 7.56 (dd, 1H, J = 4.9 and 7.9 Hz), 7.35 (dd, 1H, 1.4 and 4.7 Hz), 7.15-7.11 (m, 1H), 6.81 (t, 1H, J = 8.8 Hz), 2.27 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -120.40 (s). LCMS: rt 4.71 min (A), purity 97 %, MS (m/e) 305 (MH⁺).

[0328] 3-(3-(1H-Pyrazolo[3,4-b]pyridin-5-yl)pyridin-2-yl)benzotrile (Compound 154). LCMS: rt 4.61 min (A), purity 97 %, MS (m/e) 298 (MH⁺).

[0329] 5-(2-(3-Methoxyphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 155). ¹H NMR (DMSO-d₆): δ 13.58 (s, 1H), 8.71 (dd, 1H, J = 1.7 and 4.7 Hz), 8.18 (d, 1H, J = 2.0 Hz), 8.13 (d, 1H, J = 2.0 Hz), 8.12 (s, 1H), 7.97 (dd, 1H, J = 1.7 and 7.6 Hz), 7.54 (dd, 1H, J = 4.6 and 7.6 Hz), 7.12 (t, 1H, J = 7.9 Hz), 6.89-6.88 (app m, 1H), 6.82 (dd, 1H, J = 2.3 and 8.5 Hz), 6.78 (d, 1H, J = 8.5 Hz), 3.56 (s, 3H). LCMS: rt 3.96 min (A), purity 97 %, MS (m/e) 303 (MH⁺).

[0330] 3-(3-(1H-Pyrazolo[3,4-b]pyridin-5-yl)pyridin-2-yl)phenol (Compound 156). LCMS: rt 3.30 min, purity 97 %, MS (m/e) 289 (MH⁺).

[0331] 5-(2-(4-Fluoro-3-methoxyphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 157). LCMS: rt 4.26 min (A), purity 97 %, MS (m/e) 321 (MH⁺).

[0332] 5-(3-(1H-Pyrazolo[3,4-b]pyridin-5-yl)pyridin-2-yl)-2-fluorobenzotrile (Compound 158). LCMS: rt 5.18 min (A), purity 97 %, MS (m/e) 316 (MH⁺).

[0333] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)benzo[d]thiazole (Compound 159). ¹H NMR (DMSO-d₆): δ 9.37 (d, 1H, J = 2.1 Hz), 8.66 (app d, 1H, J = 4.7 Hz), 8.08 (s, 1H), 7.96 (d, 1H, J = 8.5 Hz), 7.88 (d, 1H, J = 7.6 Hz), 7.48 (dd, 1H, J = 4.7 and 7.6 Hz), 7.36 (d, 1H, J = 7.9 Hz), 7.22 (dd, 1H, J = 0.88 and 8.5 Hz), 6.93-6.87 (m, 2H), 2.11 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.59 (s). LCMS: rt 5.51 min (A), purity 97 %, MS (m/e) 321 (MH⁺).

[0334] 6-(2-*m*-Tolylpyridin-3-yl)benzo[d]thiazole (Compound 160). ¹H NMR (DMSO-d₆): δ 9.36 (d, 1H, J = 2.1 Hz), 8.67 (app d, 1H, J = 4.7 Hz), 8.07 (s, 1H), 7.93 (d, 1H, J = 8.2 Hz), 7.88 (d, 1H, J = 8.2 Hz), 7.47 (dd, 1H, J = 4.9 and 7.9 Hz), 7.25-7.20 (m, 2H), 7.03-6.99 (m, 2H), 6.91 (d, 1H, J = 4.9 Hz), 2.18 (s, 3H). LCMS: rt 5.15 min (A), purity 97 %, MS (m/e) 303 (MH⁺).

[0335] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine (Compound 161). ¹H NMR (DMSO-d₆): δ 9.24 (s, 1H), 8.71 (dd, 1H, J = 1.4 and 4.7 Hz), 8.63 (s, 1H), 7.93 (d, 1H, J = 7.6 Hz), 7.61 (d, 1H, J = 9.4 Hz), 7.52 (dd, 1H, J = 4.7 and 7.7 Hz), 7.43 (d, 1H, J = 7.6 Hz), 7.12-7.08 (m, 1H), 6.99 (app t, 1H, J = 9.3 Hz), 6.90 (d, 1H, J = 9.7 Hz), 2.16 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -117.98 (s). LCMS: rt 4.20 min (A), purity 97 %, MS (m/e) 305 (MH⁺).

[0336] 6-(2-*m*-Tolylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine (Compound 162). ¹H NMR (DMSO-d₆): δ 9.23 (s, 1H), 8.72 (dd, 1H, J = 1.4 and 7.9 Hz), 8.62 (s, 1H), 7.93 (dd, 1H, J = 1.4 and 7.9 Hz), 7.58 (d, 1H, J = 9.4 Hz), 7.51 (dd, 1H, J = 4.9 and 7.9 Hz), 7.32 (s, 1H), 7.12 (app d, 1H, J = 4.9 Hz), 7.11 (s, 1H), 7.07-7.05 (app m, 1H), 6.89 (dd, 1H, J = 1.4 and 8.7 Hz), 2.23 (s, 3H). LCMS: rt 3.76 min (A), purity 97 %, MS (m/e) 287 (MH⁺).

[0337] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)benzo[d]thiazole (Compound 163). ¹H NMR (DMSO-d₆): δ 9.38 (d, 1H, J = 1.7 Hz), 8.66 (dd, 1H, J = 1.4 and 4.7 Hz), 8.06 (d, 1H, J = 8.5 Hz), 7.95 (s, 1H), 7.90 (dd, 1H, J = 1.4 and 7.9 Hz), 7.49 (dd, 1H, J = 4.7 and 7.9 Hz), 7.37 (d, 1H, J = 7.6 Hz), 7.20 (d, 1H, J = 8.2 Hz), 6.97-6.87 (m, 2H), 2.12 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.65 (s). LCMS: rt 5.56 min (A), purity 97 %, MS (m/e) 321 (MH⁺).

[0338] 5-(2-*m*-Tolylpyridin-3-yl)benzo[d]thiazole (Compound 164). LCMS: rt 5.23 min (A), purity 97 %, MS (m/e) 303 (MH⁺).

[0339] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 165). ¹H NMR (DMSO-d₆): δ 8.69 (s, 2H), 8.02 (s, 1H), 7.92 (d, 1H, J = 1.5 and 7.6 Hz), 7.72 (s, 1H), 7.52-7.49 (m, 2H), 7.44 (d, 1H, J = 7.2 Hz), 7.09-7.04 (m, 1H), 7.00-6.94 (m, 2H), 2.16 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.16 (s). LCMS: rt 3.56 min (A), purity 97 %, MS (m/e) 304 (MH⁺).

[0340] 6-(2-*m*-Tolylpyridin-3-yl)imidazo[1,2-a]pyridine (Compound 166). ¹H NMR (DMSO-d₆): δ 8.68 (d, 1H, J = 5.7 Hz), 8.57 (s, 1H), 7.92-7.89 (m, 2H), 7.55 (s, 1H), 7.48 (dd, 1H, J = 4.9 and 8.1 Hz), 7.38 (d, 1H, J = 8.3 Hz), 7.31 (s, 1H), 7.10-7.04 (app m, 2H), 7.04-7.02 (app m, 1H), 6.79 (d, 1H, J = 8.4 Hz), 2.22 (s, 3H). LCMS: rt 3.05 min (A), purity 97 %, MS (m/e) 286 (MH⁺).

[0341] 5-(2-(3-Isopropylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (Compound 167). LCMS: rt 4.81 min (A), purity 97 %, MS (m/e) 315 (MH⁺).

[0342] 5-(2-(3-*tert*-Butylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-*b*]pyridine (Compound 168). LCMS: rt 5.08 min (A), purity 97 %, MS (m/e) 329 (MH⁺).

[0343] 5-(2-(3-Biphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-*b*]pyridine (Compound 169). LCMS: rt 5.30 min (A), purity 97 %, MS (m/e) 349 (MH⁺).

[0344] 5-(2-(3-Cyclopentenylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-*b*]pyridine (Compound 170). LCMS: rt 5.33 min (A), purity 97 %, MS (m/e) 339 (MH⁺).

[0345] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-6-methyl-1H-indazole (Compound 173). ¹H NMR (DMSO-*d*₆): δ 8.75 (dd, 1H, J = 1.4 and 4.9 Hz), 7.98 (s, 1H), 7.93 (dd, 1H, J = 1.4 and 7.6 Hz), 7.61 (dd, 1H, J = 4.9 and 7.6 Hz), 7.53 (s, 1H), 7.37 (d, 1H, J = 7.6 Hz), 7.33 (s, 1H), 7.02-6.97 (m, 1H), 6.98 (t, 1H, J = 8.8 Hz), 2.07 (s, 3H), 1.93 (s, 3H). ¹⁹F NMR (DMSO-*d*₆): δ -117.35 (s). LCMS: rt 5.01 min(A), purity 97 %, MS (m/e) 318 (MH⁺).

[0346] 6-Methyl-5-(2-*m*-tolylpyridin-3-yl)-1H-indazole (Compound 174). LCMS: rt 4.73 min (A), purity 97 %, MS (m/e) 300 (MH⁺).

[0347] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-7-methyl-1H-indazole (Compound 175). ¹H NMR (DMSO-*d*₆): δ 8.69 (d, 1H, J = 1.7 and 4.9 Hz), 8.08 (d, 1H, J = 7.6 Hz), 8.02 (s, 1H), 7.64 (app t, 1H, J = 7.6 Hz), 7.43-7.41 (app m, 2H), 7.01-6.91 (m, 3H), 2.40 (s, 3H), 2.13 (s, 3H). ¹⁹F NMR (DMSO-*d*₆): δ -117.30 (s). LCMS: rt 4.80 min, purity 97 %, MS (m/e) 318 (MH⁺).

[0348] 7-Methyl-5-(2-*m*-tolylpyridin-3-yl)-1H-indazole (Compound 176). ¹H NMR (DMSO-*d*₆): δ 13.04 (s, 1H), 8.73 (d, 1H, J = 2.8 Hz), 8.14 (d, 1H, J = 7.9 Hz), 8.00 (s, 1H), 7.69 (dd, 1H, J = 4.9 and 7.9 Hz), 7.41 (s, 1H), 7.31 (s, 1H), 7.14-7.06 (m, 2H), 6.97 (d, 1H, J = 7.2 Hz), 6.90 (s, 1H), 2.38 (s, 3H), 2.21 (s, 3H). LCMS: rt 5.03 min (A), purity 97 %, MS (m/e) 300 (MH⁺).

[0349] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-benzo[*d*]imidazole (Compound 177). ¹H NMR (DMSO-*d*₆): δ 8.62 (d, 1H, J = 0.2 and 3.7 Hz), 8.24 (s, 1H), 7.83 (dd, 1H, J = 1.5 and 7.6 Hz), 7.49 (d, 1H, J = 8.1 Hz), 7.45 (d, 1H, J = 4.7 Hz), 7.43-7.42 (m, 1H), 7.36 (d, 1H, J = 7.3 Hz), 6.96-6.84 (m, 3H), 2.11 (s, 3H). ¹⁹F NMR (DMSO-*d*₆): δ -118.99 (s). LCMS: rt 3.41 min, purity 97 %, MS (m/e) 304 (MH⁺).

[0350] 6-(2-*m*-Tolylpyridin-3-yl)-1H-benzo[*d*]imidazole (Compound 178). ¹H NMR (DMSO-*d*₆): δ 8.64 (d, 1H, J = 5.1 Hz), 8.42 (s, 1H), 7.84 (d, 1H, J = 7.3 Hz), 7.51 (d, 1H, J = 8.5 Hz), 7.44 (dd, 1H, J = 4.5 and 7.5 Hz), 7.26 (s, 1H), 7.02 (s, 2H), 6.98 (d, 1H, J = 7.6 Hz),

6.90 (d, 1H, J = 7.3 Hz), 2.18 (s, 3H). LCMS: rt 1.75 min (A), purity 97 %, MS (m/e) 286 (MH⁺).

[0351] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)benzo[d]oxazole (Compound 180). ¹H NMR (DMSO-d₆): δ 8.71 (d, 1H, J = 2.0 Hz), 8.66 (app d, 1H, J = 2.8 Hz), 7.87 (d, 1H, J = 7.3 Hz), 7.69 (d, 1H, J = 8.8 Hz), 7.68 (app s, 1H), 7.47 (dd, 1H, J = 4.8 and 7.9 Hz), 7.33 (d, 1H, J = 7.0 Hz), 7.12 (dd, 1H, J = 1.7 and 8.4 Hz), 6.93-6.87 (m, 2H), 2.12 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.61 (s). LCMS: rt 5.33 min (A), purity 97 %, MS (m/e) 305 (MH⁺).

[0352] 6-(2-*m*-Tolylpyridin-3-yl)benzo[d]oxazole (Compound 181). LCMS: rt 4.90 min (A), purity 92 %, MS (m/e) 287 (MH⁺).

[0353] 2-Ethyl-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazole (Compound 182). ¹H NMR (DMSO-d₆): δ 8.69 (d, 1H, J = 4.9 Hz), 8.37 (s, 1H), 8.02 (d, 1H, J = 7.9 Hz), 7.63 (s, 1H), 7.60 (dd, 1H, J = 5.2 and 7.6 Hz), 7.45 (app t 2H, J = 9.1 Hz), 7.02-6.92 (app m, 2H), 6.88 (d, 1H, J = 8.1 Hz), 4.35 (qt, 2H, J = 7.0 Hz), 2.14 (s, 3H), 1.48 (t, 3H, J = 7.0 Hz). ¹⁹F NMR (DMSO-d₆): δ -117.62 (s). LCMS: rt 5.30 min (A), purity 97 %, MS (m/e) 332 (MH⁺).

[0354] 2-Ethyl-5-(2-*m*-tolylpyridin-3-yl)-2H-indazole (Compound 183). LCMS: rt 5.06 min (A), purity 97 %, MS (m/e) 314 (MH⁺).

[0355] 1-Ethyl-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole (Compound 184). ¹H NMR (DMSO-d₆): δ 8.70 (dd, 1H, J = 1.7 and 4.9 Hz), 8.08 -8.04 (m, 2H), 7.68 (d, 1H, J = 0.9 Hz), 7.66-7.55 (m, 1H), 7.57 (d, 1H, J = 8.8 Hz), 7.40 (d, 1H, J = 7.9 Hz), 7.05 (dd, 1H, J = 1.8 and 8.8 Hz), 7.03-6.92 (m, 2H), 4.39 (qt, 2H, J = 7.0 Hz), 2.13 (s, 3H), 1.35 (t, 3H, J = 7.3 Hz). ¹⁹F NMR (DMSO-d₆): δ -117.42 (s). LCMS: rt 5.71 min(A), purity 97 %, MS (m/e) 332 (MH⁺).

[0356] 1-Ethyl-5-(2-*m*-tolylpyridin-3-yl)-1H-indazole (Compound 185). LCMS: rt 5.43 min (A), purity 97 %, MS (m/e) 314 (MH⁺).

[0357] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridine (Compound 191). ¹H NMR (DMSO-d₆): δ 9.01 (t, 1H, J = 0.77 Hz), 8.71 (dd, 1H, J = 1.7 and 4.7 Hz), 8.50 (s, 1H), 8.00 (dd, 1H, J = 1.7 and 7.9 Hz), 7.70 (dd, 1H, J = 1.7 and 9.1 Hz), 7.51 (dd, 1H, J = 4.6 and 7.6 Hz), 7.43 (dd, 1H, J = 1.7 and 7.9 Hz), 7.23 (dd, 1H, J = 1.7 and 9.3 Hz), 7.08-7.04 (m, 1H), 6.97 (app t, 1H, J = 9.3 Hz), 2.16 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.12 (s). LCMS: 4.76 min (A), purity 97 %, MS (m/e) 305 (MH⁺).

[0358] 6-(2-*m*-Tolylpyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridine (Compound 192). ¹H NMR (DMSO-*d*₆): δ 8.98 (s, 1H), 8.72 (dd, 1H, J = 1.7 and 4.7 Hz), 8.49 (s, 1H), 8.01 (d, 1H, J = 1.7 and 7.9 Hz), 7.68 (d, 1H, J = 9.2 Hz), 7.54-7.49 (m, 1H), 7.30 (s, 1H), 7.23 (dd, 1H, J = 1.4 and 7.6 Hz), 7.10-7.09 (app m, 2H), 7.03-7.02 (m, 1H), 2.22 (s, 3H). ¹⁹F NMR (DMSO-*d*₆): δ -118.31 (s). LCMS: rt 4.31 min (A), purity 95 %, MS (m/e) 287 (MH⁺).

[0359] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)H-imidazo[1,2-*a*]pyridine (Compound 193). ¹H NMR (DMSO-*d*₆): δ 8.68 (dd, 1H, J = 1.7 and 4.7 Hz), 8.53 (app s, 1H), 7.91 (dd, 1H, J = 1.6 and 9.3 Hz), 7.90 (s, 1H), 7.53 (d, 1H, J = 1.2 Hz), 7.46 (dd, 1H, J = 4.6 and 7.6 Hz), 7.38 (dd, 1H, J = 9.3 Hz), 7.12-7.04 (m, 2H), 7.02-6.99 (m, 2H), 6.78 (dd, 1H, J = 1.7 and 9.3 Hz), 1.81-1.76 (m, 1H), 0.79-0.75 (m, 2H), 0.36-0.32 (m, 2H). LCMS: rt 4.73 min (A), purity 97 %, MS (m/e) 312 (MH⁺).

[0360] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)benzo[*d*]thiazole (Compound 194). ¹H NMR (DMSO-*d*₆): δ 9.19 (s, 1H), 8.68 (dd, 1H, J = 1.4 and 4.7 Hz), 8.05 (d, 1H, J = 1.2 Hz), 7.96 (d, 1H, J = 8.5 Hz), 7.86 (app dd, 1H, J = 1.4 and 7.6 Hz), 7.47 (dd, 1H, J = 4.7 and 7.6 Hz), 7.21 (dd, 1H, J = 1.7 and 7.6 Hz), 7.09-7.07 (m, 2H), 6.99-6.97 (m, 1H), 6.84 (s, 1H), 1.76-1.71 (m, 1H), 0.75-0.69 (m, 2H), 0.24-0.19 (m, 2H). LCMS: rt 5.53 min (A), purity 97 %, MS (m/e) 329 (MH⁺).

[0361] 5-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)-1H-indazole (Compound 197). ¹H NMR (DMSO-*d*₆): δ 13.02 (s, 1H), 8.70 (dd, 1H, J = 1.4 and 4.7 Hz), 8.04 (s, 1H), 7.91 (dd, 1H, J = 0.7 and 7.6 Hz), 7.68 (s, 1H), 7.63 (s, 1H), 7.58 (d, 1H, J = 8.2 Hz), 7.54-7.50 (m, 2H), 7.50-7.41 (m, 2H), 7.03 (d, 1H, J = 8.5 Hz). ¹⁹F NMR (DMSO-*d*₆): δ -61.47. LCMS: rt 5.78 min (A), purity 97 %, MS (m/e) 340 (MH⁺).

[0362] 5-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)-1H-pyrazolo[3,4-*b*]pyridine (Compound 198). ¹H NMR (DMSO-*d*₆): δ 13.65 (s, 1H), 8.75 (dd, 1H, J = 1.7 and 4.7 Hz), 8.20 (d, 1H, J = 2.0 Hz), 8.15 (d, 1H, J = 1.4 Hz), 8.12 (s, 1H), 7.99 (d, 1H, J = 1.4 and 7.9 Hz), 7.64-7.44 (m, 5H). ¹⁹F NMR (DMSO-*d*₆): δ -61.40. LCMS: rt 5.55 min (A), purity 97 %, MS (m/e) 341 (MH⁺).

[0363] 6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)H-imidazo[1,2-*a*]pyridine (Compound 199). ¹H NMR (DMSO-*d*₆): δ 8.62 (dd, 1H, J = 1.4 and 4.7 Hz), 8.06 (s, 1H), 7.65 (dd, 1H, J = 1.7 and 8.2 Hz), 7.46-7.42 (m, 3H), 7.05-7.04 (m, 2H), 6.97-6.95 (m, 1H), 6.90 (s, 1H), 6.85 (dd,

1H, $J = 1.4$ and 8.2 Hz), 3.86 (s, 3H), 1.76 - 1.69 (m, 1H), 0.84 - 0.70 (m, 2H), 0.28 - 0.23 (m, 2H). LCMS: rt 4.68 min (A), purity 97% , MS (m/e) 340 (MH⁺).

[0364] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 200). ¹H NMR (DMSO-d₆): δ 8.63 (dd, 1H, $J = 1.4$ and 4.7 Hz), 8.12 (s, 1H), 7.85 (dd, 1H, $J = 1.7$ and 8.2 Hz), 7.48 - 7.42 (m, 3H), 7.05 - 7.04 (app m, 2H), 6.97 - 6.95 (m, 1H), 6.90 (s, 1H), 6.85 (dd, 1H, $J = 1.4$ and 8.2 Hz), 3.73 (s, 3H), 1.78 - 1.69 (m, 1H), 0.76 - 0.70 (m, 2H), 0.28 - 0.23 (m, 2H). LCMS: rt 3.68 min (A), purity 97% , MS (m/e) 326 (MH⁺).

[0365] 5-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 201). ¹H NMR (DMSO-d₆): δ 8.63 (dd, 1H, $J = 1.4$ and 4.7 Hz), 8.16 (s, 1H), 7.82 (dd, 1H, $J = 1.4$ and 7.6 Hz), 7.82 (dd, 1H, $J = 1.4$ and 7.6 Hz), 7.47 - 7.41 (m, 3H), 7.05 - 6.67 (m, 5H), 3.81 (s, 3H), 1.78 - 1.71 (m, 1H), 0.78 - 0.72 (m, 2H), 0.31 - 0.26 (m, 3H). LCMS: rt 3.76 min (A), purity 97% , MS (m/e) 326 (MH⁺).

[0366] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 202). ¹H NMR (DMSO-d₆): δ 8.96 (s, 3H), 8.72 (dd, 1H, $J = 1.7$ and 4.9 Hz), 8.50 (s, 1H), 7.99 (dd, 1H, $J = 1.4$ and 7.6 Hz), 7.69 (dd, 1H, $J = 0.9$ and 9.1 Hz), 7.52 (dd, 1H, $J = 4.7$ and 7.7 Hz), 7.24 (dd, 1H, $J = 0.8$ and 9.1 Hz), 7.14 (m, 2H), 7.03 (s, 1H), 6.98 (m, 1H), 1.78 - 1.71 (m, 1H), 0.82 - 0.72 (m, 2H), 0.31 - 0.30 (m, 2H). LCMS: rt 4.93 min (A), purity 97% , MS (m/e) 313 (MH⁺).

[0367] 6-(2-(3-Isopropylphenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 204). LCMS: rt 4.16 min (A), purity 97% , MS (m/e) 328 (MH⁺).

[0368] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-1H-benzo[d]imidazole (Compound 205). LCMS: rt 3.80 min (A), purity 97% , MS (m/e) 312 (MH⁺).

[0369] 6-(2-(3-Isopropylphenyl)pyridin-3-yl)-1H-benzo[d]imidazole (Compound 206). LCMS: rt 4.06 min (A), purity 97% , MS (m/e) 314 (MH⁺).

[0370] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinoline (Compound 207). ¹H NMR (DMSO-d₆): δ 9.11 (dd, 1H, $J = 1.4$ and 4.7 Hz), 8.77 (dd, 2H, $J = 1.4$ and 4.9 Hz), 8.20 (d, 1H, 1.4 Hz), 8.13 - 8.08 (m, 2H), 7.84 (dd, 1H, $J = 4.8$ and 8.2 Hz), 7.66 - 7.59 (m, 2H), 7.40 (d, 1H, $J = 7.6$ Hz), 6.99 - 6.90 (m, 2H), 2.12 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -117.48 (s). LCMS: rt 4.23 min (A), purity 97% , MS (m/e) 315 (MH⁺).


[0371] 6-(2-*m*-Tolylpyridin-3-yl)quinoline (Compound 208). ¹H NMR (300 MHz, DMSO-d₆): δ 9.02 (dd, $J = 4.6$, 1.6 Hz, 1H), 8.75 (dd, $J = 4.9$, 1.7 Hz, 1H), 8.59 (d, $J = 7.7$ Hz, 1H), 8.09

(d, $J = 1.9$ Hz, 1H), 8.06 (dd, $J = 7.8, 1.7$ Hz, 1H), 8.01 (d, $J = 8.8$ Hz, 1H), 7.72 (dd, $J = 8.3, 4.6$ Hz, 1H), 7.61 (dd, $J = 7.8, 4.9$ Hz, 1H), 7.53 (dd, $J = 8.8, 2.0$ Hz, 1H), 7.28 (dd, $J = 1.5, 0.9$ Hz, 1H), 7.14 – 7.01 (m, 2H), 6.96 (ddd, $J = 6.4, 2.5, 1.4$ Hz, 1H), 2.18 (s, 3H). LCMS: rt 3.88 min (A), purity 99 %, MS (m/e) 297 (MH⁺).


[0372] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)isoquinoline (Compound 209). LCMS: rt 4.12 min (A), purity 97 %, MS (m/e) 315 (MH⁺).

[0373] 7-(2-*m*-Tolylpyridin-3-yl)isoquinoline (Compound 210). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.69 (s, 1H), 8.79 (dd, $J = 4.9, 1.6$ Hz, 1H), 8.64 (d, $J = 6.3$ Hz, 1H), 8.45 (s, 1H), 8.30 (s, 1H), 8.08 (s, 2H), 7.84 – 7.50 (m, 2H), 7.28 (s, 1H), 7.07 (dt, $J = 14.8, 7.5$ Hz, 2H), 6.96 (d, $J = 7.2$ Hz, 1H), 2.19 (s, 3H). LCMS: rt 3.75 min (A), purity 99 %, MS (m/e) 296 (MH⁺).

Example 45 Synthetic scheme towards the preparation of 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1-(substituted)-1H-benzo[d]imidazole



Example 46 **6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole (Compound 35)**



[0374] Step C: 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)-2-nitrobenzenamine

[0375] To solution of 2-(4-fluoro-3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine (100 mg) in 2 mL THF was added 2-morpholinoethanamine (64 μ L) and K_2CO_3 (76 mg). The reaction was heated at 60 °C for 15 hours in a sealed vial. The reaction mixture was cooled to room temperature, concentrated by rotary evaporation under vacuum and partitioned the concentrate between CH_2Cl_2 /water. The organic layer was separated, dried with anhydrous Na_2SO_4 , filtered and evaporated. The crude residue of 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)-2-nitrobenzenamine was used in the next step with no further purification.

[0376] Step D: 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)-2-nitrobenzenamine


[0377] The above residue of 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)-2-nitrobenzenamine was dissolved in 2 mL EtOH and charged with Pd/C (25 mg) and the reaction was hydrogenated overnight under a hydrogen balloon atmosphere. The reaction was filtered through a bed of celite and evaporated. Subsequently the crude containing 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)-2-nitrobenzenamine was used in the next with no further purification.

[0378] Step E: 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole

[0379] The above residue containing 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)-2-nitrobenzenamine was added DMA (1 mL), triethyl orthoformate (250 μ L) and treated with one drop of concentrated HCl. The homogeneous solution was heated at 65 °C


for 15 hours in a sealed vial. The reaction was cooled and the volatiles were removed with a stream of nitrogen gas. The residue was triturated with aq. NaHCO_3 , resulting solid collected by filtration and purified by HPLC to yield 25 mg of the desired product 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole. ^1H NMR (DMSO-d_6): δ 8.58 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.15 (s, 1H), 7.84 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.56 (d, $J = 8.3$ Hz, 1H), 7.43 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.28 (d, $J = 4.8$ Hz, 2H), 7.05 (dd, $J = 8.3, 1.5$ Hz, 1H), 7.03 – 6.75 (m, 2H), 4.19 (t, $J = 6.4$ Hz, 2H), 3.55 – 3.36 (m, 4H), 2.44 – 2.15 (m, 6H), 2.06 (s, 3H). MS (m/e): 417 (MH^+).

Example 47 **6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-isopropyl-1H-benzo[d]imidazole (Compound 48)**




[0380] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(4-fluoro-3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and propan-2-amine yielded 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-isopropyl-1H-benzo[d]imidazole. ^1H NMR (DMSO-d_6): δ 9.58 (s, 1H), 8.75 (d, $J = 4.9$ Hz, 1H), 8.11 (d, $J = 7.8$ Hz, 1H), 7.89 (s, 1H), 7.79 (d, $J = 8.5$ Hz, 1H), 7.65 (dd, $J = 7.8, 5.0$ Hz, 1H), 7.43 – 7.29 (m, 2H), 7.15 – 6.87 (m, 2H), 4.98 – 4.79 (m, 1H), 2.11 (s, 3H), 1.48 (d, $J = 6.6$ Hz, 6H). MS (m/e): 346 (MH^+).

Example 48 **1-(2-Morpholinoethyl)-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole (Compound 36)**




[0381] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and 2-morpholinoethanamine yielded 1-(2-Morpholinoethyl)-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole. ^1H NMR (DMSO- d_6): δ 9.46 (s, 1H), 8.81 (dd, $J = 5.0$, 1.3 Hz, 1H), 8.23 (dd, $J = 7.8$, 1.3 Hz, 1H), 8.05 (s, 1H), 7.89 – 7.62 (m, 2H), 7.33 (s, 1H), 7.18 – 7.07 (m, 3H), 6.96 (d, $J = 7.3$ Hz, 1H), 4.88 (m, 2H), 3.84 (s, 4H), 3.62 (m, 2H), 3.34 (s, 4H) 2.22 (s, 3H). MS (m/e): 399 (MH^+).

Example 49 **6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-benzo[d]imidazole (Compound 37)**




[0382] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(4-fluoro-3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and 2-(4-methylpiperazin-1-yl)ethanamine yielded 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-benzo[d]imidazole. ^1H NMR (DMSO- d_6): δ 9.52 (d, $J = 1.3$ Hz, 1H), 8.89 – 8.65 (m, 1H), 8.19 (dd, $J = 7.8$, 1.6 Hz, 1H), 7.95 (s, 1H), 7.89 – 7.65 (m, 2H), 7.46 – 7.20 (m, 2H), 7.11 (t, $J = 7.7$ Hz, 1H), 6.95 (d, $J = 5.7$ Hz, 1H), 4.55 (s, 2H), 2.82 – 2.75 (m, 10H), 2.52 (s, 3H), 2.20 (s, 3H). MS (m/e): 430 (MH^+).

Example 50 **1-(3-Ethoxypropyl)-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole**
(Compound 39)




[0383] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and 3-ethoxypropan-1-amine yielded 1-(3-Ethoxypropyl)-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole. ¹H NMR (DMSO-d₆): δ 9.55 (d, *J* = 1.2 Hz, 1H), 8.97 – 8.67 (m, 1H), 8.32 – 8.13 (m, 1H), 7.86 (s, 1H), 7.82 – 7.66 (m, 2H), 7.36 (d, *J* = 8.6 Hz, 1H), 7.25 (s, 1H), 7.21 – 7.01 (m, 2H), 6.96 (d, *J* = 6.4 Hz, 1H), 4.45 (t, *J* = 6.7 Hz, 2H), 3.43 – 3.10 (m, 4H), 2.19 (s, 3H), 2.00 – 1.78 (m, 2H), 0.95 (td, *J* = 7.0, 1.1 Hz, 3H). MS (m/e): 372 (MH⁺).

Example 51 **6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(3-(4-methylpiperazin-1-yl)propyl)-1H-benzo[d]imidazole (Compound 40)**




[0384] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(4-fluoro-3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and 2-(4-methylpiperazin-1-yl)ethanamine yielded 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-benzo[d]imidazole. ¹H NMR (DMSO-d₆): δ 9.42 (s, 1H), 8.79 (d, *J* = 5.4 Hz, 1H), 8.74 – 7.84 (m, 1H), 7.75 (d, *J* = 8.6 Hz, 2H), 7.35 (d, *J* = 8.5 Hz, 1H), 7.07 – 6.63 (m, 2H), 4.55 (s, 2H), 3.15 (s, 2H), 2.93 – 2.86 (m, 8H), 2.78 (s, 2H), 2.52 (s, 3H), 2.09 (s, 3H). MS (m/e): 444 (MH⁺).

Example 52 **3-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)propan-1-ol (Compound 41)**




[0385] In like manner to the preparation of 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(4-fluoro-3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and 3-aminopropan-1-ol yielded 3-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)propan-1-ol. ¹H NMR (DMSO-d₆): δ 9.51 (s, 1H), 8.78 (dd, *J* = 5.1, 1.5 Hz, 1H), 8.37 – 8.13 (m, 1H), 7.87 (s, 1H), 7.82 – 7.69 (m, 2H), 7.35 (dd, *J* = 8.5, 1.4 Hz, 2H), 6.98 (dd, *J* = 9.5, 5.7 Hz, 2H), 3.35 (t, *J* = 5.7 Hz, 2H), 2.52 (s, 2H), 2.10 (s, 3H), 1.95 – 1.62 (m, 2H). MS (m/e): 362 (MH⁺).

Example 53 **1-(3-Ethoxypropyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-benzo[d]imidazole (Compound 42)**




[0386] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(4-fluoro-3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and 3-ethoxypropan-1-amine yielded 1-(3-ethoxypropyl)-6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-benzo[d]imidazole. ¹H NMR (DMSO-d₆): δ 9.55 (d, *J* = 1.3 Hz, 1H), 8.83 – 8.65 (m, 1H), 8.10 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.87 (s, 1H), 7.80 (d, *J* = 8.5 Hz, 1H), 7.72 – 7.58 (m, 1H), 7.46 – 7.26 (m, 2H), 6.96 (t, *J* = 7.2 Hz, 2H), 4.46 (t, *J* = 6.5 Hz, 2H), 3.32 – 3.25 (m, 4H), 2.11 (s, 3H), 2.02 – 1.74 (m, 2H), 0.96 (t, *J* = 7.0, 3H). MS (m/e): 390 (MH⁺).

Example 54 **1-Ethyl-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole (Compound 43)**




[0387] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and ethanamine yielded 1-Ethyl-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole¹H NMR (DMSO-d₆): δ 9.53 (s, 1H), 8.77 (dd, *J* = 5.0, 1.5 Hz, 1H), 8.13 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.92 (s, 1H), 7.76 (d, *J* = 8.6 Hz, 1H), 7.67 (dd, *J* = 7.8, 5.0 Hz, 1H), 7.43 – 7.19 (m, 2H), 7.16 – 6.97 (m, 2H), 6.93 (d, *J* = 6.6 Hz, 1H), 4.42 (q, *J* = 7.2 Hz, 2H), 2.20 (s, 3H), 1.35 (t, *J* = 7.2 Hz, 3H). MS (m/e): 314 (MH⁺).

Example 55 **1-(Tetrahydro-2H-pyran-4-yl)-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole (Compound 44)**




[0388] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and tetrahydro-2H-pyran-4-amine yielded 1-(tetrahydro-2H-pyran-4-yl)-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole¹H NMR (DMSO-d₆): δ 9.59 (d, *J* = 1.3 Hz, 1H), 8.90 – 8.68 (m, 1H), 8.27 – 8.11 (m, 1H), 7.96 (s, 1H), 7.89 – 7.63 (m, 2H), 7.75 – 7.61 (m, 1H), 7.38 (d, *J* = 8.6 Hz, 1H), 7.30 (s, 1H), 7.19 – 6.98 (m, 2H), 6.92 (d, *J* = 7.1 Hz, 1H), 4.82 (s, 1H), 3.98 (m, 2H), 3.47 (m, 2H), 2.21 (s, 3H), 1.96 (bs, 4H). MS (m/e): 370 (MH⁺).

Example 56 **1-(1-Methylpiperidin-4-yl)-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole (Compound 45)**




[0389] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and 1-methylpiperidin-4-amine yielded 1-(1-Methylpiperidin-4-yl)-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole. ¹H NMR (DMSO-d₆): δ 9.43 (s, 1H), 8.78 (d, *J* = 3.9 Hz, 1H), 8.15 (d, *J* = 7.2 Hz, 1H), 7.94 (s, 1H), 7.76 (d, *J* = 8.5 Hz, 1H), 7.68 (dd, *J* = 7.7, 5.0 Hz, 1H), 7.43 – 7.19 (m, 2H), 7.08 (d, *J* = 7.2 Hz, 2H), 6.93 (d, *J* = 6.9 Hz, 1H), 4.87 (s, 1H), 3.62 (m, 2H), 3.17 (m, 2H), 2.85 (s, 3H), 2.26 (s, 4H), 2.20 (s, 3H). MS (m/e): 383 (MH⁺).

Example 57 **1-Ethyl-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-benzo[d]imidazole (Compound 46)**




[0390] In like manner to the preparation of 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole, the reaction of 2-(4-fluoro-3-methylphenyl)-3-(3-fluoro-4-nitrophenyl)pyridine and ethanamine yielded 1-Ethyl-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-benzo[d]imidazole. ¹H NMR (DMSO-d₆): δ 9.38 (s, 1H), 8.76 (d, *J* = 5.4 Hz, 1H), 8.38 (d, *J* = 7.8 Hz, 1H), 7.99 – 7.67 (m, 2H), 7.74 (d, *J* = 8.6 Hz, 1H), 7.34 (t, *J* = 6.1 Hz, 2H), 7.16 – 6.87 (m, 2H), 4.49 – 4.29 (m, 2H), 2.08 (s, 3H), 1.32 (t, *J* = 7.2 Hz, 3H). MS (m/e): 332 (MH⁺).

Example 58 **5-(2-(3-Cyclopentylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine**
(Compound 171)



[0391] 5-(2-(3-cyclopentylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (130 mg) was hydrogenated with Pd/C (15 mg) in EtOH (15 mL) over a period of 10 h under balloon H₂ after degassing and back filling the flask with the hydrogen. The reaction mixture was filtered through celite and purified by preparative HPLC to provide 5-(2-(3-cyclopentylphenyl)pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine as a white solid. ¹H NMR (DMSO-d₆): δ 8.84 (d, 1H, J = 4.7 Hz), 8.41 (d, 1H, J = 7.9 Hz), 8.16 (app s, 2H), 8.14 (app s, 1H), 7.89 (app t, 1H, J = 7.5 Hz), 7.23 (app s, 2H), 7.22-7.20 (m, 1H), 7.08 (s, 1H), 2.80 (q, 1H, J = 8.2 Hz), 1.75-1.68 (m, 2H), 1.48-1.39 (m, 4H), 1.17-1.07 (m, 2H). LCMS: rt 5.13 min (A), purity 97 %, MS (m/e) 341 (MH⁺).


Example 59 **5-(2-(6-Methylpyridin-2-yl)pyridin-3-yl)-1H-indazole** **(Compound 116)**



[0392] A vial with a piercable teflon cap containing a magnetic stir bar was charged with 5-[2-(4-fluoro-3-methylphenyl)pyridin-3-yl]-1H-indazole (0.2 g, 0.87 mmol), Pd₂(dba)₃ (30 mg, 0.03 mmol) and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPHOS, 60 mg, 0.13 mmol) under argon atmosphere. 6-Methyl-2-pyridylzinc bromide (0.5 M in THF, 4.0 mL, 2 mmol) was added to above reactants and degassed under vacuum. After three degas cycles, the reaction mixture was heated at 65 °C under argon. After 6 h, the reaction mixture was cooled to the room temperature and diluted with Rochelle salt (5 mL) and concentrated to remove the volatiles. The concentrated aqueous solution was diluted with EtOAc (30 mL) and separated the organic layer. Aqueous solution was further extracted with EtOAc (30 mL). Combined organic layers washed with aq. NaCl (10 mL), stirred over MgSO₄, and filtered through a pad of Florosil/celite. The filtrate was concentrated and purified by preparative HPLC. The collected fractions were concentrated, diluted with water and neutralized with aq. NaHCO₃. The resultant


solid formed was collected by filtration and dried to provide 5-(2-(6-Methylpyridin-2-yl)pyridin-3-yl)-1H-indazole (118 mg, 47%) as a white solid. ¹H NMR (DMSO-d₆): δ 13.01 (s, 1H), 8.63 (dd, 1H, J = 0.8 and 4.7 Hz), 7.99 (s, 1H), 7.89 (d, 1H, J = 7.9 Hz), 7.57 (app d, 2H, J = 8.5 Hz), 7.51 (dd, 1H, J = 4.9 and 7.6 Hz), 7.34 (d, 1H, J = 8.8 Hz), 7.26 (d, 1H, J = 7.6 Hz), 7.07 (d, 1H, J = 7.6 Hz), 6.97 (d, 1H, J = 8.8 Hz), 2.15 (s, 3H). LCMS: rt 2.13 min (B), purity 97 %, MS (m/e) 287 (MH⁺).

Example 60 Methyl 2-Amino-5-bromo-3-methylbenzoate



[0393] 2-Amino-5-bromo-3-methylbenzoic acid (5.0 g, 21.7 mmol) in dry DMF (35 mL) was stirred with Cs₂CO₃ (10.62 g, 32.6 mmol) at room temperature for 1h under nitrogen. Iodomethane (3.4 g, 1.5 mL, 23.95 mmol) in dry DMF (7 ml) was added dropwise to the above stirring reaction mixture over a period of 30 min and continued the reaction for 24 h. Reaction mixture was diluted with water (200 mL) and stirred to observe heterogeneous suspension. The purple solid was collected by filtration and dried to obtain methyl 2-amino-5-bromo-3-methylbenzoate (4.72 g, 89%). ¹H NMR (DMSO-d₆): δ 7.67 (app d, 1H, J = 2.1 Hz), 7.34 (s, 1H), 6.60 (s, 2H), 3.78 (s, 3H), 2.09 (s, 3H). LCMS: rt 7.98 min (A), purity 99 %, MS (m/e) 245 (MH⁺).


Example 61 Methyl 5-bromo-1H-indazole-7-carboxylate



[0394] Acetic anhydride (4.5 g, 4.1 mL, 44 mmol) was added dropwise to the homogeneous solution of methyl 2-amino-5-bromo-3-methylbenzoate (4.72 g, 19 mmol) in chloroform (55 mL) over a period of 20 min at room temperature and allowed to stir for 1h. Potassium acetate (5.7 g, 58 mmol) and isoamyl nitrate (6.6 g, 7.6 mL, 57 mmol) were added at once to the reaction mixture under nitrogen. The clear reaction mixture turned to dark upon heating at 90 °C. The reaction mixture was cooled to room temperature after overnight reflux, concentrated, diluted with water and stirred. The beige solid formed was collected by filtration and dried to obtain


methyl 5-bromo-1H-indazole-7-carboxylate (2.1 g, 42%). ¹H NMR (DMSO-d₆): δ 13.44 (s, 1H), 8.33 (s, 1H), 8.21 (s, 1H), 7.99 (s, 1H), 3.95 (s, 3H). LCMS: rt 6.86 min (A), purity 99 %, MS (m/e) 255 (MH⁺).

Example 62 Methyl 5-(2-chloropyridin-3-yl)-1H-indazole-7-carboxylate



[0395] Analogous to the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole, methyl 5-(2-chloropyridin-3-yl)-1H-indazole-7-carboxylate was prepared by heating the mixture of methyl 5-bromo-1H-indazole-7-carboxylate (2.0 g, 7.8 mmol), 2-chloro-3-pyridine boronic acid pinacol ester (1.9 g, 7.9 mmol), Pd(PPh₃)₄ (540 mg, 0.46 mmol) and 2M aq. Na₂CO₃ (8 mL, 16 mmol) in 1,4-dioxane (70 mL). Methyl 5-(2-chloropyridin-3-yl)-1H-indazole-7-carboxylate was isolated as a white solid (920 mg, 41%) upon work-up and purification generalized in the preparation of 5-(2-chloropyridin-3-yl)-1H-indazole. ¹H NMR (DMSO-d₆): δ 13.41 (s, 1H), 8.45 (d, 1H, J = 4.7 Hz), 8.31 (s, 1H), 8.21 (s, 1H), 7.97 (d, 1H, J = 7.3 Hz), 7.54 (dd, 1H, J = 4.7 and 7.3 Hz), 3.99 (s, 3H). LCMS: rt 6.41 min (A), purity 95 %, MS (m/e) 288 (MH⁺)


Example 63 Methyl 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-7-carboxylate (Compound 190)



[0396] A single necked round bottom flask (100 mL) equipped with a magnetic stirring bar was charged with methyl 5-(2-chloropyridin-3-yl)-1H-indazole-7-carboxylate (0.88 g, 3.0 mmol), 4-fluoro-3-methylphenyl boronic acid (0.56 g, 3.63 mmol), PdCl₂(PPh₃)₄ (214 mg, 1.0


mmol), 1,4-dioxane (75 mL) and 2M aq. Na_2CO_3 (4.2 mL, 8.4 mmol mL) under argon atmosphere. The rubber septum was replaced with reflux condenser containing three-way stopcock. The system was then evacuated three times and back filled with argon and externally heated at 100 °C (oil bath) for 48h. The heterogeneous reaction mixture was allowed to cool to room temperature and concentrated under vacuum to remove the volatiles by rotary evaporator. The crude concentrate flask was charged with chloroform (100 mL)/water (30 mL) and stirred. Organic layer was separated and the aqueous layer further extracted with chloroform (75 mL). Combined organic layers were stirred over $\text{MgSO}_4/\text{Celite}^{\text{®}}$ for 20 min, suction filtered and filter cake washed with chloroform (30 mL). The filtrate collected was concentrated and purified by silica gel flash chromatography [Combiflash[®] companion system[®] with RediSep[®] silica gel column (24 g), solvent eluent gradient 30-50% EtOAc/hexanes] to obtain methyl 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-7-carboxylate (420 mg, 39%) as a white solid. ¹H NMR (DMSO-d₆): δ 13.1 (s, 1H), 8.62 (dd, 1H, J = 0.5 and 4.7 Hz), 8.04 (s, 1H), 7.83 (d, 1H, J = 7.6 Hz), 7.66 (s, 1H), 7.45-7.34 (app m, 3H), 7.02 (d, 1H, J = 8.5 Hz), 6.96-6.85 (m, 2H), 2.11 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.91. LCMS: rt 5.23 min (A), purity 93 %, MS (m/e) 362 (MH^+).

Example 64 **5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-7-carboxylic acid (Compound 195)**




[0397] Methyl 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-7-carboxylate (300 mg, 0.55 mmol) was saponified by LiOH (0.12 g,) in THF/H₂O (1:1, 8 mL) for 2 days. The reaction mixture was concentrated to dryness, diluted with water (4 mL) and neutralized by the addition of aq. 2N HCl. The solid formed after the neutralization was filtered and suction dried to obtain the title compound as a white solid (220 mg). ¹H NMR (DMSO-d₆): δ 13.15 (s, 1H), 8.67 (app dd, 1H, J = 1.4 and 4.7 Hz), 8.17 (s, 1H), 7.97-7.92 (m, 2H), 7.68 (d, 1H, J = 1.7 Hz), 7.51 (dd, 1H, J = 4.7 and 7.6 Hz), 7.38 (d, 1H, 7.6 Hz), 6.93-6.90 (m, 2H), 2.12 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.43(s). LCMS: 97 %, MS (m/e) 348 (MH^+).

Example 65 **(5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-7-yl)(morpholino)methanone (Compound 196)**



[0398] A capped vial containing a stir-bar, was charged with 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-7-carboxylic acid (100 mg, 0.28 mmol), HBTU (140 mg, 0.36 mmol), morpholine (29 mg, 0.03 mL, 0.34 mmol), NEt_3 (57 mg, 0.08 mL, 0.57 mmol) and acetonitrile (3 mL) successively and stirred the contents at room temperature. After 12h, the reaction mixture was concentrated and diluted with EtOAc (15 mL)/ H_2O (5 mL). Organic layer was separated, washed with brine, dried over anhydrous Na_2SO_4 , concentrated and purified by preparative HPLC. Product fractions were concentrated, diluted with water and neutralized with aq. Na_2CO_3 solution. The resulting white precipitate was filtered and dried to obtain (5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-7-yl)(morpholino)methanone. ^1H NMR (DMSO- d_6): δ 13.27 (s, 1H), 8.66 (d, 1H, $J = 4.7$ Hz), 8.17 (s, 1H), 7.97-7.92 (m, 2H), 7.48 (dd, 1H, $J = 4.9$ and 7.6 Hz), 7.33 (d, 1H, $J = 7.8$ Hz), 6.97-6.88 (m, 3H), 3.62-3.42 (m, 8H), 2.10 (s, 3H). ^{19}F NMR (DMSO- d_6): δ -118.69 (s). LCMS: rt 4.45 min (A), purity 97 %, MS (m/e) 417 (MH^+).


Example 66 **5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-N,N-dimethyl-1H-indazole-7-carboxamide (Compound 203)**



[0399] 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-N,N-dimethyl-1H-indazole-7-carboxamide was prepared analogous to the preparation of 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-7-yl(morpholino)methanone by the reaction of dimethylamine (0.55 mL, 1.1 mmol, 2M in THF) with 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-

indazole-7-carboxylic acid (100 mg, 0.28 mmol), HBTU (140 mg, 0.36 mmol), NEt₃ (57 mg, 0.08 mL, 0.57 mmol) in acetonitrile (4 mL). Extractive work-up followed by preparative HPLC purification and neutralization procedure as discussed previously provided desired 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-N,N-dimethyl-1H-indazole-7-carboxamide as a white solid. ¹H NMR (DMSO-d₆): δ 13.05 (s, 1H), 8.63 (dd, 1H, J = 1.7 and 4.7 Hz), 8.13 (s, 1H), 7.87 (dd, 1H, J = 1.4 and 7.6 Hz), 7.81 (s, 1H), 7.46 (dd, 1H, J = 4.7 and 7.6 Hz), 7.32 (d, 1H, J = 7.3 Hz), 7.02-6.98 (m, 1H), 6.95-6.89 (app m, 2H), 2.93 (br s, 3H), 2.57 (br s, 3H), 2.09 (s, 3H). ¹⁹F NMR (DMSO-d₆): δ -118.91. LCMS: rt 4.63 min (A), purity 97 %, MS (m/e) 375 (MH⁺).

Example 67 [5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl]methyl dihydrogen phosphate (Compound 172)



[0400] Step A: Di-*tert*-butyl [5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl]methyl phosphate.

[0401] Freshly prepared chloromethyl di-*tert*-butylphosphate (93% pure, 0.5 g, 1.93 mmol) dissolved in anhydrous DMF (1 mL) was added in one portion to a heterogeneous stirring mixture of 5-[2-(4-fluoro-3-methylphenyl)pyridin-3-yl]-1H-indazole (0.5 g, 1.65 mmol), cesium carbonate (0.64 g, 1.96 mmol) and DMF (3 mL) at room temperature under argon. The contents were heated at 50 °C and the progress of the reaction monitored by LC/MS. After 24h, analysis of the reaction indicated the consumption of 5-[2-(4-fluoro-3-methylphenyl)pyridin-3-yl]-1H-indazole (3%) with the generation of alkylated regio-isomeric product mixture of di-*tert*-butyl [5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl]methyl phosphate (N2, 28%) and di-*tert*-butyl [5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-1-yl]methyl phosphate (N1, 60%). The reaction mixture was diluted with EtOAc (15 mL), upon cooling to room temperature, stirred for 10 min and suction filtered. The filter cake was washed with EtOAc (15 mL) and discarded. Upon dilution of the filtrate with H₂O (20 mL)/*t*-BuOMe (30 mL), the aqueous layer


was separated and the organic layer was washed with water (20 mL). The combined aqueous layers were re-extracted with a mixture of *t*-BuOMe/EtOAc (1/1, 30 mL). The combined organic layers were washed with saturated aq. NaCl (30 mL), stirred over MgSO₄, filtered and resulting filtrate evaporated under vacuum by rotary evaporator (water bath temperature 26-28 °C). The crude (1.2 g) product was subjected to purification by flash chromatography [Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g (pretreated with 5%NEt₃ in 30% EtOAc/hexanes followed by wash with 30% EtOAc/hexanes), 30/50/60/90% EtOAc/hexanes eluting solvent gradient upon liquid loading on to column]. Concentration of the fractions by rotary evaporator under vacuum provided the desired minor N2-regio-isomer, di-*tert*-butyl [5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl]methyl phosphate, as a viscous material (110 mg, 12%). ¹H NMR (DMSO-*d*₆): δ 8.63 (dd, 1H, J = 1.7 and 4.7 Hz), 8.51 (d, 1H, J = 0.9 Hz), 7.84 (dd, 1H, J = 1.8 and 8.0 Hz), 7.66 (d, 1H, J = 0.9 Hz), 7.52 (d, 1H, J = 8.8 Hz), 7.43 (dd, 1H, J = 4.5 and 7.6 Hz), 7.37 (d, 1H, J = 2.0 and 7.6 Hz), 7.01-6.85 (m, 3H), 6.10 (d, 2H, ³J_{PH} = 11 Hz), 2.11 (s, 3H), 1.34 (s, 18 Hz). ³¹P NMR (DMSO-*d*₆): δ -11.9. LCMS: 94%, MS (m/e) 526 (MH⁺).

[0402] Step B: [5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl]methyl dihydrogen phosphate

[0403] Di-*tert*-butyl [5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl]methyl phosphate (*N*2, 100 mg, 0.21 mmol) was dissolved in AcOH:H₂O (0.5 mL, 4:1) and the clear homogenous solution heated at 60 °C. After 1h, analysis of the reaction mixture LC/MS indicated the 97% consumption of di-*tert*-butyl [5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl]methyl phosphate leading to the desired product of [5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl]methyl dihydrogen phosphate (AUC 85%). At this stage heating was discontinued and the reaction mixture was polish filtered by suction. Concentration of the filtrate by rotary evaporator under vacuum (water bath temp 26-28 °C) resulted in a thick viscous liquid which was diluted with acetone (7 mL). The white heterogenous suspension was stirred for 30 min and filtered. The filter cake was washed with acetone (25 mL) and suction dried for a period of 1h. The collected filter cake was further processed by drying under high vacuum over P₂O₅ for 24 h to provide [5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl]methyl dihydrogen phosphate (63 mg, 71%). ¹H NMR (DMSO-*d*₆): δ 8.64 (dd, 1H, J = 0.5 and 4.7 Hz), 8.51 (s, 1H), 7.86 (d, 1H, J = 7.6 Hz), 7.70 (s, 1H), 7.50-7.41 (app

m, 3H), 7.00-6.88 (m, 3H), 6.05 (d, 2H, $^3J_{\text{PH}} = 10$ Hz), 2.13 (s, 3H). ^{19}F NMR (DMSO- d_6): δ -118.60. ^{31}P NMR (DMSO- d_6): δ -2.63. LCMS: 97 %, MS (m/e) 414 (MH^+).

Example 68 **(S)-2-Amino-3-(1H-indol-3-yl)propyl** **5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxylate trifluoroacetic acid salt (Compound 179)**



[0404] Step A: 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxyl chloride

[0405] A single neck round bottom flask with a stir bar was charged with 5-[2-(4-fluoro-3-methylphenyl)pyridin-3-yl]-1H-indazole (100 mg, 0.33 mmol) and triphosgene (120 mg, 0.40 mmol). The reaction flask was capped with a septum with a nitrogen inlet subsequently. Dichloroethane (3 mL) was transferred and cooled the reaction flask to -70 °C. *i*-Pr $_2$ NEt (80 mg, 0.11 mL, 0.60 mmol) was added dropwise to the above stirring reaction mixture over a period 5 min and allowed to stir for 15 min after the completion of addition. The heterogenous suspension was allowed to warm to room temperature and heated at 90 °C. Analysis of the reaction by LC/MS after 18h of heating indicated the formation of 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxyl chloride [rt 6.55 min (A), AUC 59%] and bis(5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-1-yl)methanone [dimer, rt 6.16 min (A), 27%, MH^+ 634]. The reaction mixture was cooled to room temperature and concentrated to dryness under vacuum by rotary evaporation.

[0406] Step B: (*S*)-tert-Butyl-1-(5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxyloxy)-3-(1H-indol-3-yl)propan-2-ylcarbamate

[0407] *N*-(tert-Butoxycarbonyl)-L-tryptophan (100 mg, 0.33 mmol), DMAP (40 mg, 0.33 mmol) and CH_2Cl_2 (3 mL) were added sequentially to the above concentrate containing 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxyl chloride under nitrogen


atmosphere at room temperature. The resulting pale yellow heterogenous stirring solution was treated with NEt_3 (0.5 mL) over a period of 5 min. The resulting clear dark reaction mixture was stirred for 30 min at room temperature. Analysis of the reaction mixture indicated the formation of desired product (*S*)-tert-butyl-1-(5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxyloxy)-3-(1H-indol-3-yl)propan-2-ylcarbamate [rt 7.10 min (A) AUC 56%] and dimer [rt 6.16 min (A), 20%, MH^+ 634] with complete consumption of starting material. The reaction mixture was concentrated, diluted with EtOAc/ H_2O (30 mL/10 mL) and separated the organic layer. Aqueous layer was re-extracted with EtOAc (15 mL), stirred the combined organic layers over MgSO_4 and filtered. Filtrate was concentrated and used in the next step with no further purification.

[0408] Step C: (*S*)-2-Amino-3-(1H-indol-3-yl)propyl 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxylate trifluoroacetic acid salt


[0409] The above concentrate (220 mg) containing (*S*)-tert-butyl-1-(5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxyloxy)-3-(1H-indol-3-yl)propan-2-ylcarbamate dissolved in MeOH (2 mL) was treated with 4.0 N HCl (3 mL) at room temperature and stirred the resulting homogenous solution. After 1h, the reaction mixture was concentrated and purified by reverse phase preparative HPLC containing TFA as a modifier in the mobile phase of acetonitrile/water. The collected product fractions were allowed to freeze by external cooling in dry ice/acetone. The frozen residue was lyophilized to provide (*S*)-2-amino-3-(1H-indol-3-yl)propyl 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxylate as an off-white solid (67 mg, 0.33%) as a TFA salt. ^1H NMR (DMSO-d_6): δ 11.04 (s, 1H), 8.68 (d, 1H, $J = 4.5$ Hz), 8.49 (s, 1H), 8.17 (br s, 3H), 7.99 (d, 1H, $J = 8.5$ Hz), 7.90 (d, 1H, $J = 7.9$ Hz), 7.80 (s, 1H), 7.60 (d, 1H, $J = 7.9$ Hz), 7.50 (dd, 1H, $J = 4.5$ and 7.9 Hz), 7.36-7.31 (app m, 4H), 7.09 (t, 1H, $J = 7.9$ Hz), 6.98 (t, 1H, $J = 7.9$ Hz), 6.92-6.86 (m, 3H), 4.62 (app d, 1H, $J = 9.2$ Hz), 4.52 (dd, 1H, $J = 7.0$ and 9.4 Hz), 3.92-3.87 (br s, 1H), 3.12 (d, 2H, $J = 7.0$ Hz), 2.13 (s, 3H). ^{19}F NMR (DMSO-d_6): δ -118.91 (s) and -74.47(s). LCMS: rt 5.15 min (A), purity 94 %, MS (m/e) 520 (MH^+)-TFA.

Example 69


[0410] Certain starting materials suitable for use in making the compounds described herein can be synthesized using the following reference syntheses.




[0411] Synthesis, 16, 2551-2560 (2008).



[0412] Int'l Pat. App. Pub. no. 2009/027283



[0413] Int'l Pat. App. Pub. no. 2008/147822



[0414] Int'l Pat. App. Pub. no. 2008/078091

Example 70


[0415] Certain intermediates useful in making compounds of the disclosure (e.g., compounds 786-89, 795, 796 and 798-801) according to Schemes 12 and 13 were prepared. General procedures are first provided. Particular structures, compound names and synthetic data are provided thereafter.

[0416] General procedure for the preparation of 5- or 6-(2-(aryl)pyridin-3-yl)-1H-indazol-3-amine: 2-Fluoro-4- or -5-(2-aryl)pyridin-3-yl)benzotrile (75 mg) and EtOH (3 mL) were transferred to a microwave tube containing a stir bar. Corresponding hydrazine was added to the stirring solution, sealed the tube with the cap and heated at 150 °C in the microwave for 35 min. The homogeneous solution was concentrated and diluted with water. The resultant solid was collected by filtration and suction dried overnight. Samples that were not solids were purified by preparative HPLC and lyophilized the purified samples after the processing the samples to neutralization.

[0417] General procedure for 5 or 6-(2-(phenyl)pyridin-3-yl)benzo[d]isoxazol-3-amine: *t*-BuOK (0.077 g, 0.69 mmol) was added to a stirring solution of *N*-acetyl hydroxylamine (0.051 g, 0.69 mmol) in DMF (3 mL) at room temperature under argon in a screw capped vial (20 mL).


After 20 min, corresponding 2-fluoro-4 *or* 5-(2-aryl)pyridin-3-yl)benzotrile (1 eq) was added all at once to the heterogeneous suspension stirred for 30 min at rt. The pale yellow heterogeneous reaction mixture was stirred eventually at 60 °C. After 8h, the reaction mixture was diluted with water and solid formed was collected by filtration. Thus collected solid was purified by either crystallization in EtOAc or preparative HPLC. Preparative HPLC purified product samples were neutralized with aq. NaHCO₃, subsequently filtered the heterogeneous suspension and dried the collected solids.

[0418] 2-Fluoro-4-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)benzotrile (intermediate for compounds 786, 787)




¹H NMR (300 MHz, DMSO-*d*₆) δ 8.70 (dd, *J* = 4.7, 1.7 Hz, 1H), 7.89 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.84 (dd, *J* = 8.1, 7.0 Hz, 1H), 7.51 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.46 (dd, *J* = 10.5, 1.5 Hz, 1H), 7.33 (dd, *J* = 7.4, 1.7 Hz, 2H), 7.14 (dd, *J* = 8.1, 1.6 Hz, 1H), 7.06 – 6.91 (m, 2H), 2.17 (d, *J* = 1.7 Hz, 5H). ¹⁹F NMR (282 MHz, DMSO-*d*₆) δ -108.32 (dd, *J* = 10.5, 7.0 Hz), -118.03 (q, *J* = 7.8 Hz).

[0419] 4-(2-(3-Chlorophenyl)pyridin-3-yl)-2-fluorobenzotrile (intermediate for compounds 798)




¹H NMR (300 MHz, DMSO-*d*₆): δ 8.74 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.94 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.87 (t, *J* = 7.5 Hz, 1H), 7.56 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.49 (d, *J* = 10.6 Hz, 1H), 7.47 – 7.41 (m, 1H), 7.41 – 7.34 (m, 1H), 7.28 (t, *J* = 7.8 Hz, 1H), 7.18 (d, *J* = 8.1 Hz, 1H), 7.10 (d, *J* = 8.8 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆) δ -108.32 (dd, *J* = 10.5, 7.1 Hz).

[0420] 2-Fluoro-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)benzotrile (intermediate for compounds 795, 788, 789)




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.68 (dd, $J = 4.7, 1.7$ Hz, 1H), 7.98 (s, 1H), 7.94 – 7.82 (m, 2H), 7.53 – 7.38 (m, 3H), 7.32 (d, $J = 7.5$ Hz, 1H), 7.00 (dd, $J = 8.9, 3.1$ Hz, 1H), 2.17 (d, $J = 1.5$ Hz, 3H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$): δ -110.59 (q, $J = 6.9$ Hz), -118.29.

[0421] 5-(2-(3-Chlorophenyl)pyridin-3-yl)-2-fluorobenzonitrile (intermediate for compound 799)




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.71 (dd, $J = 4.8, 1.6$ Hz, 1H), 7.92 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.90 – 7.86 (m, 1H), 7.58 – 7.44 (m, 3H), 7.44 – 7.33 (m, 2H), 7.27 (t, $J = 7.8$ Hz, 1H), 7.16 – 7.04 (m, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -110.39 (dt, $J = 9.1, 5.9$ Hz).

[0422] 4-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-2-fluorobenzonitrile (intermediate for compound 800)



^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.73 (dd, $J = 4.7, 1.6$ Hz, 1H), 7.92 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.87 (dd, $J = 8.0, 7.0$ Hz, 1H), 7.63 – 7.47 (m, 3H), 7.27 (t, $J = 7.8$ Hz, 1H), 7.18 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.16 – 7.09 (m, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -108.18 (dd, $J = 10.5, 7.0$ Hz), -116.79 (td, $J = 8.6, 4.9$ Hz).

[0423] 5-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-2-fluorobenzonitrile (intermediate for compound 796, 801)



^1H NMR (300 MHz, DMSO- d_6): δ 8.71 (d, $J = 1.6$ Hz, 1H), 7.92 (t, $J = 1.7$ Hz, 1H), 7.90 (d, $J = 1.7$ Hz, 1H), 7.62 – 7.41 (m, 4H), 7.37 – 7.24 (m, 1H), 7.14 (ddd, $J = 8.6, 4.8, 2.2$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -110.28 (dt, $J = 8.9, 5.9$ Hz), -117.04 (ddd, $J = 9.3, 7.3, 4.7$ Hz).


Example 73

[0424] Compound 291 was prepared according to the reaction sequence shown in Scheme 22. The starting amine, 2'-(3-chloro-4-fluorophenyl)-[3,3'-bipyridin]-6-amine, was prepared from N-(2'-(3-chloro-4-fluorophenyl)-[3,3'-bipyridin]-6-yl)acetamide (^1H NMR (300 MHz, DMSO- d_6) δ 10.51 (s, 1H), 8.67 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.08 (dd, $J = 2.5, 0.8$ Hz, 1H), 8.02 (d, $J = 8.6$ Hz, 1H), 7.90 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.60 (dd, $J = 8.6, 2.5$ Hz, 1H), 7.55 (dd, $J = 7.4, 4.4$ Hz, 1H), 7.51 (dd, $J = 7.4, 4.4$ Hz, 1H), 7.31 (t, $J = 8.6$ Hz, 1H), 7.18 (ddd, $J = 8.6, 4.8, 2.2$ Hz, 1H), 2.07 (s, 3H); ^{19}F NMR (282 MHz, DMSO- d_6) δ -117.24 (td, $J = 8.3, 4.8$ Hz)) via the following procedure: N-(2'-chloro-[3,3'-bipyridin]-6-yl)acetamide (2.5 g) and freshly prepared MeOH. HCl (10 mL) in 1,4-dioxane (35 mL) were heated to stir at 90 °C for 4h. The reaction mixture was concentrated and the crude residue was diluted with water (25 mL). The clear solution was neutralized with aq. NaHCO_3 and extracted into CH_2Cl_2 (2x125 mL). Work-up and drying of the pale yellow residue under high vacuum for 2 days provided 2'-(3-chloro-4-fluorophenyl)-[3,3'-bipyridin]-6-amine as a pale yellow solid. (1.9 g, purity: 96%). ^1H NMR (300 MHz, DMSO- d_6) δ 8.59 (dd, $J = 4.8, 1.7$ Hz, 1H), 7.79 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.73 (d, $J = 2.5$ Hz, 1H), 7.53 (dd, $J = 7.3, 2.1$ Hz, 1H), 7.44 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.33 (t, $J = 8.6$ Hz, 1H), 7.24 (ddd, $J = 8.6, 4.9, 2.1$ Hz, 1H), 7.12 (dd, $J = 8.5, 2.5$ Hz, 1H), 6.35 (dd, $J = 8.6, 0.8$ Hz, 1H), 6.04 (s, 2H).


Example 74

[0425] Compounds in which the Z group is an amine-substituted pyrimidine (e.g., Compounds 903-909 and 919) can be prepared via the reactions outlined in Scheme 29, described in more detail below:

Scheme 29




[0426] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-2-methoxypyrimidine (Compound 207).



¹H NMR (300 MHz, DMSO-*d*₆): δ 8.74 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.48 (d, *J* = 5.1 Hz, 1H), 8.08 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.54 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.34 (dd, *J* = 7.6, 2.1 Hz, 0H), 7.11 – 6.98 (m, 2H), 6.90 (d, *J* = 5.1 Hz, 1H), 3.77 (s, 3H), 2.18 (app d, *J* = 2.1 Hz, 2H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.09 (q, *J* = 8.0, 7.5 Hz). LCMS: rt 5.04 min (B), purity 99 %, MS (m/e) 296 (MH⁺).

[0427] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrimidin-2(1H)-one



Aqueous HCl (2N, 20 mL) was added to the stirring solution of 4-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2-methoxypyrimidine (1.3 g) in MeOH (10 mL) and heated at 90 °C for 12h. The reaction mixture was concentrated by rotary evaporator under reduced pressure and neutralized the resultant pale yellow viscous material with aq. NaHCO₃ solution. The slurry thus formed upon neutralization was stirred at room temperature for 20 min. The solid was collected by filtration, washed with water, suction dried. After 6h, the solid was further dried over P₂O₅ under high vacuum to provide 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrimidin-2(1H)-one

as a white solid (0.87 g). ^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 11.92 (s, 1H), 8.74 (dd, $J = 4.8, 1.7$ Hz, 1H), 7.98 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.80 (app d, $J = 6.0$ Hz, 1H), 7.51 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.43 (dd, $J = 7.7, 2.1$ Hz, 1H), 7.24 – 7.02 (m, 2H), 5.96 (d, $J = 6.0$ Hz, 1H), 2.22 (app s, 3H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -117.63.

[0428] 2-Chloro-4-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrimidine



6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrimidin-2(1H)-one (0.83 g) and POCl_3 (3 mL) were heated at 130 °C under nitrogen. The reaction mixture was cooled to room temperature upon completion of the reaction (2h). The volatiles were removed and quenched the concentrate with ice. The semi-heterogeneous slurry was neutralized with aq. NaHCO_3 solution while stirring, warmed to room temperature and diluted with EtOAc (200 mL). The organic layer was separated, stirred over MgSO_4 , filtered, concentrated and purified by flash chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 12 g and 10-50% EtOAc/Hexanes as eluting solvent) to obtain 2-chloro-4-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrimidine as a clear viscous liquid.


[0429] General procedure for 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-arylpyrimidin-2-amine: 2-chloro-4-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrimidine (1 eq), Ar-NH_2 (1.3 eq), EtOH (3 mL) and catalytic amount of 4.0 M HCl (0.02 mL) were added successively to a microwave tube containing a stir bar. The contents were stirred for 2 min and heated in the microwave at 160 °C for 50 min. The reaction mixture was concentrated and purified by preparative HPLC. The concentrated product fractions thus obtained as salts were neutralized with aq. NaHCO_3 solution and extracted into EtOAc. Organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated. The concentrate was dissolved in acetonitrile/water (1:1) and lyophilized upon freezing the samples to obtain the desired compounds as solids.

[0430] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrimidin-2-amine (Compound 919) was prepared as follows: A screw capped vial was charged with 2-chloro-4-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrimidine (125 mg), 28% aq. Ammonia (3 mL), 1,4-dioxane (3 mL) and a stir bar. The vial was capped tightly, heated and stirred at 60 °C for 12h. The

heterogeneous solution was cooled to room temperature, diluted with water, filtered. The solid (90 mg) was suspended in 50% EtOAc/hexanes, stirred and heated at 80 °C for 30 min. Upon cooling to room temperature, the suspension was filtered and the solid was suction dried to provide 4-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrimidin-2-amine as a white solid (73 mg). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.69 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.07 (d, *J* = 5.0 Hz, 1H), 7.93 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.47 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.38 (dd, *J* = 7.4, 1.6 Hz, 1H), 7.18 – 6.95 (m, 2H), 6.70 (s, 2H), 6.20 (d, *J* = 5.0 Hz, 1H), 2.19 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.16 (q, *J* = 7.7 Hz). LCMS: rt 4.40 min (A), purity 99 %, MS (m/e) 281 MH⁺.

Example 75

[0431] N-alkyl indazole compounds (e.g., Compounds 750 and 751) can be prepared from the corresponding indazoles via the reaction outlined in Scheme 29, described in more detail below:



[0432] 2-(5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-1-yl)acetamide (Compound 750) and 2-(5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl)acetamide (Compound 751). 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole (0.2 g, 0.66 mmol), 2-bromoacetamide (0.1 g, 0.72 mmol) and Cs₂CO₃ (0.25 g, 0.79 mmol) in dry DMF (2.5 mL) was stirred under argon in a screw capped vial at room temperature. The reaction mixture was diluted with water after 2 days and the resultant solid was collected by filtration. Individual alkylated indazole regio-isomers (2:1 ratio Cpd 750:751) were isolated from the crude solid by flash column chromatographic purification (Combiflash[®] companion system[®] with RediSep[®] silica gel column 12 g and 0-1.5% MeOH/EtOAc as an eluting solvent).

Example 76

[0433] 6- or 7-(2-(Aryl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylic acids or esters via the reaction outlined in Scheme 19.

[0434] For example, ethyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (Compound 256) and 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylic acid (Compound 257) can be prepared using the intermediates and preparations described below:

[0435] 2'-(4-Fluoro-3-methylphenyl)-[3,3'-bipyridine]-6-carbonitrile. ^1H NMR (300 MHz, DMSO- d_6): δ 8.73 (dd, $J = 4.7, 1.3$ Hz, 1H), 8.52 (d, $J = 1.9$ Hz, 1H), 8.01 (d, $J = 8.0$ Hz, 1H), 7.96 (dd, $J = 7.8, 1.3$ Hz, 1H), 7.87 (dd, $J = 8.0, 2.1$ Hz, 1H), 7.54 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.31 (d, $J = 7.7$ Hz, 1H), 7.06 – 6.93 (m, 2H), 2.16 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6) δ -117.91 (q, $J = 7.6, 6.9$ Hz).

[0436] (2'-(4-Fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methanamine. 2'-(4-Fluoro-3-methylphenyl)-[3,3'-bipyridine]-6-carbonitrile (2.2 g), Pd/C (0.4g) and conc. HCl (3 mL) in EtOH (100 mL) was hydrogenated in a par shaker at 40 psi overnight. The reaction mixture was filtered through Celite® and concentrated. The concentrate was treated with CH_2Cl_2 (120 mL) and sat. aq. NaHCO_3 (25mL). Organic layer was separated and the aqueous layer was re-extracted with CH_2Cl_2 (2 X 50 ml). Combined organic layers were stirred over anhydrous Na_2SO_4 for 30 min, filtered, concentrated and dried under high vacuum to obtain thick viscous liquid of (2'-(4-Fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methanamine (2.1 g, purity 97%). ^1H NMR (300 MHz, DMSO- d_6): δ 8.66 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.26 (s, 1H), 7.86 (d, $J = 1.6$ Hz, 1H), 7.54 (dd, $J = 8.0, 2.2$ Hz, 1H), 7.48 (dd, $J = 7.7, 4.8$ Hz, 1H), 7.37 (d, $J = 8.1$ Hz, 1H), 7.32 (d, $J = 8.0$ Hz, 1H), 6.97 (dd, $J = 6.9, 1.5$ Hz, 2H), 3.78 (s, 2H), 2.58 (br s, 2H), 2.16 (s, 3H).

[0437] Ethyl 2-(((2'-(4-fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methyl)amino)-2-oxoacetate. To a stirring solution of (2'-(4-fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methanamine (2.0g) in CH_2Cl_2 (30 mL) under nitrogen atmosphere, *i*-Pr₂NEt (2.6 mL) was added and stirred for 10 min at room temperature. Ethyl 2-chloro-2-oxoacetate (1.1 mL) as neat was added dropwise for 10 min. After 1h, the reaction mixture was concentrated, partitioned between CH_2Cl_2 (75 mL)/aq. NaCl (20 mL) and the organic layer was separated. Usual workup and purification by chromatography (Combiflash® companion system® with RediSep® silica gel column 40 g and 50-100% EtOAc/hexanes as an elutant) provided 1.4 g of ethyl 2-(((2'-(4-fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methyl)amino)-2-oxoacetate as an off-white solid. ^1H NMR (300 MHz, DMSO- d_6): δ 9.41 (t, $J = 6.2$ Hz, 1H), 8.67 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.30

(dd, $J = 2.4, 0.9$ Hz, 1H), 7.87 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.56 (dd, $J = 8.1, 2.3$ Hz, 1H), 7.49 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.29-7.22 (m, 2H), 6.98 (dd, $J = 7.7, 1.1$ Hz, 2H), 4.42 (d, $J = 6.1$ Hz, 2H), 4.23 (q, $J = 7.1$ Hz, 2H), 2.21 – 2.09 (m, 3H), 1.26 (t, $J = 7.1$ Hz, 3H).

[0438] Ethyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (Compound 256). Ethyl 2-(((2'-(4-fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methyl)amino)-2-oxoacetate (1.4g) and POCl₃ (15 mL) were stirred and heated at 105 °C under argon balloon. The reaction mixture was cooled to room temperature, added an additional amount of POCl₃ (10 mL) was added to the reaction mixture and heated at 90 °C for 2 days. The reaction mixture was cooled to room temperature and concentrated. Subsequently, ice/water solution was added to the crude residue followed by CH₂Cl₂ and aq. NaHCO₃. Upon allowing the contents warm to room temperature, organic layer was separated, stirred over Na₂SO₄, filtered and concentrated. Purification of the crude residue by flash column chromatography (CombiFlash[®] companion system[®] with RediSep[®] silica gel column 40 g and 0-50-75% EtOAC/hexanes as an eluting solvent) provided 315 mg of Ethyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate as a white pale yellow solid.

[0439] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylic acid (Compound 257). Ethyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (2.1 g) and LiOH·H₂O (400 mg) were stirred in THF/H₂O (1:1, 60 mL) at 70 °C for 2h. The reaction mixture was concentrated to dryness and diluted the pale yellow solid with water. The resulting semi-heterogeneous suspension was cooled in ice-bath, stirred and neutralized with aq. 3N HCl to pH 6. The solid aggregate was collected by filtration on Buchner funnel, washed with water and suction dried. Further processing the sample by drying over P₂O₅ in a vacuum desiccator provided the desired 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylic acid (1.5 g, purity: 97%) as a pale yellow solid.

[0440] Similarly, ethyl 7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (Compound 255) and 7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylic acid (Compound 258) can be prepared using the intermediates described below:

[0441] 2-(4-Fluoro-3-methylphenyl)-[3,4'-bipyridine]-2'-carbonitrile. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.74 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.63 (dd, $J = 5.1, 0.7$ Hz, 1H), 8.02 – 7.90 (m, 2H),

7.54 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.45 (dd, $J = 5.1, 1.7$ Hz, 1H), 7.33 (d, $J = 6.4$ Hz, 1H), 7.09 – 6.94 (m, 2H), 2.17 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -117.73 (q, $J = 7.7, 7.2$ Hz).

[0442] (2-(4-Fluoro-3-methylphenyl)-[3,4'-bipyridin]-2'-yl)methanamine. ^1H NMR (300 MHz, DMSO- d_6): δ 8.69 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.34 (d, $J = 3.8$ Hz, 1H), 7.87 (d, $J = 1.6$ Hz, 1H), 7.50 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.42 – 7.22 (m, 2H), 6.99-6.90 (m, 3H), 3.76 (s, 2H), 3.28 (br s, 2H), 2.16 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -118.23 (d, $J = 7.8$ Hz). 3HCL: ^{19}F NMR (282 MHz, DMSO- d_6): δ 11.13 (s, 2H), 8.87 (d, $J = 4.9$ Hz, 3H), 8.54 (d, $J = 5.3$ Hz, 1H), 8.30 (d, $J = 7.6$ Hz, 1H), 8.06 – 7.80 (m, 2H), 7.43 (d, $J = 6.9$ Hz, 1H), 7.31 – 6.88 (m, 3H), 4.23 (d, $J = 5.2$ Hz, 3H), 2.18 (s, 3H).


[0443] Ethyl 2-(((2-(4-fluoro-3-methylphenyl)-[3,4'-bipyridin]-2'-yl)methyl)amino)-2-oxoacetate. ^1H NMR (300 MHz, DMSO- d_6): δ 9.29 (t, $J = 6.0$ Hz, 1H), 8.69 (d, $J = 4.7$ Hz, 1H), 8.42 (d, $J = 5.0$ Hz, 1H), 7.83 (d, $J = 7.8$ Hz, 1H), 7.50 (dd, $J = 8.0, 4.5$ Hz, 1H), 7.25 (d, $J = 7.5$ Hz, 1H), 7.14 (s, 1H), 7.07 (d, $J = 5.0$ Hz, 1H), 7.01 – 6.88 (m, 2H), 4.37 (d, $J = 6.1$ Hz, 2H), 4.23 (q, $J = 6.9$ Hz, 2H), 2.13 (s, 3H), 1.27 (t, $J = 6.9$ Hz, 3H).

Example 75

[0444] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine (Compound 269) can be prepared via the reactions shown in the first two steps of Scheme 20: (2'-(4-Fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methanamine (2.18 g) and formic acid (15 mL) were stirred and heated under nitrogen atmosphere at 100 °C. After 72h, the reaction mixture was concentrated and partitioned between CH_2Cl_2 /aq. NaHCO_3 . Usual work-up and purification by flash column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g and 50-100%EtOAc/hexanes as elutant) provided 630 mg of N-((2'-(4-fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methyl)formamide as an off-white solid. N-((2'-(4-fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methyl)formamide (630 mg) and POCl_3 (3 mL) were stirred and heated in benzene (20 mL) overnight at 75 °C. The reaction mixture was cooled to room temperature and concentrated. Subsequently, ice/water solution was added to the crude residue followed by CH_2Cl_2 and aq. NaHCO_3 . Upon allowing the solution warm to room temperature, organic layer was separated, stirred over Na_2SO_4 , filtered and concentrated. Purification of the crude residue by flash column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g and 2-8% MeOH/ CH_2Cl_2 as an eluting solvent) provided 320 mg of 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine as an off-white solid.

Example 76

[0445] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridin-3-amine (Compound 285) can be prepared via the reactions shown in Scheme 30, below:

Scheme 30

Cyanogen bromide (62 mg) in dry acetonitrile (1 mL) was added to a screw capped vial containing a stirring solution of (2'-(4-fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-yl)methanamine.xHCl (120 mg), *i*-Pr₂NEt (0.2 mL) and anhydrous toluene. After 4h, the reaction mixture was concentrated and purified by reverse phase preparative HPLC conditions provided 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridin-3-amine (28 mg).


Example 77

[0446] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Compound 291) can be prepared via the reactions shown in Scheme 22: Ethoxycarbonyl isothiocyanate (66 mg) added to a screw capped vial containing 2'-(3-Chloro-4-fluorophenyl)-[3,3'-bipyridin]-6-amine (150 mg) and 1,4-dioxane (1.5 mL). After 6h, the reaction mixture was concentrated in the same vial to dryness and the residue was transferred to a microwave vial by dissolving in MeOH (1 mL) and EtOH (1 mL). Subsequently, hydroxylamine hydrochloride (35 mg) was added, capped the vial, introduced *i*-Pr₂NEt (87 μ L) and heated at 150 °C. Reaction mixture was concentrated after overnight and diluted with water. The solid was collected by filtration and purified by reverse phase preparative HPLC conditions.

Example 78

[0447] Pyrido[3,2-d]pyrimidine compounds can be prepared via the reactions shown in Scheme 31, below:

Scheme 31



[0448] 6-Chloro-4-methoxypyrido[3,2-d]pyrimidine. 4,6-Dichloropyrido[3,2-d]pyrimidine (prepared from Int'l Pat. App. Pubs. nos.2005058913, 2011131741 and 201009469)(2.5 g, 12.4 mmol) and NaHCO_3 (3.1 g, 31 mmol) in MeOH (20 mL) were heated at 70 °C for 12h under nitrogen atmosphere. The reaction mixture was filtered and concentrated the filtrate. The crude concentrate was diluted with water and filtered. The suction dried solid was stirred in EtOAc (20 mL) and filtered to obtain 6-chloro-4-methoxypyrido[3,2-d]pyrimidine (1.8 g) as an off-white solid. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ 8.88 (s, 1H), 8.37 (d, $J = 8.8$ Hz, 1H), 8.00 (d, $J = 8.8$ Hz, 1H), 4.14 (s, 3H).

[0449] 6-(2-Chloropyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine. A reaction flask was charged 6-chloro-4-methoxypyrido[3,2-d]pyrimidine (3.5 g, 17.8 mmol), 2-chloro-3-pyridineboronic acid pinacol ester (4.35 g, 18.2 mmol), Na_2CO_3 (4.0 g, 38.2 mmol) and 1,4-dioxane (100 mL) and a stir bar. The contents were degassed by vacuum and back filled with argon three times while stirring. Subsequently, $\text{Pd}(\text{PPh}_3)_3$ (0.87 g, 0.75 mmol) was added to the reaction contents, repeated degassing cycles and heated under argon at 98 °C. The heating was stopped after overnight, the yellow hot heterogeneous reaction mixture was suction filtered on a Buchner funnel and washed the cake with additional amount of dioxane (30 mL). The pale yellow clear filtrate solution was passed through a pad of Celite® and concentrated the filtrate. The crude pale yellow solid residue was partitioned between CH_2Cl_2 (150 mL)/water (50 mL). The organic layer was separated, dried over MgSO_4 , filtered and concentrated. The crude concentrate was stirred in EtOAc (30 mL) and suction filtered. The filter cake was washed further with EtOAc (10 mL) and dried to obtain 1.6 g of 6-(2-chloropyridin-3-yl)-4-

methoxypyrido[3,2-d]pyrimidine (purity: 95%) as a white solid. The filtrate was concentrated and purified the concentrate by flash column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g, 0-30-60% EtOAc/hexanes eluting solvent gradient) to obtain additional 0.65 g of titled compound. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.92 (s, 1H), 8.57 (dd, *J* = 4.8, 2.0 Hz, 1H), 8.45 (d, *J* = 8.7 Hz, 1H), 8.28 (d, *J* = 8.7 Hz, 1H), 8.13 (dd, *J* = 7.6, 2.0 Hz, 1H), 7.63 (dd, *J* = 7.6, 4.8 Hz, 1H), 4.16 (s, 3H).

[0450] 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine (Compound 968). 6-(2-chloropyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine (2.0 g, 7.3 mmol), 3-chloro-4-fluoro-phenylboronic acid (2.5 g, 14.3 mmol), KF (2.5 g, 43.0 mmol) and 1,4-dioxane (75 mL) and stir bar were added to a reaction flask. The contents were degassed by vacuum and back filled with argon three times while stirring. Subsequently, commercially available catalyst Pd₂(dba)₃.*t*-Bu₃P. HBF₄ (1:2) (1 g, 0.67 mmol) was added to the reaction contents, repeated degassing cycles and heated at 90 °C under argon. Colorimetric changes were observed after the introduction of catalyst and as the reaction progressed from pale pink to yellow to off-green slurries. After 6h, the reaction stirring was stopped, filtered the hot slurry and washed the cake with additional amount of dioxane (30 mL). The pale yellow clear filtrate solution was passed through a pad of Celite[®] and concentrated the filtrate. The crude solid residue was partitioned between CH₂Cl₂ (150 mL)/water (50 mL). The organic layer was separated, dried over MgSO₄, filtered and concentrated. The crude concentrate was stirred in 60% EtOAc/hexanes (30 mL), suction filtered and dried the solid to obtain 1.6 g of (purity: 95%) 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine as an off-white solid. The filtrate was concentrated and purified the concentrate by flash column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g, 0-30-60% EtOAc/hexanes eluting solvent gradient) to obtain additional 0.65 of titled compound.

[0451] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one (Compound 960). Conc. HCl (0.2 ml) was added to a stirring heterogeneous slurry of 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine (2.2 g) in EtOH (25 mL) at room temperature and heated the slurry gradually to 60 °C. The pale yellow heterogeneous slurry transformed to homogeneous solution in 15 min and turned to heterogeneous slurry back again after 2h of heating. Heating and stirring was continued for 4h and cooled the reaction mixture to room temperature. The solid was collected by filtration and concentrated the filtrate.

The solid was neutralized with aq. NaHCO₃, filtered and dried to obtain title compound as a white solid (1.3 g).

[0452] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4-amine (Compound 964). 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one (100 mg, 0.28 mmol), phosphonitrilic chloride (100 mg, 0.28 mmol) and as stir bar were transferred to a vial, capped and placed under nitrogen atmosphere. Dry acetonitrile (3 mL) was transferred and allowed the contents to stir at room temperature. *i*-Pr₂NEt was added for 2 min to the heterogeneous slurry. Upon stirring the red homogeneous slurry for 2h, nitrogen balloon was replaced with NH₃ balloon and stirred. After stirring the contents for 6h, the reaction mixture was concentrated and the crude residue was partitioned between chloroform/water. Organic layer was removed and re-extracted the aqueous layer with chloroform. Usual workup and purification by preparative HPLC provided 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4-amine (16 mg) as a white solid.

Example 79

[0453] 6,7-Diaryl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-ones (e.g., Compounds 292, 293, 294) and 6,7-diaryl-1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazines (e.g., Compounds 295, 296, 300) can be prepared from 6,7-dibromo-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one (Int'l Pat. App. Publication no. 2011/077098) by adopting analogous Suzuki-Miyaura reaction conditions from previous examples, as shown in Scheme 23. Particular intermediates and reactions are described below.

[0454] 7-Bromo-6-(4-fluoro-3-methylphenyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one. ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.56 – 7.26 (m, 3H), 7.19 (dd, *J* = 9.8, 8.4 Hz, 1H), 4.83 (s, 2H), 2.26 (d, *J* = 2.0 Hz, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆) δ -117.58 (ddt, *J* = 8.5, 6.0, 3.0 Hz).


[0455] 7-Bromo-6-(4-fluoro-3-methylphenyl)-1-methyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one. ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.84 (s, 1H), 7.59 – 7.34 (m, 2H), 7.20 (dd, *J* = 9.8, 8.5 Hz, 1H), 4.90 (s, 2H), 3.27 (s, 3H), 2.27 (d, *J* = 1.8 Hz, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆) δ -117.43 (m).

[0456] 7-Bromo-6-(4-fluoro-3-methylphenyl)-1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine. To the stirring solution of 7-bromo-6-(4-fluoro-3-methylphenyl)-1-methyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one (595 mg) and THF (15 mL) under argon was added BH₃.

THF (5.1 mL, 1N solution in THF) dropwise for 20 min. After 12h, the reaction mixture was cooled in ice-bath and transferred 1N aq. HCl (16 mL). Subsequently, cooling bath was removed and heated at 80 °C for 1h. The reaction mixture was concentrated, basified with aq. NaHCO₃ solution and extracted with EtOAc (2 X 125 mL). Workup of the combined organic layers followed by flash column chromatographic purification (Combiflash[®] companion system[®] with RediSep[®] silica gel column 24 g and 30-50% EtOAc/hexanes eluting solvent) provided 450 mg of 7-bromo-6-(4-fluoro-3-methylphenyl)-1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine as an off-white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.45 – 7.32 (m, 2H), 7.21 (s, 1H), 7.13 (dd, *J* = 9.8, 8.5 Hz, 1H), 4.59 – 4.21 (m, 2H), 3.47 – 3.25 (m, 2H), 2.88 (s, 3H), 2.25 (d, *J* = 1.9 Hz, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆) δ -118.92 (m).

Example 80

[0457] Free amino-substituted amide compounds (e.g., Compounds 514, 663, 679) can be prepared according to Scheme 32, below. General synthetic procedures are also provided.



[0458] Step A: A single necked pear shaped round bottom flask containing a stir bar and acid ArCOOH (100 mg, 1eq) is stoppered with a rubber septum and nitrogen is introduced. Methylene chloride (4 mL) is added and stirred for 5 min. Oxalyl chloride is added all at once followed by catalytic DMF (0.05 mL from stock solution of 0.05 mL of dry DMF dissolved in 4 mL of dry DMF) at room temp. The heterogeneous reaction solution turns to clear solution upon addition of DMF which eventually progresses to a heterogeneous slurry. After 3h, reaction mixture is concentrated by rotary evaporator under nitrogen atmosphere to dryness to form acid chloride ArCOCl.

[0459] Step B: DMAP (5 mol%) and the desired N-Boc-diamine (Boc-R-NH₂) (1.2 eq) are weighed into the flask containing the acid chloride (as a semi-solid) with the stir bar. The flask is stoppered with a rubber septum and nitrogen is introduced. Methylene chloride (7 mL) is transferred and allowed to stir with the reaction contents. After stirring the contents for 10 min, *i*-Pr₂NEt is added drop-wise over a period of 5 min. The pale yellow homogeneous reaction mixture is concentrated after 1h to yield crude amide ArCONHR-Boc.

[0460] Step C: The crude residue from step B is stirred with 4.0 N HCl in dioxane (3 mL) and MeOH (3 mL) at room temperature for 1h. At the end of the reaction, the reaction mixture is concentrated and purified by preparative reverse HPLC. The purified concentrate (obtained as either TFA salt or formic acid salt/solvate) is neutralized with aq. NaHCO₃ solution and extracted with EtOAc. The organic layer is stirred with Na₂SO₄, polish filtered and concentrated. The concentrate is dissolved in acetonitrile/water and lyophilized to obtain the desired product ArCONHR.

Example 81

[0461] The following additional compounds were prepared substantially as described herein. In certain cases, synthetic preparations are provided below.

[0462] 5-(2-(3-Cyclopropyl-4-fluorophenyl)pyridin-3-yl)-1H-indazole (Compound 211). LCMS: rt 5.21 min (A), MS (m/e) 330 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.78 (dd, J = 5.4, 1.5 Hz, 1H), 8.55 (dd, J = 7.8, 1.5 Hz, 1H), 8.08 (m, 1H), 7.98 (dd, J = 7.8, 5.4 Hz, 1H), 7.75 (m, 1H), 7.50 (m, 1H), 7.28 (m, 1H), 7.14-7.05 (m, 2H), 6.88 (dd, J = 6.9, 2.1 Hz, 1H), 1.96 (m, 1H), 0.82 (m, 2H), 0.24 (m, 2H);

[0463] N-Cyclopropyl-6-(4-fluoro-3-methylphenyl)-5-(1H-indazol-5-yl)pyridin-3-amine (Compound 212). LCMS: rt 5.65 min (A), MS (m/e) 359 MH⁺.

[0464] 1-(6-(3-Cyclopropylphenyl)-5-(1H-indazol-5-yl)pyridin-3-yl)-3-isopropylurea (Compound 213). LCMS: rt 5.48 min (A), MS (m/e) 412 MH⁺.

[0465] 1-(5-(1H-Indazol-5-yl)-6-(*m*-tolyl)pyridin-3-yl)-3-isopropylurea (Compound 214). LCMS: rt 5.15 min (A), MS (m/e) 386 MH⁺.

[0466] 5-(2-(4-Fluoro-3-methylphenyl)-5-(3-isopropylureido)pyridin-3-yl)-N-isopropyl-1H-indazole-1-carboxamide (Compound 215). LCMS: rt 6.56 min (A), MS (m/e) 489 MH⁺.

[0467] 2-(2-(3-cyclopropyl-4-fluorophenyl)pyridin-3-yl)-1,5-naphthyridine (Compound 216). LCMS: rt 5.81 min (A), MS (m/e) 342 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.03 (dd, J =

4.5, 1.8 Hz, 1H), 8.85 (dd, J = 5.4, 1.8 Hz, 1H), 8.57-8.50 (m, 2H), 8.28 (dd, J = 8.7, 0.9 Hz, 1H), 7.87 (m, 2H), 7.46 (d, J = 8.7 Hz, 1H), 7.22 (m, 1H), 7.04 (dd, J = 10.2, 8.7 Hz, 1H), 6.88 (dd, J = 7.2, 2.4 Hz, 1H), 1.98 (m, 1H), 0.82 (m, 2H), 0.26 (m, 2H).

[0468] 6-(2-(3-Cyclopropyl-4-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 217). LCMS: rt 5.35 min (A), MS (m/e) 331 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.81 (dd, J = 1.8, 0.9 Hz, 1H), 8.45 (s, 1H), 8.18 (dd, J = 7.8, 1.8 Hz, 1H), 7.69-7.64 (m, 2H), 7.38 (dd, J = 9.3, 1.8 Hz, 1H), 7.21 (m, 1H), 7.01 (dd, J = 9.9, 8.4 Hz, 1H), 6.92 (dd, J = 7.2, 2.4 Hz, 1H), 2.03 (m, 1H), 0.85 (m, 2H), 0.36 (m, 2H).

[0469] 6-(2-(3-Cyclopropyl-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 218). LCMS: rt 4.23 min (A), MS (m/e) 330 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.85 (m, 1H), 8.85 (dd, J = 4.8, 1.5 Hz, 1H), 8.22 (dd, J = 2.1, 0.9 Hz, 1H), 8.07 (d, J = 2.1 Hz, 1H), 8.04 (dd, J = 7.8, 1.5 Hz, 1H), 7.80 (m, 1H), 7.62-7.55 (m, 2H), 7.13 (m, 1H), 7.04 (dd, J = 7.5, 2.4 Hz, 1H), 6.95 (d, J = 1.5 Hz, 1H), 2.03 (m, 1H), 0.92 (m, 2H), 0.48 (m, 2H).

[0470] N-(6-(4-Fluoro-3-methylphenyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)morpholine-4-carboxamide (Compound 219). LCMS: rt 4.00 min (A), MS (m/e) 432 MH⁺.

[0471] 1-Ethyl-3-(6-(4-fluoro-3-methylphenyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)urea (Compound 220). LCMS: rt 4.01 min (A), MS (m/e) 390 MH⁺.

[0472] 3-(6-(4-Fluoro-3-methylphenyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-1,1-dimethylurea (Compound 221). LCMS: rt 3.91 min (A), MS (m/e) 390 MH⁺.

[0473] (6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)methanol (Compound 222). LCMS: rt 5.16 min (b), MS (m/e) 346 MH⁺.

[0474] 6-(2-(3-Cyclopropyl-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 223). LCMS: rt 5.90 min (A), MS (m/e) 355 MH⁺.

[0475] 6-(2-(3-Cyclopropyl-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 224). LCMS: rt 4.28 min (A), MS (m/e) 373 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.69 (dd, J = 1.8, 0.9 Hz, 1H), 8.79 (dd, J = 5.1, 1.5 Hz, 1H), 8.52 (s, 1H), 8.27 (dd, J = 7.8, 1.8 Hz, 1H), 7.78 (m, 2H), 7.54 (dd, J = 9.3, 1.5 Hz, 1H), 7.16 (m, 1H), 7.03 (dd, J = 7.2, 2.1 Hz, 1H), 6.99 (dd, J = 10.2, 8.7 Hz, 1H), 2.03 (m, 1H), 0.92 (m, 2H), 0.51 (m, 2H).

[0476] 4-((6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)methyl)morpholine (Compound 225). LCMS: rt 5.06 min (A), MS (m/e) 415 MH⁺.

- [0477] 1-(6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)-N,N-dimethylmethanamine (Compound 226). LCMS: rt 4.98 min (A), MS (m/e) 373 MH⁺.
- [0478] 6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)nicotinic acid (Compound 227). LCMS: rt 6.33 min (A), MS (m/e) 360 MH⁺.
- [0479] 6-(2-(4-Fluoro-3-methylphenyl)-5-(methoxymethyl)pyridin-3-yl)quinoxaline (Compound 228). LCMS: rt 5.81 min (A), MS (m/e) 360 MH⁺.
- [0480] 6-(5-(Ethoxymethyl)-2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinoxaline (Compound 229). LCMS: rt 6.18 min (A), MS (m/e) 374 MH⁺.
- [0481] 6-(2-(4-Fluoro-3-methylphenyl)-5-((4-methylpiperazin-1-yl)methyl)pyridin-3-yl)quinoxaline (Compound 230). LCMS: rt 4.60 min (A), MS (m/e) 428 MH⁺.
- [0482] 2-((6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)methoxy)-N,N-dimethylacetamide (Compound 231). LCMS: rt 5.41 min (A), MS (m/e) 431 MH⁺.
- [0483] 2-((6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)methoxy)-N-methylacetamide (Compound 232). LCMS: rt 5.36 min (A), MS (m/e) 417 MH⁺.
- [0484] 2-((6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)methoxy)acetamide (Compound 233). LCMS: rt 5.11 min (A), MS (m/e) 403 MH⁺.
- [0485] 6-(4-Fluoro-3-methylphenyl)-N,N-dimethyl-5-(quinoxalin-6-yl)nicotinamide (Compound 234). LCMS: rt 6.38 min (A), MS (m/e) 387 MH⁺.
- [0486] 6-(4-Fluoro-3-methylphenyl)-N-methyl-5-(quinoxalin-6-yl)nicotinamide (Compound 235). LCMS: rt 6.28 min (A), MS (m/e) 373 MH⁺.
- [0487] 6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl(morpholino)methanone (Compound 236). LCMS: rt 6.41 min (A), MS (m/e) 429 MH⁺.
- [0488] (6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)(4-methylpiperazin-1-yl)methanone (Compound 237). LCMS: rt 4.98 min (A), MS (m/e) 442 MH⁺.
- [0489] 6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)nicotinamide (Compound 238). LCMS: rt 5.98 min (A), MS (m/e) 359 MH⁺.
- [0490] 6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-amine (Compound 239). LCMS: rt 4.81 min (A), MS (m/e) 331 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.93 (m, 2H), 8.09 (d, J = 2.7 Hz, 1H), 8.05 (d, J = 1.8 Hz, 1H), 8.04 (d, J = 9.0 Hz, 1H), 7.83 (d, J = 2.4 Hz, 1H), 7.62 (dd, J = 8.7, 1.8 Hz, 1H), 7.32 (dd, J = 7.2, 2.1 Hz, 1H), 7.07 (m, 1H), 6.96 (m, 1H), 2.18 (s, 3H).

- [0491] 6-(4-Fluoro-3-methylphenyl)-N-(1-methylpiperidin-4-yl)-5-(quinoxalin-6-yl)pyridin-3-amine (Compound 240). LCMS: rt 4.26 min (A), MS (m/e) 428 MH⁺.
- [0492] 6-(4-Fluoro-3-methylphenyl)-N-isopropyl-5-(quinoxalin-6-yl)pyridin-3-amine (Compound 241). LCMS: rt 5.56 min (A), MS (m/e) 373 MH⁺.
- [0493] N,N-Diethyl-6-(4-fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-amine (Compound 242). LCMS: rt 5.75 min (A), MS (m/e) 387 MH⁺.
- [0494] 2-(((6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)amino)cyclohexan-1-ol (Compound 243). LCMS: rt 5.41 min (A), MS (m/e) 429 MH⁺.
- [0495] 6-(4-Fluoro-3-methylphenyl)-N-(pyridin-3-ylmethyl)-5-(quinoxalin-6-yl)pyridin-3-amine (Compound 244). LCMS: rt 4.28 min (A), MS (m/e) 422 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.91 (m, 3H), 8.75 (d, J = 4.5 Hz, 1H), 8.53 (dd, J = 8.4, 1.5 Hz, 1H), 8.17 (d, J = 2.7 Hz, 1H), 8.01 (m, 2H), 7.95 (dd, J = 7.8, 5.7 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.58 (dd, J = 8.4, 1.8 Hz, 1H), 7.31 (dd, J = 7.8, 1.8 Hz, 1H), 7.05 (m, 1H), 6.96 (m, 1H), 4.81 (s, 2H), 2.17 (s, 3H).
- [0496] 6-(4-Fluoro-3-methylphenyl)-N-(pyridin-4-ylmethyl)-5-(quinoxalin-6-yl)pyridin-3-amine (Compound 245). LCMS: rt 4.26 min (A), MS (m/e) 422 MH⁺.
- [0497] 6-(4-Fluoro-3-methylphenyl)-N-(pyridin-2-ylmethyl)-5-(quinoxalin-6-yl)pyridin-3-amine (Compound 246). LCMS: rt 4.43 min (A), MS (m/e) 422 MH⁺.
- [0498] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(1-methylpiperidin-4-yl)pyridin-3-amine (Compound 247). LCMS: rt 4.56 min (A), MS (m/e) 433 MH⁺.
- [0499] 6-(2-m-Tolylpyridin-3-yl)isoquinoline (Compound 248).
- [0500] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)isoquinoline (Compound 249)
- [0501] 4-(3-(6-(2-m-Tolylpyridin-3-yl)-1H-benzo[d]imidazol-1-yl)propyl)morpholine (Compound 250).
- [0502] 1-(3-(4-Methylpiperazin-1-yl)propyl)-6-(2-m-tolylpyridin-3-yl)-1H-benzo[d]imidazole (Compound 251).
- [0503] 4-(3-(6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)propyl)morpholine (Compound 252).
- [0504] 1-(3-(4-Methylpiperazin-1-yl)propyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-benzo[d]imidazole (Compound 253).
- [0505] 2-Fluoro-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 254). Anhydrous THF (25 mL) was introduced to a mixture of 6-(2-(4-fluoro-3-

methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (0.42 g) and NaH (165 mg, 60% in mineral oil) under argon. The reaction mixture was stirred for 10 min and Selectofluor™ (750 mg) as solid was added in portions for 10 min. After complete addition of Selectofluor™, the reaction mixture was heated at 60 °C. After 8h, the reaction mixture was cooled to room temperature and additional amount of NaH (165 mg) and Selectofluor™ were added to the brown reaction mixture and continued to heat at 60 °C overnight. The reaction mixture was cooled with ice-bath, quenched with water slowly and concentrated. Usual work-up and purification by reverse phase preparative HPLC provided 2-fluoro-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine as a pale yellow solid (23 mg). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.74 – 8.56 (m, 1H), 8.31 (dd, *J* = 1.9, 1.0 Hz, 1H), 7.92 (dt, *J* = 7.7, 1.3 Hz, 1H), 7.56 – 7.35 (m, 3H), 7.35 – 7.21 (m, 2H), 7.06 (ddd, *J* = 8.1, 5.2, 2.3 Hz, 1H), 6.94 (dd, *J* = 9.8, 8.4 Hz, 1H), 6.68 (dt, *J* = 9.5, 1.3 Hz, 1H), 2.12 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆) δ -118.22, -157.61 (d, *J* = 7.1 Hz). LCMS: purity 99%, MS (m/e) 322 MH⁺.

[0506] Ethyl 7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (Compound 255). ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.03 (d, *J* = 7.4 Hz, 1H), 8.70 (dd, *J* = 4.7, 1.7 Hz, 1H), 7.95 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.86 (d, *J* = 1.7 Hz, 1H), 7.69 (s, 1H), 7.56 – 7.41 (m, 2H), 7.13 – 6.93 (m, 2H), 6.71 (dd, *J* = 7.5, 1.8 Hz, 1H), 4.36 (q, *J* = 7.1 Hz, 2H), 2.17 (s, 3H), 1.33 (t, *J* = 7.1 Hz, 3H). LCMS: rt5.83 min (B), purity 96%, MS (m/e) 376 MH⁺.

[0507] Ethyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (Compound 256). LCMS: rt5.81 min (B), purity 98%, MS (m/e) 376 MH⁺.

[0508] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylic acid (Compound 257). ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.23 (q, *J* = 1.2 Hz, 1H), 8.71 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.97 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.77 – 7.57 (m, 2H), 7.52 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.48 – 7.38 (m, 1H), 7.10 (ddd, *J* = 8.0, 5.1, 2.3 Hz, 1H), 6.97 (dd, *J* = 9.7, 8.5 Hz, 1H), 6.75 (dd, *J* = 9.2, 1.5 Hz, 1H), 2.16 (s, 3H). LCMS: rt4.11 min (A), purity 96%, MS (m/e) 348 MH⁺.

[0509] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylic acid (Compound 258). ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.19 – 8.96 (m, 1H), 8.68 (dd, *J* = 4.8, 1.6 Hz, 1H), 7.94 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.80 (d, *J* = 1.9 Hz, 1H), 7.63 (d, *J* = 1.6 Hz, 1H), 7.56 – 7.37 (m, 2H), 7.16 – 6.88 (m, 2H), 6.63 (dt, *J* = 7.5, 1.7 Hz, 1H), 2.17 (s, 3H). LCMS: rt3.93 min (A), purity 95%, MS (m/e) 348 MH⁺.

[0510] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 259). ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.42 (t, *J* = 1.3 Hz, 1H), 8.88 – 8.54 (m, 2H), 8.24 (d, *J* = 1.1 Hz, 0H), 7.93 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.59 (dd, *J* = 9.3, 1.2 Hz, 1H), 7.55 – 7.35 (m, 3H), 7.11 (td, *J* = 6.3, 4.9, 3.0 Hz, 1H), 6.97 (t, *J* = 9.1 Hz, 1H), 6.60 (dt, *J* = 9.4, 1.3 Hz, 1H), 3.31 (q, *J* = 6.5 Hz, 2H), 2.33 (t, *J* = 6.7 Hz, 2H), 2.16 (s, 3H), 2.14 (s, 3H), 1.67 (p, *J* = 6.8 Hz, 2H). LCMS: rt3.35 min (B), purity 99%, MS (m/e) 487 MH⁺.

[0511] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 260). LCMS: rt3.54 min (B), purity 99%, MS (m/e) 473 MH⁺.

[0512] (6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridin-3-yl)((3-morpholinopropyl)-12-azanyl)methanone (Compound 261). LCMS: rt3.72 min (B), purity 99%, MS (m/e) 474 MH⁺.

[0513] N-(3-(Dimethylamino)propyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 262). LCMS: rt3.64 min (B), purity 99%, MS (m/e) 432 MH⁺.

[0514] N-(2-(Dimethylamino)ethyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 263). LCMS: rt3.57 min (B), purity 99%, MS (m/e) 418 MH⁺.

[0515] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 264). ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.18 (dt, *J* = 7.5, 1.0 Hz, 1H), 8.74 (t, *J* = 5.8 Hz, 1H), 8.68 (dd, *J* = 4.7, 1.7 Hz, 1H), 7.93 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.74 (dd, *J* = 1.8, 1.1 Hz, 1H), 7.56 (d, *J* = 0.8 Hz, 1H), 7.52 – 7.39 (m, 2H), 7.21 – 6.90 (m, 2H), 6.55 (dd, *J* = 7.5, 1.9 Hz, 1H), 3.30 (q, *J* = 6.5 Hz, 2H), 2.43 – 2.22 (m, 2H), 2.18 (s, 3H), 2.14 (s, 3H), 1.66 (p, *J* = 6.8 Hz, 2H). LCMS: rt3.25 min (B), purity 99%, MS (m/e) 487 MH⁺.

[0516] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 265). LCMS: rt3.43 min (B), purity 99%, MS (m/e) 473 MH⁺.

[0517] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-morpholinopropyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 266). LCMS: rt 3.62 min (B), purity 99%, MS (m/e) 474 MH⁺.

[0518] N-(3-(Dimethylamino)propyl)-7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 267). LCMS: rt3.53 min (B), purity 99%, MS (m/e) 432 MH⁺.

[0519] N-(2-(Dimethylamino)ethyl)-7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 268). LCMS: rt3.47 min (B), purity 99%, MS (m/e) 418 MH⁺.

[0520] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine (Compound 269). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.68 (dd, *J* = 4.8, 1.5 Hz, 1H), 8.38 (d, *J* = 14.4 Hz, 2H), 7.91 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.55 – 7.42 (m, 2H), 7.38 (d, *J* = 9.5 Hz, 1H), 7.31 (s, 1H), 7.14 (ddd, *J* = 7.8, 5.0, 2.2 Hz, 1H), 7.00 (t, *J* = 9.1 Hz, 1H), 6.31 (dd, *J* = 9.4, 1.4 Hz, 1H), 2.17 (s, 3H). LCMS: rt2.70 min (B), purity 99%, MS (m/e) 304 MH⁺.

[0521] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 270). LCMS: rt5.94 min (B), purity 99%, MS (m/e) 472 MH⁺.

[0522] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 271). LCMS: rt3.66 min (B), purity 99%, MS (m/e) 460 MH⁺.

[0523] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(pyrrolidin-1-yl)ethyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 272). LCMS: rt3.74 min (B), purity 99%, MS (m/e) 445 MH⁺.

[0524] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(pyrrolidin-1-yl)propyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 273). LCMS: rt3.81 min (B), purity 99%, MS (m/e) 458 MH⁺.

[0525] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 274). LCMS: rt5.88 min (B), purity 99%, MS (m/e) 472 MH⁺.

- [0526] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 275). LCMS: rt3.58 min (B), purity 99%, MS (m/e) 460 MH⁺.
- [0527] N-(2-Acetamidoethyl)-7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 276). LCMS: rt5.21 min (B), purity 99%, MS (m/e) 432 MH⁺.
- [0528] N-(3-(1H-Imidazol-1-yl)propyl)-7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 277). LCMS: rt3.70 min (B), purity 99%, MS (m/e) 455 MH⁺.
- [0529] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(pyrrolidin-1-yl)propyl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 278). LCMS: rt3.71 min (B), purity 99%, MS (m/e) 457 MH⁺.
- [0530] N-(((1*R*,2*R*,3*S*,4*S*)-3-Carbamoylbicyclo[2.2.1]hept-5-en-2-yl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 279). LCMS: rt6.67 min (B), purity 99%, MS (m/e) 482 MH⁺.
- [0531] N-(((1*R*,2*R*,3*S*,4*S*)-3-Carbamoylbicyclo[2.2.1]hept-5-en-2-yl)-7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxamide (Compound 280). LCMS: rt6.65 min (B), purity 99%, MS (m/e) 482 MH⁺.
- [0532] 4-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)benzenesulfonamide (Compound 281). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.67 (d, *J* = 4.7 Hz, 1H), 8.46 (s, 1H), 8.02 (d, *J* = 7.8 Hz, 1H), 7.88 (d, *J* = 7.7 Hz, 3H), 7.69 (d, *J* = 7.0 Hz, 2H), 7.58 (d, *J* = 9.3 Hz, 1H), 7.54 – 7.39 (m, 4H), 7.03 (dt, *J* = 9.2, 4.6 Hz, 2H), 2.21 (s, 3H). LCMS: rt3.16 min (B), purity 99%, MS (m/e) 459 MH⁺.
- [0533] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-(pyridin-4-yl)imidazo[1,5-a]pyridine (Compound 282). LCMS: rt3.73 min (B), purity 99%, MS (m/e) 381 MH⁺.
- [0534] 3-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridin-3-yl)aniline (Compound 283). LCMS: rt3.95 min (B), purity 99%, MS (m/e) 395 MH⁺.
- [0535] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-(3-methoxyphenyl)imidazo[1,5-a]pyridine (Compound 284). LCMS: rt5.35 min (B), purity 99%, MS (m/e) 410 MH⁺.
- [0536] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridin-3-amine (Compound 285). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.74 – 8.57 (m, 1H), 8.22 (d, *J* = 2.1 Hz,

1H), 7.93 – 7.78 (m, 2H), 7.47 (qd, $J = 5.3, 4.7, 2.9$ Hz, 2H), 7.19 (dd, $J = 5.5, 2.8$ Hz, 1H), 7.03 (ddd, $J = 10.3, 8.5, 1.7$ Hz, 2H), 6.82 (s, 1H), 5.98 – 5.79 (m, 2H), 2.20 (s, 3H). LCMS: rt2.78 min (B), purity 99%, MS (m/e) 319 MH⁺.

[0537] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-(3-methoxyphenyl)imidazo[1,5-a]pyridine (Compound 286). LCMS: rt5.36 min (B), purity 99%, MS (m/e) 410 MH⁺.

[0538] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-(pyridin-4-yl)imidazo[1,5-a]pyridine (Compound 287). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.66 (dt, $J = 4.4, 2.1$ Hz, 1H), 8.33 (dd, $J = 4.4, 2.0$ Hz, 1H), 8.22 (s, 1H), 8.07 – 7.85 (m, 1H), 7.59 – 7.38 (m, 5H), 7.19 (ddt, $J = 7.6, 5.0, 2.4$ Hz, 1H), 7.13 – 6.94 (m, 3H), 6.62 (td, $J = 5.0, 2.4$ Hz, 1H), 6.55 – 6.35 (m, 1H), 2.21 (s, 3H). LCMS: rt3.36 min (B), purity 99%, MS (m/e) 381 MH⁺.

[0539] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-(4-methoxyphenyl)imidazo[1,5-a]pyridine (Compound 288). LCMS: rt4.73 min (B), purity 99%, MS (m/e) 410 MH⁺.

[0540] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-phenylimidazo[1,5-a]pyridine (Compound 289). LCMS: rt5.09 min (B), purity 95%, MS (m/e) 380 MH⁺.

[0541] 3-(7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridin-3-yl)aniline (Compound 290). LCMS: rt4.38 min (A), purity 97%, MS (m/e) 395 MH⁺.

[0542] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Compound 291). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.68 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.56 (dt, $J = 1.8, 0.7$ Hz, 1H), 8.00 – 7.90 (m, 1H), 7.63 (dd, $J = 7.3, 2.0$ Hz, 1H), 7.52 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.33 – 7.18 (m, 3H), 7.05 (dd, $J = 9.1, 1.8$ Hz, 1H), 6.04 (s, 2H). LCMS: rt5.35 min (B), purity 99%, MS (m/e) 340 MH⁺.

[0543] 7-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one (Compound 292). ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.37 (s, 1H), 8.05 – 7.90 (m, 2H), 7.31 – 7.15 (m, 5H), 4.86 (s, 2H), 2.10 (s, 3H). LCMS: rt7.13 min (A), purity 99%, MS (m/e) 392 MH⁺.

[0544] 6-(4-Fluoro-3-methylphenyl)-7-(quinolin-6-yl)-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one (Compound 293). LCMS: rt5.10 min (A), purity 99%, MS (m/e) 386 MH⁺.

[0545] 7-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-1-methyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one (Compound 294). LCMS: rt 7.83 min (A), purity 99%, MS (m/e) 406 MH⁺.

[0546] 7-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (Compound 295). ^1H NMR (300 MHz, DMSO- d_6) δ 9.35 (s, 1H), 8.05 (d, $J = 1.7$ Hz, 1H), 7.92 (d, $J = 8.4$ Hz, 1H), 7.26 – 7.12 (m, 2H), 7.02 (s, 1H), 6.90 – 6.68 (m, 2H), 4.41 (t, $J = 8.9$ Hz, 2H), 3.37 – 3.24 (m, 2H), 2.90 (s, 3H), 2.09 (s, 3H). LCMS: rt7.35 min (A), purity 99%, MS (m/e) 392 MH^+ .

[0547] 6-(4-Fluoro-3-methylphenyl)-1-methyl-7-(quinolin-6-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (Compound 296). LCMS: rt5.41 min (A), purity 99%, MS (m/e) 386 MH^+ .

[0548] 7-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)isoquinolin-1-amine (Compound 297). LCMS: rt5.11 min (A), purity 99%, MS (m/e) 350 MH^+ .

[0549] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)isoquinolin-1-amine (Compound 298). ^1H NMR (300 MHz, DMSO- d_6) δ 8.62 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.21 (s, 1H), 7.87 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.73 (d, $J = 5.8$ Hz, 1H), 7.54 – 7.38 (m, 2H), 7.34 (dd, $J = 7.5, 2.0$ Hz, 1H), 7.10 (dd, $J = 8.4, 1.7$ Hz, 1H), 6.96 – 6.82 (m, 2H), 6.79 (d, $J = 5.9$ Hz, 1H), 6.71 (s, 2H), 2.08 (s, 3H). LCMS: rt4.38 min (A), purity 97%, MS (m/e) 330 MH^+ .

[0550] 7-(2-(3-Fluorophenyl)pyridin-3-yl)isoquinolin-1-amine (Compound 299). LCMS: rt4.78 min (A), purity 98%, MS (m/e) 332 MH^+ .

[0551] 6-(4-Fluoro-3-methylphenyl)-7-(1H-indazol-5-yl)-1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (Compound 300). LCMS: rt6.80 min (B), purity 96%, MS (m/e) 375 MH^+ .

[0552] 5-(2-(3-Chlorophenyl)pyridin-3-yl)thiazolo[5,4-b]pyridin-2-amine (Compound 301). ^1H NMR (300 MHz, DMSO- d_6) δ 8.68 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.02 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.86 (s, 2H), 7.55 – 7.45 (m, 2H), 7.41 – 7.37 (m, 1H), 7.34 (ddd, $J = 7.8, 2.1, 1.1$ Hz, 1H), 7.25 (t, $J = 7.8$ Hz, 1H), 7.09 (dt, $J = 7.7, 1.3$ Hz, 1H), 7.00 (dd, $J = 8.2, 0.8$ Hz, 1H). LCMS: rt4.85 min (A), purity 99%, MS (m/e) 339 MH^+ .

[0553] 5-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)thiazolo[5,4-b]pyridin-2-amine (Compound 302). ^1H NMR (300 MHz, DMSO- d_6) δ 8.68 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.02 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.87 (s, 2H), 7.55 – 7.45 (m, 3H), 7.28 (t, $J = 7.8$ Hz, 1H), 7.12 (ddd, $J = 8.6, 4.8, 2.2$ Hz, 1H), 7.04 (dd, $J = 8.3, 0.5$ Hz, 1H). LCMS: rt5.26 min (A), purity 95%, MS (m/e) 357 MH^+ .

[0554] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)thiazolo[5,4-b]pyridine (Compound 303). ^1H NMR (300 MHz, DMSO- d_6) δ 9.55 (d, $J = 0.9$ Hz, 1H), 8.73 (ddd, $J = 4.8, 1.8, 0.9$ Hz,

1H), 8.33 (dd, $J = 8.5, 0.8$ Hz, 1H), 8.08 (ddd, $J = 7.9, 1.8, 0.9$ Hz, 1H), 7.52 (ddd, $J = 7.8, 4.7, 0.9$ Hz, 2H), 7.35 (ddd, $J = 7.9, 1.8, 0.8$ Hz, 1H), 7.28 (dd, $J = 8.5, 0.9$ Hz, 1H), 7.01 – 6.85 (m, 3H), 2.13 (s, 3H). LCMS: rt 5.53 min (A), purity 99%, MS (m/e) 322 MH^+ .

[0555] 5-(2-(*m*-Tolyl)pyridin-3-yl)thiazolo[5,4-*b*]pyridine (Compound 304). LCMS: rt 3.37 min (A), purity 96%, MS (m/e) 304 MH^+ .

[0556] 5-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)thiazolo[5,4-*b*]pyridine (Compound 305). 1H NMR (300 MHz, DMSO- d_6) δ 9.56 (s, 1H), 8.76 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.40 (d, $J = 8.5$ Hz, 1H), 8.12 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.68 – 7.50 (m, 2H), 7.42 (d, $J = 8.5$ Hz, 1H), 7.25 (t, $J = 9.0$ Hz, 1H), 7.09 (ddd, $J = 8.7, 4.8, 2.2$ Hz, 1H). LCMS: rt 6.76 min (A), purity 96%, MS (m/e) 342 MH^+ .

[0557] 5-(Benzo[*d*]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-*N*-(pyridin-3-ylmethyl)pyridin-3-amine (Compound 306). LCMS: rt 4.48 min (A), MS (m/e) 427 MH^+ . 1H NMR (CD $_3$ OD, 300 MHz): 9.29 (s, 1H), 8.92 (d, $J = 2.1$ Hz, 1H), 8.79 (d, $J = 5.7$ Hz, 1H), 8.60 (dd, $J = 7.8, 1.5$ Hz, 1H), 8.16 (d, $J = 2.7$ Hz, 1H), 7.03-7.91 (m, 3H), 7.85 (d, $J = 3.0$ Hz, 1H), 7.33 (dd, $J = 8.4, 1.8$ Hz, 1H), 7.21 (dd, $J = 7.5, 1.8$ Hz, 1H), 7.05 (m, 1H), 6.98 (m, 1H), 4.83 (s, 2H), 2.18 (s, 3H).

[0558] 4-(((6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)amino)methyl)benzamide (Compound 307). LCMS: rt 4.41 min (A), MS (m/e) 464 MH^+ .

[0559] 4-(((6-(4-Fluoro-3-methylphenyl)-5-(quinoxalin-6-yl)pyridin-3-yl)amino)methyl)benzotrile (Compound 308). LCMS: rt 5.81 min (A), MS (m/e) 446 MH^+ .

[0560] 4-(((5-(Benzo[*d*]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)benzotrile (Compound 309). LCMS: rt 5.85 min (A), MS (m/e) 451 MH^+ .

[0561] 4-(((5-(Benzo[*d*]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)benzamide (Compound 310). LCMS: rt 5.53 min (A), MS (m/e) 455 MH^+ .

[0562] 5-(Benzo[*d*]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-*N*-(pyridin-4-yl)pyridin-3-amine (Compound 311). LCMS: rt 4.53 min (A), MS (m/e) 413 MH^+ .

[0563] *N*-(5-(Benzo[*d*]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)-3-morpholinopropanamide (Compound 312). LCMS: rt 3.76 min (A), MS (m/e) 477 MH^+ .

[0564] *N*-(5-(Benzo[*d*]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)-4-cyanobenzamide (Compound 313). LCMS: rt 7.59 min (A), MS (m/e) 465 MH^+ .

- [0565] N-(5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)isonicotinamide (Compound 314). LCMS: rt 6.26 min (A), MS (m/e) 441 MH⁺.
- [0566] N-(5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)nicotinamide (Compound 315). LCMS: rt 6.28 min (A), MS (m/e) 441 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.24 (s, 1H), 9.15 (dd, J = 2.1, 0.9 Hz, 1H), 8.99 (d, J = 2.4 Hz, 1H), 8.75 (dd, J = 8.4, 1.8 Hz, 1H), 8.39 (m, 2H), 7.98 (m, 2H), 7.67-7.53 (m, 2H), 7.35 (dd, J = 8.7, 1.8 Hz, 1H), 7.26 (dd, J = 4.5, 1.8 Hz, 1H), 7.02 (m, 1H), 6.84 (m, 1H), 2.13 (s, 3H);
- [0567] N-(5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)butyramide (Compound 316). LCMS: rt 6.72 min (A), MS (m/e) 406 MH⁺.
- [0568] N-(5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)-4-(pyridin-4-yl)butanamide (Compound 317). LCMS: rt 4.03 min (A), MS (m/e) 483 MH⁺.
- [0569] 4-(5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)benzamide (Compound 318). LCMS: rt 7.15 min (B), MS (m/e) 440 MH⁺.
- [0570] 6-(2-(4-Fluoro-3-methylphenyl)-5-(4-methylpiperazin-1-yl)pyridin-3-yl)benzo[d]thiazole (Compound 319). LCMS: rt 3.86 min (B), MS (m/e) 419 MH⁺.
- [0571] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(3-(4-methylpiperazin-1-yl)propyl)pyridin-3-amine (Compound 320). LCMS: rt 2.72 min (A), MS (m/e) 476 MH⁺.
- [0572] 5-(Benzo[d]thiazol-6-yl)-N-((6-chloropyridin-3-yl)methyl)-6-(4-fluoro-3-methylphenyl)pyridin-3-amine (Compound 321). LCMS: rt 6.08 min (A), MS (m/e) 461 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.30 (s, 1H), 8.46 (d, J = 1.8 Hz, 1H), 8.04-7.98 (m, 3H), 7.92 (dd, J = 8.1, 2.7 Hz, 1H), 7.80 (d, J = 3.0 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.32 (dd, J = 8.4, 2.1 Hz, 1H), 7.25 (dd, J = 7.2, 1.8 Hz, 1H), 7.04 (m, 1H), 6.95 (m, 1H), 4.60 (s, 2H), 2.18 (s, 3H);
- [0573] N-((1H-Imidazol-5-yl)methyl)-5-(benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-amine (Compound 322). LCMS: rt 3.47 min (B), MS (m/e) 416 MH⁺.
- [0574] 5-(Benzo[d]thiazol-6-yl)-N-((2-ethyl-1H-imidazol-5-yl)methyl)-6-(4-fluoro-3-methylphenyl)pyridin-3-amine (Compound 323). LCMS: rt 3.63 min (B), MS (m/e) 444 MH⁺.
- [0575] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-((6-methoxypyridin-3-yl)methyl)pyridin-3-amine (Compound 324). LCMS: rt 5.46 min (A), MS (m/e) 457 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.24 (s, 1H), 8.16 (d, J = 1.8 Hz, 1H), 8.02 (d, J = 2.7 Hz, 1H), 7.92 (d, J = 8.7 Hz, 1H), 7.86 (d, J = 1.5 Hz, 1H), 7.74 (dd, J = 8.4, 2.4 Hz, 1H), 7.27 (dd, J = 8.4, 1.8 Hz, 1H), 7.12 (m, 2H), 6.92-6.74 (m, 3H), 4.38 (s, 2H), 3.88 (s, 3H), 2.10 (s, 3H);

- [0576] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-((5-methoxypyridin-3-yl)methyl)pyridin-3-amine (Compound 325). LCMS: rt 4.43 min (A), MS (m/e) 457 MH⁺.
- [0577] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(thiazol-2-ylmethyl)pyridin-3-amine (Compound 326). LCMS: rt 5.64 min (B), MS (m/e) 433 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.16 (s, 1H), 8.08 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 8.7 Hz, 1H), 7.81 (m, 1H), 7.74 (d, J = 3.0 Hz, 1H), 7.46 (d, J = 3.3 Hz, 1H), 7.26 (dd, J = 8.4, 1.8 Hz, 1H), 7.15 (dd, J = 7.5, 1.8 Hz, 1H), 7.12 (d, J = 2.7 Hz, 1H), 6.87 (m, 1H), 6.79 (m, 1H), 4.76 (s, 2H), 2.12 (s, 3H);
- [0578] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(thiazol-5-ylmethyl)pyridin-3-amine (Compound 327). LCMS: rt 5.34 min (B), MS (m/e) 433 MH⁺.
- [0579] N-([2,3'-Bipyridin]-5-ylmethyl)-5-(benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-amine (Compound 328). LCMS: rt 4.78 min (A), MS (m/e) 504 MH⁺.
- [0580] N-((1H-Pyrrolo[2,3-b]pyridin-5-yl)methyl)-5-(benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-amine (Compound 329). LCMS: rt 4.97 min (B), MS (m/e) 466 MH⁺.
- [0581] N-((1H-Pyrrolo[2,3-b]pyridin-3-yl)methyl)-5-(benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-amine (Compound 330). LCMS: rt 4.74 min (B), MS (m/e) 466 MH⁺.
- [0582] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-((2-methylpyridin-3-yl)methyl)pyridin-3-amine (Compound 331). LCMS: rt 3.62 min (B), MS (m/e) 441 MH⁺.
- [0583] 3-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)phenol (Compound 332). LCMS: rt 5.29 min (B), MS (m/e) 442 MH⁺.
- [0584] 4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)phenol (Compound 333). LCMS: rt 4.76 min (A), MS (m/e) 442 MH⁺.
- [0585] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-((6-methylpyridin-3-yl)methyl)pyridin-3-amine (Compound 334). LCMS: rt 3.68 min (B), MS (m/e) 441 MH⁺.
- [0586] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-((3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)methyl)pyridin-3-amine (Compound 335). LCMS: rt 4.50 min (B), MS (m/e) 481 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.19 (s, 1H), 8.50 (d, J = 1.5 Hz, 1H), 8.32 (s, 1H), 8.12 (d, J = 1.5 Hz, 1H), 8.06 (d, J = 2.7 Hz, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.83 (d, J = 1.5 Hz, 1H), 7.23 (dd, J = 8.7, 1.8 Hz, 1H), 7.14 (d, J = 2.7 Hz, 1H), 7.10 (dd, J = 8.7, 1.8 Hz, 1H), 6.87 (m, 1H), 6.78 (m, 1H), 4.61 (s, 2H), 3.90 (s, 3H), 2.08 (s, 3H).
- [0587] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(quinolin-8-ylmethyl)pyridin-3-amine (Compound 336). LCMS: rt 6.02 min (B), MS (m/e) 477 MH⁺. ¹H

NMR (CD₃OD, 300 MHz): 9.19 (s, 1H), 8.34 (dd, J = 8.1, 1.8 Hz, 1H), 8.04 (d, J = 2.4 Hz, 1H), 7.85 (m, 3H), 7.14 (d, J = 1.2 Hz, 1H), 7.55 (m, 2H), 7.19 (dd, J = 8.7, 1.8 Hz, 1H), 7.15 (d, J = 2.7 Hz, 1H), 7.10 (dd, J = 7.8, 2.1 Hz, 1H), 6.86 (m, 1H), 6.78 (m, 1H), 5.09 (s, 2H), 2.09 (s, 3H);

[0588] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(isoquinolin-5-ylmethyl)pyridin-3-amine (Compound 337). LCMS: rt 4.47 min (B), MS (m/e) 477 MH⁺.

[0589] N-(4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)phenyl)acetamide (Compound 338). LCMS: rt 5.14 min (B), MS (m/e) 483 MH⁺.

[0590] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(quinolin-3-ylmethyl)pyridin-3-amine (Compound 339). LCMS: rt 5.41 min (B), MS (m/e) 477 MH⁺.

[0591] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-methylquinazolin-4(3H)-one (Compound 340). LCMS: rt 4.70 min (A), MS (m/e) 346 MH⁺.

[0592] 3-Methyl-6-(2-(m-tolyl)pyridin-3-yl)quinazolin-4(3H)-one (Compound 341). LCMS: rt 4.08 min (A), MS (m/e) 328 MH⁺.

[0593] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-3-methylquinazolin-4(3H)-one (Compound 342). LCMS: rt 4.69 min (A), MS (m/e) 354 MH⁺.

[0594] 3-(5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)phenol (Compound 343). LCMS: rt 6.83 min (A), MS (m/e) 413 MH⁺.

[0595] N-(3-(5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)phenyl)acetamide (Compound 344). LCMS: rt 6.65 min (A), MS (m/e) 454 MH⁺.

[0596] 6-(2-(4-Fluoro-3-methylphenyl)-5-(1H-pyrazol-4-yl)pyridin-3-yl)benzo[d]thiazole (Compound 345). LCMS: rt 5.70 min (A), MS (m/e) 387 MH⁺.

[0597] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4(1H)-one (Compound 346). LCMS: rt 3.79 min (A), MS (m/e) 332 MH⁺.

[0598] 3-(5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)benzenesulfonamide (Compound 347). LCMS: rt 6.93 min (A), MS (m/e) 476 MH⁺.

[0599] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4(1H)-one (Compound 348). LCMS: rt 4.45 min (A), MS (m/e) 332 MH⁺.

[0600] 7-(2-(m-Tolyl)pyridin-3-yl)quinazolin-4(1H)-one (Compound 349). LCMS: rt 4.08 min (A), MS (m/e) 314 MH⁺.

- [0601] 7-(2-(3-cyclopropylphenyl)pyridin-3-yl)quinazolin-4(1H)-one (Compound 350). LCMS: rt 4.56 min (A), MS (m/e) 340 MH⁺.
- [0602] 4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)-2-methoxyphenol (Compound 351). LCMS: rt 4.52 min (A), MS (m/e) 472 MH⁺.
- [0603] 2-(5-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)-2-methoxyphenoxy)acetamide (Compound 352). LCMS: rt 4.26 min (A), MS (m/e) 529 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.21 (s, 1H), 8.00 (d, J = 2.7 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.82 (m, 1H), 7.23 (dd, J = 8.4, 1.8 Hz, 1H), 7.11-7.04 (m, 4H), 7.05 (d, J = 2.7 Hz, 1H), 6.86 (m, 1H), 6.78 (m, 1H), 4.47 (s, 2H), 4.35 (s, 2H), 3.84 (s, 3H), 2.09 (s, 3H).
- [0604] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(4-morpholinobenzyl)pyridin-3-amine (Compound 353). LCMS: rt 5.03 min (A), MS (m/e) 511 MH⁺.
- [0605] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(3-morpholinobenzyl)pyridin-3-amine (Compound 354). LCMS: rt 5.13 min (A), MS (m/e) 511 MH⁺.
- [0606] 6-(2-(4-Fluoro-3-methylphenyl)-5-(1H-pyrazol-1-yl)pyridin-3-yl)benzo[d]thiazole (Compound 355). LCMS: rt 6.85 min (A), MS (m/e) 387 MH⁺.
- [0607] 2-(4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)-2-methoxyphenoxy)ethan-1-ol (Compound 356). LCMS: rt 4.41 min (A), MS (m/e) 516 MH⁺.
- [0608] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(4-((tetrahydro-2H-pyran-4-yl)oxy)benzyl)pyridin-3-amine (Compound 357). LCMS: rt 5.51 min (A), MS (m/e) 526 MH⁺.
- [0609] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(4-(morpholinomethyl)benzyl)pyridin-3-amine (Compound 358). LCMS: rt 3.05 min (A), MS (m/e) 525 MH⁺.
- [0610] 4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)benzenesulfonamide (Compound 359). LCMS: rt 4.34 min (A), MS (m/e) 505 MH⁺.
- [0611] N-((2-Ethyl-1H-imidazol-5-yl)methyl)-6-(4-fluoro-3-methylphenyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-amine (Compound 360). LCMS: rt 3.56 min (A), MS (m/e) 427 MH⁺.

- [0612] 6-(2-(m-tolyl)pyridin-3-yl)quinazolin-4(1H)-one (Compound 361). LCMS: rt 4.21 min (B), MS (m/e) 314 MH⁺.
- [0613] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)quinazolin-4(1H)-one (Compound 362). LCMS: rt 4.84 min (B), MS (m/e) 340 MH⁺.
- [0614] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazoline (Compound 363). LCMS: rt 3.81 min (A), MS (m/e) 316 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.82 (dd, J = 5.4, 1.2 Hz, 1H), 8.54 (m, 1H), 8.38 (d, J = 2.1 Hz, 1H), 7.98 (dd, J = 8.1, 5.7 Hz, 1H), 7.64 (s, 1H), 7.39(m, 2H), 7.18 (m, 2H), 7.06 (m, 2H), 2.22 (s, 3H).
- [0615] 6-(2-(m-Tolyl)pyridin-3-yl)quinazoline (Compound 364). LCMS: rt 3.46 min (A), MS (m/e) 298 MH⁺.
- [0616] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)quinazoline (Compound 365). LCMS: rt 3.98 min (A), MS (m/e) 324 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.78 (dd, J = 5.4, 1.5 Hz, 1H), 8.45 (dd, J = 7.8, 1.5 Hz, 1H), 8.25 (d, J = 2.1 Hz, 1H), 7.93 (dd, J = 8.1, 5.7 Hz, 1H), 7.59 (m, 1H), 7.32-7.12 (m, 4H), 7.01 (m, 2H), 1.84 (m, 1H), 0.85 (m, 2H), 0.45 (m, 2H).
- [0617] 4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)-2,6-dimethoxyphenol (Compound 366). LCMS: rt 5.18 min (B), MS (m/e) 502 MH⁺.
- [0618] 5-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)-2,3-dimethoxyphenol (Compound 367). LCMS: rt 5.34 min (B), MS (m/e) 502 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.16 (s, 1H), 8.01 (d, J = 2.7 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.80 (bs, 1H), 7.25 (dd, J = 8.4, 1.5 Hz, 1H), 7.13 (dd, J = 7.5, 2.1 Hz, 1H), 7.05 (d, J = 2.7 Hz, 1H), 7.90 (m, 1H), 6.78 (m, 1H), 6.58 (m, 2H), 4.32 (s, 2H), 3.82 (s, 3H), 3.79 (s, 3H), 2.11 (s, 3H);
- [0619] 4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)benzene-1,2-diol (Compound 368). LCMS: rt 4.82 min (A), MS (m/e) 458 MH⁺.
- [0620] 4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)-2-fluorophenol (Compound 369). LCMS: rt 5.48 min (B), MS (m/e) 460 MH⁺.
- [0621] 4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)-2-(trifluoromethyl)phenol (Compound 370). LCMS: rt 6.32 min (B), MS (m/e) 510 MH⁺.

[0622] 4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)-2-(trifluoromethoxy)phenol (Compound 371). LCMS: rt 6.38 min (B), MS (m/e) 526 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.19 (s, 1H), 8.01 (d, J = 2.7 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.80 (bs, 1H), 7.61-7.50 (m, 3H), 7.22 (m, 1H), 7.08 (d, J = 2.7 Hz, 1H), 7.05-6.95 (m, 2H), 6.75 (m, 1H), 4.33 (s, 3H), 2.08 (s, 3H);

[0623] 4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)-2-methylphenol (Compound 372). LCMS: rt 5.70 min (B), MS (m/e) 456 MH⁺.

[0624] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(4-(4-methylpiperazin-1-yl)benzyl)pyridin-3-amine (Compound 373). LCMS: rt 3.71 min (B), MS (m/e) 524 MH⁺.

[0625] 1-(4-(((5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)pyridin-3-yl)amino)methyl)phenyl)piperidin-4-ol (Compound 374). LCMS: rt 4.19 min (B), MS (m/e) 525 MH⁺.

[0626] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-methoxyquinazoline (Compound 375). LCMS: rt 6.91 min (B), MS (m/e) 346 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.66 (dd, J = 5.1, 1.5 Hz, 1H), 8.15 (d, J = 2.1 Hz, 1H), 8.07 (s, 1H), 7.95 (m, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.59-7.49 (m, 2H), 7.26 (d, J = 7.5 Hz, 1H), 7.04 (m, 1H), 6.86 (m, 1H), 4.20 (s, 3H), 2.18 (s, 3H).

[0627] 4-Methoxy-6-(2-(m-tolyl)pyridin-3-yl)quinazoline (Compound 376). LCMS: rt 6.29 min (B), MS (m/e) 328 MH⁺.

[0628] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-4-methoxyquinazoline (Compound 377). LCMS: rt 6.94 min (B), MS (m/e) 354 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.64 (m, 1H), 8.08 (m, 2H), 7.97 (m, 1H), 7.60-7.48 (m, 3H), 7.16-7.02 (m, 3H), 6.91 (m, 1H), 4.17 (s, 3H), 1.77 (m, 1H), 0.84 (m, 2H), 0.38 (m, 2H).

[0629] 3-(3-(4-Methoxyquinazolin-6-yl)pyridin-2-yl)phenol (Compound 378). LCMS: rt 3.78 min (A), MS (m/e) 330 MH⁺.

[0630] 6-(2-(3-Hydroxyphenyl)pyridin-3-yl)-3-methylquinazolin-4(3H)-one (Compound 379). LCMS: rt 3.80 min (B), MS (m/e) 330 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.62 (dd, J = 4.8, 1.5 Hz, 1H), 8.28 (s, 1H), 8.16 (m, 1H), 7.97 (dd, J = 7.5, 1.5 Hz, 1H), 7.54 (m, 3H), 7.05 (m, 1H), 6.72 (m, 3H), 3.57 (s, 3H);

- [0631] N-(3-(3-(3-Methyl-4-oxo-3,4-dihydroquinazolin-6-yl)pyridin-2-yl)phenyl)acetamide (Compound 380). LCMS: rt 3.84 min (B), MS (m/e) 371 MH⁺.
- [0632] 6-(2-(4-Fluorophenyl)pyridin-3-yl)-3-methylquinazolin-4(3H)-one (Compound 381). LCMS: rt 5.03 min (B), MS (m/e) 332 MH⁺.
- [0633] 3-Methyl-6-(2-(quinolin-8-yl)pyridin-3-yl)quinazolin-4(3H)-one (Compound 382). LCMS: rt 3.50 min (B), MS (m/e) 365 MH⁺.
- [0634] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-2-amine (Compound 383). LCMS: rt 4.06 min (B), MS (m/e) 331 MH⁺.
- [0635] 6-(2-(m-Tolyl)pyridin-3-yl)quinazolin-2-amine (Compound 384). LCMS: rt 3.53 min (B), MS (m/e) 313 MH⁺.
- [0636] 4-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)morpholine (Compound 385). LCMS: rt 4.28 min (A), MS (m/e) 401 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.81 (dd, J = 5.7, 1.5 Hz, 1H), 8.65 (s, 1H), 8.45 (dd, J = 8.1, 1.5 Hz, 1H), 8.24 (dd, J = 7.8, 1.5 Hz, 1H), 8.17 (m, 2H), 7.90 (m, 1H), 7.63 (m, 1H), 7.44-7.36 (m, 1H), 7.18(m, 1H), 7.03 (m, 1H), 3.89 (m, 4H), 3.22 (m, 4H), 2.21 (s, 3H).
- [0637] 4-(6-(2-(m-Tolyl)pyridin-3-yl)quinazolin-4-yl)morpholine (Compound 386). LCMS: rt 3.83 min (A), MS (m/e) 383 MH⁺.
- [0638] 4-(6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)quinazolin-4-yl)morpholine (Compound 387). LCMS: rt 4.26 min (A), MS (m/e) 409 MH⁺.
- [0639] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazolin-4(1H)-one (Compound 388). LCMS: rt 5.16 min (A), MS (m/e) 352 MH⁺.
- [0640] 6-(2-(3-Chlorophenyl)pyridin-3-yl)quinazolin-4(1H)-one (Compound 389). LCMS: rt 4.76 min (A), MS (m/e) 334 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.75 (dd, J = 5.1, 1.5 Hz, 1H), 8.23 (dd, J = 8.1, 1.5 Hz, 1H), 8.17 (s, 1H), 8.15 (m, 2H), 7.76 (dd, J = 8.1, 5.1 Hz, 1H), 7.62 (m, 1H), 7.45 (m, 1H), 7.37 (m, 1H), 7.36-7.18 (m, 2H).
- [0641] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-3-methylquinazolin-4(3H)-one (Compound 390). LCMS: rt 5.70 min (A), MS (m/e) 366 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.75-8.73 (m, 1H), 8.36 (s, 1H), 8.20 (dd, 1H), 8.14 (m, 1H), 7.77-7.72 (m, 1H), 7.63(m, 2H), 7.55 (dd, 1H), 7.28-7.22 (m, 1H), 7.19 (d, 1H), 3.59 (s, 3H).
- [0642] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-3-methylquinazolin-4(3H)-one (Compound 391). LCMS: rt 5.28 min (A), MS (m/e) 348 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.67 (dd, 1H), 8.31

(s, 1H), 8.13 (m, 1H), 8.01 (dd, 1H), 7.58 (m, 3H), 7.38(m, 1H), 7.28 (m, 1H), 7.23-7.14 (m, 2H), 3.58 (s, 3H).

[0643] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 392). LCMS: rt 2.43 min (A), MS (m/e) 331 MH⁺.

[0644] 6-(2-(3-Chlorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 393). LCMS: rt 3.26 min (B), MS (m/e) 333 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.65 (dd, J = 5.1, 1.8 Hz, 1H), 8.37 (s, 1H), 8.16 (m, 1H), 8.03 (dd, J = 7.8, 1.8 Hz, 1H), 7.59 (dd, J = 7.8, 1.8 Hz, 2H), 7.31 (m, 1H), 7.23-7.13 (m, 2H).

[0645] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 394). LCMS: rt 3.47 min (B), MS (m/e) 351 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.67 (dd, J = 4.8, 1.5 Hz, 1H), 8.38 (s, 1H), 8.16 (d, J = 1.5 Hz, 1H), 8.01 (dd, J = 7.8, 1.5 Hz, 1H), 7.61-7.48 (m, 4H), 7.318-7.06 (m, 2H).

[0646] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-4-methoxyquinazoline (Compound 395). LCMS: rt 6.42 min (A), MS (m/e) 366 MH⁺.

[0647] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-2-amine (Compound 396). LCMS: rt 4.39 min (B), MS (m/e) 331 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.05 (br, 1H), 8.65 (dd, J = 5.1, 1.8 Hz, 1H), 7.95 (dd, J = 7.8, 1.8 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.53 (m, 1H), 7.36 (m, 1H), 7.29 (m, 1H), 7.08-7.02 (m, 2H), 6.87 (m, 1H), 2.15 (s, 3H).

[0648] N,N-Diethyl-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 397). LCMS: rt 3.89 min (B), MS (m/e) 387 MH⁺.

[0649] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N,N-diethylquinazolin-4-amine (Compound 398). LCMS: rt 4.22 min (B), MS (m/e) 407 MH⁺.

[0650] 3-(3-(4-(Diethylamino)quinazolin-6-yl)pyridin-2-yl)phenol (Compound 399). LCMS: rt 3.05 min (B), MS (m/e) 371 MH⁺.

[0651] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-isopropylquinazolin-4-amine (Compound 400). LCMS: rt 3.85 min (B), MS (m/e) 373 MH⁺.

[0652] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N-isopropylquinazolin-4-amine (Compound 401). LCMS: rt 4.17 min (B), MS (m/e) 393 MH⁺.

[0653] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-propylquinazolin-4-amine (Compound 402). LCMS: rt 3.25 min (A), MS (m/e) 373 MH⁺.

- [0654] N-Butyl-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 403). LCMS: rt 3.65 min (A), MS (m/e) 387 MH⁺.
- [0655] N-Cyclopropyl-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 404). LCMS: rt 3.68 min (B), MS (m/e) 371 MH⁺.
- [0656] N-Cyclopentyl-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 405). LCMS: rt 4.30 min (B), MS (m/e) 399 MH⁺.
- [0657] 4-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)amino)benzamide (Compound 406). LCMS: rt 3.63 min (A), MS (m/e) 450 MH⁺.
- [0658] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(4-methoxyphenyl)quinazolin-4-amine (Compound 407). LCMS: rt 4.73 min (B), MS (m/e) 437 MH⁺.
- [0659] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(4-morpholinophenyl)quinazolin-4-amine (Compound 408). LCMS: rt 4.46 min (B), MS (m/e) 492 MH⁺.
- [0660] 4-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)amino)benzotrile (Compound 409). LCMS: rt 6.52 min (B), MS (m/e) 432 MH⁺.
- [0661] 3-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)amino)benzamide (Compound 410). LCMS: rt 4.05 min (B), MS (m/e) 450 MH⁺.
- [0662] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 411). LCMS: rt 3.13 min (B), MS (m/e) 339 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.65 (dd, J = 4.8, 1.5 Hz, 1H), 8.37 (s, 1H), 8.13 (d, J = 2.1 Hz, 1H), 8.03 (dd, J = 7.8, 1.5 Hz, 1H), 7.56-7.51 (m, 2H), 7.41 (dd, J = 9.0, 2.1 Hz, 1H), 7.15-7.04 (m, 3H), 6.89 (m, 1H), 1.76 (m, 1H), 0.79 (m, 2H), 0.34 (m, 2H).
- [0663] 3-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-1,8-naphthyridine (Compound 412). LCMS: rt 5.84 min (B), MS (m/e) 114 MH⁺.
- [0664] 3-(2-(3-Chlorophenyl)pyridin-3-yl)-1,8-naphthyridine (Compound 413). LCMS: rt 5.58 min (B), MS (m/e) 318 MH⁺.
- [0665] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(pyridin-3-yl)ethyl)quinazolin-4-amine (Compound 414). LCMS: rt 2.82 min (B), MS (m/e) 436 MH⁺.
- [0666] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(pyridin-4-ylmethyl)quinazolin-4-amine (Compound 415). LCMS: rt 2.78 min (B), MS (m/e) 422 MH⁺.
- [0667] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(pyridin-3-ylmethyl)quinazolin-4-amine (Compound 416). LCMS: rt 3.03 min (B), MS (m/e) 422 MH⁺.

- [0668] 3-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1,8-naphthyridine (Compound 417). LCMS: rt 5.23 min (B), MS (m/e) 316 MH⁺.
- [0669] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinoline-2-carbonitrile (Compound 418). LCMS: rt 7.75 min (B), MS (m/e) 340 MH⁺.
- [0670] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinoline-2-carbonitrile (Compound 419). LCMS: rt 8.26 min (B), MS (m/e) 360 MH⁺.
- [0671] 6-(2-(3-Chlorophenyl)pyridin-3-yl)quinoline-2-carbonitrile (Compound 420). LCMS: rt 8.07 min (B), MS (m/e) 342 MH⁺.
- [0672] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-((1-methylpiperidin-4-yl)methyl)quinazolin-4-amine (Compound 421). LCMS: rt 2.32 min (B), MS (m/e) 442 MH⁺.
- [0673] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(1-methylpiperidin-4-yl)ethyl)quinazolin-4-amine (Compound 422). LCMS: rt 1.97 min (A), MS (m/e) 456 MH⁺.
- [0674] N1-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)-N3,N3-dimethylpropane-1,3-diamine (Compound 423). LCMS: rt 3.55 min (A), MS (m/e) 416 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.79 (s, 1H), 8.67 (dd, J = 5.4, 1.5 Hz, 1H), 8.49 (m, 1H), 8.21 (dd, J = 7.8, 1.8 Hz, 1H), 7.77 (dd, J = 8.1, 5.4 Hz, 1H), 7.66 (m, 2H), 7.37 (m, 1H), 7.09 (m, 1H), 6.94 (m, 1H), 3.94 (t, J = 6.6 Hz, 2H), 3.29 (m, 2H), 2.91 (s, 6H), 2.24 (m, 2H), 2.20 (s, 3H);
- [0675] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-morpholinopropyl)quinazolin-4-amine (Compound 424). LCMS: rt 3.61 min (A), MS (m/e) 458 MH⁺.
- [0676] 4-(2-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)oxy)ethyl)morpholine (Compound 425). LCMS: rt 3.42 min (B), MS (m/e) 445 MH⁺.
- [0677] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinolin-2-amine (Compound 426). LCMS: rt 3.19 min (B), MS (m/e) 330 MH⁺.
- [0678] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinolin-2-amine (Compound 427). LCMS: rt 3.72 min (B), MS (m/e) 350 MH⁺.
- [0679] 6-(2-(3-Chlorophenyl)pyridin-3-yl)quinolin-2-amine (Compound 428). LCMS: rt 3.50 min (B), MS (m/e) 332 MH⁺.
- [0680] 3-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)oxy)-N,N-dimethylpropan-1-amine (Compound 429). LCMS: rt 3.47 min (B), MS (m/e) 417 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.74 (s, 1H), 8.66 (dd, J = 5.1, 1.5 Hz, 1H), 8.10 (m, 1H), 8.03 (dd, J = 7.8, 1.5 Hz, 1H), 7.77 (m, 1H), 7.67 (dd, J = 7.8, 5.1 Hz, 1H), 7.56 (m, 2H), 7.27 (m, 1H), 7.06

(m, 1H), 6.88 (m, H), 4.67 (t, J = 6.0 Hz, 2H), 2.88 (m, 2H), 2.56 (s, 6H), 2.21 (m, 2H), 2.14 (s, 3H).

[0681] 2-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)oxy)acetonitrile (Compound 430). LCMS: rt 6.76 min (B), MS (m/e) 371 MH⁺.

[0682] 1-(3-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)oxy)propyl)pyrrolidin-2-one (Compound 431). LCMS: rt 4.92 min (A), MS (m/e) 457 MH⁺.

[0683] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-(((6-methylpyridin-3-yl)oxy)quinazoline (Compound 432). LCMS: rt 6.58 min (B), MS (m/e) 423 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.69 (s, 1H), 8.67 (dd, J = 5.4, 1.8 Hz, 1H), 8.35 (dd, J = 7.8, 1.5 Hz, 1H), 8.16 (m, 1H), 8.07 (m, 1H), 7.70 (m, 2H), 7.57 (m, 2H), 7.27-7.02 (m, 3H), 6.89 (m, 1H), 2.41 (s, 3H), 2.18 (s, 3H).

[0684] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-(2-(4-methylpiperazin-1-yl)ethoxy)quinazoline (Compound 433). LCMS: rt 3.45 min (B), MS (m/e) 458 MH⁺.

[0685] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline (Compound 434). LCMS: rt 3.42 min (B), MS (m/e) 472 MH⁺.

[0686] 3-(((6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazolin-4-yl)oxy)-N,N-dimethylpropan-1-amine (Compound 435). LCMS: rt 3.83 min (B), MS (m/e) 437 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.74 (s, 1H), 8.65 (dd, J = 5.4, 1.5 Hz, 1H), 8.10 (m, 2H), 8.03 (dd, J = 7.8, 1.5 Hz, 1H), 7.84 (m, 1H), 7.67 (dd, J = 7.8, 5.1 Hz, 1H), 7.56 (m, 1H), 7.20 (m, 1H), 7.12 (m, 1H), 4.66 (t, J = 6.6 Hz, 2H), 2.77 (m, 2H), 2.46 (s, 6H), 2.14 (m, 2H);

[0687] 1-(3-(((6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazolin-4-yl)oxy)propyl)pyrrolidin-2-one (Compound 436). LCMS: rt 6.60 min (B), MS (m/e) 477 MH⁺.

[0688] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-4-(((6-methylpyridin-3-yl)oxy)quinazoline (Compound 437). LCMS: rt 7.36 min (B), MS (m/e) 443 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.70 (s, 1H), 8.67 (dd, J = 5.4, 1.5 Hz, 1H), 8.37 (dd, J = 7.8, 1.5 Hz, 1H), 8.15 (m, 2H), 8.08 (m, 2H), 7.96 (m, 1H), 7.57 (m, 2H), 7.23-7.06 (m, 3H), 2.41 (s, 3H).

[0689] 2-(((6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazolin-4-yl)oxy)-N,N-diethylethan-1-amine (Compound 438). LCMS: rt 3.89 min (B), MS (m/e) 451 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.76 (s, 1H), 8.67 (dd, J = 5.1, 1.5 Hz, 1H), 8.11 (dd, J = 7.8, 1.8 Hz, 1H), 7.99 (m, 1H), 7.82 (m, 1H), 7.59-7.48 (m, 3H), 7.21-7.05 (m, 2H), 4.76 (t, J = 2.4 Hz, 2H), 3.83 (t, J = 2.4 Hz, 2H), 2.84 (q, J = 7.2 Hz, 4H), 1.30 (t, J = 7.2 Hz, 6H).

[0690] 2-(((6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazolin-4-yl)oxy)-N,N-dimethylethan-1-amine (Compound 439). LCMS: rt 3.69 min (B), MS (m/e) 423 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.76 (s, 1H), 8.61 (dd, J = 5.4, 1.5 Hz, 1H), 8.23 (m, 1H), 8.10 (m, 1H), 8.01 (dd, J = 7.8, 1.5 Hz, 1H), 7.86 (m, 1H), 7.65 (dd, J = 7.8, 5.1 Hz, 1H), 7.61 (m, 1H), 7.16 (m, 1H), 7.09 (m, 1H), 4.75 (t, J = 5.7 Hz, 2H), 3.80 (t, J = 5.7 Hz, 2H), 2.78 (s, 6H).

[0691] 4-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)oxy)benzotrile (Compound 440). LCMS: rt 8.03 min (B), MS (m/e) 433 MH⁺.

[0692] 3-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)oxy)benzotrile (Compound 441). LCMS: rt 8.06 min (B), MS (m/e) 433 MH⁺.

[0693] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-(pyridin-3-yloxy)quinazoline (Compound 442). LCMS: rt 6.66 min (B), MS (m/e) 409 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.70 (s, 1H), 8.67 (dd, J = 4.8, 1.5 Hz, 1H), 8.15 (s, 1H), 8.07 (m, 1H), 7.95 (dd, J = 7.5, 1.5 Hz, 1H), 7.86 (m, 1H), 7.62-7.50 (m, 3H), 7.59 (m, 1H), 7.35-7.23 (m, 2H), 7.03 (m, 1H), 6.88 (m, 1H), 2.19 (s, 3H).

[0694] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-(2-(pyrrolidin-1-yl)ethoxy)quinazoline (Compound 443). LCMS: rt 2.87 min (A), MS (m/e) 429 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.65 (m, 1H), 8.14 (s, 1H), 7.96 (m, 2H), 7.78 (m, 1H), 7.64-7.50 (m, 2H), 7.27 (m, 1H), 7.04 (m, 1H), 6.87 (m, 1H), 4.78 (t, J = 5.4 Hz, 2H), 3.06 (t, J = 5.4 Hz, 2H), 3.71 (m, 3H), 2.17 (s, 3H), 2.16 (m, 2H), 1.87 (m, 3H);

[0695] 4-(3-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)oxy)phenyl)morpholine (Compound 444). LCMS: rt 8.06 min (B), MS (m/e) 493 MH⁺.

[0696] 5-(2-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)oxy)ethyl)-4-methylthiazole (Compound 445). LCMS: rt 7.23 min (B), MS (m/e) 457 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.75 (s, 1H), 8.66 (dd, J = 5.1, 1.8 Hz, 1H), 8.11 (s, 1H), 8.11 (m, 1H), 7.99 (dd, J = 6.9, 1.8 Hz, 1H), 7.77 (s, 1H), 7.57 (m, 2H), 7.27 (m, 1H), 7.04 (m, 1H), 6.88 (m, 1H), 4.78 (t, J = 6.0 Hz, 2H), 3.38 (t, J = 6.0 Hz, 2H), 2.24 (s, 3H), 2.14 (s, 3H).

[0697] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-(quinolin-6-yloxy)quinazoline (Compound 446). LCMS: rt 5.71 min (A), MS (m/e) 459 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.75-8.59 (m, 2H), 8.42 (s, 1H), 8.12 (m, 2H), 7.99 (dd, J = 8.1, 1.8 Hz, 1H), 7.88 (m, 1H), 7.76 (s, 1H), 7.59 (m, 2H), 7.43-7.27 (m, 3H), 7.25 (m, 1H), 7.06 (m, 1H), 6.88 (m, 1H), 2.17 (s, 3H).

[0698] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-((1-(pyridin-4-yl)piperidin-4-yl)oxy)quinazoline (Compound 447). LCMS: rt 3.31 min (A), MS (m/e) 492 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.74 (s, 1H), 8.67 (dd, J = 5.4, 1.8 Hz, 1H), 8.52 (s, 1H), 8.09 (m, 3H), 7.98 (m, 1H), 7.87 (m, 1H), 7.57 (m, 2H), 7.25 (m, 1H), 7.14-7.01 (m, 2H), 6.87 (m, 1H), 3.77 (m, 4H), 3.47 (m, 1H), 2.21 (s, 3H), 1.96 (m, 4H).

[0699] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 448). LCMS: rt 4.46 min (A), MS (m/e) 351 MH⁺. ¹H NMR (DMSO-*d*₆, 300 MHz): 8.67 (dd, J = 4.8, 1.5 Hz, 1H), 8.32 (s, 1H), 8.20 (d, J = 2.1 Hz, 1H), 7.91 (dd, J = 7.5, 1.8 Hz, 1H), 7.69 (bs, 2H), 7.55-7.46 (m, 3H), 7.36 (dd, J = 8.4, 1.8 Hz, 1H), 7.16 (m, 1H), 7.09-7.04 (m, 1H).

[0700] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 449). LCMS: rt 4.51 min (A), MS (m/e) 351 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.79 (dd, J = 4.8, 1.5 Hz, 1H), 8.67 (s, 1H), 8.34 (d, J = 1.5 Hz, 1H), 8.13 (dd, J = 7.8, 1.5 Hz, 1H), 7.80 (dd, J = 8.7, 1.8 Hz, 1H), 7.71 (m, 2H), 7.64 (dd, J = 6.3, 3.0 Hz, 1H), 7.42 (m, 1H), 6.92 (m, 1H).

[0701] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 450). LCMS: rt 4.80 min (A), MS (m/e) 369 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.79 (dd, J = 4.8, 1.5 Hz, 1H), 8.68 (s, 1H), 8.34 (d, J = 1.8 Hz, 1H), 8.10 (dd, J = 7.2, 1.5 Hz, 1H), 7.83 (dd, J = 7.5, 2.1 Hz, 1H), 7.79 (m, 1H), 7.71 (m, 2H), 6.99 (m, 1H).

[0702] 6-(2-(3-Methoxyphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 451). LCMS: rt 3.26 min (A), MS (m/e) 329 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.50 (dd, J = 5.4, 1.8 Hz, 1H), 8.68 (s, 1H), 8.43 (m, 2H), 7.94 (dd, J = 8.1, 5.4 Hz, 1H), 7.76 (dd, J = 8.4, 1.8 Hz, 1H), 7.65 (m, 1H), 7.26 (m, 1H), 7.01 (m, 2H), 6.88 (m, 1H), 3.71 (s, 3H).

[0703] 6-(2-(3-(Trifluoromethoxy)phenyl)pyridin-3-yl)quinazolin-4-amine (Compound 452). LCMS: rt 4.71 min (A), MS (m/e) 383 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.80 (dd, J = 5.1, 1.5 Hz, 1H), 8.69 (s, 1H), 8.36 (m, 1H), 8.18 (dd, J = 7.8, 1.8 Hz, 1H), 7.77-7.65 (m, 3H), 7.43 (m, 2H), 7.28 (m, 1H), 7.19 (m, 2H).

[0704] 6-(2-(3,4-Difluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 453). LCMS: rt 4.01 min (A), MS (m/e) 335 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.76 (dd, J = 5.4, 1.5 Hz, 1H), 8.69 (s, 1H), 8.38 (m, 1H), 8.14 (dd, J = 7.8, 1.5 Hz, 1H), 7.70-7.65 (m, 2H), 7.35 (m, 2H), 7.18 (m, 1H), 7.09 (m, 1H).

[0705] 6-(2-(2,5-Difluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 454). LCMS: rt 4.11 min (A), MS (m/e) 335 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.79 (dd, J = 4.8, 1.5 Hz,

1H), 8.67 (s, 1H), 8.33 (d, J = 1.8 Hz, 1H), 8.11 (dd, J = 7.8, 1.8 Hz, 1H), 7.82 (dd, J = 8.4, 1.5 Hz, 1H), 7.79-7.65 (m, 2H), 7.36 (m, 2H), 7.16 (m, 1H), 6.92 (m, 1H).

[0706] 6-(2-(2,4-Difluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 455). LCMS: rt 2.26 min (A), MS (m/e) 335 MH⁺.

[0707] 3-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)phenol (Compound 456). LCMS: rt 2.16 min (A), MS (m/e) 315 MH⁺. ¹H NMR (DMSO-*d*₆, 300 MHz): 9.31 (s, 1H), 8.68 (dd, J = 4.8, 1.5 Hz, 1H), 8.37 (s, 1H), 8.28 (m, 1H), 7.90 (dd, J = 7.8, 1.5 Hz, 1H), 7.74 (bs, 2H), 7.51 (dd, J = 7.8, 4.5 Hz, 1H), 7.43 (m, 1H), 7.31 (dd, J = 8.7, 1.5 Hz, 1H), 7.00 (m, 1H), 6.77 (m, 1H), 6.65-6.62 (m, 2H).

[0708] N-(3-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)phenyl)acetamide (Compound 457). LCMS: rt 2.18 min (A), MS (m/e) 356 MH⁺.

[0709] 6-(2-(3-Fluoro-5-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 458). LCMS: rt 2.45 min (A), MS (m/e) 331 MH⁺.

[0710] 6-(2-(3-Fluoro-4-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 459). LCMS: rt 2.41 min (A), MS (m/e) 331 MH⁺.

[0711] 6-(2-(3-Chloro-5-fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 460). LCMS: rt 2.77 min (A), MS (m/e) 351 MH⁺.

[0712] 6-(2-(3-Fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 461). LCMS: rt 2.16 min (A), MS (m/e) 317 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.68 (dd, J = 5.1, 1.8 Hz, 1H), 8.37 (s, 1H), 8.15 (m, 1H), 8.01 (dd, J = 7.8, 1.5 Hz, 1H), 7.59-7.54 (m, 2H), 7.48 (dd, J = 8.4, 1.8 Hz, 1H), 7.22 (m, 1H), 7.12 (m, 1H), 7.03 (m, 1H).

[0713] 6-(2-(*o*-Tolyl)pyridin-3-yl)quinazolin-4-amine (Compound 462). LCMS: rt 1.85 min (A), MS (m/e) 313 MH⁺.

[0714] 6-(2-(5-Chloro-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 463). LCMS: rt 2.58 min (A), MS (m/e) 347 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.68 (dd, J = 5.1, 1.8 Hz, 1H), 8.37 (s, 1H), 8.14 (m, 1H), 8.08 (dd, J = 7.8, 1.8 Hz, 1H), 7.64 (dd, J = 8.1, 5.1 Hz, 1H), 7.52-7.43 (m, 2H), 7.28-7.21 (m, 2H), 7.11 (m, 1H), 1.90 (s, 3H).

[0715] 6-(2-(3-Chloro-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 464). LCMS: rt 2.58 min (A), MS (m/e) 347 MH⁺.

[0716] 6-(2-(6-Chloro-2-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 465). LCMS: rt 2.97 min (A), MS (m/e) 365 MH⁺.

- [0717] 6-(2-(5-Fluoro-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 466). LCMS: rt 2.23 min (A), MS (m/e) 331 MH⁺.
- [0718] 6-(2-(4-Fluoro-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 467). LCMS: rt 2.07 min (A), MS (m/e) 331 MH⁺.
- [0719] 6-(2-(3-Fluoro-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 468). LCMS: rt 2.25 min (A), MS (m/e) 331 MH⁺.
- [0720] 6-(2-(3,4,5-Trifluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 469). LCMS: rt 2.74 min (A), MS (m/e) 353 MH⁺.
- [0721] 6-(2-(2,3-Dihydro-1H-inden-5-yl)pyridin-3-yl)quinazolin-4-amine (Compound 470). LCMS: rt 2.34 min (A), MS (m/e) 339 MH⁺.
- [0722] 5-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-one (Compound 471). LCMS: rt 2.09 min (A), MS (m/e) 353 MH⁺.
- [0723] (E)-5-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-one oxime (Compound 472). LCMS: rt 2.15 min (A), MS (m/e) 367 MH⁺.
- [0724] 6-(2-(2-Fluoro-5-methoxyphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 473). LCMS: rt 2.32 min (A), MS (m/e) 347 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.69 (dd, J = 5.1, 1.8 Hz, 1H), 8.40 (s, 1H), 8.16 (m, 1H), 8.02 (dd, J = 7.8, 1.5 Hz, 1H), 7.62 (dd, J = 7.8, 5.1 Hz, 1H), 7.54 (m, 2H), 7.03 (m, 1H), 6.91-6.77 (m, 2H), 3.75 (s, 3H).
- [0725] 6-(2-(4-Fluoro-3-methoxyphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 474). LCMS: rt 2.14 min (A), MS (m/e) 347 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.68 (dd, J = 4.8, 1.5 Hz, 1H), 8.43 (s, 1H), 8.20 (m, 1H), 8.02 (dd, J = 7.8, 1.8 Hz, 1H), 7.60-7.51 (m, 3H), 7.08 (dd, J = 8.1, 2.1 Hz, 1H), 6.96 (dd, J = 8.7, 11.1 Hz, 1H), 6.83-6.78 (m, 1H), 3.63 (s, 3H).
- [0726] N-(3-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)phenyl)-N',N'-dimethylsulfonyldiamine (Compound 475). LCMS: rt 2.12 min (A), MS (m/e) 421 MH⁺.
- [0727] 6-(2-(4-Fluoro-3-(trifluoromethyl)phenyl)pyridin-3-yl)quinazolin-4-amine (Compound 476). LCMS: rt 3.13 min (A), MS (m/e) 385 MH⁺.
- [0728] 5-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)-2-fluorobenzonitrile (Compound 477). LCMS: rt 2.35 min (A), MS (m/e) 342 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.72 (dd, J = 4.8, 1.5 Hz, 1H), 8.42 (s, 1H), 8.15 (m, 1H), 8.02 (dd, J = 6.0, 1.8 Hz, 1H), 7.64-7.51 (m, 4H), 7.21 (m, 1H).

- [0729] 6-(2-(3-Isopropylphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 478). LCMS: rt 2.70 min (A), MS (m/e) 341 MH⁺.
- [0730] 6-(2-(3-(Benzyloxy)phenyl)pyridin-3-yl)quinazolin-4-amine (Compound 479). LCMS: rt 3.20 min (A), MS (m/e) 405 MH⁺.
- [0731] 6-(2-(3-isopropoxyphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 480). LCMS: rt 2.51 min (A), MS (m/e) 357 MH⁺.
- [0732] 2-(3-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)phenoxy)acetonitrile (Compound 481). LCMS: rt 2.09 min (A), MS (m/e) 354 MH⁺.
- [0733] 6-(2-(3-(2-Methoxyethoxy)phenyl)pyridin-3-yl)quinazolin-4-amine (Compound 482). LCMS: rt 2.09 min (A), MS (m/e) 373 MH⁺.
- [0734] 6-(2-(3-(Cyclopropylmethoxy)phenyl)pyridin-3-yl)quinazolin-4-amine (Compound 483). LCMS: rt 2.70 min (A), MS (m/e) 369 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.65 (dd, J = 4.8, 1.5 Hz, 1H), 8.40 (s, 1H), 8.18 (m, 1H), 8.01 (dd, J = 7.8, 1.5 Hz, 1H), 7.57-7.51 (m, 2H), 7.46 (dd, J = 9.0, 2.1 Hz, 1H), 7.17 (m, 1H), 6.92-6.89 (m, 1H), 6.85-6.78 (m, 2H), 3.53 (d, J = 7.2 Hz, 2H), 0.93 (m, 1H), 0.43 (m, 2H), 0.13 (m, 2H).
- [0735] 6-(2-(3-(2,2,2-Trifluoroethoxy)phenyl)pyridin-3-yl)quinazolin-4-amine (Compound 484). LCMS: rt 3.59 min (A), MS (m/e) 387 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.69 (dd, J = 4.8, 1.5 Hz, 1H), 8.42 (s, 1H), 8.18 (m, 1H), 8.02 (dd, J = 7.8, 1.5 Hz, 1H), 7.59-7.53 (m, 3H), 7.19 (m, 1H), 7.03 (m, 1H), 6.97-6.90 (m, 2H), 3.53 (q, J = 7.8 Hz, 2H).
- [0736] 6-(2-(3-Morpholinophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 485). LCMS: rt 2.66 min (A), MS (m/e) 384 MH⁺.
- [0737] 7-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazoline-2,4-diamine (Compound 486). LCMS: rt 2.96 min (A), MS (m/e) 366 MH⁺.
- [0738] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazoline-2,4-diamine (Compound 487). LCMS: rt 2.53 min (A), MS (m/e) 346 MH⁺.
- [0739] 7-(2-(3-Chlorophenyl)pyridin-3-yl)quinazoline-2,4-diamine (Compound 488). LCMS: rt 2.77 min (A), MS (m/e) 348 MH⁺.
- [0740] 7-(2-(m-Tolyl)pyridin-3-yl)quinazoline-2,4-diamine (Compound 489). LCMS: rt 2.89 min (B), MS (m/e) 328 MH⁺.
- [0741] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N-(pyridin-3-yl)quinazolin-4-amine (Compound 490). LCMS: rt 3.85 min (A), MS (m/e) 428 MH⁺.

[0742] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N-(6-methylpyridin-3-yl)quinazolin-4-amine (Compound 491). LCMS: rt 3.54 min (A), MS (m/e) 442 MH⁺.

[0743] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N-(pyridin-4-yl)quinazolin-4-amine (Compound 492). LCMS: rt 3.42 min (A), MS (m/e) 428 MH⁺.

[0744] 3-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)-5-chlorophenol (Compound 493). LCMS: rt 2.32 min (A), MS (m/e) 349 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.66 (dd, J = 4.8, 1.5 Hz, 1H), 8.42 (s, 1H), 8.21 (m, 1H), 8.03 (dd, J = 7.8, 1.5 Hz, 1H), 7.61-7.49 (m, 3H), 6.83 (m, 1H), 6.73 (m, 1H), 6.60 (m, 1H).

[0745] 3-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)-5-fluorophenol (Compound 494). LCMS: rt 1.94 min (A), MS (m/e) 333 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.65 (dd, J = 4.8, 1.5 Hz, 1H), 8.41 (s, 1H), 8.12 (m, 1H), 7.95 (dd, J = 7.8, 1.5 Hz, 1H), 7.60-7.45 (m, 3H), 6.58 (m, 1H), 6.53-6.46 (m, 2H).

[0746] 3-(3-(4-Aminoquinazolin-6-yl)pyridin-2-yl)-5-methylphenol (Compound 495). LCMS: rt 1.69 min (A), MS (m/e) 329 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.63 (dd, J = 4.8, 1.5 Hz, 1H), 8.44 (s, 1H), 8.23 (m, 1H), 8.16 (m, 1H), 8.01 (dd, J = 7.8, 1.5 Hz, 1H), 7.56-7.51 (m, 3H), 6.65 (m, 1H), 6.56 (m, 1H), 6.47 (m, 1H), 2.15 (s, 3H).

[0747] 7-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazolin-2-amine (Compound 496). LCMS: rt 2.36 min (A), MS (m/e) 351 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 9.06 (bs, 1H), 8.68 (dd, J = 4.8, 1.5 Hz, 1H), 7.99 (dd, J = 7.8, 1.5 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.57 (dd, J = 7.8, 4.8 Hz, 1H), 7.53 (m, 1H), 7.36 (m, 1H), 7.22-7.17 (m, 1H), 7.11-7.05 (m, 2H).

[0748] 6-(2-(2-Chlorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 497). LCMS: rt 2.29 min (A), MS (m/e) 333 MH⁺.

[0749] 6-(2-(2,3-Dichlorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 498). LCMS: rt 2.78 min (A), MS (m/e) 368 MH⁺.

[0750] 6-(2-(2-Chloro-4-fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 499). LCMS: rt 2.48 min (A), MS (m/e) 351 MH⁺.

[0751] 6-(2-(2,4-Dichlorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 500). LCMS: rt 3.63 min (B), MS (m/e) 368 MH⁺.

[0752] 6-(2-(2,5-Dichlorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 501). LCMS: rt 3.55 min (B), MS (m/e) 368 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.69 (dd, J = 5.1, 1.5 Hz,

1H), 8.36 (s, 1H), 8.13 (m, 1H), 8.07 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.66 (dd, $J = 7.8, 5.1$ Hz, 1H), 7.56-7.53 (m, 3H), 7.33 (m, 1H), 6.26 (m, 1H).

[0753] 6-(2-(2,4-Difluoro-5-methoxyphenyl)pyridin-3-yl)quinazolin-4-amine (Compound 502). LCMS: rt 3.21 min (B), MS (m/e) 365 MH^+ .

[0754] 6-(2-(2-Chloro-3-fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 503). LCMS: rt 3.27 min (B), MS (m/e) 351 MH^+ .

[0755] 6-(2-(2-Chloro-5-fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 504). LCMS: rt 3.23 min (B), MS (m/e) 351 MH^+ .

[0756] 6-(2-(2,4-Dichloro-5-fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 505). LCMS: rt 3.79 min (B), MS (m/e) 386 MH^+ .

[0757] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinazoline (Compound 506). LCMS: rt 5.24 min (A), MS (m/e) 336 MH^+ .

[0758] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-4-cyclopropylquinazoline (Compound 507). LCMS: rt 7.15 min (A), MS (m/e) 376 MH^+ .

[0759] 2-(2-Fluorophenyl)-3,4'-bipyridine (Compound 508). 1H NMR (300 MHz, DMSO- d_6): δ 8.74 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.45 (dd, $J = 4.4, 1.7$ Hz, 2H), 7.94 (dd, $J = 1.7, 7.8$ Hz, 1H), 7.58 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.58 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.47 (td, $J = 7.5, 1.8$ Hz, 1H), 7.44 – 7.34 (m, 1H), 7.23 (td, $J = 7.5, 1.1$ Hz, 1H), 7.15 (dd, $J = 4.4, 1.7$ Hz, 2H), 7.08 – 7.00 (m, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -115.75 (ddd, $J = 10.4, 7.5, 5.4$ Hz). LCMS: rt 4.35 min (A), purity 99 %, MS (m/e) 251 (MH^+).

[0760] 5-(Benzo[d]thiazol-6-yl)-6-(4-fluoro-3-methylphenyl)-N-(pyridin-4-ylmethyl)pyridin-3-amine (Compound 509). LCMS: rt 4.46 min (A), MS (m/e) 427 MH^+ .

[0761] 4-(2-(2-Fluorophenyl)pyridin-3-yl)quinolone (Compound 510). LCMS: rt 4.08 min (B), purity 99 %, MS (m/e) 301 (MH^+).

[0762] 4-(2-(3,4-Difluorophenyl)pyridin-3-yl)quinolone (Compound 511). LCMS: rt 4.82 min (B), purity 99 %, MS (m/e) 319 (MH^+).

[0763] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinoline (Compound 512). LCMS: rt 4.73 min (B), purity 99 %, MS (m/e) 315 (MH^+).

[0764] 4-(2-(3-Fluorophenyl)pyridin-3-yl)quinolone (Compound 513). LCMS: rt 4.46 min (B), purity 99%, MS (m/e) 301 (MH^+).

- [0765] 4-(2-(4-Fluorophenyl)pyridin-3-yl)quinoline (Compound 514). LCMS: rt 4.34 min (B), purity 99 %, MS (m/e) 301 (MH⁺).
- [0766] 4-(2-(*m*-Tolyl)pyridin-3-yl)quinoline (Compound 515). LCMS: rt 4.32 min (B), purity 99%, MS (m/e) 297 (MH⁺).
- [0767] 4-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)quinolone (Compound 516). LCMS: rt 6.04 min (B), purity 99 %, MS (m/e) 315(MH⁺).
- [0768] 5-(6-Methyl-[2,3'-bipyridin]-2'-yl)-1H-indazole (Compound 517). ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.97 (s, 1H), 8.63 (dd, *J* = 4.7, 1.7 Hz, 1H), 7.92 (dd, *J* = 9.7, 1.7 Hz, 1H), 7.64 (s, 1H), 7.40 (dd, *J* = 8.0, 4.5 Hz, 2H), 7.37 – 7.29 (m, 2H), 7.16 (dd, *J* = 8.7, 1.5 Hz, 1H), 7.05 (d, *J* = 7.6 Hz, 1H), 6.73 (d, *J* = 7.8 Hz, 1H), 2.41 (s, 3H). LCMS: rt 2.34 min (B), purity 99 %, MS (m/e) 287 (MH⁺).
- [0769] 2'-(Benzo[d][1,3]dioxol-5-yl)-6-methyl-2,3'-bipyridine (Compound 518). LCMS: rt 2.82 min (B), purity 99 %, MS (m/e) 291(MH⁺).
- [0770] 6-(6-Methyl-[2,3'-bipyridin]-2'-yl)quinoxaline (Compound 519). LCMS: rt 2.80 min (B), purity 99 %, MS (m/e) 299 (MH⁺).
- [0771] 5-(6-Methyl-[2,3'-bipyridin]-2'-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (Compound 520). LCMS: rt 2.01 min (B), purity 99 %, MS (m/e) 303 (MH⁺).
- [0772] 6-(6-Methyl-[2,3'-bipyridin]-2'-yl)-1H-benzo[d]imidazole (Compound 521). ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.1 (br s, 1H), 8.68 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.16 (s, 1H), 7.96 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.50-7.37 (ddd, *J* = 15.4, 14.4, 8.8 Hz, 4H), 7.10 (d, *J* = 7.7 Hz, 2H), 6.76 (d, *J* = 7.7 Hz, 1H), 2.47 (s, 3H). LCMS: rt 1.23 min (B), purity 99 %, MS (m/e) 287 (MH⁺).
- [0773] 6-(6-Methyl-[2,3'-bipyridin]-2'-yl)isoquinoline (Compound 522). LCMS: rt 1.93 min (B), purity 99 %, MS (m/e) 298 (MH⁺).
- [0774] 2-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1,6-naphthyridine (Compound 523). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.35 (d, *J* = 0.9 Hz, 1H), 8.78 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.74 (d, *J* = 5.9 Hz, 1H), 8.38 (dd, *J* = 8.6, 0.9 Hz, 1H), 8.14 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.91 (d, *J* = 5.9 Hz, 1H), 7.57 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.38 (dd, *J* = 7.6, 1.9 Hz, 1H), 7.30 (d, *J* = 8.5 Hz, 1H), 7.01 – 6.86 (m, 2H), 2.13 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.88 (d, *J* = 8.1 Hz). LCMS: rt 4.58 min (A), purity 99 %, MS (m/e) 316 (MH⁺).
- [0775] 2-(2-(*m*-Tolyl)pyridin-3-yl)-1,6-naphthyridine (Compound 524). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.33 (s, 1H), 8.74 (d, *J* = 5.9 Hz, 2H), 8.33 (d, *J* = 8.6 Hz, 1H), 8.14 (d, *J* = 7.7 Hz,

1H), 7.91 (d, $J = 5.9$ Hz, 1H), 7.56 (dd, $J = 7.7, 4.8$ Hz, 1H), 7.26 (d, $J = 7.8$ Hz, 2H), 7.08 (d, $J = 7.6$ Hz, 2H), 6.93 (d, $J = 6.8$ Hz, 1H), 2.18 (s, 3H). LCMS: rt 4.11 min (A), purity 99 %, MS (m/e) 298 (MH⁺).

[0776] 2-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-1,6-naphthyridine (Compound 525). LCMS: rt 4.71 min (A), purity 99 %, MS (m/e) 324 (MH⁺).

[0777] 2'-(4-Fluoro-3-methylphenyl)-[3,3'-bipyridin]-6-amine (Compound 526). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.60 (dd, $J = 4.7, 1.6$ Hz, 1H), 7.85 – 7.73 (m, 2H), 7.42 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.35 (d, $J = 7.8$ Hz, 1H), 7.24 (dd, $J = 8.8, 2.4$ Hz, 1H), 7.13 – 6.95 (m, 2H), 6.66 (br s, 2H), 6.51 (d, $J = 8.8$ Hz, 1H), 2.19 (d, $J = 1.5$ Hz, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.73 (s). LCMS: rt 1.76 min (A), purity 99 %, MS (m/e) 280 (MH⁺).

[0778] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-methylimidazo[1,2-*a*]pyridine (Compound 527). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.68 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.28 (dd, $J = 1.7, 0.9$ Hz, 1H), 7.98 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.49 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.45 (app dd, $J = 8.6$ and 0.9 Hz, 1H), 7.38 (d, $J = 0.9$ Hz, 1H), 7.36 (dd, $J = 8.6, 0.9$ Hz, 1H), 7.09-7.05 (m, 1H), 6.97 (dd, $J = 9.6, 8.6$ Hz, 1H), 6.77 (dd, $J = 9.3, 1.8$ Hz, 1H), 2.43 (s, 3H), 2.16 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.43 (ddd, $J = 10.0, 7.5, 3.8$ Hz). LCMS: rt 3.83 min (A), purity 99 %, MS (m/e) 318 (MH⁺).

[0779] 3-Methyl-6-(2-(*m*-Tolyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine (Compound 528). LCMS: rt 3.40 min (A), purity 99 %, MS (m/e) 300 (MH⁺).

[0780] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-3-methylimidazo[1,2-*a*]pyridine (Compound 529). LCMS: rt 3.98 min (A), purity 99 %, MS (m/e) 326 (MH⁺).

[0781] 3-Methyl-6-(2-(3-(trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine (Compound 530). LCMS: rt 4.90 min (A), purity 99 %, MS (m/e) 354 (MH⁺).

[0782] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-2-methylimidazo[1,2-*a*]pyridine (Compound 531). LCMS: rt 3.86 min (A), purity 99 %, MS (m/e) 318 (MH⁺).

[0783] 2-Methyl-6-(2-(*m*-tolyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine (Compound 532). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.67 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.43 (dd, $J = 1.8, 1.0$ Hz, 1H), 7.88 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.61 (s, 1H), 7.46 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.31 (d, $J = 1.2$ Hz, 1H), 7.25 (d, $J = 9.3$ Hz, 1H), 7.10-7.08 (app m, 2H), 7.06 – 7.00 (m, 1H), 6.75 (dd, $J = 9.3, 1.8$ Hz, 1H), 2.30 (s, 3H), 2.22 (s, 3H). LCMS: rt 3.41 min (A), purity 99 %, MS (m/e) 300 (MH⁺).

- [0784] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-2-methylimidazo[1,2-a]pyridine (Compound 533). LCMS: rt 3.96 min (A), purity 99 %, MS (m/e) 326 (MH⁺).
- [0785] 2-Methyl-6-(2-(3-trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 534). LCMS: rt 4.86 min (A), purity 99 %, MS (m/e) 354 (MH⁺).
- [0786] 2-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1,5-naphthyridine (Compound 535). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.00 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.80 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.44 (dd, *J* = 8.9, 1.1 Hz, 1H), 8.35 – 8.17 (m, 2H), 7.81 (dd, *J* = 8.5, 4.2 Hz, 1H), 7.63 (dd, *J* = 7.8, 4.9 Hz, 1H), 7.40 (d, *J* = 8.7 Hz, 2H), 6.96 (d, *J* = 7.9 Hz, 2H), 2.28 – 1.96 (m, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.43 (dd, *J* = 13.7, 6.5 Hz), -117.43 (dd, *J* = 13.7, 6.5 Hz). LCMS: rt 5.20 min (A), purity 99%, MS (m/e) 316 (MH⁺).
- [0787] 2-(2-(*m*-Tolyl)pyridin-3-yl)-1,5-naphthyridine (Compound 536). LCMS: rt 4.78 min (A), purity 99 %, MS (m/e) 298 (MH⁺).
- [0788] 2-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-1,5-naphthyridine (Compound 537). LCMS: rt 5.30 min (A), purity 99 %, MS (m/e) 324 (MH⁺).
- [0789] 2-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)-1,5-naphthyridine (Compound 538). LCMS: rt 5.43 min (A), purity 99 %, MS (m/e) 352 (MH⁺).
- [0790] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinoxaline (Compound 539). LCMS: rt 5.25 min (A), purity 99 %, MS (m/e) 316 (MH⁺).
- [0791] 6-(2-(*m*-Tolyl)pyridin-3-yl)quinoxaline (Compound 540). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.93 (s, 2H), 8.78 (dd, *J* = 4.9, 1.6 Hz, 1H), 8.17 (dd, *J* = 7.8, 1.6 Hz, 1H), 8.03 (d, *J* = 2.0 Hz, 1H), 7.96 (d, *J* = 8.7 Hz, 1H), 7.66 (dd, *J* = 7.8, 5.0 Hz, 1H), 7.53 (dd, *J* = 8.7, 2.0 Hz, 1H), 7.31 (d, *J* = 0.5 Hz, 1H), 7.16 – 7.03 (m, 2H), 6.98 (d, *J* = 7.2 Hz, 1H), 2.19 (s, 3H). LCMS: rt 4.86 min (A), purity 99 %, MS (m/e) 298 (MH⁺).
- [0792] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)quinoxaline (Compound 541). LCMS: rt 5.35 min (A), purity 99 %, MS (m/e) 324 (MH⁺).
- [0793] 6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)quinoxaline (Compound 542). LCMS: rt 6.61 min (A), purity 99 %, MS (m/e) 351 (MH⁺).
- [0794] 4-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)morpholine (Compound 543). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.67 (dd, *J* = 4.7, 1.7 Hz, 1H), 7.98 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.90 (dd, *J* = 1.7, 1.0 Hz, 1H), 7.50 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.47 – 7.39 (m, 2H), 7.26 (s, 1H), 7.11 – 7.04 (m, 1H), 7.00 (d, *J* = 9.6 Hz, 1H), 6.98 – 6.92 (m,

1H), 3.68 (dd, $J = 5.5, 3.7$ Hz, 4H), 2.81 (dd, $J = 5.5, 3.7$ Hz, 4H), 2.17 (d, $J = 1.6$ Hz, 3H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$): δ -118.33 – -118.66 (m). LCMS: rt4.25 min (A), purity 99 %, MS (m/e) 389 (MH^+).

[0795] 4-(6-(2-(*m*-Tolyl)pyridin-3-yl)imidazo[1,2-*a*]pyridin-3-yl)morpholine (Compound 544). LCMS: rt3.85 min (A), purity 99 %, MS (m/e) 371 (MH^+).

[0796] 4-(6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridin-3-yl)morpholine (Compound 545). LCMS: rt4.33 min (A), purity 99 %, MS (m/e) 397 (MH^+).

[0797] 4-(6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridin-3-yl)morpholine (Compound 546). LCMS: rt5.15 min (A), purity 99 %, MS (m/e) 425 (MH^+).

[0798] 4-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinolin-4-yl)morpholine (Compound 547). LCMS: rt4.15 min (A), purity 99 %, MS (m/e) 400 (MH^+).

[0799] 4-(6-(2-(*m*-Tolyl)pyridin-3-yl)quinolin-4-yl)morpholine (Compound 548). ^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.69 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.65 (d, $J = 5.0$ Hz, 1H), 7.99 (d, $J = 8.6$ Hz, 1H), 7.92 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.75 (dd, $J = 8.6, 2.0$ Hz, 1H), 7.62 (d, $J = 1.8$ Hz, 1H), 7.50 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.31 (s, 1H), 7.09 – 6.99 (m, 2H), 6.99 – 6.94 (app m, 1H), 6.91 (d, $J = 5.1$ Hz, 1H), 3.75 – 3.41 (m, 4H), 2.89 – 2.62 (m, 4H), 2.19 (s, 3H). LCMS: rt3.81 min (A), purity 99 %, MS (m/e) 381 (MH^+).

[0800] 4-(6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)quinolin-4-yl)morpholine (Compound 549). LCMS: rt4.20 min (A), purity 99 %, MS (m/e) 408 (MH^+).

[0801] 4-(6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)quinolin-4-yl)morpholine (Compound 550). LCMS: rt5.11 min (A), purity 99 %, MS (m/e) 436(MH^+).

[0802] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-*N,N*-dimethylimidazo[1,2-*a*]pyridin-3-amine (Compound 551). LCMS: rt4.33 min (A), purity 99%, MS (m/e) 347 (MH^+).

[0803] *N,N*-Dimethyl-6-(2-(*m*-tolyl)pyridin-3-yl)imidazo[1,2-*a*]pyridin-3-amine (Compound 552). LCMS: rt3.93 min (A), purity 99%, MS (m/e) 329 (MH^+).

[0804] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-*N,N*-dimethylimidazo[1,2-*a*]pyridin-3-amine (Compound 553). LCMS: rt4.45 min (A), purity 99%, MS (m/e) 355 (MH^+).

[0805] *N,N*-Dimethyl-6-(2-(3-(trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridin-3-amine (Compound 554). LCMS: rt5.33 min (A), purity 99%, MS (m/e) 383(MH^+).

[0806] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-(trifluoromethyl)imidazo[1,2-*a*]pyridine (Compound 555). ^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.71 (dd, $J = 4.8, 1.6$ Hz, 1H),

8.29 (s, 1H), 8.17 (d, $J = 1.0$ Hz, 1H), 7.99 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.71 (dd, $J = 9.4, 0.8$ Hz, 1H), 7.52 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.42 (dd, $J = 7.7, 1.6$ Hz, 1H), 7.24 (dd, $J = 9.4, 1.7$ Hz, 1H), 7.06 (ddd, $J = 7.6, 5.3, 2.3$ Hz, 1H), 7.02 – 6.93 (m, 1H), 2.16 (d, $J = 1.7$ Hz, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -60.01 (s), -118.29 (d, $J = 5.5$ Hz). LCMS: rt5.90 min (A), purity 99%, MS (m/e) 372 (MH^+).

[0807] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-3-(trifluoromethyl)imidazo[1,2-a]pyridine (Compound 556). LCMS: rt5.90 min (A), purity 99%, MS (m/e) 380 (MH^+).

[0808] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 557). LCMS: rt5.38 min (A), purity 99%, MS (m/e) 329 (MH^+).

[0809] 6-(2-(*m*-Tolyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 558). ^1H NMR (300 MHz, DMSO- d_6): δ 8.72 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.62 (d, $J = 0.6$ Hz, 1H), 8.44 (s, 1H), 8.05 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.64 (d, $J = 9.3$ Hz, 1H), 7.52 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.34 (s, 1H), 7.16 – 7.02 (m, 4H), 2.24 (s, 3H). LCMS: rt4.93 min (A), purity 99%, MS (m/e) 311 (MH^+).

[0810] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 559). LCMS: rt5.48 min (A), purity 99%, MS (m/e) 337 (MH^+).

[0811] 6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 560). LCMS: rt6.66 min (A), purity 99%, MS (m/e) 365 (MH^+).

[0812] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-(pyrrolidin-1-yl)imidazo[1,2-a]pyridine (Compound 561). LCMS: rt4.90 min (A), purity 99%, MS (m/e) 373 (MH^+).

[0813] 3-(Pyrrolidin-1-yl)-6-(2-(*m*-tolyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 562). LCMS: rt4.46 min (A), purity 99%, MS (m/e) 355 (MH^+).

[0814] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-3-(pyrrolidin-1-yl)imidazo[1,2-a]pyridine (Compound 563). LCMS: rt4.93 min (A), purity 99%, MS (m/e) 381 (MH^+).

[0815] 3-(Pyrrolidin-1-yl)-6-(2-(3-(trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 564). ^1H NMR (300 MHz, DMSO- d_6): δ 8.73 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.02 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.96 – 7.87 (m, 1H), 7.81 (s, 1H), 7.63 (d, $J = 7.7$ Hz, 1H), 7.56 (dt, $J = 7.8, 3.7$ Hz, 2H), 7.47 (t, $J = 7.7$ Hz, 1H), 7.38 (dd, $J = 9.3, 0.8$ Hz, 1H), 7.15 (s, 1H), 6.91 (dd, $J = 9.3, 1.8$ Hz, 1H), 2.93 (t, $J = 6.5$ Hz, 4H), 1.96 – 1.52 (m, 4H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -61.36 (s). LCMS: rt5.78 min (A), purity 99%, MS (m/e) 409 (MH^+).

[0816] (6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methanol (Compound 565). ^1H NMR (300 MHz, DMSO- d_6): δ 8.69 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.46 (s, 1H), 7.96 (dd, $J = 7.7, 1.6$ Hz, 1H), 7.54 (s, 1H), 7.53 – 7.48 (m, 1H), 7.44 (t, $J = 8.6$ Hz, 2H), 7.11 – 7.02 (m, 1H), 6.98 (t, $J = 9.1$ Hz, 1H), 6.84 (dd, $J = 9.3, 1.6$ Hz, 1H), 5.26 (s, 1H), 4.78 (s, 2H), 2.17 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -118.29 (s). LCMS: rt3.36 min (A), purity 99%, MS (m/e) 334 (MH^+).

[0817] (6-(2-(*m*-Tolyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methanol (Compound 566). LCMS: rt2.55 min (A), purity 99%, MS (m/e) 316 (MH^+).

[0818] (6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methanol (Compound 567). LCMS: rt3.53 min (A), purity 99%, MS (m/e) 342 (MH^+).

[0819] (6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methanol (Compound 568). LCMS: rt4.38 min (A), purity 99%, MS (m/e) 370 (MH^+).

[0820] 4-(((6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine (Compound 569). ^1H NMR (300 MHz, DMSO- d_6): δ 8.69 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.33 (dd, $J = 1.7, 0.9$ Hz, 1H), 7.90 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.55 – 7.46 (m, 3H), 7.43 (dd, $J = 7.6, 1.6$ Hz, 1H), 7.12 – 7.04 (m, 1H), 7.04 – 6.93 (m, 2H), 3.72 (s, 2H), 3.49 – 3.36 (m, 4H), 2.33 – 2.18 (m, 4H), 2.14 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -118.39 (s, 1H). LCMS: rt3.38 min (A), purity 99%, MS (m/e) 403 (MH^+).

[0821] 4-(((6-(2-(*m*-Tolyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine (Compound 570). LCMS: rt2.65 min (A), purity 99%, MS (m/e) 385 (MH^+).

[0822] 4-(((6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine (Compound 571). LCMS: rt3.53 min (A), purity 99%, MS (m/e) 411 (MH^+).

[0823] 4-(((6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine (Compound 572). LCMS: rt4.15 min (A), purity 99%, MS (m/e) 439 (MH^+).

[0824] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 573). ^1H NMR (300 MHz, DMSO- d_6): δ 10.25 (s, 1H), 9.54 (s, 1H), 8.75 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.67 (s, 1H), 8.05 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.70 (d, $J = 9.4$ Hz, 1H), 7.59 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.47 (dd, $J = 7.5, 1.6$ Hz, 1H), 7.20 (dd, $J = 9.3, 1.8$ Hz, 1H), 7.16 (s, 2H), 7.14 – 7.06 (m, 1H) 6.93 (m, $J = 9.1$ Hz,

1H), 3.77 (s, 6H), 3.63 (s, 3H), 2.17 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.82 (s, 1H). LCMS: rt5.53 min (A), purity 99%, MS (m/e) 513 (MH⁺).

[0825] 6-(2-(*m*-Tolyl)pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)imidazo[1,2-*a*]pyridine-3-carboxamide (Compound 574). LCMS: rt5.18 min (A), purity 99%, MS (m/e) 495 (MH⁺).

[0826] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)imidazo[1,2-*a*]pyridine-3-carboxamide (Compound 575). LCMS: rt5.55 min (A), purity 99%, MS (m/e) 521 (MH⁺).

[0827] 6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)imidazo[1,2-*a*]pyridine-3-carboxamide (Compound 576). LCMS: rt 6.26 min (A), purity 99%, MS (m/e) 549 (MH⁺).

[0828] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-*a*]pyridine (Compound 577). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.69 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.61 (s, 1H), 8.04 (d, *J* = 9.3, 1.6 Hz, 1H), 8.01 (s, 1H), 7.68 (d, *J* = 9.3 Hz, 1H), 7.56 – 7.39 (m, 2H), 7.17 (d, *J* = 9.4 Hz, 1H), 7.09 (ddd, *J* = 7.6, 5.1, 2.3 Hz, 1H), 7.01 – 6.87 (app m, 3H), 3.82 (s, 6H), 3.76 – 3.67 (m, 3H), 2.17 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.31 (s, 1H). LCMS: rt5.05 min (A), purity 99%, MS (m/e) 470 (MH⁺).

6-(2-(*m*-Tolyl)pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-*a*]pyridine (Compound 578). LCMS: rt4.68 min (A), purity 99%, MS (m/e) 452 (MH⁺).

[0829] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine-3-carboxylic acid (Compound 579). ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.01 (br s, 1H), 9.21 (dd, *J* = 1.9, 1.0 Hz, 1H), 8.71 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.23 (s, 1H), 7.97 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.65 (dd, *J* = 9.3, 1.0 Hz, 1H), 7.52 (dd, *J* = 7.7, 4.8 Hz, 1H), 7.43 (dd, *J* = 7.7, 2.3 Hz, 1H), 7.14 (dd, *J* = 9.3, 1.9 Hz, 1H), 7.06 (ddd, *J* = 7.8, 5.1, 2.3 Hz, 1H), 6.96 (dd, *J* = 9.7, 8.4 Hz, 1H), 2.16 (s, 3H). LCMS: rt3.70 min (A), purity 99%, MS (m/e) 348 (MH⁺).

[0830] (6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridin-3-yl)(morpholino)methanone (Compound 580). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.89 – 8.83 (app m, 1H), 8.70 (dd, *J* = 4.8, 1.2 Hz, 1H), 8.03 (d, *J* = 0.5 Hz, 1H), 7.94 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.57 (d, *J* = 9.3 Hz, 1H), 7.51 (dd, *J* = 7.6, 5.0 Hz, 1H), 7.44 (d, *J* = 7.8 Hz, 1H), 7.13 – 7.04 (m, 1H), 7.02- 6.95 (m, 2H), 3.71-3.69 (m, 4H), 3.65-3.62 (m, 4H), 2.17 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.29 (s, 1H). LCMS: rt 4.58 min (A), purity 99%, MS (m/e) 417 (MH⁺).

[0831] (6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(4-methylpiperazin-1-yl)methanone (Compound 581). LCMS: rt3.41 min (A), purity 99%, MS (m/e) 430 (MH⁺).

[0832] N-(3,4-Dimethoxyphenyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 582). ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.32 (s, 1H), 9.58 (dd, *J* = 1.7, 0.9 Hz, 1H), 8.77 (dd, *J* = 4.9, 1.6 Hz, 1H), 8.73 (s, 1H), 8.07 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.76 (dd, *J* = 9.3, 0.9 Hz, 1H), 7.61 (dd, *J* = 7.8, 4.9 Hz, 1H), 7.47 (dd, *J* = 7.5, 1.5 Hz, 1H), 7.41 (d, *J* = 2.4 Hz, 1H), 7.28 (ddd, *J* = 10.3, 9.1, 2.1 Hz, 2H), 7.10 (dd, *J* = 5.2, 2.5 Hz, 1H), 6.97 (dd, *J* = 17.6, 9.1 Hz, 2H), 3.75 (s, 3H), 3.73 (s, 3H), 2.17 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.32 (s, 1H). LCMS: rt5.23 min (A), purity 99%, MS (m/e) 483 (MH⁺).

[0833] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-propylimidazo[1,2-a]pyridine-3-carboxamide (Compound 583). LCMS: rt4.51 min (B), purity 99%, MS (m/e) 389 (MH⁺).

[0834] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-methylimidazo[1,2-a]pyridine-3-carboxamide (Compound 584). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.48 (s, 1H), 8.71 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.48 (app qt, *J* = 4.7 Hz, 1H), 8.26 (s, 1H), 7.93 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.55 (d, *J* = 9.3 Hz, 1H), 7.51 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.42 (d, *J* = 5.4 Hz, 1H), 7.11 – 7.04 (m, 1H), 7.04 – 6.91 (m, 2H), 2.79 (d, *J* = 4.6 Hz, 3H), 2.15 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.32 (s, 1H). LCMS: rt3.57 min (B), purity 99%, MS (m/e) 361 (MH⁺).

[0835] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 585). LCMS: rt2.42 min (B), purity 99%, MS (m/e) 460 (MH⁺).

[0836] 1-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-one (Compound 586). LCMS: rt4.68 min (A), purity 99%, MS (m/e) 346 (MH⁺).

[0837] 1-(6-(2-(*m*-Tolyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-one (Compound 587). LCMS: rt4.26 min (A), purity 99%, MS (m/e) 328 (MH⁺).

[0838] 1-(6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-one (Compound 588).

[0839] ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.44 (dd, *J* = 1.7, 0.8 Hz, 1H), 8.72 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.60 (s, 1H), 7.94 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.69 (dd, *J* = 9.2, 0.7 Hz, 1H), 7.51 (dd, *J* = 7.7, 4.8 Hz, 1H), 7.23 (dd, *J* = 9.2, 1.8 Hz, 1H), 7.16 – 7.04 (m, 2H), 7.03 – 6.96 (m, 2H),

2.53 (s, 3H), 1.87 – 1.66 (m, 1H), 0.89 – 0.66 (m, 2H), 0.44 – 0.20 (m, 2H). LCMS: rt 4.81 min (A), purity 99%, MS (m/e) 354 (MH⁺).

[0840] 1-(6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-one (Compound 589). LCMS: rt 5.71 min (A), purity 99%, MS (m/e) 382 (MH⁺).

[0841] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 590). LCMS: rt 2.89 min (B), purity 99%, MS (m/e) 473 (MH⁺).

[0842] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 591). LCMS: rt 2.76 min (B), purity 99%, MS (m/e) 487 (MH⁺).

[0843] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(1-methylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 592). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.54 (dd, *J* = 1.8, 0.9 Hz, 1H), 8.78 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.43 (s, 1H), 8.34 (d, *J* = 7.6 Hz, 1H), 8.01 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.69 – 7.54 (m, 2H), 7.50 (dd, *J* = 7.6, 2.0 Hz, 1H), 7.19 – 6.99 (m, 3H), 3.95 – 3.70 (m, 1H), 2.85 (d, *J* = 11.7 Hz, 2H), 2.24 (s, 6H), 2.01 (t, *J* = 10.7 Hz, 2H), 1.85 (d, *J* = 9.3 Hz, 2H), 1.76 – 1.51 (m, 2H). LCMS: rt 3.03 min (B), purity 99%, MS (m/e) 444 (MH⁺).

[0844] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(tetrahydro-2H-pyran-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 593). LCMS: rt 4.78 min (B), purity 99%, MS (m/e) 431 (MH⁺).

[0845] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine (Compound 594). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.65 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.31 (s, 1H), 8.17 (dd, *J* = 7.3, 0.9 Hz, 1H), 7.89 (dd, *J* = 7.6, 1.4 Hz, 1H), 7.55 (s, 1H), 7.46 (dd, *J* = 7.3, 4.7 Hz, 2H), 7.36 (s, 1H), 7.11 (ddd, *J* = 7.8, 5.0, 2.5 Hz, 1H), 7.06 – 6.94 (m, 1H), 6.20 (d, *J* = 7.3 Hz, 1H), 2.18 (s, 4H). LCMS: rt 3.53 min (A), purity 99%, MS (m/e) 304 (MH⁺).

[0846] 7-(2-(*m*-Tolyl)pyridin-3-yl)imidazo[1,5-a]pyridine (Compound 595). LCMS: rt 3.01 min (A), purity 99%, MS (m/e) 286 (MH⁺).

[0847] 7-(2-(3-Cyclopropylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine (Compound 596). LCMS: rt 3.73 min (A), purity 99%, MS (m/e) 312 (MH⁺).

[0848] 7-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,5-a]pyridine (Compound 597). LCMS: rt 4.66 min (A), purity 99%, MS (m/e) 340 (MH⁺).

[0849] *rac*-1-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-ol (Compound 598). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.69 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.40 (d, *J* = 0.9 Hz, 1H), 7.95 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.51 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.47 – 7.37 (m, 3H), 7.12 – 7.02 (m, 1H), 6.98 (t, *J* = 9.1 Hz, 1H), 6.86 (dd, *J* = 9.3, 1.8 Hz, 1H), 5.33 (br s, 1H), 5.07 (app qt, *J* = 6.5 Hz, 1H), 2.14 (s, 3H), 1.50 (d, *J* = 6.5 Hz, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.42 (s). LCMS: rt3.78 min (A), purity 99%, MS (m/e) 348 (MH⁺).

[0850] 2-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)propan-2-ol (Compound 599). LCMS: rt 4.03 min (A), purity 99%, MS (m/e) 362 (MH⁺).

[0851] 6-(2-(3-(Methyl-*d*₃)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 600). LCMS: rt3.35 min (A), purity 99%, MS (m/e) 289 (MH⁺).

[0852] 6-(2-(3-(Methyl-*d*₃)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 601). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.72 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.62 (dd, *J* = 1.7, 1.0 Hz, 1H), 8.44 (s, 1H), 8.05 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.64 (dd, *J* = 9.3, 0.9 Hz, 1H), 7.52 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.34 (dd, *J* = 2.6, 1.4 Hz, 1H), 7.16 – 7.01 (m, 4H). LCMS: rt4.96 min (A), purity 99%, MS (m/e) 314 (MH⁺).

[0853] 5-(2-(3-(Methyl-*d*₃)phenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 602). LCMS: rt5.00 min (A), purity 99%, MS (m/e) 290(MH⁺).

[0854] 6-(2-(3-(Methyl-*d*₃)phenyl)pyridin-3-yl)benzo[d]thiazole (Compound 603). LCMS: rt5.15 min (A), purity 99%, MS (m/e) 306(MH⁺).

[0855] 7-(2-(3-(Methyl-*d*₃)phenyl)pyridin-3-yl)imidazo[1,5-a]pyridine (Compound 604). LCMS: rt3.35 min (A), purity 99%, MS (m/e) 289 (MH⁺).

[0856] 6-(2-(3-(Methyl-*d*₃)phenyl)pyridin-3-yl)quinoxaline (Compound 605). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.87 (s, 2H), 8.67 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.00 – 7.93 (m, 2H), 7.89 (d, *J* = 8.7 Hz, 1H), 7.53 – 7.43 (m, 2H), 7.24 (s, 1H), 6.99 (dt, *J* = 7.5, 4.1 Hz, 2H), 6.90 (ddd, *J* = 5.0, 2.7, 1.5 Hz, 1H). LCMS: rt4.83 min (A), purity 99%, MS (m/e) 301 (MH⁺).

[0857] 1-(6-(2-(3-(Methyl-*d*₃)phenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-one (Compound 606). LCMS: rt 4.25 min (A), purity 99%, MS (m/e) 331 (MH⁺).

[0858] N-(2-(Dimethylamino)ethyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 607). LCMS: rt2.62 min (B), purity 99%, MS (m/e) 418 (MH⁺).

[0859] N-(3-(Dimethylamino)propyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 608). LCMS: rt2.62 min (B), purity 99%, MS (m/e) 432 (MH⁺).

[0860] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-morpholinopropyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 609). LCMS: rt2.64 min (B), purity 99%, MS (m/e) 474 (MH⁺).

[0861] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(pyrrolidin-1-yl)ethyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 610). LCMS: rt2.72 min (B), purity 99%, MS (m/e) 444 (MH⁺).

[0862] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(piperidin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 611). LCMS: rt2.78 min (B), purity 99%, MS (m/e) 472 (MH⁺).

[0863] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 612). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.47 (s, 1H), 8.71 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.51 (t, *J* = 4.9 Hz, 1H), 8.31 (s, 1H), 7.95 (d, *J* = 7.8 Hz, 1H), 7.57 (app d, *J* = 9.5 Hz, 1H), 7.52 (dd, *J* = 7.7, 4.8 Hz, 1H), 7.43 (d, *J* = 7.9 Hz, 1H), 7.05 (d, *J* = 9.2 Hz, 2H), 6.97 (app dd, *J* = 17.6, 9.1 Hz, 1H), 3.34 (t, *J* = 6.8 Hz, 2H), 3.23 (t, *J* = 6.8 Hz, 4H), 2.21 (t, *J* = 8.1 Hz, 2H), 2.16 (s, 3H), 1.99 – 1.82 (m, 2H), 1.80 – 1.64 (m, 2H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.24 (s). LCMS: rt2.94 min (B), purity 99%, MS (m/e) 472 (MH⁺).

[0864] N-(2,3-Dihydroxypropyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 613). LCMS: rt 4.15 min (A), purity 99%, MS (m/e) 421 (MH⁺).

[0865] (*S*)-2-((*tert*-Butoxycarbonyl)amino)-3-(1H-indol-3-yl)propyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxylate (Compound 614). ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.81 (s, 1H), 9.13 (s, 1H), 8.71 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.33 (s, 1H), 7.97 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.66 (d, *J* = 9.3 Hz, 1H), 7.57 – 7.46 (m, 2H), 7.42 (dd, *J* = 8.1, 1.6 Hz, 1H), 7.31 (d, *J* = 8.0 Hz, 1H), 7.13 (app dd, *J* = 4.1, 1.9 Hz, 2H), 7.04 (app t, *J* = 7.7 Hz, 3H), 6.99 – 6.90 (m, 2H), 4.29 (dd, *J* = 10.3, 4.9 Hz, 1H), 4.19 (app qt, *J* = 6.9 Hz, 1H), 2.90 (t, *J* = 8.7 Hz, 2H), 2.14 (s, 3H), 1.28 (s, 9H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.18 (s). LCMS: rt7.10 min (A), purity 99%, MS (m/e) 620 (MH⁺).

- [0866] (S)-2-Amino-3-(1H-indol-3-yl)propyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxylate formic acid salt (Compound 615). LCMS: rt 5.10 min (A), purity 99%, MS (m/e) 520 (MH⁺-HCOOH).
- [0867] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-sulfamoylphenyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 616). LCMS: rt 4.05 min (A), purity 99%, MS (m/e) 502 (MH⁺).
- [0868] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(4-sulfamoylphenyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 617). LCMS: rt 4.71 min (A), purity 99%, MS (m/e) 502 (MH⁺).
- [0869] N-(4-Carbamoylphenyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 618). LCMS: rt 4.48 min (A), purity 99%, MS (m/e) 466 (MH⁺).
- [0870] N-(3-Carbamoylphenyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 619). ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.59 (s, 1H), 9.73 – 9.51 (m, 1H), 8.82 (s, 1H), 8.80–8.72 (m, 1H), 8.24 (s, 1H), 8.09 (d, *J* = 7.8 Hz, 1H), 7.95 – 7.89 (m, 1H), 7.76 (d, *J* = 9.3 Hz, 1H), 7.63 (dd, *J* = 7.9, 4.7 Hz, 2H), 7.45 (dd, *J* = 16.4, 8.5 Hz, 2H), 7.33 – 7.24 (m, 1H), 7.12 (dd, *J* = 8.0, 5.4 Hz, 1H), 6.99 (app t, *J* = 9.3 Hz, 1H), 6.95 (br s, 2H), 2.18 (s, 3H). LCMS: rt 4.56 min (A), purity 96%, MS (m/e) 466 (MH⁺).
- [0871] (R)-2-Amino-3-(1H-indol-3-yl)propyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxylate formic acid salt (Compound 620). ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.85 (s, 1H), 9.16 (s, 1H), 8.71 (dd, *J* = 4.7, 1.7 Hz, 1H), 7.96 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.67 (d, *J* = 8.9 Hz, 1H), 7.57 – 7.45 (m, 2H), 7.42 (d, *J* = 8.1 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 1H), 7.22 – 7.10 (m, 2H), 7.12 – 6.98 (m, 2H), 7.00 – 6.86 (m, 2H), 4.40 – 3.91 (m, 2H), 3.38–3.33 (m, 1H), 3.02 – 2.68 (m, 2H), 2.15 (s, 3H). LCMS: rt 5.10 min (A), purity 98%, MS (m/e) 520 (MH⁺-HCOOH).
- [0872] 6-(2-(3-Fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 621). LCMS: rt 5.64 min (A), purity 99%, MS (m/e) 315 (MH⁺).
- [0873] 6-(2-(3,4-Difluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 622). LCMS: rt 6.19 min (A), purity 99%, MS (m/e) 333 (MH⁺).
- [0874] 6-(2-(2-Fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 623). LCMS: rt 5.55 min (A), purity 99%, MS (m/e) 333 (MH⁺).

- [0875] 6-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 624). LCMS: rt6.02 min (A), purity 99%, MS (m/e) 333 (MH⁺).
- [0876] 6-(2-(4-Fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 625). LCMS: rt5.24 min (A), purity 99%, MS (m/e) 333 (MH⁺).
- [0877] 6-(2-(3-Methoxyphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 626). LCMS: rt4.97 min (A), purity 99%, MS (m/e) 333 (MH⁺).
- [0878] 6-(2-(3-Cyanophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 627). LCMS: rt5.77 min (A), purity 99%, MS (m/e) 333 (MH⁺).
- [0879] 6-(2-(3-Cyano-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 628). LCMS: rt6.29 min (A), purity 99%, MS (m/e) 333 (MH⁺).
- [0880] (*R*)-2-Amino-3-(1H-indol-3-yl)propyl 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxylate TFA salt (Compound 628). LCMS: rt5.15 min (A), purity 95%, MS (m/e) 520 (MH⁺-TFA).
- [0881] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)-1H-indazole-1-carboxamide (Compound 630). LCMS: rt6.71 min (A), purity 98%, MS (m/e) 513 (MH⁺).
- [0882] N-(3,4-Dimethoxybenzyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxamide (Compound 631). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.92 (t, *J* = 6.3 Hz, 1H), 8.66 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.37 (d, *J* = 0.7 Hz, 1H), 8.13 (d, *J* = 8.7 Hz, 1H), 7.86 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.73 (s, 1H), 7.47 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 7.28 (dd, *J* = 8.7, 1.7 Hz, 1H), 7.01 (s, 1H), 6.95 – 6.84 (m, 4H), 4.39 (d, *J* = 6.3 Hz, 2H), 3.72 (s, 3H), 3.70 (s, 3H), 2.12 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.67 (d, *J* = 7.8 Hz). LCMS: rt 7.05 min (A), purity 99%, MS (m/e) 497 (MH⁺).
- [0883] N-(2-(1H-Indol-3-yl)ethyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxamide (Compound 632). LCMS: rt 6.48 min (A), purity 99%, MS (m/e) 490 (MH⁺).
- [0884] N-(2-(Dimethylamino)ethyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxamide (Compound 633). LCMS: rt 4.16 min (A), purity 98%, MS (m/e) 418 (MH⁺).

- [0885] N-(3-(Dimethylamino)propyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxamide (Compound 634). LCMS: rt 5.30 min (A), purity 98%, MS (m/e) 431 (MH⁺)
- [0886] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)-1H-indazole-1-carboxamide (Compound 635). LCMS: rt 5.30 min (A), purity 97%, MS (m/e) 472 (MH⁺).
- [0887] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(pyrrolidin-1-yl)ethyl)-1H-indazole-1-carboxamide (Compound 636). LCMS: rt 4.33 min (A), purity 99%, MS (m/e) 444 (MH⁺).
- [0888] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(piperidin-1-yl)propyl)-1H-indazole-1-carboxamide (Compound 637). LCMS: rt 4.53 min (A), purity 98%, MS (m/e) 472 (MH⁺).
- [0889] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-morpholinopropyl)-1H-indazole-1-carboxamide (Compound 638). LCMS: rt 4.21 min (A), purity 99%, MS (m/e) 474 (MH⁺).
- [0890] N-(2-Aminoethyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxamide (Compound 639). LCMS: rt 4.00 min (A), purity 99%, MS (m/e) 390 (MH⁺).
- [0891] N-(3-Aminopropyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxamide (Compound 640). LCMS: rt 3.41 min (A), purity 99%, MS (m/e) 404 (MH⁺).
- [0892] (S)-2-((*tert*-Butoxycarbonyl)amino)-3-(1H-indol-3-yl)propyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (Compound 641). ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.82 (s, 1H), 9.17 (s, 1H), 8.71 (d, *J* = 4.7 Hz, 1H), 7.97 (d, *J* = 7.8 Hz, 1H), 7.70 (d, *J* = 9.8 Hz, 2H), 7.60 – 7.38 (m, 3H), 7.32 (d, *J* = 8.1 Hz, 1H), 7.21 – 6.86 (m, 6H), 6.75 (d, *J* = 9.3 Hz, 1H), 4.45 – 4.29 (m, 1H), 4.23 (t, *J* = 9.6 Hz, 1H), 4.13-4.02 (m, 1H), 2.92 (d, *J* = 6.4 Hz, 2H), 2.15 (s, 3H), 1.27 (s, 9H). LCMS: rt 7.41 min (A), purity 96%, MS (m/e) 620 (MH⁺).
- [0893] (R)-2-((*tert*-Butoxycarbonyl)amino)-3-(1H-indol-3-yl)propyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (Compound 642). LCMS: rt 7.41 min (A), purity 96%, MS (m/e) 620 (MH⁺).
- [0894] (S)-2-((*tert*-Butoxycarbonyl)amino)-3-(1H-indol-3-yl)propyl 7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (Compound 643). ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.82 (s, 1H), 8.96 (d, *J* = 7.4 Hz, 1H), 8.80 – 8.63 (m, 1H), 7.94 (d, *J*

= 7.8 Hz, 1H), 7.86 (s, 1H), 7.71 (s, 1H), 7.66 – 7.40 (m, 3H), 7.31 (d, $J = 7.8$ Hz, 1H), 7.15 (s, 1H), 7.00 (ddd, $J = 12.4, 7.2, 3.1$ Hz, 5H), 6.67 (d, $J = 7.4$ Hz, 1H), 4.36 (dd, $J = 10.7, 4.3$ Hz, 1H), 4.28 – 4.13 (m, 1H), 4.13 – 4.01 (m, 1H), 2.91 (d, $J = 6.3$ Hz, 2H), 2.17 (s, 3H), 1.28 (s, 9H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -118.08 (s). LCMS: rt 7.36 min (A), purity 99%, MS (m/e) 620 (MH^+).

[0895] (*R*)-2-((*tert*-Butoxycarbonyl)amino)-3-(1H-indol-3-yl)propyl 7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate (Compound 644). LCMS: rt 7.36 min (A), purity 99%, MS (m/e) 620 (MH^+).

[0896] (*S*)-2-Amino-3-(1H-indol-3-yl)propyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate formic acid salt (Compound 645). LCMS: rt 5.45 min (A), purity 99%, MS (m/e) 520 ($\text{MH}^+ - \text{HCOOH}$).

[0897] (*R*)-2-Amino-3-(1H-indol-3-yl)propyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate formic acid salt (Compound 646). LCMS: rt 5.45 min (A), purity 99%, MS (m/e) 520 ($\text{MH}^+ - \text{HCOOH}$).

[0898] (*S*)-2-Amino-3-(1H-indol-3-yl)propyl 7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate formic acid salt (Compound 647). LCMS: rt 5.41 min (A), purity 99%, MS (m/e) 520 ($\text{MH}^+ - \text{HCOOH}$).

[0899] (*R*)-2-Amino-3-(1H-indol-3-yl)propyl 7-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxylate formic acid salt (Compound 648). LCMS: rt 5.41 min (A), purity 99%, MS (m/e) 520 ($\text{MH}^+ - \text{HCOOH}$).

[0900] N-((1*R*,2*R*)-2-Aminocyclohexyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxamide hydrochloride salt (Compound 649). ^1H NMR (300 MHz, DMSO- d_6): δ 8.82 (d, $J = 5.2$ Hz, 1H), 8.71 (s, 1H), 8.49 (d, $J = 9.0$ Hz, 1H), 8.42 (d, $J = 0.7$ Hz, 1H), 8.32 (d, $J = 7.8$ Hz, 1H), 8.16 (d, $J = 8.8$ Hz, 3H), 7.95 – 7.81 (m, 1H), 7.80 (s, 1H), 7.48 (d, $J = 6.7$ Hz, 1H), 7.33 (dd, $J = 8.7, 1.6$ Hz, 1H), 7.16 – 6.89 (m, 2H), 3.75 – 3.52 (m, 2H), 3.46 (dd, $J = 8.0, 4.0$ Hz, 1H), 2.12 (s, 3H), 1.94 – 1.78 (m, 1H), 1.75-1.55 (m, 3H), 1.50-1.35 (m, 1H), 1.31 – 1.02 (m, 2H). LCMS: rt 4.63 min (A), purity 92%, MS (m/e) 444 ($\text{MH}^+ - \text{HCl}$).

[0901] N-((1*S*,2*S*)-2-Aminocyclohexyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazole-1-carboxamide (Compound 650). LCMS: rt 4.58 min (A), purity 94%, MS (m/e) 444 ($\text{MH}^+ - \text{HCl}$).

- [0902] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-((1-methylpiperidin-4-yl)methyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 651). LCMS: rt 3.70 min (A), purity 99%, MS (m/e) 458 (MH⁺).
- [0903] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(piperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 652). LCMS: rt 3.56 min (A), purity 98%, MS (m/e) 430 (MH⁺).
- [0904] N-(3-(1H-Imidazol-1-yl)propyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 653). LCMS: rt 3.71 min (A), purity 99%, MS (m/e) 455 (MH⁺).
- [0905] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(pyridin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 654). ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.50 (s, 1H), 9.44 (s, 1H), 8.73 (d, *J* = 4.7 Hz, 1H), 8.63 (s, 1H), 8.46 (d, *J* = 6.2 Hz, 2H), 7.98 (d, *J* = 7.7 Hz, 1H), 7.73 (d, *J* = 6.3 Hz, 2H), 7.65 (d, *J* = 9.3 Hz, 1H), 7.53 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.45 (d, *J* = 6.9 Hz, 1H), 7.20 – 7.04 (m, 2H), 7.03 – 6.90 (m, 1H), 2.17 (s, 3H). LCMS: rt 4.08 min (A), purity 99%, MS (m/e) 424 (MH⁺).
- [0906] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(1-methylpiperidin-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 655). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.71 – 8.62 (m, 1H), 8.57 (d, *J* = 7.2 Hz, 1H), 8.53 (s, 1H), 8.10 (d, *J* = 2.0 Hz, 1H), 8.05 (d, *J* = 7.2 Hz, 1H), 7.92 – 7.83 (m, 1H), 7.47 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.39 (d, *J* = 6.0 Hz, 1H), 6.99 (dd, *J* = 5.3, 2.3 Hz, 1H), 6.93 (t, *J* = 9.0 Hz, 1H), 6.57 (dd, *J* = 7.1, 2.0 Hz, 1H), 3.96-3.82 (m, 1H), 3.22-3.11 (m, 2H), 2.80-2.63 (m, 2H), 2.56 (s, 3H), 2.12 (s, 3H), 1.95-1.82 (m, 2H), 1.68-1.65 (m, 2H). LCMS: rt 4.03 min (A), purity 99%, MS (m/e) 444 (MH⁺).
- [0907] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-((1-methylpiperidin-4-yl)methyl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 656). LCMS: rt 4.06 min (A), purity 99%, MS (m/e) 458 (MH⁺).
- [0908] 6-(2-(2-Fluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 657). LCMS: rt 5.60 min (A), purity 99%, MS (m/e) 307 (MH⁺).
- [0909] 6-(2-(3-Fluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 658). LCMS: rt 5.65 min (A), purity 99%, MS (m/e) 307 (MH⁺).
- [0910] 6-(2-(4-Fluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 659). LCMS: rt 5.25 min (A), purity 99%, MS (m/e) 307 (MH⁺).

- [0911] 6-(2-(3,5-Difluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 660). LCMS: rt 6.32 min (A), purity 99%, MS (m/e) 325 (MH⁺).
- [0912] 6-(2-(3,4-Difluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 661). LCMS: rt 6.25 min (A), purity 99%, MS (m/e) 325 (MH⁺).
- [0913] 6-(2-(2,3-Difluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 662). LCMS: rt 6.58min (A), purity 99%, MS (m/e) 325 (MH⁺).
- [0914] N-((1*R*,2*R*)-2-Aminocyclohexyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-*a*]pyridine-3-carboxamide (Compound 663). LCMS: rt 4.40 min (A), purity 99%, MS (m/e) 444 (MH⁺).
- [0915] N-((1*S*,2*S*)-2-Aminocyclohexyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-*a*]pyridine-3-carboxamide (Compound 664). LCMS: rt 4.38 min (A), purity 99%, MS (m/e) 444 (MH⁺).
- [0916] 6-(2-(2,4-Difluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 665). LCMS: rt 6.60 min (A), purity 99%, MS (m/e) 325 (MH⁺).
- [0917] 6-(2-(3,4,5-Trifluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 666). LCMS: rt 5.54 min (B), purity 99%, MS (m/e) 343 (MH⁺).
- [0918] 6-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)benzo[d]thiazole (Compound 667). LCMS: rt 5.91 min (A), purity 99%, MS (m/e) 321 (MH⁺).
- [0919] 6-(2-(3-Chlorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 668). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.39 (s, 1H), 8.72 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.12 (d, *J* = 1.8 Hz, 1H), 8.04 – 7.88 (m, 2H), 7.55 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.43 (t, *J* = 1.9 Hz, 1H), 7.34 – 7.28 (m, 1H), 7.26 (dd, *J* = 8.4, 1.8 Hz, 1H), 7.20 (t, *J* = 7.8 Hz, 1H), 7.11 (dt, *J* 7.7, 1.4 Hz, 1H). LCMS: rt 6.20 min (A), purity 99%, MS (m/e) 323 (MH⁺).
- [0920] 6-(2-(3-Methoxyphenyl)pyridin-3-yl)benzo[d]thiazole (Compound 669). LCMS: rt 5.05 min (A), purity 99%, MS (m/e) 319 (MH⁺).
- [0921] 3-(3-(Benzo[d]thiazol-6-yl)pyridin-2-yl)benzonitrile (Compound 670). LCMS: rt 5.93 min (A), purity 99%, MS (m/e) 314 (MH⁺).
- [0922] 6-(2-(Benzo[d][1,3]dioxol-5-yl)pyridin-3-yl)benzo[d]thiazole (Compound 671). LCMS: rt 4.78 min (A), purity 99%, MS (m/e) 333 (MH⁺).

[0923] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-morpholinopropyl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 672). LCMS: rt min 2.86 (B), purity 99%, MS (m/e) 474 (MH⁺)

[0924] N-(2-(Dimethylamino)ethyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 673). LCMS: rt 2.72 min (B), purity 99%, MS (m/e) 418 (MH⁺)

[0925] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-morpholinoethyl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 674). LCMS: rt 2.80 min (B), purity 99%, MS (m/e) 460 (MH⁺)

[0926] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(pyrrolidin-1-yl)propyl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 675). LCMS: rt 2.91 min (B), purity 99%, MS (m/e) 458 (MH⁺)

[0927] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 676). LCMS: rt 2.47 min (B), purity 99%, MS (m/e) 487 (MH⁺)

[0928] Ethyl 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (Compound 677). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.76 (dd, *J* = 7.2, 0.9 Hz, 1H), 8.72 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.44 (s, 1H), 7.99 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.94 (dd, *J* = 2.1, 0.9 Hz, 1H), 7.53 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.45 (dd, *J* = 7.7, 1.8 Hz, 1H), 7.10 – 6.94 (m, 2H), 6.80 (dd, *J* = 7.2, 2.0 Hz, 1H), 4.24 (q, *J* = 7.1 Hz, 2H), 2.17 (s, 3H), 1.26 (t, *J* = 7.1 Hz, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.06 - -118.13 (m). LCMS: rt 6.51 min (A), purity 96%, MS (m/e) 376 (MH⁺)

[0929] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (Compound 678). ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.47 (s, 1H), 8.76 – 8.65 (m, 2H), 8.39 (s, 1H), 8.05 – 7.91 (m, 2H), 7.52 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.45 (dd, *J* = 7.5, 2.2 Hz, 1H), 7.11 – 6.90 (m, 2H), 6.71 (dd, *J* = 7.2, 2.0 Hz, 1H), 2.17 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.05. LCMS: rt 5.01 min (A), purity 97%, MS (m/e) 348 (MH⁺)

[0930] N-((1*R*,2*R*)-2-Aminocyclohexyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 679). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.48 (s, 1H), 8.70 (d, *J* = 4.4 Hz, 1H), 8.37 (s, 1H), 8.27 – 8.13 (m, 1H), 7.93 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.62 – 7.46 (m, 2H), 7.43 (dd, *J* = 7.8, 2.0 Hz, 1H), 7.12 – 6.84 (m, 3H), 3.75 – 3.52 (m,

2H), 3.46 (dd, $J = 8.0, 4.0$ Hz, 1H), 2.12 (s, 3H), 1.94 – 1.78 (m, 1H), 1.75-1.55 (m, 3H), 1.50-1.35 (m, 1H), 1.31 – 1.02 (m, 2H). LCMS: rt 4.05 min (A), purity 98%, MS (m/e) 444 (MH⁺)

[0931] N-((1*S*,2*S*)-2-Aminocyclohexyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine-3-carboxamide (Compound 680). LCMS: rt 4.00 min (A), purity 98%, MS (m/e) 444 (MH⁺)

[0932] N-(2-Aminoethyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine-3-carboxamide (Compound 681). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.48 (s, 1H), 9.04 (t, $J = 5.6$ Hz, 1H), 8.78 (dd, $J = 4.9, 0.7$ Hz, 1H), 8.56 (s, 1H), 8.27 – 8.13 (m, 3H), 7.93 (dd, $J = 7.8, 1.4$ Hz, 1H), 7.62 (dd, $J = 7.8, 4.9$ Hz, 1H), 7.44 (d, $J = 7.5$ Hz, 1H), 7.35 (dd, $J = 9.3, 1.1$ Hz, 1H), 7.15 – 7.04 (m, 1H), 6.98 (t, $J = 9.1$ Hz, 1H), 3.54 (q, $J = 5.9$ Hz, 2H), 3.02 (dd, $J = 11.6, 5.8$ Hz, 2H), 2.16 (s, 3H). LCMS: rt 3.48 min (A), purity 98%, MS (m/e) 390 (MH⁺)

[0933] N-(3-Aminopropyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine-3-carboxamide (Compound 682). LCMS: rt 3.53 min (A), purity 98%, MS (m/e) 404 (MH⁺)

[0934] N-(2-Aminoethyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-*a*]pyridine-3-carboxamide (Compound 683). LCMS: rt 3.88 min (A), purity 98%, MS (m/e) 390 (MH⁺)

[0935] N-(3-Aminopropyl)-5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-*a*]pyridine-3-carboxamide (Compound 684). LCMS: rt 3.93 min (A), purity 98%, MS (m/e) 404 (MH⁺)

[0936] Methyl 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine-3-carboxylate (Compound 685). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.16 (s, 1H), 8.72 (dd, $J = 4.7, 1.4$ Hz, 1H), 8.31 (s, 1H), 7.97 (dd, $J = 7.7, 1.5$ Hz, 1H), 7.68 (d, $J = 9.2$ Hz, 1H), 7.53 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.43 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.18 (dd, $J = 9.2, 1.6$ Hz, 1H), 7.12 – 7.01 (m, 1H), 6.97 (t, $J = 9.1$ Hz, 1H), 3.87 (s, 3H), 2.16 (s, 3H). LCMS: rt 5.08 min (A), purity 96%, MS (m/e) 362 (MH⁺).

[0937] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)benzo[*d*]thiazole (Compound 686). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.40 (d, $J = 0.7$ Hz, 1H), 8.70 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.13 (dd, $J = 1.8, 0.6$ Hz, 1H), 7.99 (dd, $J = 8.4, 0.7$ Hz, 1H), 7.93 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.60 – 7.47 (m, 2H), 7.27 (dd, $J = 8.5, 1.8$ Hz, 1H), 7.22 (d, $J = 9.3$ Hz, 1H), 7.13 (ddd, $J = 8.6, 4.9, 2.2$ Hz,

1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.36 (td, *J* = 8.5, 8.0, 5.0 Hz). LCMS: rt 6.37 min (A), purity 99%, MS (m/e) 341 (MH⁺)

[0938] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 687). LCMS: rt 4.53 min (A), purity 99%, MS (m/e) 324 (MH⁺)

[0939] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinoline (Compound 688). LCMS: rt 5.03 min (A), purity 99%, MS (m/e) 335 (MH⁺)

[0940] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 689). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.74 (ddd, *J* = 4.8, 1.7, 0.8 Hz, 1H), 8.69 (dt, *J* = 1.8, 0.9 Hz, 1H), 8.47 (d, *J* = 0.8 Hz, 1H), 8.09 (ddd, *J* = 7.7, 1.7, 0.8 Hz, 1H), 7.76 – 7.64 (m, 2H), 7.57 (ddd, *J* = 7.8, 4.8, 0.8 Hz, 1H), 7.34 – 7.25 (m, 2H), 7.13 (ddd, *J* = 9.3, 1.8, 0.8 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.87 (q, *J* = 7.8 Hz). LCMS: rt 6.58 min (A), purity 99%, MS (m/e) 349 (MH⁺)

[0941] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinoxaline (Compound 690). LCMS: rt 6.48 min (A), purity 99%, MS (m/e) 336 (MH⁺)

[0942] 2-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-1,5-naphthyridine (Compound 691). LCMS: rt 6.23 min (A), purity 99%, MS (m/e) 336 (MH⁺).

[0943] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 692). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.05 (dd, *J* = 1.8, 0.9 Hz, 1H), 8.74 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.52 (s, 1H), 8.03 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.73 (dd, *J* = 9.2, 0.9 Hz, 1H), 7.67 (ddd, *J* = 7.3, 1.9, 0.6 Hz, 1H), 7.56 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.32 – 7.23 (m, 3H). LCMS: rt 5.80 min (A), purity 99%, MS (m/e) 325 (MH⁺).

[0944] 6-(2-(2,4,5-Trifluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 693). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.00 (dd, *J* = 4.3, 1.8 Hz, 1H), 8.85 – 8.76 (m, 1H), 8.39 (d, *J* = 8.7 Hz, 1H), 8.31 (d, *J* = 8.9 Hz, 1H), 8.18 (ddd, *J* = 7.8, 1.7, 0.6 Hz, 1H), 7.80 (dd, *J* = 8.5, 4.2 Hz, 1H), 7.66 – 7.56 (m, 2H), 7.53 (d, *J* = 8.7 Hz, 1H), 7.24 (t, *J* = 9.0 Hz, 1H), 7.10 (ddd, *J* = 8.7, 4.9, 2.3 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.93 (td, *J* = 8.1, 5.5 Hz). LCMS: rt 7.16 min (A), purity 99%, MS (m/e) 343 (MH⁺).

[0945] 6-(2-(2,4,5-Trifluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 694). LCMS: rt 4.41 min (A), purity 99%, MS (m/e) 326 (MH⁺).

[0946] 6-(2-(2,4,5-Trifluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 695). LCMS: rt 6.61 min (A), purity 99%, MS (m/e) 351 (MH⁺).

[0947] 6-(2-(2,4,5-Trifluorophenyl)pyridin-3-yl)quinoline (Compound 696). LCMS: rt 5.06 min (A), purity 99%, MS (m/e) 337 (MH⁺).

[0948] 6-(2-(3-Chlorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 697). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.75 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.68 (dd, *J* = 1.8, 1.0 Hz, 1H), 8.46 (s, 1H), 8.09 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.67 (dd, *J* = 9.3, 1.0 Hz, 1H), 7.58-7.55 (app m, 2H), 7.44 – 7.30 (m, 1H), 7.25 (appd, *J* = 4.8 Hz, 1H), 7.12 (dd, *J* = 9.3, 1.8 Hz, 1H). LCMS: rt 6.15 min (A), purity 99%, MS (m/e) 331 (MH⁺).

[0949] 6-(2-(3-Chlorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 698). LCMS: rt 4.16 min (A), purity 99%, MS (m/e) 306 (MH⁺).

[0950] 6-(2-(3-Chlorophenyl)pyridin-3-yl)quinolone (Compound 699). LCMS: rt 4.65 min (A), purity 99%, MS (m/e) 317 (MH⁺).

[0951] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(1-isopropylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 700). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.46 (s, 1H), 8.70 (d, *J* = 4.2 Hz, 1H), 8.35 (s, 1H), 8.26 (d, *J* = 8.3 Hz, 1H), 7.93 (d, *J* = 7.8 Hz, 1H), 7.62 – 7.36 (m, 3H), 7.14 – 6.84 (m, 3H), 3.77-3.70 (m, 1H), 2.82 (d, *J* = 10.0 Hz, 2H), 2.72 (dt, *J* = 14.0, 7.0 Hz, 1H), 2.15 (s, 4H), 1.81 (d, *J* = 11.4 Hz, 2H), 1.66 – 1.35 (m, 2H), 0.97 (d, *J* = 6.5 Hz, 6H). LCMS: rt 3.21 min (B), purity 99%, MS (m/e) 472 (MH⁺).

[0952] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(1-isopropylpiperidin-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 701). LCMS: rt 3.53 min (B), purity 99%, MS (m/e) 472 (MH⁺).

[0953] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 702). LCMS: rt 2.90 min (A), purity 99%, MS (m/e) 500 (MH⁺).

[0954] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 703). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.71 (dd, *J* = 4.9, 1.7 Hz, 1H), 8.59 (d, *J* = 7.3 Hz, 1H), 8.56 (s, 1H), 8.21 (s, 1H), 7.93 (t, *J* = 8.2 Hz, 2H), 7.51 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.44 (d, *J* = 7.6 Hz, 1H), 7.14 – 6.89 (m, 2H), 6.57 (dd, *J* = 7.3, 2.1 Hz, 1H), 4.37 – 3.93 (m, 1H), 2.18 (s, 6H), 1.71 (dd, *J* = 12.7, 3.4 Hz, 2H), 1.39 (t, *J* = 12.3 Hz, 2H), 1.08 (s, 6H), 1.02 (s, 6H). LCMS: rt 3.16 min (A), purity 99%, MS (m/e) 500 (MH⁺).

[0955] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-hydroxypropyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 704). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.48 (dd, *J* = 1.9, 1.0 Hz, 1H), 8.70 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.47 (t, *J* = 5.7 Hz, 1H), 8.31 (s, 1H), 7.93 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.60 – 7.46 (m, 2H), 7.43 (dd, *J* = 7.9, 1.8 Hz, 1H), 7.13 – 6.87 (m, 3H), 4.54 – 4.33 (app m, 1H), 3.46 (q, *J* = 5.8 Hz, 2H), 3.39-3.29 (m, 2H), 2.16 (s, 3H), 1.81 – 1.55 (m, 2H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.29. LCMS: rt 3.95 min (A), purity 99%, MS (m/e) 405 (MH⁺)

[0956] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-hydroxyethyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 705). LCMS: rt 3.85 min (A), purity 99%, MS (m/e) 391 (MH⁺).

[0957] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-hydroxypropyl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 706). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.71 (ddd, *J* = 4.8, 1.7, 0.6 Hz, 1H), 8.60 (d, *J* = 7.2 Hz, 1H), 8.52 (s, 1H), 8.25 – 8.07 (m, 2H), 7.94 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.51 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.45 (dd, *J* = 7.5, 1.9 Hz, 1H), 7.06 (ddd, *J* = 7.6, 5.2, 2.3 Hz, 1H), 7.02 – 6.92 (app m, 1H), 6.57 (dd, *J* = 7.2, 2.0 Hz, 1H), 4.46 (t, *J* = 5.2 Hz, 1H), 3.45 (q, *J* = 6.1 Hz, 2H), 3.28-3.25 (q, *J* = 6.1 Hz, 2H), 2.17 (s, 3H), 1.67 (q, *J* = 6.7 Hz, 2H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.29 (s). LCMS: rt 4.50 min (A), purity 99%, MS (m/e) 405 (MH⁺).

[0958] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-hydroxyethyl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 707). LCMS: rt 4.35 min (A), purity 99%, MS (m/e) 391 (MH⁺).

[0959] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-N-(1-methylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 708). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.48 (dd, *J* = 1.9, 0.9 Hz, 1H), 8.74 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.36 (s, 1H), 8.27 (d, *J* = 7.8 Hz, 1H), 7.97 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.62 – 7.52 (m, 2H), 7.49 (ddd, *J* = 2.2, 1.5, 0.7 Hz, 1H), 7.35 (dt, *J* = 7.5, 2.0 Hz, 1H), 7.31 – 7.14 (m, 2H), 7.05 (ddd, *J* = 9.3, 1.9, 0.6 Hz, 1H), 3.84 – 3.61 (m, 1H), 2.76 (d, *J* = 12.8 Hz, 2H), 2.15 (s, 3H), 2.04 – 1.86 (m, 2H), 1.77 (d, *J* = 11.1 Hz, 2H), 1.67 – 1.45 (m, 2H). LCMS: rt 3.96 min (A), purity 99%, MS (m/e) 446 (MH⁺).

[0960] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N-(1-methylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 709). LCMS: rt 4.21 min (A), purity 99%, MS (m/e) 464 (MH⁺).

[0961] N-(1-Methylpiperidin-4-yl)-6-(2-(2,4,5-Trifluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 710). LCMS: rt 4.10 min (A), purity 99%, MS (m/e) 466 (MH⁺).

[0962] *rac*-6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 711). LCMS: rt 2.66 min (B), purity 99%, MS (m/e) 470 (MH⁺).

[0963] *exo*-6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 712). LCMS: rt 2.73 min (B), purity 99%, MS (m/e) 470 (MH⁺).

[0964] *endo*-6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 713). LCMS: rt 2.67 min (B), purity 99%, MS (m/e) 470 (MH⁺).

[0965] *rac*-5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 714). LCMS: rt 3.42 min (B), purity 99%, MS (m/e) 470 (MH⁺).

[0966] *exo*-5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 715). LCMS: rt 3.44 min (B), purity 99%, MS (m/e) 470 (MH⁺).

[0967] *endo*-5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 716). LCMS: rt 3.46 min (B), purity 99%, MS (m/e) 470 (MH⁺).

[0968] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 717). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.38 (s, 1H), 8.72 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.09 (dd, *J* = 1.8, 0.6 Hz, 1H), 8.02 – 7.89 (m, 2H), 7.66 – 7.54 (m, 2H), 7.40 (ddd, *J* = 8.8, 4.3, 2.8 Hz, 1H), 7.27 (dd, *J* = 8.5, 1.8 Hz, 1H), 7.03 (appt, *J* = 8.8 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.29 (s). LCMS: rt 7.31 min (A), purity 99%, MS (m/e) 341 (MH⁺).

[0969] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 718). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.38 (d, *J* = 0.6 Hz, 1H), 8.73 (ddd, *J* = 4.8, 1.7, 0.6 Hz, 1H), 8.11 (dd, *J* = 1.8, 0.6 Hz, 1H), 8.03 – 7.95 (m, 2H), 7.80 (dd, *J* = 8.4, 7.4 Hz, 1H), 7.61 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.33 (app t, *J* = 9.2 Hz, 1H), 7.28 (dd, *J* = 9.1 Hz, 1H), 7.38 – 7.24 (m, 2H). ¹⁹F

NMR (282 MHz, DMSO- d_6): δ -111.43 (q, J = 8.7 Hz), -111.62 (t, J = 8.9 Hz). LCMS: rt 7.66 min (A), purity 99%, MS (m/e) 359 (MH⁺).

[0970] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 719). LCMS: rt 6.76 min (A), purity 99%, MS (m/e) 349 (MH⁺).

[0971] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 720). LCMS: rt 7.08 min (A), purity 99%, MS (m/e) 367 (MH⁺).

[0972] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 721). LCMS: rt 4.61 min (A), purity 99%, MS (m/e) 324 (MH⁺).

[0973] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-N-(1-methylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 722). LCMS: rt 4.23 min (A), purity 99%, MS (m/e) 464 (MH⁺).

[0974] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-N-(1-methylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 723). ¹H NMR (300 MHz, DMSO- d_6): δ 9.39 (s, 1H), 8.75 (dd, J = 4.6, 1.4 Hz, 1H), 8.33 (s, 1H), 8.25 (d, J = 7.8 Hz, 1H), 8.04 (dd, J = 7.8, 1.5 Hz, 1H), 7.83 (t, J = 7.8 Hz, 1H), 7.72 – 7.54 (m, 2H), 7.38 (t, J = 9.7 Hz, 1H), 7.20 (dd, J = 9.3, 1.6 Hz, 1H), 3.92 – 3.60 (m, 1H), 2.82 (d, J = 13.8 Hz, 2H), 2.21 (s, 3H), 2.03 (t, J = 10.9 Hz, 2H), 1.79 (d, J = 13.1 Hz, 2H), 1.69 – 1.40 (m, 2H). ¹⁹F NMR (282 MHz, DMSO- d_6): δ -111.36 (q, J = 9.1 Hz), -112.11 (q, J = 8.7 Hz). LCMS: rt 4.43 min (A), purity 99%, MS (m/e) 482 (MH⁺).

[0975] N-(3-(2-Oxopyrrolidin-1-yl)propyl)-6-(2-(*m*-tolyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 724). LCMS: rt 4.08 min (A), purity 99%, MS (m/e) 454 (MH⁺).

[0976] 6-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 725). LCMS: rt 4.58 min (A), purity 99%, MS (m/e) 472 (MH⁺).

[0977] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 726). LCMS: rt 4.73 min (A), purity 99%, MS (m/e) 474 (MH⁺).

[0978] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 727). LCMS: rt 5.00 min (A), purity 99%, MS (m/e) 492 (MH⁺).

[0979] N-(3-(2-Oxopyrrolidin-1-yl)propyl)-6-(2-(2,4,5-Trifluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 728). LCMS: rt 4.95 min (A), purity 99%, MS (m/e) 494 (MH⁺).

[0980] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 729). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.48 (s, 1H), 8.78 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.63 (t, *J* = 5.5 Hz, 1H), 8.43 (s, 1H), 8.05 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.74 (d, *J* = 9.3 Hz, 1H), 7.70 – 7.56 (m, 2H), 7.50 – 7.31 (m, 2H), 7.08 (t, *J* = 9.2 Hz, 1H), 3.34 (t, *J* = 7.0 Hz, 2H), 3.22 (t, *J* = 7.0 Hz, 4H), 2.20 (t, *J* = 8.0 Hz, 2H), 1.91 (p, *J* = 7.5 Hz, 2H), 1.71 (p, *J* = 7.2 Hz, 2H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.76 (ddd, *J* = 10.0, 5.9, 4.2 Hz). LCMS: rt 5.03 min (A), purity 99%, MS (m/e) 492 (MH⁺).

[0981] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 730). LCMS: rt 5.25 min (A), purity 99%, MS (m/e) 510 (MH⁺).

[0982] 7-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 731). LCMS: rt 4.85 min (A), purity 99%, MS (m/e) 305 (MH⁺).

[0983] 7-(2-(*m*-Tolyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 732). LCMS: rt 4.40 min (A), purity 99%, MS (m/e) 287 (MH⁺).

[0984] 7-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 733). LCMS: rt 5.88 min (A), purity 99%, MS (m/e) 325 (MH⁺).

[0985] 7-(2-(3-Chlorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 734). LCMS: rt 5.43 min (A), purity 99%, MS (m/e) 307 (MH⁺).

[0986] 7-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 735). LCMS: rt 6.41 min (A), purity 99%, MS (m/e) 343 (MH⁺).

[0987] 7-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 736). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.88 (dd, *J* = 7.1, 0.9 Hz, 1H), 8.78 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.49 (s, 1H), 8.07 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.74 (dd, *J* = 1.9, 0.9 Hz, 1H), 7.68 (dd, *J* = 6.2, 2.8 Hz, 1H), 7.64 (dd, *J* = 7.9, 4.8 Hz, 1H), 7.46 (ddd, *J* = 8.8, 4.4, 2.8 Hz, 1H), 7.09 (dd, *J* = 9.6, 8.9 Hz, 1H), 6.97 (dd, *J* = 7.1, 1.9 Hz, 1H). LCMS: rt 6.10 min (A), purity 99 %, MS (m/e) MH⁺ 325.

[0988] 7-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 737). LCMS: rt min (A), purity 99 %, MS (m/e) 305 MH⁺.

- [0989] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrido[2,3-b]pyrazine (Compound 738). LCMS: rt 5.06 min (A), purity 99 %, MS (m/e) 317 MH⁺.
- [0990] 6-(2-(3-Chlorophenyl)pyridin-3-yl)pyrido[2,3-b]pyrazine (Compound 739). LCMS: rt 5.63min (A), purity 99 %, MS (m/e) 319 MH⁺.
- [0991] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrido[2,3-b]pyrazine (Compound 740). LCMS: rt 6.06 min (A), purity 99 %, MS (m/e) 337 MH⁺.
- [0992] 6-(2-(2,4,5-Trifluorophenyl)pyridin-3-yl)pyrido[2,3-b]pyrazine (Compound 741). LCMS: rt 6.03 min (A), purity 99 %, MS (m/e) 339 MH⁺.
- [0993] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)pyrido[2,3-b]pyrazine (Compound 742). LCMS: rt 6.20 min (A), purity 99 %, MS (m/e) 337MH⁺.
- [0994] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)pyrido[2,3-b]pyrazine (Compound 743). LCMS: rt 6.56 min (A), purity 99 %, MS (m/e) 355 MH⁺.
- [0995] N-((7*R*,8*aS*)-5,5-Dimethyloctahydroindolizin-7-yl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 744). LCMS: rt 4.06 min (A), purity 99 %, MS (m/e) 498 MH⁺.
- [0996] N-((7*R*,8*aS*)-5,5-Dimethyloctahydroindolizin-7-yl)-5-(2-(4-difluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 745). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.71 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.61 – 8.57 (m, 1H), 8.55 (s, 1H), 8.18 (dd, *J* = 2.1, 0.9 Hz, 1H), 8.02 – 7.79 (m, 2H), 7.52 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.45 (dd, *J* = 8.0, 2.3 Hz, 1H), 7.13 – 6.87 (m, 2H), 6.58 (dd, *J* = 7.2, 2.1 Hz, 1H), 4.18 – 3.89 (m, 1H), 2.84 (td, *J* = 8.5, 3.3 Hz, 1H), 2.44 – 2.35 (m, 2H), 2.28 (q, *J* = 8.5 Hz, 1H), 2.17 (s, 3H), 1.95 (d, *J* = 11.7 Hz, 1H), 1.87 – 1.71 (m, 1H), 1.69 – 1.54 (m, 3H), 1.46 – 1.26 (m, 2H), 1.08 (s, 3H), 0.95 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.10. LCMS: rt 4.45 min (A), purity 99 %, MS (m/e) 498 MH⁺.
- [0997] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 746). LCMS: rt 5.40 min (A), purity 99 %, MS (m/e) 307 MH⁺.
- [0998] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 747). LCMS: rt 6.10 min (A), purity 99 %, MS (m/e) 325 MH⁺.
- [0999] 6-(2-(2-Fluoro-5-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 748). LCMS: rt 5.21 min (A), purity 99 %, MS (m/e) 305 MH⁺.

[1000] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 749). ^1H NMR (300 MHz, DMSO- d_6): δ 9.01 (dd, $J = 1.8, 1.0$ Hz, 1H), 8.77 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.50 (s, 1H), 8.08 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.86 (dd, $J = 8.5, 7.4$ Hz, 1H), 7.76 (dd, $J = 9.2, 0.9$ Hz, 1H), 7.64 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.41 (dd, $J = 9.1$ Hz, 0.9 Hz, 1H), 7.37 (app t, $J = 9.3$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -111.06 (q, $J = 9.0$ Hz), -111.78 (q, $J = 8.8$ Hz). LCMS: rt 6.43 min (A), purity 99 %, MS (m/e) 343 MH^+ .

[1001] 2-(5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-1-yl)acetamide (Compound 750). ^1H NMR (300 MHz, DMSO- d_6): δ 8.63 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.04 (d, $J = 1.0$ Hz, 1H), 7.84 (dd, $J = 7.8, 1.8$ Hz, 1H), 7.65 (s, 1H), 7.59 – 7.51 (m, 1H), 7.50 – 7.43 (m, 2H), 7.38 (dd, $J = 8.0, 2.2$ Hz, 1H), 7.20 (br s, 1H), 7.06 (dd, $J = 8.7, 1.7$ Hz, 1H), 6.99 – 6.82 (m, 2H), 5.02 (s, 2H), 2.13 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -118.90 (s). LCMS: r 4.33 min (A), purity 99 %, MS (m/e) 361 MH^+ .

[1002] 2-(5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl)acetamide (Compound 751). ^1H NMR (300 MHz, DMSO- d_6): δ 8.63 (dd, $J = 4.7, 1.6$ Hz, 1H), 8.33 (d, $J = 0.9$ Hz, 1H), 7.83 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.72 – 7.61 (m, 2H), 7.48 – 7.43 (m, 2H), 7.43 – 7.40 (m, 1H), 7.36 – 7.29 (m, 1H), 6.98 (ddd, $J = 7.7, 5.2, 2.1$ Hz, 1H), 6.93 (d, $J = 9.4$ Hz, 1H), 6.87 (dd, $J = 8.9, 1.6$ Hz, 1H), 5.07 (s, 2H), 2.15 (s, 3H). LCMS: rt 4.18 min (A), purity 99 %, MS (m/e) 361 MH^+ .

[1003] 2-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-1-yl)acetamide (Compound 752). ^1H NMR (300 MHz, DMSO- d_6): δ 8.66 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.03 (d, $J = 0.9$ Hz, 1H), 7.84 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.61 (br s, 1H), 7.59 (dd, $J = 8.3, 0.8$ Hz, 1H), 7.47 (dd, $J = 7.8, 4.7$ Hz, 2H), 7.36 (dd, $J = 7.8, 2.2$ Hz, 1H), 7.16 (br s, 1H), 6.97 (ddd, $J = 7.5, 5.3, 2.1$ Hz, 1H), 6.89 (dd, $J = 9.6, 8.5$ Hz, 1H), 6.76 (dd, $J = 8.3, 1.4$ Hz, 1H), 5.01 (s, 2H), 2.21 (s, 3H). LCMS: rt 4.55 min (A), purity 99 %, MS (m/e) 361 MH^+ .

[1004] 2-(6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-1H-indazol-1-yl)acetamide (Compound 753). LCMS: rt 5.18 min (A), purity 99 %, MS (m/e) 381 MH^+ .

[1005] 2-(6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-2H-indazol-2-yl)acetamide (Compound 754). ^1H NMR (300 MHz, DMSO- d_6): δ 8.65 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.30 (s, 1H), 7.87 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.62 (s, 1H), 7.57 (dd, $J = 8.6, 0.9$ Hz, 1H), 7.52 (q, $J = 1.1$ Hz, 1H), 7.51 – 7.37 (m, 2H), 7.29 (s, 1H), 7.01 (ddd, $J = 7.8, 5.2, 2.4$ Hz, 1H), 6.91 (dd, $J = 9.7, 8.5$

Hz, 1H), 6.68 (dd, $J = 8.6, 1.5$ Hz, 1H), 5.07 (s, 2H), 2.14 (s 3H). LCMS: rt 4.40 min (A), purity 99 %, MS (m/e) 361 MH⁺.

[1006] 2-(6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-2H-indazol-2-yl)acetamide (Compound 755). LCMS: rt 5.01 min (A), purity 99 %, MS (m/e) 381 MH⁺.

[1007] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine (Compound 756). LCMS: rt 5.58 min (A), purity 99 %, MS (m/e) 304 MH⁺.

[1008] 5-(2-(*m*-Tolyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine (Compound 757). LCMS: rt 5.15 min (A), purity 99 %, MS (m/e) 286 MH⁺.

[1009] 5-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine (Compound 758). LCMS: rt 6.71 min (A), purity 99 %, MS (m/e) 324 MH⁺.

[1010] 5-(2-(3-Chlorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine (Compound 759). LCMS: rt 6.28 min (A), purity 99 %, MS (m/e) 306 MH⁺.

[1011] 5-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine (Compound 760). LCMS: rt 7.48 min (A), purity 99 %, MS (m/e) 342 MH⁺.

[1012] 5-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine (Compound 761). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.73 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.56 (dt, $J = 7.2, 1.0$ Hz, 1H), 8.01 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.96 (d, $J = 2.3$ Hz, 1H), 7.65 – 7.57 (m, 2H), 7.56 (dd, $J = 2.0, 1.0$ Hz, 1H), 7.44 (ddd, $J = 8.8, 4.4, 2.8$ Hz, 1H), 7.10 (dd, $J = 9.6, 8.9$ Hz, 1H), 6.60 (dd, $J = 7.2, 2.0$ Hz, 1H), 6.57 (dd, $J = 2.3, 0.9$ Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.44 (dt, $J = 10.1, 5.4$ Hz). LCMS: rt 7.13 min (A), purity 99 %, MS (m/e) 324 MH⁺.

[1013] 1-(6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-one (Compound 762). LCMS: rt 5.58 min (A), purity 99 %, MS (m/e) 366 MH⁺.

[1014] 1-(6-(2-(3-Chlorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-one (Compound 763). LCMS: rt 5.21 min (A), purity 99 %, MS (m/e) 348 MH⁺.

[1015] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-3-methylimidazo[1,2-a]pyridine (Compound 764). LCMS: rt 4.83 min (A), purity 99 %, MS (m/e) 338 MH⁺.

[1016] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-3-methylimidazo[1,2-a]pyridine (Compound 765). LCMS: rt 4.46 min (A), purity 99 %, MS (m/e) 320 MH⁺.

[1017] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-3-methylimidazo[1,2-a]pyridine (Compound 766). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.73 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.20 (dd, $J = 1.8, 1.0$ Hz, 1H), 8.07 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.82 (dd, $J = 8.4, 7.4$ Hz, 1H), 7.61 (dd, $J = 7.8,$

4.8 Hz, 1H), 7.50 – 7.28 (m, 3H), 6.91 (dd, $J = 9.3, 1.8$ Hz, 1H), 2.37 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -111.47 (q, $J = 9.0$ Hz), -111.57 (q, $J = 8.8$ Hz). LCMS: rt 5.10 min (A), purity 99 %, MS (m/e) 356 MH^+ .

[1018] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-3-methylimidazo[1,2-a]pyridine (Compound 767). LCMS: rt 4.86 min (A), purity 99 %, MS (m/e) 338 MH^+ .

[1019] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 768). ^1H NMR (300 MHz, DMSO- d_6): δ 8.67 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.18 (s, 1H), 7.91 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.60 – 7.46 (m, 4H), 7.28 – 7.09 (m, 2H), 6.90 (dd, $J = 8.3, 1.7$ Hz, 1H), 3.79 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -117.66 (s). LCMS: rt 4.48 min (A), purity 99 %, MS (m/e) 338 MH^+ .

[1020] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 769). LCMS: rt 4.10 min (A), purity 99 %, MS (m/e) 320 MH^+ .

[1021] 6-(2-(3-Chloro-5-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 770). LCMS: rt 6.23 min (A), purity 99 %, MS (m/e) 325 MH^+ .

[1022] 6-(2-(2,5-Dichlorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 771). LCMS: rt 6.30 min (A), purity 99 %, MS (m/e) 341 MH^+ .

[1023] 6-(2-(3-Chloro-2-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 772). LCMS: rt 5.91 min (A), purity 99 %, MS (m/e) 325 MH^+ .

[1024] 6-(2-(3-Chloro-2-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 773). LCMS: rt 5.30 min (A), purity 99 %, MS (m/e) 321 MH^+ .

[1025] 6-(2-(5-Chloro-2-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 774). LCMS: rt 5.75 min (A), purity 99 %, MS (m/e) 321 MH^+ .

[1026] 6-(2-(3-Chloro-5-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 775). LCMS: rt 5.36 min (A), purity 99 %, MS (m/e) 321 MH^+ .

[1027] 6-(2-(3,5-Dichlorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 776). LCMS: rt 6.80 min (A), purity 99 %, MS (m/e) 341 MH^+ .

[1028] 6-(2-(3,4-Dimethylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 777). LCMS: rt 4.63 min (A), purity 99 %, MS (m/e) 301 MH^+ .

[1029] 6-(2-(2,4-Dichlorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 778). LCMS: rt 6.21 min (A), purity 99 %, MS (m/e) 341 MH^+ .

[1030] 6-(2-(3-Methoxyphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 779). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.99 (dd, *J* = 1.9, 0.9 Hz, 1H), 8.77 (ddd, *J* = 4.9, 1.7, 0.6 Hz, 1H), 8.50 (s, 1H), 8.11 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.70 (dd, *J* = 9.3, 0.9 Hz, 1H), 7.61 (ddd, *J* = 7.9, 4.9, 0.9 Hz, 1H), 7.29 (ddd, *J* = 9.2, 1.8, 0.6 Hz, 1H), 7.23 – 7.10 (m, 1H), 7.05 – 6.96 (m, 1H), 6.92 – 6.83 (m, 2H), 3.62 (s, 3H). LCMS: rt 4.26min (A), purity 99 %, MS (m/e) 303 MH⁺.

[1031] 6-(2-(3-(Trifluoromethoxy)phenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 780). LCMS: rt 6.23 min (A), purity 99 %, MS (m/e) 357 MH⁺.

[1032] 6-(2-Phenylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 781). LCMS: rt 3.93 min (A), purity 99 %, MS (m/e) 273 MH⁺.

[1033] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-1H-benzo[d]imidazole (Compound 782). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.66 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.36 (s, 1H), 7.88 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.60 – 7.45 (m, 4H), 7.27 – 7.10 (m, 2H), 7.01 (dd, *J* = 8.4, 1.7 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.47 – -117.92 (m). LCMS: rt 4.35 min (A), purity 99 %, MS (m/e) 324 MH⁺.

[1034] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-1H-benzo[d]imidazole (Compound 783). LCMS: rt 4.00 min (A), purity 99 %, MS (m/e) 306 MH⁺.

[1035] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 784). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.68 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.16 (s, 1H), 7.97 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.74 (dd, *J* = 8.4, 7.3 Hz, 1H), 7.58 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.53 – 7.45 (m, 2H), 7.29 (t, *J* = 9.6 Hz, 1H), 6.92 (dd, *J* = 8.3, 1.7 Hz, 1H), 3.76 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -111.26 (q, *J* = 8.5 Hz), -112.11 (q, *J* = 8.9 Hz). LCMS: rt 5.05 min (A), purity 99 %, MS (m/e) 356 MH⁺.

[1036] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 785). LCMS: rt 4.78 min (A), purity 99 %, MS (m/e) 338 MH⁺.

[1037] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-3-amine (Compound 786). ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.33 (s, 1H), 8.63 (dd, *J* = 4.7, 1.7 Hz, 1H), 7.82 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.56 (dd, *J* = 8.3, 0.8 Hz, 1H), 7.43 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.38 (ddd, *J* = 7.5, 2.2, 1.2 Hz, 1H), 7.05 (dd, *J* = 1.4, 0.8 Hz, 1H), 7.02 – 6.93 (m, 1H), 6.90 (dd, *J* = 9.7, 8.5 Hz, 1H), 6.63 (dd, *J* = 8.3, 1.4 Hz, 1H), 5.27 (s, 2H), 2.13 (s, 3H). LCMS: rt 4.13 min (A), purity 99 %, MS (m/e) 319 MH⁺.

- [1038] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-methyl-1H-indazol-3-amine (Compound 787). LCMS: rt 4.63 min (A), purity 99 %, MS (m/e) 333 MH⁺.
- [1039] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-indazol-3-amine (Compound 788). LCMS: rt 4.05 min (A), purity 99 %, MS (m/e) 319 MH⁺.
- [1040] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-methyl-1H-indazol-3-amine (Compound 789). LCMS: rt 4.73 min (A), purity 99 %, MS (m/e) 333 MH⁺.
- [1041] (*S*)-6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(quinuclidin-3-yl)imidazo[1,2-*a*]pyridine-3-carboxamide (Compound 790). LCMS: rt 3.81 min (A), purity 99 %, MS (m/e) 456 MH⁺.
- [1042] (*R*)-6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(quinuclidin-3-yl)imidazo[1,2-*a*]pyridine-3-carboxamide (Compound 791). LCMS: rt 3.81 min (A), purity 99 %, MS (m/e) 456 MH⁺.
- [1043] (*S*)-5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(quinuclidin-3-yl)pyrazolo[1,5-*a*]pyridine-3-carboxamide (Compound 792). LCMS: rt 4.23 min (A), purity 99 %, MS (m/e) 456 MH⁺.
- [1044] (*R*)-5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(quinuclidin-3-yl)pyrazolo[1,5-*a*]pyridine-3-carboxamide (Compound 793). LCMS: rt 4.23 min (A), purity 99 %, MS (m/e) 456 MH⁺.
- [1045] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)benzo[d]isoxazol-3-amine (Compound 794). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.67 (dd, *J* = 4.7, 1.7 Hz, 1H), 7.87 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.68 (d, *J* = 8.1 Hz, 1H), 7.47 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.40 – 7.25 (m, 2H), 7.02 – 6.82 (m, 3H), 6.35 (s, 2H), 2.13 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.64 (app s). LCMS: rt 5.11 min (A), purity 99 %, MS (m/e) 320 MH⁺.
- [1046] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)benzo[d]isoxazol-3-amine (Compound 795). LCMS: rt 5.11 min (A), purity 99 %, MS (m/e) 320 MH⁺.
- [1047] 5-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)benzo[d]isoxazol-3-amine (Compound 796). LCMS: rt 5.98 min (A), purity 99 %, MS (m/e) 340 MH⁺.
- [1048] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)benzo[d]isoxazol-3-amine (Compound 797). LCMS: rt 6.15 min (A), purity 99 %, MS (m/e) 340 MH⁺.
- [1049] 6-(2-(3-Chlorophenyl)pyridin-3-yl)benzo[d]isoxazol-3-amine (Compound 798). LCMS: rt 5.76 min (A), purity 99 %, MS (m/e) 321 MH⁺.

- [1050] 5-(2-(3-Chlorophenyl)pyridin-3-yl)benzo[d]isoxazol-3-amine (Compound 799). LCMS: rt 5.53 min (A), purity 99 %, MS (m/e) 322 MH⁺.
- [1051] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-1H-indazol-3-amine (Compound 800). LCMS: rt 4.85 min (A), purity 99 %, MS (m/e) 339 MH⁺.
- [1052] 5-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-1H-indazol-3-amine (Compound 801). LCMS: rt 4.63 min (A), purity 99 %, MS (m/e) 339 MH⁺.
- [1053] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-((tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 802). LCMS: rt 4.08 min (A), purity 99 %, MS (m/e) 470 MH⁺.
- [1054] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 803). LCMS: rt 3.98 min (A), purity 99 %, MS (m/e) 484 MH⁺.
- [1055] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-((tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 804). LCMS: rt 4.53 min (A), purity 99 %, MS (m/e) 470 MH⁺.
- [1056] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(tetrahydro-1H-pyrrolizin-7a(5H)-yl)ethyl)pyrazolo[1,5-a]pyridine-3-carboxamide (Compound 805). LCMS: rt 4.38 min (A), purity 99 %, MS (m/e) 484 MH⁺.
- [1057] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine (Compound 806). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.73 (app dd, *J* = 4.8, 1.9 Hz, 2H), 8.53 (app d, *J* = 2.7 Hz, 2H), 8.15 (s, 2H), 7.99 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.56 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.39 (ddt, *J* = 7.7, 2.1, 1.0 Hz, 1H), 6.99 – 6.93 (m, 2H), 2.16 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.12 (dd, *J* = 9.1, 6.4 Hz). LCMS: rt 3.76 min (A), purity 99 %, MS (m/e) 332 MH⁺.
- [1058] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine (Compound 807). LCMS: rt 4.41 min (A), purity 99 %, MS (m/e) 352 MH⁺.
- [1059] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-7-methylimidazo[1,2-a]pyridine (Compound 808). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.87 (s, 1H), 8.80 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.21 (dd, *J* = 2.1, 0.7 Hz, 1H), 8.14 (d, *J* = 2.1 Hz, 1H), 7.86 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.77 (q, *J* = 1.0 Hz, 1H), 7.56 (dd, *J* = 7.7, 4.8 Hz, 1H), 7.45 (ddd, *J* = 7.6, 2.4, 1.0 Hz, 1H), 7.06 (ddd, *J* = 7.8, 5.0, 2.3 Hz, 1H), 6.94 (dd, *J* = 9.6, 8.5 Hz, 1H), 2.14 (s, 3H), 1.96 (app s, 3H). ¹⁹F NMR

(282 MHz, DMSO-*d*₆): δ -117.60 (app s). LCMS: rt 4.23 min (A), purity 99 %, MS (m/e) 318 MH⁺.

[1060] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compound 809). LCMS: rt 5.08 min (A), purity 99 %, MS (m/e) 319 MH⁺.

[1061] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compound 810). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.78 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.53 (s, 1H), 7.99 – 7.92 (m, 1H), 7.72 (dd, *J* = 9.2, 0.8 Hz, 1H), 7.64 – 7.55 (m, 2H), 7.45 (d, *J* = 9.1 Hz, 1H), 7.24 (t, *J* = 8.9 Hz, 1H), 7.16 (ddd, *J* = 8.6, 4.9, 2.1 Hz, 1H), 2.41 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.72 (app td, *J* = 8.3, 5.1 Hz). LCMS: rt 6.15 min (A), purity 99 %, MS (m/e) 339 MH⁺.

[1062] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compound 811). LCMS: rt 5.71 min (A), purity 99 %, MS (m/e) 321 MH⁺.

[1063] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compound 812). LCMS: rt 6.35 min (A), purity 99 %, MS (m/e) 339 MH⁺.

[1064] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compound 813). LCMS: rt 6.65 min (A), purity 99 %, MS (m/e) 357 MH⁺.

[1065] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compound 814). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.92 (s, 1H), 8.79 (ddd, *J* = 4.9, 1.7, 0.8 Hz, 1H), 8.47 (d, *J* = 0.9 Hz, 1H), 7.97 (ddd, *J* = 7.7, 1.7, 0.9 Hz, 1H), 7.67 (q, *J* = 1.0 Hz, 1H), 7.60 (ddd, *J* = 7.7, 4.9, 0.9 Hz, 1H), 7.43 (ddd, *J* = 7.6, 2.3, 1.0 Hz, 1H), 7.09 (ddd, *J* = 8.5, 5.1, 2.3 Hz, 1H), 6.97 (dd, *J* = 9.7, 8.6 Hz, 1H), 2.12 (s, 3H), 1.92 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.35 (app s). LCMS: rt 5.08 min (A), purity 99 %, MS (m/e) 319 MH⁺.

[1066] N-(2-Acetamidoethyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 815). LCMS: rt 3.93 min (A), purity 99 %, MS (m/e) 432 MH⁺.

[1067] N-(3-Acetamidopropyl)-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 816). LCMS: rt 4.03 min (A), purity 99 %, MS (m/e) 446 MH⁺.

[1068] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(2-(2-oxooxazolidin-3-yl)ethyl)imidazo[1,2-a]pyridine-3-carboxamide (Compound 817). LCMS: rt 4.16 min (A), purity 99 %, MS (m/e) 460 MH⁺.

[1069] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 818). ^1H NMR (300 MHz, DMSO- d_6): δ 8.73 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.34 (s, 1H), 8.25 – 8.18 (m, 1H), 8.00 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.83 – 7.66 (br s, 2H), 7.66 – 7.56 (m, 2H), 7.48 (d, $J = 8.6$ Hz, 1H), 7.45 – 7.35 (m, 2H), 7.02 (dd, $J = 9.6, 8.8$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -117.11 – -117.25 (app m). LCMS: rt 4.55 min (A), purity 99 %, MS (m/e) 351 MH^+ .

[1070] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)quinazolin-4-amine (Compound 819). ^1H NMR (300 MHz, DMSO- d_6): δ 8.73 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.36 (s, 1H), 8.21 (d, $J = 1.9$ Hz, 1H), 8.01 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.80 (dd, $J = 8.5, 7.3$ Hz, 1H), 7.75 (br s, 2H), 7.63 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.52 (d, $J = 8.6$ Hz, 1H), 7.43 (dd, $J = 8.6, 1.9$ Hz, 1H), 7.31 (t, $J = 9.7$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -111.32 (q, $J = 8.8$ Hz), -111.57 (q, $J = 8.9$ Hz). LCMS: rt 4.80 min (A), purity 99 %, MS (m/e) 369 MH^+ .

[1071] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-4-methoxyquinazoline (Compound 820). ^1H NMR (300 MHz, DMSO- d_6): δ 8.78 (s, 1H), 8.75 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.05 (dd, $J = 8.6, 1.6$ Hz, 1H), 8.00 (dd, $J = 2.1, 0.6$ Hz, 1H), 7.79 (dd, $J = 8.6, 0.6$ Hz, 1H), 7.70 – 7.58 (m, 3H), 7.42 (ddd, $J = 8.8, 4.4, 2.8$ Hz, 1H), 7.03 (dd, $J = 9.6, 8.9$ Hz, 1H), 4.09 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -117.61 (ddd, $J = 10.1, 6.3, 4.4$ Hz). LCMS: rt 6.91 min (A), purity 99 %, MS (m/e) 366 MH^+ .

[1072] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-4-methoxyquinazoline (Compound 821). ^1H NMR (300 MHz, DMSO- d_6): δ 8.79 (s, 1H), 8.75 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.06 (dd, $J = 7.8, 1.6$ Hz, 1H), 8.01 (dd, $J = 2.1, 0.6$ Hz, 1H), 7.86 (d, $J = 7.4$ Hz, 1H), 7.81 (d, $J = 8.8$ Hz, 1H), 7.70 – 7.57 (m, 2H), 7.32 (t, $J = 9.7$ Hz, 1H), 4.10 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -111.35 (q, $J = 8.9$ Hz), -111.82 (q, $J = 8.7$ Hz). LCMS: rt 7.26 min (A), purity 99 %, MS (m/e) 384 MH^+ .

[1073] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)quinazolin-4(3H)-one (Compound 822). ^1H NMR (300 MHz, DMSO- d_6): δ 12.25 (br, 1H), 8.73 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.08 (s, 1H), 8.00 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.92 (dd, $J = 1.7, 1.0$ Hz, 1H), 7.67 – 7.53 (m, 4H), 7.42 (ddd, $J = 8.9, 4.4, 2.8$ Hz, 1H), 7.06 (dd, $J = 9.6, 8.8$ Hz, 1H). LCMS: rt 5.53 min (A), purity 99 %, MS (m/e) 352 MH^+ .

[1074] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)quinazolin-4(3H)-one (Compound 823). ^1H NMR (300 MHz, DMSO- d_6): δ 12.28 (s, 1H), 8.73 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.08 (s, 1H), 8.01 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.93 (t, $J = 1.4$ Hz, 1H), 7.83 (dd, $J = 8.5, 7.3$ Hz, 1H), 7.63

– 7.59 (m, 1H), 7.58 (d, $J = 1.4$ Hz, 2H), 7.36 (t, $J = 9.6$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -111.43 (q, $J = 9.0$ Hz), -111.78 (q, $J = 8.7$ Hz). LCMS: rt 5.83 min (A), purity 99 %, MS (m/e) 370 MH^+ .

[1075] 2-(2,3-Dihydro-1H-inden-5-yl)-3,4'-bipyridine (Compound 824). LCMS: rt 4.23 min (A), purity 99 %, MS (m/e) 273 MH^+ .

[1076] 6-(2-(2,3-Dihydro-1H-inden-5-yl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 825). ^1H NMR (300 MHz, DMSO- d_6): δ 9.00 (dd, $J = 1.8, 0.9$ Hz, 1H), 8.70 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.50 (s, 1H), 7.97 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.68 (dd, $J = 9.2, 0.9$ Hz, 1H), 7.48 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.35 (d, $J = 1.5$ Hz, 1H), 7.24 (dd, $J = 9.2, 1.8$ Hz, 1H), 7.05 (d, $J = 7.9$ Hz, 1H), 6.99 (dd, $J = 7.7, 1.6$ Hz, 1H), 2.78 (q, $J = 8.1$ Hz, 4H), 1.96 (p, $J = 7.5$ Hz, 2H). LCMS: rt 4.84 min (A), purity 99 %, MS (m/e) 313 MH^+ .

[1077] 6-(2-(2,3-Dihydro-1H-inden-5-yl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (Compound 826). LCMS: rt 5.46 min (A), purity 99 %, MS (m/e) 337 MH^+ .

[1078] 6-(2-(2,3-Dihydro-1H-inden-5-yl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 827). LCMS: rt 3.81 min (A), purity 99 %, MS (m/e) 312 MH^+ .

[1079] 3-(Benzo[d][1,3]dioxol-5-yl)-2-(2,3-dihydro-1H-inden-5-yl)pyridine (Compound 828). LCMS: rt 6.06 min (A), purity 99 %, MS (m/e) 316 MH^+ .

[1080] 4-(2-(2,3-Dihydro-1H-inden-5-yl)pyridin-3-yl)quinolone (Compound 829). LCMS: rt 5.78 min (A), purity 99 %, MS (m/e) 323 MH^+ .

[1081] 6-(2-(2,3-Dihydro-1H-inden-5-yl)pyridin-3-yl)benzo[d]thiazole (Compound 830). LCMS: rt 5.68 min (A), purity 99 %, MS (m/e) 329 MH^+ .

[1082] 6-(2-(2,3-Dihydro-1H-inden-5-yl)pyridin-3-yl)quinoxaline (Compound 831). LCMS: rt 5.39 min (A), purity 99 %, MS (m/e) 324 MH^+ .

[1083] 5-([3,4'-Bipyridin]-2-yl)-2,3-dihydro-1H-inden-1-one (Compound 832). ^1H NMR (300 MHz, DMSO- d_6): δ 8.76 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.53 – 8.45 (m, 2H), 7.94 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.63 – 7.52 (m, 2H), 7.48 (dd, $J = 8.0, 0.8$ Hz, 1H), 7.24 – 7.16 (m, 3H), 3.09 – 2.92 (m, 2H), 2.62 (d, $J = 11.8$ Hz, 2H). LCMS: rt 3.61 min (A), purity 99 %, MS (m/e) 287 MH^+ .

[1084] 2-(3-Methyl-1H-inden-6-yl)-3,4'-bipyridine (Compound 833). MeMgBr [2 mL, 1.4 M solution in toluene/THF (75:25)] was added to a stirring solution of 5-([3,4'-bipyridin]-2-yl)-2,3-dihydro-1H-inden-1-one (175 mg) in THF (4 mL) at -78 °C under argon. The reaction was stirred for 30 min and warmed to room temperature after complete addition of MeMgBr and.

After 1h, the complete consumption of 5-([3,4'-bipyridin]-2-yl)-2,3-dihydro-1H-inden-1-one to 5-([3,4'-bipyridin]-2-yl)-1-methyl-2,3-dihydro-1H-inden-1-ol was observed. Subsequently, the reaction was cooled in ice-bath, quenched with conc. HCl (5 mL) over a period of 30 min. The cooling was removed and allowed the reaction to warm to temperature. After 4h, the reaction mixture was concentrated, diluted with EtOAc (50 mL) and aq. NaHCO₃ solution (15 mL). Aqueous layer was discarded, washed the organic layer with brine, dried over MgSO₄, filtered, concentrated and purified by flash column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 12 g, 30-50-70% EtOAc/hexanes as an eluting solvent) to obtain 2-(3-Methyl-1H-inden-6-yl)-3,4'-bipyridine as an oil. LCMS: rt 4.47 min (A), purity 95 %, MS (m/e) 285(MH⁺).

[1085] *rac*-5-([3,4'-Bipyridin]-2-yl)-2,3-dihydro-1H-inden-1-ol (Compound 834). Sodium borohydride (21 mg) was added to a stirring solution of 5-([3,4'-bipyridin]-2-yl)-2,3-dihydro-1H-inden-1-one (162 mg) in MeOH (4 mL). The reaction mixture was concentrated and quenched with aq. NH₄Cl. The resultant solid was extracted into CH₂Cl₂ (2x20 mL). Combined organic layers were stirred over MgSO₄, filtered and concentrated. Flash chromatographic purification (Combiflash[®] companion system[®] with RediSep[®] silica gel column 12 g, 50-75% EtOAc/hexanes as eluting solvent) provided *rac*-5-([3,4'-bipyridin]-2-yl)-2,3-dihydro-1H-inden-1-ol (170mg) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.69 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.48 (d, *J* = 6.0 Hz, 2H), 7.85 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.48 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.25 – 7.11 (m, 4H), 7.00 (dd, *J* = 7.8, 1.5 Hz, 1H), 5.29 – 5.20 (m, 1H), 5.00 (q, *J* = 6.4 Hz, 1H), 2.81 (ddd, *J* = 16.0, 8.7, 3.9 Hz, 1H), 2.61 (dt, *J* = 15.9, 8.0 Hz, 1H), 2.36 – 2.21 (m, 1H), 1.74 (dtd, *J* = 12.8, 8.2, 6.3 Hz, 1H). LCMS: rt 2.81 min (A), purity 99 %, MS (m/e) 289 (MH⁺).

[1086] (E/Z)-5-([3,4'-bipyridin]-2-yl)-2,3-dihydro-1H-inden-1-one oxime (Compound 835). 5-([3,4'-Bipyridin]-2-yl)-2,3-dihydro-1H-inden-1-one (162 mg), NH₂OH. HCl (55 mg) and NaOAc (84 mg) were stirred and heated at 80 °C for 4h in EtOH(3 mL). The reaction mixture was diluted with water and filtered the solid The solid was washed with water and dried to obtain 130 mg of (E/Z)-5-([3,4'-bipyridin]-2-yl)-2,3-dihydro-1H-inden-1-one oxime as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.93 (s, 1H), 8.71 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.50 – 8.45 (m, 2H), 7.88 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.51 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.41 – 7.33 (m, 2H), 7.23 – 7.16 (m, 2H), 7.05 (dd, *J* = 7.9, 1.6 Hz, 1H), 2.97 – 2.83 (m, 2H), 2.76 (ddd, *J* = 9.7, 5.3, 2.1 Hz, 2H). LCMS: rt 3.56 min (A), purity 99 %, MS (m/e) 302 MH⁺.

[1087] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinolin-4-amine (Compound 836).

LCMS: rt 3.98 min (A), purity 99 %, MS (m/e) 330 MH⁺.

[1088] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinolin-4-amine (Compound 837). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.72 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.36 – 8.28 (m, 2H), 7.96 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.73 (d, *J* = 9.9 Hz, 2H), 7.66 (d, *J* = 8.7 Hz, 1H), 7.61 – 7.54 (m, 2H), 7.38 (dt, *J* = 8.8, 1.6 Hz, 1H), 7.23 (dd, *J* = 9.3, 8.6 Hz, 1H), 7.13 (ddd, *J* = 8.6, 4.8, 2.2 Hz, 1H), 6.64 (dd, *J* = 6.0, 1.3 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.19 (td, *J* = 8.3, 4.9 Hz). LCMS: rt 4.70 min (A), purity 99 %, MS (m/e) 350 MH⁺.

[1089] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-methoxyquinoline (Compound 838).

¹H NMR (300 MHz, DMSO-*d*₆): δ 8.72 (d, *J* = 5.2 Hz, 1H), 8.68 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.07 (dd, *J* = 2.1, 0.6 Hz, 1H), 7.92 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.77 (dd, *J* = 8.7, 0.6 Hz, 1H), 7.48 (dd, *J* = 7.7, 4.7 Hz, 1H), 7.41 – 7.36 (m, 1H), 7.33 (dd, *J* = 8.7, 2.1 Hz, 1H), 7.03 (d, *J* = 5.3 Hz, 1H), 6.98 – 6.84 (m, 2H), 4.01 (s, 3H), 2.12 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.46 – -118.69 (m). LCMS: rt 4.30 min (A), purity 99 %, MS (m/e) 345 MH⁺.

[1090] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-4-methoxyquinoline (Compound 839).

LCMS: rt 5.08 min (A), purity 99 %, MS (m/e) 365 MH⁺.

[1091] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-4-methoxyquinoline (Compound 840).

LCMS: rt 5.28 min (A), purity 99 %, MS (m/e) 365 MH⁺.

[1092] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-4-methoxyquinoline (Compound 841). LCMS: rt 4.76 min (A), purity 99 %, MS (m/e) 347 MH⁺.

[1093] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-4-methoxyquinoline (Compound 842). LCMS: rt 5.52 min (A), purity 99 %, MS (m/e) 383 MH⁺.

[1094] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine-3-carboxamide (Compound 843). Conc. H₂SO₄ was added dropwise to stirring TFA at room temperature for 5 min. 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-*a*]pyridine-3-carbonitrile (870 mg) was added all at once to the homogenous solution after fuming subsided from acid mixture. Additional TFA and conc. H₂SO₄ were added successively to the heterogeneous reaction mixture. After 6h, the reaction mixture was added to ice/water and stirred. The homogeneous solution was basified with aq. NaOH (50%). The resultant heterogeneous slurry was filtered and dried. Subsequently, the white solid was purified by flash chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 24 g, 70% EtOAc/hexanes-3%

MeOH/EtOH) to obtain 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (720 mg). ^1H NMR (300 MHz, DMSO- d_6): δ 9.48 (s, 1H), 8.72 (dd, J = 4.8, 1.6 Hz, 1H), 8.33 (s, 1H), 7.97 (dd, J = 7.8, 1.7 Hz, 2H), 7.64 (d, J = 6.8 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.55 (dd, J = 7.9, 4.9 Hz, 1H), 7.52-7.48 (br s, 2H), 7.26 (dd, J = 7.7, 1.5 Hz, 1H), 7.10 (dd, J = 9.4, 1.9 Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -117.01 (q, J = 7.5, 7.1 Hz). LCMS: rt 4.65 min (A), purity 99 %, MS (m/e) 367 MH^+ .

[1095] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-3-(1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (Compound 844). 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide (290 mg) and DMF. DMA (5 mL) were heated at 95 °C and stirred in a screw capped vial overnight. The pale yellow homogeneous reaction mixture was cooled to room temperature and concentrated the heterogeneous slurry by rotary evaporator under vacuum. The off- white solid residue was transferred to a screw capped vial, treated with AcOH (3 mL) dropwise for 3 min followed by N_2H_4 . H_2O (0.05 mL) and heated for 1h at 90 °C. The homogeneous reaction mixture was concentrated, diluted with ice/water and allowed the resulting suspension warm to room temperature. Upon filtration, the collected solid was neutralized with aq. NaHCO_3 and filtered again to obtain 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)-3-(1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine as an off-white solid (220 mg). ^1H NMR (300 MHz, DMSO- d_6): δ 14.03 (br s, 1H), 9.46 (dd, J = 1.9, 1.0 Hz, 1H), 8.79 – 8.70 (m, 1H), 8.70 – 8.52 (m, 1H), 8.18 (s, 1H), 8.02 (dd, J = 7.8, 1.6 Hz, 1H), 7.67 (dd, J = 6.2, 1.4 Hz, 1H), 7.61 (dd, J = 9.3, 1.0 Hz, 1H), 7.56 (dd, J = 7.8, 4.7 Hz, 1H), 7.28 (d, J = 0.7 Hz, 1H), 7.27 – 7.20 (m, 1H), 7.04 (dd, J = 9.3, 1.8 Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -114.49 – -119.56 (m). LCMS: rt 4.70 min (A), purity 99 %, MS (m/e) 391 MH^+ .

[1096] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-3-(1H-imidazol-2-yl)imidazo[1,2-a]pyridine (Compound 845). Aminoacetaldehyde (0.2 mL, 0.193 g, 1.72mmol) was added to dry THF(8 mL) under argon and cooled the homogenous solution to -78 °C and stirred for 5 min. *n*-BuLi (1.2 mL, 1.6 M solution in hexanes, 1.97 mmol) was added dropwise for 10 min and stirred for 30 min. 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (0.3 g, 0.86 mmol) dissolved in dry THF (5 mL) was added to the above faint yellow homogeneous solution. The red solution was cooled and stirred at 0 °C for 2h. Subsequently, dark reaction mixture was concentrated under vacuum by rotary evaporator, treated with 6N aq. HCl (15 mL), stirred and heated at 90 °C for 2h. The reaction mixture was concentrated,

neutralized with aq. NaOH and extracted into CH₂Cl₂. Workup and purification by preparative HPLC provided (6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile (120 mg). ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.70 (s, 1H), 9.73 (s, 1H), 8.73 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.14 (s, 1H), 8.00 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.67 (d, *J* = 6.4 Hz, 1H), 7.62 – 7.50 (m, 3H), 7.34 – 7.18 (m, 3H), 7.02 (dd, *J* = 9.3, 1.9 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.11 (q, *J* = 7.3 Hz). LCMS: rt 4.81 min (A), purity 99 %, MS (m/e) 390 MH⁺.

[1097] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinoline-4-carboxamide (Compound 846). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.99 (d, *J* = 4.4 Hz, 1H), 8.76 (dd, *J* = 5.0, 1.6 Hz, 1H), 8.24 (t, *J* = 2.2 Hz, 2H), 8.09 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.95 (d, *J* = 8.7 Hz, 1H), 7.90 (s, 2H), 7.71 – 7.58 (m, 2H), 7.44 (ddd, *J* = 11.6, 8.1, 2.0 Hz, 2H), 7.06 – 6.87 (m, 1H), 2.14 (d, *J* = 1.9 Hz, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.44 (s). LCMS: rt 4.11 min (A), purity 99 %, MS (m/e) 358 MH⁺.

[1098] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinoline-4-carboxamide (Compound 847). LCMS: rt 4.76 min (A), purity 99 %, MS (m/e) 378 MH⁺.

[1099] 6-(2-(3-Chlorophenyl)pyridin-3-yl)quinoline-4-carboxamide (Compound 848). LCMS: rt 4.36 min (A), purity 99 %, MS (m/e) 360 MH⁺.

[1100] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)quinoline-4-carboxamide (Compound 849). LCMS: rt 4.86 min (A), purity 99 %, MS (m/e) 378 MH⁺.

[1101] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)quinoline-4-carboxamide (Compound 850). LCMS: rt 5.20 min (A), purity 99 %, MS (m/e) 396 MH⁺.

[1102] 7-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine (Compound 851). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.20 (t, *J* = 0.8 Hz, 1H), 8.76 (ddd, *J* = 4.8, 1.6, 0.6 Hz, 1H), 8.47 (dt, *J* = 7.2, 0.9 Hz, 1H), 8.05 (ddd, *J* = 7.9, 1.7, 0.6 Hz, 1H), 7.70 – 7.59 (m, 3H), 7.46 (dddd, *J* = 8.9, 4.3, 2.8, 0.6 Hz, 1H), 7.11 (ddd, *J* = 9.5, 8.8, 0.6 Hz, 1H), 6.76 (ddd, *J* = 7.1, 1.6, 0.6 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -115.57 – -119.56 (m). LCMS: rt 5.00 min (A), purity 99 %, MS (m/e) 325 MH⁺.

[1103] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-3-(1H-pyrazol-3-yl)imidazo[1,2-a]pyridine (Compound 852). 1-(6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-one (300 mg) and DMF. DMA (5 mL) were heated at 95 °C and stirred in a screw capped vial overnight. The reaction mixture was concentrated and the semi-solid residue was diluted with Et₂O/hexanes (1:1). The solid was filtered and dried. The enamine (75 mg) and

the hydrazine (1.2 eq) were heated in a screw capped vial at 100 °C for 12 h. The reaction mixture was concentrated and purified by preparative HPLC. ¹H NMR (300 MHz, DMSO-*d*₆): δ 13.02 (br s), 9.71 (dd, *J* = 1.8, 1.0 Hz, 1H), 8.79 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.62 (s, 1H), 8.06 (dd, *J* = 7.8, 1.7 Hz, 1H), 8.01 (d, *J* = 2.4 Hz, 1H), 7.89 (dd, *J* = 9.3, 0.9 Hz, 1H), 7.74 (dd, *J* = 7.3, 2.1 Hz, 1H), 7.62 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.50 (dd, *J* = 9.3, 1.7 Hz, 1H), 7.37 – 7.14 (m, 2H), 6.95 (d, *J* = 2.4 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.76 (q, *J* = 7.3 Hz). LCMS: rt 4.98 min (A), purity 99 %, MS (m/e) 390 MH⁺.

[1104] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-3-(1-methyl-1H-pyrazol-3-yl)imidazo[1,2-*a*]pyridine (Compound 853). 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-3-(1-methyl-1H-pyrazol-3-yl)imidazo[1,2-*a*]pyridine was prepared by the reaction of MeNHNH₂ and enamine, analogous to the preparation of 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-3-(1H-pyrazol-3-yl)imidazo[1,2-*a*]pyridine. ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.74 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.43 (dd, *J* = 1.7, 0.9 Hz, 1H), 8.42 (s, 1H), 8.04 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.89 (dd, *J* = 9.4, 0.8 Hz, 1H), 7.73 (dt, *J* = 8.1, 1.1 Hz, 1H), 7.67 (d, *J* = 2.0 Hz, 1H), 7.56 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.51 (dd, *J* = 9.3, 1.6 Hz, 1H), 7.31 – 7.21 (m, 2H), 6.74 (d, *J* = 2.0 Hz, 1H), 3.82 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.76 (q, *J* = 7.3 Hz). LCMS: rt 5.09 min (A), purity 99 %, MS (m/e) 404 MH⁺.

[1105] 7-(2-(4-Fluoro-3-methylphenyl)-5-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridine (Compound 854). LCMS: rt 5.78 min (A), purity 99 %, MS (m/e) 335 MH⁺.

[1106] 7-(2-(3-Chlorophenyl)-5-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridine (Compound 855). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.85 (dd, *J* = 7.1, 0.9 Hz, 1H), 8.52 (s, 1H), 8.47 (d, *J* = 2.8 Hz, 1H), 7.94 – 7.89 (m, 1H), 7.62 (d, *J* = 2.8 Hz, 1H), 7.45 (t, *J* = 1.9 Hz, 1H), 7.32 (ddd, *J* = 8.0, 2.2, 1.2 Hz, 1H), 7.22 (t, *J* = 7.8 Hz, 1H), 7.12 (dt, *J* = 7.7, 1.4 Hz, 1H), 6.85 (dd, *J* = 7.1, 1.9 Hz, 1H), 3.94 (s, 3H). LCMS: rt 6.40 min (A), purity 99 %, MS (m/e) 337 MH⁺.

[1107] 7-(2-(3-Chloro-4-fluorophenyl)-5-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridine (Compound 856). LCMS: rt 6.75 min (A), purity 99 %, MS (m/e) 355 MH⁺.

[1108] 7-(2-(5-Chloro-2,4-difluorophenyl)-5-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridine (Compound 857). LCMS: rt 6.71 min (A), purity 99 %, MS (m/e) 373 MH⁺.

[1109] 7-(2-(5-Chloro-2-fluorophenyl)-5-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridine (Compound 858). LCMS: rt 6.71 min (A), purity 99 %, MS (m/e) 355 MH⁺.

[1110] 7-(2-(3-(Difluoro-13-methyl)-12-fluoranyl)phenyl)-5-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 859). LCMS: rt 7.05 min (A), purity 99 %, MS (m/e) 372 MH⁺.

[1111] 7-(2-(3-Chloro-4-fluorophenyl)-5-fluoropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 860). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.87 (dd, *J* = 7.0, 0.9 Hz, 1H), 8.77 (d, *J* = 2.8 Hz, 1H), 8.53 (s, 1H), 8.07 (dd, *J* = 9.3, 2.8 Hz, 1H), 7.93 (dd, *J* = 1.9, 0.9 Hz, 1H), 7.64 (dd, *J* = 7.3, 2.2 Hz, 1H), 7.28 (dd, *J* = 9.3, 8.6 Hz, 1H), 7.19 (ddd, *J* = 8.6, 4.9, 2.2 Hz, 1H), 6.88 (dd, *J* = 7.1, 1.9 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.71 (ddd, *J* = 9.4, 7.3, 4.8 Hz), -129.02 (d, *J* = 9.2 Hz). LCMS: rt 7.28 min (A), purity 99 %, MS (m/e) 343 MH⁺.

[1112] 7-(2-(5-Chloro-2,4-difluorophenyl)-5-fluoropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 861). LCMS: rt 7.30 min (A), purity 99 %, MS (m/e) 361 MH⁺.

[1113] 7-(2-(5-Chloro-2-fluorophenyl)-5-fluoropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 862). LCMS: rt 7.08 min (A), purity 99 %, MS (m/e) 343 MH⁺.

[1114] 7-(2-(3-((Difluoro-13-methyl)-12-fluoranyl)phenyl)-5-fluoropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 863). LCMS: rt 7.55 min (A), purity 99 %, MS (m/e) 370 MH⁺.

[1115] 7-(2-(3-Chloro-4-fluorophenyl)-5-methylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 864). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.85 (dd, *J* = 7.0, 0.9 Hz, 1H), 8.60 (d, *J* = 1.8 Hz, 1H), 8.52 (s, 1H), 7.90 (s, 1H), 7.86 (s, 1H), 7.65 (dd, *J* = 7.3, 2.1 Hz, 1H), 7.27 (t, *J* = 8.9 Hz, 1H), 7.19 (ddd, *J* = 8.5, 4.9, 2.2 Hz, 1H), 6.85 (dd, *J* = 7.1, 1.8 Hz, 1H), 2.42 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.87 (dd, *J* = 7.6, 3.3 Hz). LCMS: rt 5.86 min (A), purity 99 %, MS (m/e) 339 MH⁺.

[1116] 7-(2-(5-Chloro-2,4-difluorophenyl)-5-methylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 865). LCMS: rt 6.65 min (A), purity 99 %, MS (m/e) 357 MH⁺.

[1117] 7-(2-(5-Chloro-2-fluorophenyl)-5-methylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 866). LCMS: rt 6.25 min (A), purity 99 %, MS (m/e) 339 MH⁺.

[1118] 7-(2-(3-((Difluoro-13-methyl)-12-fluoranyl)phenyl)-5-methylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 867). LCMS: rt 6.26 min (A), purity 99 %, MS (m/e) 356 MH⁺.

[1119] 7-(2-(3-Chlorophenyl)-5-methylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 868). LCMS: rt 5.30 min (A), purity 99 %, MS (m/e) 321 MH⁺.

[1120] 6-(2-(2,5-Dichlorophenyl)pyridin-3-yl)benzo[d]thiazole (Compound 869). ^1H NMR (300 MHz, DMSO- d_6): δ 9.37 (s, 1H), 8.70 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.05 (dd, $J = 1.8, 0.6$ Hz, 1H), 7.99 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.94 (dd, $J = 8.4, 0.6$ Hz, 1H), 7.60 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.54 (dd, $J = 2.5, 0.6$ Hz, 1H), 7.39 (dd, $J = 8.6, 2.4$ Hz, 1H), 7.34 (dd, $J = 8.6, 0.6$ Hz, 1H), 7.26 (dd, $J = 8.5, 1.8$ Hz, 1H). LCMS: rt 7.38 min (A), purity 99 %, MS (m/e) 356 MH^+ .

[1121] 6-(2-(2,5-Dichlorophenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 870). ^1H NMR (300 MHz, DMSO- d_6): δ 8.67 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.33 (s, 1H), 7.98 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.59 (dd, $J = 7.9, 4.7$ Hz, 1H), 7.54 – 7.48 (m, 3H), 7.41 – 7.30 (m, 2H), 6.99 (dd, $J = 8.4, 1.7$ Hz, 1H), 3.75 (s, 3H). LCMS: rt 4.81 min (A), purity 99 %, MS (m/e) 354 MH^+ .

[1122] 6-(2-(2,5-Dichlorophenyl)pyridin-3-yl)-1H-benzo[d]imidazole (Compound 871). LCMS: rt 4.61 min (A), purity 99 %, MS (m/e) 340 MH^+ .

[1123] 6-(2-(2,5-Dichlorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 872). LCMS: rt 4.70 min (A), purity 99 %, MS (m/e) 340 MH^+ .

[1124] 7-(2-(2,5-Dichlorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 873). LCMS: rt 6.21 min (A), purity 99 %, MS (m/e) 341 MH^+ .

[1125] 7-(2-(2,4,5-Trifluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 874). LCMS: rt 5.88 min (A), purity 99 %, MS (m/e) 327 MH^+ .

[1126] 7-(2-(3,4,5-Trifluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 875). LCMS: rt 6.15 min (A), purity 99 %, MS (m/e) 327 MH^+ .

[1127] 7-(2-(2-Chloro-5-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 876). LCMS: rt 6.40 min (A), purity 99 %, MS (m/e) 321 MH^+ .

[1128] 7-(2-(4,5-Difluoro-2-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 877). LCMS: rt 5.31 min (A), purity 99 %, MS (m/e) 323 MH^+ .

[1129] 7-(2-(2-Methyl-5-(trifluoromethyl)phenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 878). LCMS: rt 6.18 min (A), purity 99 %, MS (m/e) 355 MH^+ .

[1130] 7-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 879). LCMS: rt 6.20 min (A), purity 99 %, MS (m/e) 341 MH^+ .

[1131] 7-(2-(3-Methoxyphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 880). ^1H NMR (300 MHz, DMSO- d_6): δ 8.87 – 8.74 (m, 2H), 8.51 (d, $J = 1.3$ Hz, 1H), 8.15 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.84 (dd, $J = 2.1, 1.1$ Hz, 1H), 7.67 (dd, $J = 7.8, 5.0$ Hz, 1H), 7.18 (t, $J = 7.9$

Hz, 1H), 7.02 (dt, $J = 2.8, 1.5$ Hz, 1H), 6.95 – 6.80 (m, 3H), 3.62 (s, 3H). LCMS: rt 4.28 min (A), purity 99 %, MS (m/e) 303 MH^+ .

[1132] 7-(2-(5-Chloro-2-methoxyphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 881). LCMS: rt 4.98 min (A), purity 99 %, MS (m/e) 337 MH^+ .

[1133] 7-(2-(3-(Trifluoromethoxy)phenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 882). LCMS: rt 6.28 min (A), purity 99 %, MS (m/e) 357 MH^+ .

[1134] 7-(2-(3-(Difluoromethoxy)phenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 883). 1H NMR (300 MHz, $DMSO-d_6$): δ 8.83 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.78 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.51 (s, 1H), 8.09 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.84 (dd, $J = 2.0, 1.0$ Hz, 1H), 7.62 (ddd, $J = 7.8, 4.8, 0.8$ Hz, 1H), 7.32 (t, $J = 7.6$ Hz, 1H), 7.24 – 7.07 (m, 4H), 6.85 (dd, $J = 7.1, 1.9$ Hz, 1H). ^{19}F NMR (282 MHz, $DMSO-d_6$): δ -82.56 (d, $J = 73.8$ Hz). LCMS: rt 5.36 min (A), purity 99 %, MS (m/e) 339 MH^+ .

[1135] 7-(2-(2-Fluoro-5-(trifluoromethoxy)phenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 884). LCMS: rt 6.83 min (A), purity 99 %, MS (m/e) 375 MH^+ .

[1136] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl-1-oxy)quinazolin-4-amine (Compound 885). 4-Chloro-6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)quinazoline (75 mg), EtOH, 4-amino-2,2,6,6-tetramethyl-1-piperidinyloxy and *i*-Pr₂NEt were added successively to a screw capped vial, stirred and heated at 90 °C for 3 days. The reaction mixture was concentrated and purified by preparative HPLC to obtain pale pink solid. LCMS: rt 5.85 min (A), purity 99 %, MS (m/e) 505 MH^+ .

[1137] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N-methylquinazolin-4-amine (Compound 886). 4-Chloro-6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)quinazoline (75 mg), 2M MeNH₂ in THF (2 mL) and *i*-PrOH (3 mL) were heated and stirred in a screw capped vial for 12h at 65 °C. The heterogeneous reaction mixture was cooled and filtered. The solid on the funnel was washed with water and dried to obtain 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)-N-methylquinazolin-4-amine (53 mg) as a white solid. 1H NMR (300 MHz, $DMSO-d_6$): δ 8.72 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.47 (s, 1H), 8.31 (q, $J = 4.7$ Hz, 1H), 8.25 (d, $J = 1.9$ Hz, 1H), 7.95 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.61 – 7.50 (m, 3H), 7.36 (dd, $J = 8.6, 1.9$ Hz, 1H), 7.24 (t, $J = 8.9$ Hz, 1H), 7.13 (ddd, $J = 8.6, 4.8, 2.2$ Hz, 1H), 2.98 (d, $J = 4.4$ Hz, 3H). ^{19}F NMR (282 MHz, $DMSO-d_6$): δ -117.17 (td, $J = 8.6, 5.1$ Hz). LCMS: rt 4.68 min (A), purity 99 %, MS (m/e) 365 MH^+ .

- [1138] 7-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-1-methylquinoxalin-2(1H)-one (Compound 887). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.73 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.30 – 8.18 (m, 1H), 8.01 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.71 (d, *J* = 8.3 Hz, 1H), 7.62 (dt, *J* = 7.3, 1.5 Hz, 1H), 7.60 – 7.51 (m, 2H), 7.25 (t, *J* = 8.9 Hz, 1H), 7.16 (ddd, *J* = 8.4, 4.8, 2.1 Hz, 1H), 7.07 (dd, *J* = 8.3, 1.7 Hz, 1H), 3.53 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.11 (td, *J* = 8.6, 5.1 Hz). LCMS: rt 6.26 min (A), purity 99 %, MS (m/e) 366 MH⁺.
- [1139] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-methylquinoxalin-2(1H)-one (Compound 888). LCMS: rt 5.16 min (A), purity 99 %, MS (m/e) 346 MH⁺.
- [1140] 7-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-1-methylquinoxalin-2(1H)-one (Compound 889). LCMS: rt 6.66 min (A), purity 99 %, MS (m/e) 366 MH⁺.
- [1141] 7-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)quinoxalin-2(1H)-one (Compound 890). LCMS: rt 5.63 min (A), purity 99 %, MS (m/e) 352 MH⁺.
- [1142] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinoxalin-2(1H)-one (Compound 891). LCMS: rt 4.73 min (A), purity 99 %, MS (m/e) 332 MH⁺.
- [1143] 7-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)quinoxalin-2(1H)-one (Compound 892). ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.35 (s, 1H), 8.69 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.08 (s, 1H), 7.90 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.64 (d, *J* = 8.8 Hz, 1H), 7.60 – 7.46 (m, 2H), 7.46 – 7.30 (m, 1H), 7.15 – 6.92 (m, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.11 – -117.91 (m). LCMS: rt 5.93 min (A), purity 99 %, MS (m/e) 352 MH⁺.
- [1144] 7-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (Compound 893). LCMS: rt 5.53 min (A), purity 99 %, MS (m/e) 388 MH⁺.
- [1145] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (Compound 894). LCMS: rt 4.50 min (A), purity 97 %, MS (m/e) 368 MH⁺.
- [1146] 7-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (Compound 895). ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.35 (s, 1H), 8.69 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.08 (s, 1H), 7.90 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.64 (d, *J* = 8.8 Hz, 1H), 7.60 – 7.50 (m, 2H), 7.39 (ddd, *J* = 8.7, 4.4, 2.9 Hz, 1H), 7.11 – 6.91 (m, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.44 – -117.69 (m). LCMS: rt 5.86 min (A), purity 97 %, MS (m/e) 388 MH⁺.
- [1147] 5-(2-(3-Cyclopropyl-4-fluorophenyl)pyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (Compound 896). LCMS: rt 6.03 min (A), MS (m/e) 331 MH⁺.

[1148] Ethyl 5-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (Compound 897). ^1H NMR (300 MHz, DMSO- d_6) δ 8.86 (ddd, $J = 4.8, 1.7, 0.6$ Hz, 1H), 8.81 (dd, $J = 4.4, 0.6$ Hz, 1H), 8.44 (s, 1H), 8.12 (ddd, $J = 7.8, 1.7, 0.6$ Hz, 1H), 7.61 (dd, $J = 7.7, 4.7$ Hz, 1H), 7.38 – 7.25 (m, 2H), 6.94 – 6.85 (m, 2H), 4.27 (q, $J = 7.0$ Hz, 2H), 2.08 (s, 3H), 1.29 (t, $J = 7.0$ Hz, 3H). LCMS: rt6.88 min (A), purity 99%, MS (m/e) 376 MH^+ .

[1149] Ethyl 5-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (Compound 898). ^1H NMR (300 MHz, DMSO- d_6) δ 9.15 (d, $J = 7.2$ Hz, 1H), 8.82 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.62 (s, 1H), 8.21 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.73 (dd, $J = 7.3, 2.2$ Hz, 1H), 7.64 (dd, $J = 7.9, 4.8$ Hz, 1H), 7.28 (t, $J = 8.9$ Hz, 1H), 7.23 – 7.16 (m, 1H), 7.00 (d, $J = 7.3$ Hz, 1H), 4.25 (q, $J = 7.1$ Hz, 2H), 1.97 (s, 1H), 1.27 (t, $J = 7.1$ Hz, 3H). LCMS: rt 7.38 min (A), purity 95%, MS (m/e) 397 MH^+ .

[1150] 5-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-N-(1-methylpiperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Compound 899). ^1H NMR (300 MHz, DMSO- d_6) δ 9.25 (d, $J = 7.3$ Hz, 1H), 8.83 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.55 (s, 1H), 8.27 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.76 (dd, $J = 7.2, 2.2$ Hz, 1H), 7.66 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.58 (d, $J = 7.7$ Hz, 1H), 7.28 (t, $J = 8.9$ Hz, 1H), 7.12 (d, $J = 7.3$ Hz, 1H), 3.86 – 3.66 (m, 1H), 2.67 (d, $J = 11.7$ Hz, 2H), 2.21 – 2.14 (m, 5H), 1.77 (d, $J = 13.1$ Hz, 2H), 1.52 – 1.33 (m, 2H). LCMS: rt 3.48 min (B), purity 97%, MS (m/e) 465 MH^+ .

[1151] 5-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (Compound 900). ^1H NMR (300 MHz, DMSO- d_6) δ 9.21 (dd, $J = 7.3, 2.6$ Hz, 1H), 8.89 – 8.77 (m, 2H), 8.31 – 8.17 (m, 1H), 7.79 – 7.71 (m, 1H), 7.69 – 7.59 (m, 1H), 7.29 (t, $J = 8.9$ Hz, 1H), 7.24 – 7.14 (m, 1H), 7.04 (dd, $J = 7.3, 2.7$ Hz, 1H). LCMS: rt7.05 min (B), purity 99%, MS (m/e) 350 MH^+ .

[1152] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (Compound 901). ^1H NMR (300 MHz, DMSO- d_6) δ 9.15 (d, $J = 7.3$ Hz, 1H), 8.86 – 8.76 (m, 2H), 8.21 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.66 – 7.53 (m, 3H), 7.06 – 6.98 (m, 1H), 6.87 (d, $J = 7.3$ Hz, 1H), 2.20 (s, 3H). LCMS: rt6.80 min (B), purity 99%, MS (m/e) 330 MH^+ .

[1153] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-2-methoxypyrimidine (Compound 902). ^1H NMR (300 MHz, DMSO- d_6): δ 8.74 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.48 (d, $J = 5.1$ Hz, 1H), 8.08 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.54 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.34 (dd, $J = 7.6, 2.1$ Hz, 0H), 7.11 – 6.98 (m, 2H), 6.90 (d, $J = 5.1$ Hz, 1H), 3.77 (s, 3H), 2.18 (app d, $J = 2.1$ Hz, 2H). ^{19}F NMR (282

MHz, DMSO-*d*₆): δ -118.09 (q, J = 8.0, 7.5 Hz). LCMS: rt5.04 min (B), purity 99 %, MS (m/e) 296 (MH⁺).

[1154] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine (Compound 903). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.58 (s, 1H), 8.73 (dd, J = 4.7, 1.7 Hz, 1H), 8.31 (d, J = 5.1 Hz, 1H), 8.16 – 8.08 (m, 1H), 7.53 (dd, J = 7.8, 4.7 Hz, 1H), 7.42 (dd, J = 7.0, 2.3 Hz, 1H), 7.19 (s, 2H), 7.13 – 6.99 (m, 2H), 6.45 (d, J = 5.0 Hz, 1H), 3.70 (s, 6H), 3.59 (s, 3H), 2.19 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.92 (d, J = 7.5 Hz). LCMS: rt6.14 min (B), purity 99 %, MS (m/e) 447 (MH⁺).

[1155] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine (Compound 904). LCMS: rt5.17 min (A), purity 99 %, MS (m/e) 442 (MH⁺).

[1156] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(3-morpholinophenyl)pyrimidin-2-amine (Compound 905). LCMS: rt5.90 min (A), purity 99 %, MS (m/e) 442 (MH⁺).

[1157] 4-(((4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrimidin-2-yl)amino)benzenesulfonamide (Compound 906). LCMS: rt5.43 min (A), purity 99 %, MS (m/e) 436 (MH⁺).

[1158] 3-(((4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrimidin-2-yl)amino)benzenesulfonamide (Compound 907). ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.02 (s, 1H), 8.75 (dd, J = 4.8, 1.7 Hz, 1H), 8.42 (d, J = 5.1 Hz, 1H), 8.22 (s, 1H), 8.11 (dd, J = 7.8, 1.7 Hz, 1H), 7.65 (dt, J = 6.4, 2.5 Hz, 1H), 7.54 (dd, J = 7.8, 4.8 Hz, 1H), 7.44 (dd, J = 7.3, 2.2 Hz, 1H), 7.40 – 7.31 (m, 2H), 7.27 (s, 2H), 7.17 – 6.95 (m, 2H), 6.67 (d, J = 5.1 Hz, 1H), 2.20 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.92. LCMS: rt5.58 min (A), purity 99 %, MS (m/e) 436 (MH⁺).

[1159] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(4-(piperazin-1-yl)phenyl)pyrimidin-2-amine (Compound 908). LCMS: rt4.73 min (A), purity 99 %, MS (m/e) 441 (MH⁺).

[1160] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-N-(6-(piperazin-1-yl)pyridin-3-yl)pyrimidin-2-amine (Compound 909). LCMS: rt4.60 min (A), purity 99 %, MS (m/e) 442 (MH⁺).

[1161] 5-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (Compound 910). LCMS: rt5.41 min (A), purity 99%, MS (m/e) 305 (MH⁺).

[1162] 5-(2-(*m*-Tolyl)pyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (Compound 911). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.90 (dd, J = 7.3, 0.9 Hz, 1H), 8.76 (dd, J = 4.7, 1.7 Hz, 1H), 8.22 (d, J

= 2.3 Hz, 1H), 8.12 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.54 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.33 (s, 1H), 7.15 (dd, $J = 3.9, 1.5$ Hz, 2H), 7.01 (dd, $J = 5.1, 1.5$ Hz, 1H), 6.75 (dd, $J = 2.3, 0.9$ Hz, 1H), 6.53 (d, $J = 7.3$ Hz, 1H), 2.25 (s, 3H). LCMS: rt4.90 min (A), purity 99%, MS (m/e) 287 (MH⁺).

[1163] 5-(2-(3-Cyclopropylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 912). LCMS: rt5.51 min (A), purity 99%, MS (m/e) 313 (MH⁺).

[1164] 5-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine. (Compound 913). LCMS: rt6.71 min (A), purity 99%, MS (m/e) 341 (MH⁺)

[1165] 5-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 914). ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.00 (d, $J = 7.2$ Hz, 1H), 8.79 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.23 (d, $J = 2.4$ Hz, 1H), 8.15 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.68 (dd, $J = 7.4, 2.1$ Hz, 1H), 7.59 (dd, $J = 7.9, 4.9$ Hz, 1H), 7.32 (t, $J = 8.9$ Hz, 1H), 7.25 – 7.10 (m, 1H), 6.73 (d, $J = 7.1$ Hz, 2H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.52 – -116.67 (m). LCMS: rt 6.68 min (A), purity 99%, MS (m/e) 325 (MH⁺).

[1166] 5-(2-(2,4,5-Trifluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 915). LCMS: rt 6.66 min (A), purity 99%, MS (m/e) 327 (MH⁺).

[1167] 5-(2-(3-Chlorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 916). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.98 (dd, $J = 7.3, 0.9$ Hz, 1H), 8.79 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.23 (d, $J = 2.4$ Hz, 1H), 8.15 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.64 – 7.54 (m, 2H), 7.41 (ddd, $J = 8.0, 2.2, 1.1$ Hz, 1H), 7.29 (t, $J = 7.8$ Hz, 1H), 7.16 (dt, $J = 7.7, 1.4$ Hz, 1H), 6.74 (dd, $J = 2.4, 0.9$ Hz, 1H), 6.69 (d, $J = 7.3$ Hz, 1H). LCMS: rt 4.16 min (A), purity 99%, MS (m/e) 307 (MH⁺).

[1168] 5-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 917). LCMS: rt 6.86 min (A), purity 99%, MS (m/e) 325 (MH⁺).

[1169] 5-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 918). LCMS: rt 7.18 min (A), purity 99%, MS (m/e) 343 (MH⁺).

[1170] 4-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)pyrimidin-2-amine (Compound 919). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.69 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.07 (d, $J = 5.0$ Hz, 1H), 7.93 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.47 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.38 (dd, $J = 7.4, 1.6$ Hz, 1H), 7.18 – 6.95 (m, 2H), 6.70 (s, 2H), 6.20 (d, $J = 5.0$ Hz, 1H), 2.19 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -118.16 (q, $J = 7.7$ Hz). LCMS: rt4.40 min (A), purity 99 %, MS (m/e) 281 MH⁺.

[1171] 5-(2-(2,5-Dichlorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 920). LCMS: rt 7.06 min (A), purity 99 %, MS (m/e) 342 MH⁺.

[1172] 5-(2-(3-(Difluoromethoxy)phenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 921). ^1H NMR (300 MHz, DMSO- d_6): δ 8.95 (dd, $J = 7.3, 0.9$ Hz, 1H), 8.80 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.22 (s, 1H), 8.14 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.59 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.43 – 7.28 (m, 1H), 7.21 (t, $J = 2.1$ Hz, 1H), 7.19 – 7.11 (m, 3H), 6.73 (dd, $J = 2.3, 0.9$ Hz, 1H), 6.64 (d, $J = 7.3$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -82.40 (d, $J = 73.8$ Hz). LCMS: rt4.95 min (B), purity 99 %, MS (m/e) 338MH $^+$.

[1173] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (Compound 922). LCMS: rt4.60 min (A), purity 99%, MS (m/e) 306 (MH $^+$).

[1174] 6-(2-(*m*-Tolyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (Compound 923). LCMS: rt4.13 min (A), purity 99 %, MS (m/e) 288 (MH $^+$).

[1175] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (Compound 924). LCMS: rt4.81 min (A), purity 99%, MS (m/e) 314 (MH $^+$).

[1176] 6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (Compound 925). LCMS: rt5.95 min (A), purity 99%, MS (m/e) 342 (MH $^+$).

[1177] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyrimidine (Compound 926). LCMS: rt3.75 min (A), purity 99%, MS (m/e) 305 (MH $^+$).

[1178] 6-(2-(*m*-Tolyl)pyridin-3-yl)imidazo[1,2-a]pyrimidine (Compound 927). LCMS: rt3.25 min (A), purity 99%, MS (m/e) 287 (MH $^+$).

[1179] 6-(2-(3-Cyclopropylphenyl)pyridin-3-yl)imidazo[1,2-a]pyrimidine (Compound 928). LCMS: rt3.96 min (A), purity 99%, MS (m/e) 313 (MH $^+$).

[1180] 6-(2-(3-(Trifluoromethyl)phenyl)pyridin-3-yl)imidazo[1,2-a]pyrimidine (Compound 929). LCMS: rt4.73 min (A), purity 99%, MS (m/e) 341 (MH $^+$).

[1181] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-7-methylimidazo[1,2-a]pyridine (Compound 930). LCMS: rt 4.90 min (A), purity 99 %, MS (m/e) 338 MH $^+$.

[1182] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-7-methylimidazo[1,2-a]pyridine (Compound 931). ^1H NMR (300 MHz, DMSO- d_6): δ 8.87 (d, $J = 0.8$ Hz, 1H), 8.84 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.22 (d, $J = 2.2$ Hz, 1H), 8.14 (d, $J = 2.1$ Hz, 1H), 7.90 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.80 (s, 1H), 7.61 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.53 (t, $J = 1.9$ Hz, 1H), 7.36 (dt, $J = 7.6, 2.0$ Hz, 1H), 7.23 (t, $J = 7.7$ Hz, 1H), 7.18 (dt, $J = 7.8, 1.6$ Hz, 1H), 2.00 (s, 3H). LCMS: rt 4.58 min (A), purity 99 %, MS (m/e) 320 MH $^+$.

- [1183] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-7-methylimidazo[1,2-a]pyridine (Compound 932). LCMS: rt 4.86 min (A), purity 99 %, MS (m/e) 338 MH⁺.
- [1184] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-7-methylimidazo[1,2-a]pyridine (Compound 933). LCMS: rt 5.11 min (A), purity 99 %, MS (m/e) 356 MH⁺.
- [1185] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine (Compound 934). LCMS: rt 4.61 min (A), purity 99 %, MS (m/e) 305 MH⁺.
- [1186] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine (Compound 935). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.76 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.26 (dt, *J* = 1.2, 0.6 Hz, 1H), 8.08 (ddd, *J* = 7.8, 1.7, 0.5 Hz, 1H), 7.97 (dt, *J* = 9.4, 0.6 Hz, 1H), 7.76 (dd, *J* = 1.2, 0.5 Hz, 1H), 7.62 (dd, *J* = 7.3, 2.3 Hz, 1H), 7.56 (ddd, *J* = 7.8, 4.8, 0.5 Hz, 1H), 7.25 (dd, *J* = 9.3, 8.6 Hz, 1H), 7.14 (dddd, *J* = 8.6, 4.8, 2.2, 0.5 Hz, 1H), 6.89 (dd, *J* = 9.5, 0.5 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.49 (td, *J* = 8.3, 4.9 Hz). LCMS: rt 5.13 min (A), purity 99 %, MS (m/e) 325 MH⁺.
- [1187] 6-(2-(3-Chlorophenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine (Compound 936). LCMS: rt 4.83 min (A), purity 99 %, MS (m/e) 307 MH⁺.
- [1188] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine (Compound 937). LCMS: rt 5.03 min (A), purity 99 %, MS (m/e) 325 MH⁺.
- [1189] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine (Compound 938). LCMS: rt 5.28 min (A), purity 99 %, MS (m/e) 343 MH⁺.
- [1190] 8-Fluoro-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (Compound 939). LCMS: rt 5.45 min (A), purity 99 %, MS (m/e) 323 MH⁺.
- [1191] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridine (Compound 940). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.95 (t, *J* = 1.0 Hz, 1H), 8.75 (ddd, *J* = 4.8, 1.7, 0.6 Hz, 1H), 8.61 (d, *J* = 0.6 Hz, 1H), 8.04 (ddd, *J* = 7.8, 1.7, 0.6 Hz, 1H), 7.70 (ddd, *J* = 7.3, 1.9, 0.6 Hz, 1H), 7.58 (ddd, *J* = 7.8, 4.8, 0.6 Hz, 1H), 7.42 (ddd, *J* = 11.1, 1.4, 0.6 Hz, 1H), 7.35 – 7.17 (m, 2H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.75 (td, *J* = 8.1, 5.6 Hz), -130.02 (d, *J* = 11.2 Hz). LCMS: rt 6.55 min (A), purity 99 %, MS (m/e) 343 MH⁺.
- [1192] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridine (Compound 941). LCMS: rt 6.13 min (A), purity 99 %, MS (m/e) 325 MH⁺.
- [1193] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridine (Compound 942). LCMS: rt 6.75 min (A), purity 99 %, MS (m/e) 343 MH⁺.

[1194] 7-Chloro-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 943). LCMS: rt 4.56 min (A), purity 99 %, MS (m/e) 338 MH⁺.

[1195] 7-Chloro-6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 944). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.99 (d, *J* = 0.8 Hz, 1H), 8.82 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.19 (dd, *J* = 1.8, 0.8 Hz, 1H), 8.08 (t, *J* = 0.8 Hz, 1H), 8.04 (t, *J* = 1.4 Hz, 1H), 7.92 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.73 – 7.67 (m, 1H), 7.66 – 7.56 (m, 1H), 7.26 (app d, *J* = 1.3 Hz, 1H), 7.24 (app q, *J* = 1.0 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -116.57 (q, *J* = 7.0 Hz). LCMS: rt 5.20 min (A), purity 99 %, MS (m/e) 359 MH⁺.

[1196] 7-Chloro-6-(2-(3-chlorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 945). LCMS: rt 4.91 min (A), purity 99 %, MS (m/e) 341 MH⁺.

[1197] 7-Chloro-6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)imidazo[1,2-a]pyridine (Compound 946). LCMS: rt 5.03 min (A), purity 99 %, MS (m/e) 359 MH⁺.

[1198] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine-3-carbonitrile (Compound 947). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.78 (ddd, *J* = 4.8, 1.7, 0.8 Hz, 1H), 8.55 (s, 1H), 8.15 (dd, *J* = 9.5, 0.9 Hz, 1H), 8.10 (ddd, *J* = 7.8, 1.7, 0.8 Hz, 1H), 7.59 – 7.52 (m, 2H), 7.41 (dd, *J* = 7.7, 2.2 Hz, 1H), 7.08 (dd, *J* = 9.5, 0.9 Hz, 1H), 6.95 (dd, *J* = 9.6, 8.5 Hz, 1H), 2.13 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -117.44 (s). LCMS: rt 5.34 min (B), purity 99 %, MS (m/e) 330 MH⁺.

[1199] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine-3-carbonitrile (Compound 948). LCMS: rt 5.59 min (B), purity 99 %, MS (m/e) 350 MH⁺.

[1200] 6-(2-(3-Chlorophenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine-3-carbonitrile (Compound 949). LCMS: rt 5.43 min (B), purity 99 %, MS (m/e) 332 MH⁺.

[1201] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine-3-carbonitrile (Compound 950). LCMS: rt 5.34 min (B), purity 99 %, MS (m/e) 350 MH⁺.

[1202] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)imidazo[1,2-b]pyridazine-3-carbonitrile (Compound 951). LCMS: rt 5.56 min (B), purity 99 %, MS (m/e) 368 MH⁺.

[1203] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-b]pyridazine (Compound 952). LCMS: rt 5.68 min (A), purity 99 %, MS (m/e) 306 MH⁺.

[1204] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-b]pyridazine (Compound 953). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.84 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.70 (s, 1H), 8.34 (d, *J* = 9.3 Hz, 1H), 8.19 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.71 (dd, *J* = 7.2, 2.1 Hz, 1H), 7.65 (dd, *J*

= 7.8, 4.8 Hz, 1H), 7.39 (d, $J = 9.4$ Hz, 1H), 7.28 (dd, $J = 9.3, 8.5$ Hz, 1H), 7.19 (ddd, $J = 8.6, 4.8, 2.2$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -116.26 (ddd, $J = 9.3, 7.3, 4.7$ Hz). LCMS: rt 6.50 min (A), purity 99 %, MS (m/e) 326 MH^+ .

[1205] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-b]pyridazine (Compound 954). LCMS: rt 6.15 min (A), purity 99 %, MS (m/e) 308 MH^+ .

[1206] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-b]pyridazine (Compound 955). LCMS: rt 6.46 min (A), purity 99 %, MS (m/e) 326 MH^+ .

[1207] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-b]pyridazine (Compound 956). LCMS: rt 6.85 min (A), purity 99 %, MS (m/e) 344 MH^+ .

[1208] 7-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (Compound 957). LCMS: rt 5.91 min (A), purity 97 %, MS (m/e) 402 MH^+ .

[1209] 7-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (Compound 958). ^1H NMR (300 MHz, DMSO- d_6): δ 8.71 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.05 (s, 1H), 7.97 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.68 (d, $J = 2.1$ Hz, 1H), 7.61 – 7.50 (m, 2H), 7.44 (d, $J = 8.8$ Hz, 1H), 7.37 (ddt, $J = 7.5, 1.9, 0.8$ Hz, 1H), 7.06 – 6.94 (m, 2H), 3.59 (s, 3H), 2.17 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -117.82 (app s). LCMS: rt 4.85 min (A), purity 98 %, MS (m/e) 382 MH^+ .

[1210] 7-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (Compound 959). LCMS: rt 6.31 min (A), purity 98 %, MS (m/e) 402 MH^+ .

[1211] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one (Compound 960). ^1H NMR (300 MHz, DMSO- d_6): δ 12.60 (s, 1H), 8.77 (app ddd, $J = 4.8, 1.7, 0.6$ Hz, 1H), 8.16 (s, 1H), 8.10 (app ddd, $J = 7.8, 1.8, 0.7$ Hz, 1H), 7.94 (dd, $J = 8.6, 0.7$ Hz, 1H), 7.65 – 7.55 (m, 2H), 7.48 (dd, $J = 8.5, 0.6$ Hz, 1H), 7.27 (app t, $J = 9.0$ Hz, 1H), 7.16 – 7.03 (m, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -116.85 (app td, $J = 9.0, 8.5, 4.9$ Hz). LCMS: rt 4.73 min (A), purity 99 %, MS (m/e) 353 MH^+ .

[1212] 6-(2-(3-(Difluoromethoxy)phenyl)pyridin-3-yl)benzo[d]thiazole (Compound 961). LCMS: rt 5.67 min (A), purity 97 %, MS (m/e) 355 MH^+ .

[1213] 6-(2-(3-(Difluoromethoxy)phenyl)pyridin-3-yl)quinoxaline (Compound 962). LCMS: rt 5.23 min (B), purity 96 %, MS (m/e) 350 MH^+ .

[1214] 6-(2-(3-(Difluoromethoxy)phenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 963). LCMS: rt 2.89 min (B), purity 99 %, MS (m/e) 352 MH^+ .

[1215] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4-amine (Compound 964). ^1H NMR (300 MHz, DMSO- d_6): δ 8.77 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.40 (s, 1H), 8.27 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.94 (app d, $J = 8.7$ Hz, 2H), 7.69 – 7.54 (m, 3H), 7.52 (d, $J = 8.7$ Hz, 1H), 7.27 (dd, $J = 9.3, 8.6$ Hz, 1H), 7.11 (ddd, $J = 8.6, 4.7, 2.2$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -116.92 (ddd, $J = 9.3, 7.3, 4.7$ Hz). LCMS: rt4.61 min (A), purity 99%, MS (m/e) 352MH $^+$.

[1216] 5-(2-(3-Chloro-2,4-difluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine (Compound 965). ^1H NMR (300 MHz, DMSO- d_6): δ 9.05 (dd, $J = 7.3, 1.0$ Hz, 1H), 8.82 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.27 (dd, $J = 7.9, 1.6$ Hz, 1H), 8.21 (d, $J = 2.3$ Hz, 1H), 7.67 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.55 (td, $J = 8.5, 6.3$ Hz, 1H), 7.39 (td, $J = 8.8, 1.6$ Hz, 1H), 6.89 (dd, $J = 7.3, 1.0$ Hz, 1H), 6.62 (dd, $J = 2.3, 0.9$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -113.03 (ddd, $J = 9.3, 6.3, 3.6$ Hz), -115.55 (dd, $J = 9.1, 3.3$ Hz). LCMS: rt5.27 min (B), purity 99%, MS (m/e) 343 MH $^+$.

[1217] 6-(2-(3-Chloro-2,4-difluorophenyl)pyridin-3-yl)quinoxaline (Compound 966). LCMS: rt5.63 min (B), purity 99%, MS (m/e) 354 MH $^+$.

[1218] 6-(2-(3-Chloro-2,4-difluorophenyl)pyridin-3-yl)-1-methyl-1H-benzo[d]imidazole (Compound 967). LCMS: rt3.37 min (B), purity 99%, MS (m/e) 356 MH $^+$.

[1219] 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)-4-methoxyprido[3,2-d]pyrimidine (Compound 968). ^1H NMR (300 MHz, DMSO- d_6): δ 8.86 (s, 1H), 8.80 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.17 (d, $J = 8.8$ Hz, 1H), 8.17 (d, $J = 8.8, 1.7$ Hz, 1H), 7.77 – 7.46 (m, 3H), 7.22 (app t, $J = 9.2$ Hz, 1H), 7.07 (ddd, $J = 8.6, 4.7, 2.2$ Hz, 1H), 4.15 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -116.74 (ddd, $J = 9.2, 7.2, 4.7$ Hz).

[1220] 6-(2-(3-Chloro-4-fluorophenyl)pyridin-3-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compound 969). LCMS: rt 6.15 min (A), purity 99 %, MS (m/e) 339 MH $^+$.

[1221] 6-(2-(3-Chlorophenyl)pyridin-3-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compoune 970). LCMS: rt 5.71 min (A), purity 99 %, MS (m/e) 321 MH $^+$.

[1222] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compound 971). LCMS: rt 6.20 min (A), purity 99 %, MS (m/e) 339 MH $^+$.

[1223] 6-(2-(5-Chloro-2,4-difluorophenyl)pyridin-3-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine (Compound 972). LCMS: rt 6.50 min (A), purity 99 %, MS (m/e) 357 MH $^+$.


[1224] 4-(6-Methyl-[2,3'-bipyridin]-2'-yl)quinoline (Compound 973). LCMS: rt 2.80 min (B), purity 99 %, MS (m/e) 298 (MH $^+$).

[1225] 6-(2-(3-Chloro-2,4-difluorophenyl)pyridin-3-yl)benzo[d]thiazole) (Compound 974).
LCMS: rt6.11 min (B), purity 99%, MS (m/e) 359 MH⁺.

Example 82


[1226] The following additional 2-chloro-3-(hetero)arylpyridine compounds were prepared substantially as described herein.

[1227] 2-Chloro-3,4'-bipyridine




¹H NMR (300 MHz, DMSO-*d*₆): δ 8.68 (d, *J* = 5.7 Hz, 2H), 8.49 (dd, *J* = 4.8, 1.9 Hz, 1H), 7.94 (dd, *J* = 7.6, 1.9 Hz, 1H), 7.56 (dd, *J* = 7.6, 4.8 Hz, 1H), 7.52 (d, *J* = 5.7 Hz, 2H).

[1228] 4-(2-Chloropyridin-3-yl)quinoline




¹H NMR (300 MHz, DMSO-*d*₆): δ 9.01 (d, *J* = 4.4 Hz, 1H), 8.60 (dd, *J* = 4.8, 1.9 Hz, 1H), 8.13 (d, *J* = 8.5 Hz, 1H), 7.98 (dd, *J* = 7.5, 1.9 Hz, 1H), 7.81 (ddd, *J* = 8.4, 6.9, 1.4 Hz, 1H), 7.64 (dd, *J* = 7.5, 4.8 Hz, 1H), 7.58 (dd, *J* = 6.9, 1.3 Hz, 1H), 7.51 (d, *J* = 4.4 Hz, 1H), 7.42 (dd, *J* = 8.1, 1.1 Hz, 1H).

[1229] 2'-Chloro-6-methyl-2,3'-bipyridine




¹H NMR (300 MHz, DMSO-*d*₆): δ 8.46 (dd, *J* = 4.8, 2.0 Hz, 1H), 7.99 (dd, *J* = 7.6, 1.9 Hz, 1H), 7.80 (t, *J* = 7.8 Hz, 1H), 7.58 – 7.47 (m, 2H), 7.31 (d, *J* = 7.9 Hz, 1H), 2.52 (s, 3H).

[1230] 2-(2-Chloropyridin-3-yl)-1,6-naphthyridine




¹H NMR (300 MHz, DMSO-*d*₆): δ 9.48 (d, *J* = 0.9 Hz, 1H), 8.79 (d, *J* = 6.0 Hz, 1H), 8.71 (dd, *J* = 8.6, 0.8 Hz, 1H), 8.57 (ddd, *J* = 4.8, 2.0, 0.7 Hz, 1H), 8.16 (ddd, *J* = 7.6, 1.9, 0.7 Hz, 1H), 8.03 (dd, *J* = 8.5, 0.6 Hz, 1H), 7.96 (d, *J* = 5.9 Hz, 1H), 7.63 (ddd, *J* = 7.6, 4.8, 0.7 Hz, 1H).

[1231] 2'-Chloro-[3,3'-bipyridin]-6-amine




^1H NMR (300 MHz, DMSO- d_6): δ 8.34 (dd, $J = 4.8, 1.7$ Hz, 1H), 7.99 (d, $J = 2.6$ Hz, 1H), 7.83 (dd, $J = 7.6, 1.8$ Hz, 1H), 7.52 (dd, $J = 8.6, 2.5$ Hz, 1H), 7.46 (dd, $J = 7.6, 4.7$ Hz, 1H), 6.51 (d, $J = 8.6$ Hz, 1H), 6.20 (s, 2H).

[1232] 6-(2-Chloropyridin-3-yl)-3-methylimidazo[1,2-a]pyridine




^1H NMR (300 MHz, DMSO- d_6): δ 8.47 (dd, $J = 5.2, 1.9$ Hz, 1H), 8.40 (s, 1H), 8.07 – 7.97 (m, 1H), 7.61 (d, $J = 9.3$ Hz, 1H), 7.56 (dd, $J = 7.8, 4.6$ Hz, 1H), 7.42 (s, 1H), 7.33 (dd, $J = 9.3, 1.6$ Hz, 1H), 2.46 (s, 3H).

[1233] 6-(2-Chloropyridin-3-yl)-2-methylimidazo[1,2-a]pyridine




^1H NMR (300 MHz, DMSO- d_6): δ 8.63 (dd, $J = 1.9, 1.0$ Hz, 1H), 8.46 (dd, $J = 4.8, 1.9$ Hz, 1H), 7.97 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.71 (s, 1H), 7.59 – 7.44 (m, 2H), 7.27 (dd, $J = 9.3, 1.8$ Hz, 1H), 2.34 (s, 3H).

[1234] 2-(2-Chloropyridin-3-yl)-1,5-naphthyridine




^1H NMR (300 MHz, DMSO- d_6): δ 9.06 (dd, $J = 4.2, 1.7$ Hz, 1H), 8.60 – 8.52 (m, 2H), 8.49 (dd, $J = 8.6, 0.9$ Hz, 1H), 8.17 (dd, $J = 7.6, 2.0$ Hz, 1H), 8.12 (dd, $J = 8.7, 0.6$ Hz, 1H), 7.85 (dd, $J = 8.5, 4.2$ Hz, 1H), 7.63 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1235] 6-(2-Chloropyridin-3-yl)quinoxaline




^1H NMR (300 MHz, DMSO- d_6): δ 9.01 (s, 2H), 8.51 (dd, $J = 4.7, 1.9$ Hz, 1H), 8.25 – 8.14 (m, 2H), 8.07 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.99 (dd, $J = 8.7, 1.9$ Hz, 1H), 7.59 (dd, $J = 7.5, 4.8$ Hz, 1H).

[1236] 4-(6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)morpholine




^1H NMR (300 MHz, DMSO- d_6): δ 8.47 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.28 (dd, $J = 1.8, 1.0$ Hz, 1H), 8.02 (dd, $J = 7.5, 1.9$ Hz, 1H), 7.61 – 7.51 (m, 2H), 7.35 (s, 1H), 7.27 (dd, $J = 9.3, 1.8$ Hz, 1H), 3.97 – 3.47 (m, 4H), 3.13 – 2.71 (m, 4H).

[1237] 4-(6-(2-Chloropyridin-3-yl)quinolin-4-yl)morpholine




^1H NMR (300 MHz, DMSO- d_6): δ 8.75 (d, $J = 5.0$ Hz, 1H), 8.47 (dd, $J = 4.7, 1.9$ Hz, 1H), 8.11 (d, $J = 2.1$ Hz, 1H), 8.07 – 7.95 (m, 2H), 7.79 (dd, $J = 8.7, 2.0$ Hz, 1H), 7.57 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.05 (d, $J = 5.0$ Hz, 1H), 3.85-3.82 (m, 4H), 3.25 – 3.12 (m, 4H).

[1238] 6-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidine




^1H NMR (300 MHz, DMSO- d_6): δ 9.70 (d, $J = 2.4$ Hz, 1H), 9.07 (dd, $J = 2.4$ Hz, 1H), 8.77 (s, 1H), 8.55 (dd, $J = 4.8, 2.0$ Hz, 1H), 8.12 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.63 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1239] 6-(2-Chloropyridin-3-yl)-N,N-dimethylimidazo[1,2-a]pyridin-3-amine




^1H NMR (300 MHz, DMSO- d_6): δ 8.46 (dd, $J = 4.7, 1.9$ Hz, 1H), 8.19 (dd, $J = 1.8, 1.0$ Hz, 1H), 8.03 (dd, $J = 7.5, 1.9$ Hz, 1H), 7.60 – 7.49 (m, 2H), 7.29 (s, 1H), 7.26 (dd, $J = 9.4, 1.8$ Hz, 1H), 2.75 (s, 6H).

[1240] 5-(2-Chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidine




^1H NMR (300 MHz, DMSO- d_6): δ 9.24 (dd, $J = 7.3, 0.9$ Hz, 1H), 8.55 (dd, $J = 4.8, 2.0$ Hz, 1H), 8.30 (d, $J = 2.4$ Hz, 1H), 8.14 (dd, $J = 7.6, 2.0$ Hz, 1H), 7.61 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.37 (d, $J = 7.3$ Hz, 1H), 6.82 (d, $J = 2.4$ Hz, 1H).

[1241] 6-(2-Chloropyridin-3-yl)-3-(trifluoromethyl)imidazo[1,2-a]pyridine




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.65 (s, 1H), 8.50 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.26 (s, 1H), 8.04 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.91 (d, $J = 9.6$ Hz, 1H), 7.67 (d, $J = 9.4$ Hz, 1H), 7.57 (dd, $J = 7.6, 4.8$ Hz, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -59.81(s).

[1242] 6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.82 (d, $J = 1.9$ Hz), 8.54 – 8.45 (m, 2H), 8.07 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.94 (d, $J = 9.3$ Hz, 1H), 7.75 (dd, $J = 9.3, 1.7$ Hz, 1H), 7.58 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1243] 6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyrimidine




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 9.20 (dd, $J = 2.5, 0.8$ Hz, 1H), 8.66 (d, $J = 2.5$ Hz, 1H), 8.51 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.08 (dd, $J = 7.5, 1.9$ Hz, 1H), 7.97 (s, 1H), 7.80 (s, 1H), 7.60 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1244] 6-(2-Chloropyridin-3-yl)-3-(pyrrolidin-1-yl)imidazo[1,2-a]pyridine




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.46 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.25 (d, $J = 1.7$ Hz, 1H), 8.01 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.54 (dd, $J = 5.1, 2.5$ Hz, 1H), 7.51 (d, $J = 0.6$ Hz, 1H), 7.25 (s, 1H), 7.21 (dd, $J = 9.3, 1.8$ Hz, 1H), 3.16 (t, $J = 4.3$ Hz, 4H), 2.00 – 1.82 (m, 4H).

[1245] (6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methanol




¹H NMR (300 MHz, DMSO-*d*₆): δ 8.51 (d, *J* = 1.7 Hz, 1H), 8.48 (dd, *J* = 4.8, 1.9 Hz, 1H), 8.01 (dd, *J* = 7.6, 1.9 Hz, 1H), 7.66 (d, *J* = 9.3 Hz, 1H), 7.61 – 7.53 (m, 2H), 7.40 (dd, *J* = 9.4, 1.8 Hz, 1H), 5.24 (t, *J* = 5.5 Hz, 1H), 4.82 (d, *J* = 5.5 Hz, 2H).

[1246] 4-((6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine




¹H NMR (300 MHz, DMSO-*d*₆): δ 8.65 (d, *J* = 1.7 Hz, 1H), 8.48 (dd, *J* = 4.8, 1.9 Hz, 1H), 8.00 (dd, *J* = 7.6, 1.9 Hz, 1H), 7.65 (d, *J* = 9.3 Hz, 1H), 7.62 – 7.54 (m, 2H), 7.37 (dd, *J* = 9.3, 1.8 Hz, 1H), 3.84 (s, 2H), 3.59 – 3.32 (m, 4H), 2.41 – 2.29 (m, 4H).

[1247] 6-(2-Chloropyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine-3-carboxamide




¹H NMR (300 MHz, DMSO-*d*₆): δ 10.17 (s, 1H), 9.55 (dd, *J* = 1.9, 1.0 Hz, 1H), 8.63 (s, 1H), 8.51 (dd, *J* = 4.8, 1.9 Hz, 1H), 8.06 (dd, *J* = 7.6, 1.9 Hz, 1H), 7.87 (dd, *J* = 9.3, 1.0 Hz, 1H), 7.65 (dd, *J* = 9.3, 1.8 Hz, 1H), 7.59 (dd, *J* = 7.6, 4.8 Hz, 1H), 7.16 (s, 2H), 3.76 (s, 6H), 3.63 (s, 3H).

[1248] 6-(2-Chloropyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine




¹H NMR (300 MHz, DMSO-*d*₆): δ 8.68 (d, *J* = 1.6 Hz, 1H), 8.44 (dd, *J* = 4.8, 1.9 Hz, 1H), 8.04 (dd, *J* = 7.6, 1.9 Hz, 1H), 7.81 (d, *J* = 0.8 Hz, 1H), 7.74 (d, *J* = 9.3 Hz, 1H), 7.59 – 7.45 (m, 1H), 7.41 (dd, *J* = 9.3, 1.7 Hz, 1H), 6.95 (s, 2H), 3.83 (s, 6H), 3.70 (s, 3H).

[1249] 1-(6-(2-Chloropyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)ethan-1-one




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 9.61 (d, $J = 1.8$ Hz, 1H), 8.69 (s, 1H), 8.51 (dd, $J = 4.7, 1.9$ Hz, 1H), 8.04 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.94 (d, $J = 9.2$ Hz, 1H), 7.77 (dd, $J = 9.2, 1.9$ Hz, 1H), 7.59 (dd, $J = 7.6, 4.7$ Hz, 1H), 2.58 (s, 3H).

[1250] 7-(2-Chloropyridin-3-yl)imidazo[1,5-a]pyridine




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.50 – 8.33 (m, 2H), 7.95 (d, $J = 6.9$ Hz, 1H), 7.67 (s, 1H), 7.52 (dd, $J = 7.6, 4.7$ Hz, 1H), 7.45 (s, 1H), 6.78 (d, $J = 7.3$ Hz, 1H).

[1251] Ethyl 5-(2-chloropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carboxylate




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.98 (dd, $J = 7.2, 0.9$ Hz, 1H), 8.59 – 8.32 (m, 2H), 8.12 (dd, $J = 2.1, 1.0$ Hz, 1H), 8.05 (dd, $J = 7.6, 1.8$ Hz, 1H), 7.59 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.29 (dd, $J = 7.1, 2.0$ Hz, 1H), 4.29 (q, $J = 7.1$ Hz, 2H), 1.30 (t, $J = 7.0$ Hz, 3H).

[1252] Methyl 6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxylate



^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 9.30 (d, $J = 1.6$ Hz, 1H), 8.52 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.38 (s, 1H), 8.05 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.93 (d, $J = 9.4$ Hz, 1H), 7.72 (dd, $J = 9.2, 1.6$ Hz, 1H), 7.59 (dd, $J = 7.4, 4.7$ Hz, 1H), 3.88 (s, 3H).


[1253] 6-(2-Chloropyridin-3-yl)-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide



^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 9.55 (dd, $J = 1.9, 0.9$ Hz, 1H), 8.54 (t, $J = 5.7$ Hz, 1H), 8.50 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.36 (s, 1H), 8.03 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.81 (d, $J = 9.4$ Hz, 1H),


7.58 (dd, $J = 9.4, 2.0$ Hz, 2H), 3.33 (t, $J = 6.9$ Hz, 2H), 3.23 (t, $J = 7.0$ Hz, 4H), 2.19 (t, $J = 8.0$ Hz, 2H), 1.91 (dq, $J = 15.0, 7.5$ Hz, 2H), 1.71 (p, $J = 7.2$ Hz, 2H).

[1254] 7-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine




^1H NMR (300 MHz, DMSO- d_6): δ 9.06 (d, $J = 6.5$ Hz, 1H), 8.58 (s, 1H), 8.51 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.03 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.99 (s, 1H), 7.58 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.34 (dd, $J = 7.1, 1.8$ Hz, 1H).

[1255] 6-(2-Chloropyridin-3-yl)pyrido[2,3-b]pyrazine




^1H NMR (300 MHz, DMSO- d_6): δ 9.20 (d, $J = 1.6$ Hz, 1H), 9.12 (d, $J = 1.6$ Hz, 1H), 8.70 (d, $J = 8.6$ Hz, 1H), 8.59 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.25 (d, $J = 8.6$ Hz, 1H), 8.21 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.65 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1256] 5-(2-Chloropyridin-3-yl)pyrazolo[1,5-a]pyridine




^1H NMR (300 MHz, DMSO- d_6): δ 8.76 (dd, $J = 7.2, 0.9$ Hz, 1H), 8.47 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.06 (d, $J = 2.2$ Hz, 1H), 7.99 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.81 (dd, $J = 1.9, 0.9$ Hz, 1H), 7.55 (dd, $J = 7.6, 4.8$ Hz, 1H), 6.99 (dd, $J = 7.2, 2.0$ Hz, 1H), 6.70 (dd, $J = 2.2, 0.9$ Hz, 1H).

[1257] 4-(2-Chloropyridin-3-yl)-2-fluorobenzonitrile



^1H NMR (300 MHz, DMSO- d_6): δ 8.50 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.05 (dd, $J = 8.0, 7.0$ Hz, 1H), 7.95 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.76 (dd, $J = 10.4, 1.5$ Hz, 1H), 7.62 – 7.51 (m, 2H). ^{19}F NMR (282 MHz, DMSO- d_6): δ -108.27 (dd, $J = 10.5, 7.0$ Hz).


[1258] 5-(2-Chloropyridin-3-yl)-2-fluorobenzonitrile



^1H NMR (300 MHz, DMSO- d_6): δ 8.47 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.11 (dd, $J = 6.2, 2.2$ Hz, 1H), 7.97 – 7.94 (m, 1H), 7.94 – 7.90 (m, 1H), 7.65 (t, $J = 9.1$ Hz, 1H), 7.55 (dd, $J = 7.6, 4.8$ Hz, 1H).


^{19}F NMR (282 MHz, DMSO- d_6): δ -109.00 (dt, $J = 9.4, 5.7$ Hz).

[1259] 6-(2-Chloropyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine




^1H NMR (300 MHz, DMSO- d_6): δ 9.09 (d, $J = 2.4$ Hz, 1H), 8.83 (d, $J = 2.4$ Hz, 1H), 8.56 (s, 1H), 8.52 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.17 (br s, 2H), 8.07 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.62 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1260] 6-(2-Chloropyridin-3-yl)-7-methylimidazo[1,2-a]pyridine




^1H NMR (300 MHz, DMSO- d_6): δ 8.50 (dd, $J = 4.8, 2.0$ Hz, 1H), 8.49 (s, 1H), 7.93 (dd, $J = 7.5, 2.0$ Hz, 1H), 7.85 (d, $J = 0.9$ Hz, 1H), 7.58 – 7.53 (m, 2H), 7.52 (app s 1H), 2.06 (d, $J = 0.9$ Hz, 3H).

[1261] 6-(2-Chloropyridin-3-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyridine




^1H NMR (300 MHz, DMSO- d_6): δ 8.59 (s, 1H), 8.53 (dd, $J = 4.8, 1.9$ Hz, 1H), 7.99 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.83 (d, $J = 9.1$ Hz, 1H), 7.62 – 7.56 (m, 2H), 2.53 (s, 3H).

[1262] 6-(2-Chloropyridin-3-yl)-7-methyl-[1,2,4]triazolo[1,5-a]pyridine




^1H NMR (300 MHz, DMSO- d_6): δ 8.97 (s, 1H), 8.53 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.48 (s, 1H), 7.97 (dd, $J = 7.5, 1.9$ Hz, 1H), 7.83 (s, 1H), 7.58 (dd, $J = 7.5, 4.8$ Hz, 1H), 2.15 (s, 3H).

[1263] 6-(2-Chloropyridin-3-yl)imidazo[1,2-b]pyridazine




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.58 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.38 (d, $J = 0.8$ Hz, 1H), 8.25 (d, $J = 9.4$ Hz, 1H), 8.13 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.87 (d, $J = 0.8$ Hz, 1H), 7.62 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.50 (d, $J = 9.4$ Hz, 1H).

[1264] 6-(2-Chloropyridin-3-yl)-8-fluoro-[1,2,4]triazolo[1,5-a]pyridine




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 9.14 (d, $J = 1.4$ Hz, 1H), 8.67 (s, 1H), 8.51 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.05 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.90 (dd, $J = 11.1, 1.4$ Hz, 1H), 7.58 (dd, $J = 7.6, 4.8$ Hz, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$): δ -129.92 (d, $J = 11.2$ Hz).

[1265] 7-Chloro-6-(2-chloropyridin-3-yl)imidazo[1,2-a]pyridine




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.76 (s, 1H), 8.53 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.03 – 7.95 (m, 2H), 7.67 (d, $J = 1.2$ Hz, 1H), 7.58 (dd, $J = 7.5, 4.8$ Hz, 1H).

[1266] 6-(2-Chloropyridin-3-yl)quinolin-4-amine




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.46 (d, $J = 4.3$ Hz, 1H), 8.33 (d, $J = 5.2$ Hz, 1H), 8.24 (s, 1H), 7.97 (d, $J = 7.2$ Hz, 1H), 7.81 (d, $J = 9.0$ Hz, 1H), 7.69 (d, $J = 9.6$ Hz, 1H), 7.56 (dd, $J = 7.4, 4.9$ Hz, 1H), 6.85 (br s, 2H), 6.56 (d, $J = 5.0$ Hz, 1H).

[1267] 6-(2-Chloropyridin-3-yl)-4-methoxyquinoline




^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ 8.79 (d, $J = 5.3$ Hz, 1H), 8.47 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.17 (d, $J = 2.1$ Hz, 1H), 8.06 – 7.94 (m, 2H), 7.83 (dd, $J = 8.7, 2.1$ Hz, 1H), 7.55 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.08 (d, $J = 5.2$ Hz, 1H), 4.04 (s, 3H).

[1268] 6-(2-Chloropyridin-3-yl)quinoline-4-carboxamide




^1H NMR (300 MHz, DMSO- d_6): δ 9.02 (d, $J = 4.3$ Hz, 1H), 8.49 (dd, $J = 4.7, 1.8$ Hz, 1H), 8.29 (d, $J = 1.8$ Hz, 2H), 8.16 (d, $J = 8.7$ Hz, 1H), 8.00 (dd, $J = 7.5, 1.8$ Hz, 1H), 7.92 (dd, $J = 8.7, 2.0$ Hz, 2H), 7.63 (d, $J = 4.3$ Hz, 1H), 7.58 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1269] 6-(2-Chloropyridin-3-yl)imidazo[1,2-b]pyridazine-3-carbonitrile




^1H NMR (300 MHz, DMSO- d_6): δ 8.67 (s, 1H), 8.62 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.52 (d, $J = 9.5$ Hz, 1H), 8.17 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.90 (d, $J = 9.5$ Hz, 1H), 7.67 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1270] 6-(2-Chloropyridin-3-yl)-[1,2,4]triazolo[1,5-b]pyridazine




^1H NMR (300 MHz, DMSO- d_6): δ 8.77 (s, 1H), 8.61 (d, $J = 4.8, 1.9$ Hz, 1H), 8.59 (d, $J = 9.4$ Hz, 1H), 8.19 (dd, $J = 7.6, 1.9$ Hz, 1H), 8.01 (d, $J = 9.4$ Hz, 1H), 7.66 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1271] 7-(2-Chloro-5-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine



^1H NMR (300 MHz, DMSO- d_6): δ 9.06 (dd, $J = 7.1, 0.9$ Hz, 1H), 8.58 (s, 1H), 8.23 (d, $J = 3.0$ Hz, 1H), 8.02 (d, $J = 1.9$ Hz, 1H), 7.67 (d, $J = 3.0$ Hz, 1H), 7.36 (dd, $J = 7.1, 1.9$ Hz, 1H), 3.89 (s, 3H).


[1272] 7-(2-Chloro-5-fluoropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine



^1H NMR (300 MHz, DMSO- d_6): δ 9.09 (dd, $J = 7.1, 0.9$ Hz, 1H), 8.60 (s, 1H), 8.59 (d, $J = 3.0$ Hz, 1H), 8.13 (dd, $J = 8.6, 3.0$ Hz, 1H), 8.05 (dd, $J = 1.8, 0.9$ Hz, 1H), 7.38 (dd, $J = 7.1, 1.8$ Hz, 2H).


[1273] 7-(2-Chloro-5-methylpyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine

316




$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 9.05 (d, $J = 8.0$ Hz, 1H), 8.57 (s, 1H), 8.34 (d, $J = 2.3$ Hz, 1H), 7.97 (d, $J = 1.8$ Hz, 1H), 7.88 (d, $J = 2.3$ Hz, 1H), 7.33 (dd, $J = 7.1, 1.9$ Hz, 1H), 2.35 (s, 3H).

[1274] 7-(2-Chloropyridin-3-yl)-1-methylquinoxalin-2(1H)-one




$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 8.49 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.27 (s, 1H), 8.00 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.91 (d, $J = 8.2$ Hz, 1H), 7.68 (d, $J = 1.7$ Hz, 1H), 7.58 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.50 (dd, $J = 8.2, 1.8$ Hz, 1H), 3.62 (s, 4H).

[1275] 7-(2-Chloropyridin-3-yl)quinoxalin-2(1H)-one




$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 12.51 (s, 1H), 8.48 (dd, $J = 4.7, 1.9$ Hz, 1H), 8.21 (s, 1H), 7.94 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.87 (d, $J = 8.3$ Hz, 1H), 7.56 (dd, $J = 7.6, 4.7$ Hz, 1H), 7.42 – 7.33 (m, 2H).

[1276] 7-(2-Chloropyridin-3-yl)-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide




$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 12.47 (s, 1H), 8.45 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.03 (s, 1H), 7.93 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.88 (d, $J = 1.9$ Hz, 1H), 7.80 (dd, $J = 8.5, 2.0$ Hz, 1H), 7.53 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.43 (d, $J = 8.5$ Hz, 1H).

[1277] 7-(2-Chloropyridin-3-yl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide




$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 8.47 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.12 (s, 1H), 7.96-7.94 (m, 2H), 7.90 (d, $J = 2.1$ Hz, 1H), 7.61 (d, $J = 8.8$ Hz, 1H), 7.55 (dd, $J = 7.6, 4.8$ Hz, 1H), 3.66 (s, 3H).

[1278] Ethyl 5-(2-chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate




$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 9.40 (d, $J = 7.3$ Hz, 1H), 8.69 (s, 1H), 8.64 – 8.50 (m, 1H), 8.17 (dd, $J = 7.7, 1.9$ Hz, 1H), 7.76 – 7.58 (m, 2H), 4.27 (q, $J = 7.1$ Hz, 2H), 1.29 (t, $J = 7.1$ Hz, 3H).

[1279] 5-(2-Chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile




$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 9.50 (dd, $J = 7.2, 0.9$ Hz, 1H), 8.90 (s, 1H), 8.60 (dd, $J = 4.7, 1.9$ Hz, 1H), 8.20 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.75 (d, $J = 7.2$ Hz, 1H), 7.65 (dd, $J = 7.6, 4.8$ Hz, 1H).

[1280] N-(2'-chloro-[3,3'-bipyridin]-6-yl)acetamide




$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$) δ 10.64 (s, 1H), 8.44 (dd, $J = 4.7, 1.9$ Hz, 1H), 8.40 (d, $J = 2.5$ Hz, 1H), 8.16 (d, $J = 8.7$ Hz, 1H), 8.02 – 7.84 (m, 2H), 7.53 (dd, $J = 7.6, 4.8$ Hz, 1H), 2.11 (s, 3H).

[1281] 5-(2-Chloropyridin-3-yl)thiazolo[5,4-b]pyridin-2-amine



$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 8.44 (dd, $J = 4.7, 1.9$ Hz, 1H), 8.04 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.94 (s, 2H), 7.70 (d, $J = 8.3$ Hz, 1H), 7.59 (d, $J = 8.3$ Hz, 1H), 7.52 (dd, $J = 7.6, 4.7$ Hz, 1H).

[1282] 5-(2-Chloropyridin-3-yl)thiazolo[5,4-b]pyridine




^1H NMR (300 MHz, DMSO- d_6): δ 9.63 (s, 1H), 8.61 (d, J = 8.5 Hz, 1H), 8.53 (dd, J = 4.7, 1.9 Hz, 1H), 8.12 (dd, J = 7.6, 1.9 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.59 (dd, J = 7.6, 4.8 Hz, 1H).

Example 83

[1283] 2-(6-(2-Chloropyridin-3-yl)-1H-indazol-1-yl)acetamide and 2-(6-(2-chloropyridin-3-yl)-2H-indazol-2-yl)acetamide can be prepared as shown in Scheme 33, and as described below:

Scheme 33




6-(2-Chloropyridin-3-yl)-1H-indazole (0.6 g, 2.6 mmol), 2-bromoacetamide (0.5 g, 3.4 mmol) and Cs_2CO_3 (1.3 g, 3.9 mmol) in dry DMF (2.5 mL) was stirred under argon in a screw capped vial at room temperature. The reaction mixture was diluted with water after 2 days and the resultant solid was collected by filtration. Individual alkylated indazole regio-isomers were isolated by from the solid by purification (Combiflash[®] companion system[®] with RediSep[®] silica gel column 24 g and 30-50-75% EtOAc/hexanes as an eluting solvent). 2-(6-(2-chloropyridin-3-yl)-1H-indazol-1-yl)acetamide (*fast eluted N1-regio-isomer*): ^1H NMR (300 MHz, DMSO- d_6): δ 8.45 (dd, J = 4.7, 1.9 Hz, 1H), 8.12 (s, 1H), 7.91 (dd, J = 7.6, 1.9 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.71 (s, 1H), 7.54 (dd, J = 7.6, 4.7 Hz, 2H), 7.23 (dd, J = 8.3, 1.4 Hz, 2H), 5.08 (s, 2H). 2-(6-(2-Chloropyridin-3-yl)-2H-indazol-2-yl)acetamide (*late eluted N2-regio-isomer*): ^1H NMR (300 MHz, DMSO- d_6): δ 8.43 (dd, J = 4.7, 1.9 Hz, 1H), 8.40 (d, J = 0.8 Hz, 1H), 7.91 (dd, J = 7.5, 1.9 Hz, 1H), 7.80 (dd, J = 8.6, 0.8 Hz, 1H), 7.74 – 7.61 (m, 2H), 7.52 (dd, J = 7.6, 4.8 Hz, 1H), 7.35 (s, 1H), 7.10 (dd, J = 8.6, 1.4 Hz, 1H), 5.12 (s, 2H).

Example 84

[1284] 6-Bromo-3-methylimidazo[1,2-a]pyridine can be prepared as shown in Scheme 34, and as described below:


Scheme 34



2-Bromo-1,1-diethoxypropane (5 g) was added to a stirring solution of aq. 1N HCl (15 mL) and heated at 90 °C for 1h. The clear reaction mixture was cooled to room temperature and treated with solid NaHCO₃ till pH 7.0. 2-amino-5-bromopyridine (1.8 G) and MeOH (25 mL) were transferred successively to the above reaction mixture and heated at 90 °C. After 8h, the reaction mixture was concentrated under vacuum by rotary evaporator. The resulting solid concentrate was stirred in CH₂Cl₂/water (200 mL/75 ml). Organic layer was separated, dried over MgSO₄, filtered and concentrated. The crude concentrate was stirred in EtOAc (30 mL) and the solid was collected by filtration to obtain 6-bromo-3-methylimidazo[1,2-a]pyridine as a tan solid (1.6 g). ¹H NMR (300 MHz, DMSO-*d*₆): δ 8.55 (s, 1H), 7.50 (d, *J* = 9.5 Hz, 1H), 7.37 (s, 1H), 7.28 (d, *J* = 9.5 Hz, 1H), 2.44 (s, 3H).

Example 85

[1285] 6-Iodo-2-methylimidazo[1,2-a]pyridine can be prepared as shown in Scheme 35, and as described below:




Chloroacetone (3 mL) was added to a stirring solution of 2-amino-5-iodopyridine (2 g) in EtOH (20 mL) and heated to reflux. The reaction progress (50% of unreacted 2-amino-5-iodopyridine) was analyzed after 12h by LC/MS and TLC. Additional amount of chloroacetone (3 mL) was transferred to the reaction mixture and heated for additional 8h to observe the >90% consumption of 2-amino-5-iodopyridine. The reaction mixture was cooled and concentrated to dryness. The crude residue was diluted with EtOAc (130 mL)/water (50 mL) and neutralized with 5% aq. NaOH (25 mL). Organic layer from the biphasic solution was separated and the aqueous phase was partitioned again with EtOAc (70 mL). Combined organic layers were dried over MgSO₄, filtered and concentrated. The crude brown residue was purified by Combiflash[®] companion system[®] with RediSep[®] silica gel column [(80 g), 50-75-100% EtOAc/hexanes as an eluting solvent gradient]. The product fractions were concentrated to provide 2.2 g of 6-iodo-2-methylimidazo[1,2-a]pyridine (1.8 g) as an off-brown solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ

8.81 (dd, $J = 1.7, 1.0$ Hz, 1H), 7.62 – 7.55 (app s, 1H), 7.31 (dd, $J = 9.4, 1.7$ Hz, 1H), 7.25 (dd, $J = 9.3, 0.8$ Hz, 1H), 2.29 (s, 3H). See Helvetica Chimica Acta, 90(12), 2349-2367 (2007).

Example 86


[1286] 6-Iodo-2-methylimidazo[1,2-a]pyridine



6-Iodo-2-methylimidazo[1,2-a]pyridine can be prepared via the procedures described in J. Med. Chem, 54(7), 2455-66 (2011). ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.38 (dd, $J = 1.9, 0.9$ Hz, 1H), 7.47 (dd, $J = 9.5, 0.8$ Hz, 1H), 7.33 (s, 1H), 7.26 (dd, $J = 9.5, 2.0$ Hz, 1H), 3.78-3.75 (m 4H), 3.07 – 2.80 (m, 5H).

Example 87


[1287] 4-(6-Bromoquinolin-4-yl)morpholine can be prepared as shown in Scheme 36, and as described below:



6-Bromo-4-chloroquinoline (1.0 G, 4.1 mmol), morpholine (0.468 g, 5.3 mmol) and K_2CO_3 (1.0G, 7.2 mmol) in NMP (5 mL) were heated at 100 °C for 12h. The reaction mixture was cooled to room temperature, diluted with water (20 mL) and the product was extracted into EtOAc/hexanes (140 mL/60 mL). The organic layer was washed with water (75 mL) and brine (20 mL) successively, dried over MgSO_4 and filtered. The filtrate was concentrated and purified by flash column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g and 30-70% EtOAc/hexanes as an eluting solvent]. The product fractions were concentrated to provide 4-(6-bromoquinolin-4-yl)morpholine (700 mg) as a white solid. ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.73 (d, $J = 5.0$ Hz, 1H), 8.13 (d, $J = 2.2$ Hz, 1H), 7.90 (d, $J = 8.9$ Hz, 1H), 7.81 (dd, $J = 9.0, 2.2$ Hz, 1H), 7.06 (d, $J = 5.0$ Hz, 1H), 3.87-3.84 (m, 4H), 3.18 – 3.02 (m, 4H).

Example 88


[1288] 6-Bromo-3-(trifluoromethyl)imidazo[1,2-a]pyridine can be prepared as shown in Scheme 37, and as described below:



A screw capped vial (20 mL) containing a stir bar was charged with 6-bromo-3-iodoimidazo[1,2-a]pyridine (0.27 g) followed by dry DMF (4 mL) and (Phen)CuCF₃ sequentially. The capped vial containing initial dark reaction mixture was stirred at 50 °C. The reaction mixture changed colors as it progressed from pink to off-yellow and off-green at the end of the reaction. The progress was monitored intermittently by LC/MS. After 48h, the reaction mixture was diluted with EtOAc/CH₂Cl₂ (1:1, 50 mL) and filtered through a pad of Celite[®]/Fluorosil[®] and washed the pad with additional amount of EtOAc/CH₂Cl₂ (1:1, 50 mL). The filtrate was concentrated by rotary evaporator under vacuum to dryness. The crude concentrate was diluted with water, sonicated for 10 min and filtered. The collected solid was suction dried to provide the desired 6-bromo-3-(trifluoromethyl)imidazo[1,2-a]pyridine along with 3-iodo-6-(trifluoromethyl)imidazo[1,2-a]pyridine (12:1) which can be used in the subsequent coupling with no further purification. See *Hartwig Angew. Int. Ed. Eng.* 2011, 50, 3793-3794.

Example 89


[1289] 6-Bromoimidazo[1,2-a]pyridine-3-carbonitrile can be prepared as shown in Scheme 38:



See *J. Med. Chem.*, 54(7), 2455-66 (2011).

Example 90


[1290] 4-(6-Bromoimidazo[1,2-a]pyridin-3-yl)morpholine:



4-(6-Bromoimidazo[1,2-a]pyridin-3-yl)morpholine can be prepared as described in J. Med. Chem., 54(7), 2455-66 (2011). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.38 (dd, *J* = 1.9, 0.9 Hz, 1H), 7.47 (dd, *J* = 9.5, 0.8 Hz, 1H), 7.33 (s, 1H), 7.26 (dd, *J* = 9.5, 2.0 Hz, 1H), 3.78-3.75 (m, 4H), 3.07 – 2.80 (m, 5H).

Example 91


[1291] 4-(6-Bromo-3-(pyrrolidin-1-yl)imidazo[1,2-a]pyridine):



4-(6-Bromo-3-(pyrrolidin-1-yl)imidazo[1,2-a]pyridine can be prepared as described in J. Med. Chem., 54(7), 2455-66 (2011).

Example 92

[1292] 6-Bromoimidazo[1,2-a]pyridine-3-carbonitrile can be prepared as shown in Scheme 39:




Stirring solution of 6-bromoimidazo[1,2-a]pyridine-3-carbaldehyde [see Bioorg. Med. Chem. Lett. 15(17), 5837-5844; 2007; Int'l Pat. App. Pub. no. 2011/055320] (1.5g, 6.6 mmol) in MeOH (20 mL) was cooled to 0 °C and NaBH₄ (0.50 g, 13.2 mmol) was added in portions for a period of 20 min. Cooling was removed after 1h and allowed to stir for 3h. The reaction mixture was quenched with water and concentrated by rotary evaporator to dryness. Subsequently, the solid concentrate was diluted with water and collected on the Buchner funnel by suction filtration. The solid was suction dried to obtain (6-bromoimidazo[1,2-a]pyridin-3-yl)methanol as a pale yellow crystalline solid (0.83 g). ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.63 (dd, *J* = 2.0, 0.9 Hz, 1H), 7.55

(dd, $J = 9.5, 0.9$ Hz, 1H), 7.52 (s, 1H), 7.36 (dd, $J = 9.5, 2.0$ Hz, 1H), 5.27 (t, $J = 5.4$ Hz, 1H), 4.79 (d, $J = 5.3$ Hz, 2H). See *J. Med. Chem.*, 54(7), 2455-66 (2011).

Example 93


[1293] 4-((6-Bromoimidazo[1,2-a]pyridin-3-yl)methyl)morpholine can be prepared as shown in Scheme 40:



Morpholine (1.91 g, 22mmol) and 37% aq. formaldehyde (5 mL, 60 mmol) in acetonitrile:water (6:1, mL) was stirred for 15 min at room temperature. 6-bromoimidazo[1,2-a]pyridine (3.94 g, 20 mmol) and Sc(OTf)_3 were added sequentially to the above solution and stirred for 36h at room temperature to observe the complete consumption of 6-bromoimidazo[1,2-a]pyridine. The reaction mixture was concentrated, diluted with aq. K_2CO_3 (150 mL) and stirred the suspension for 25 min. The solid was collected by filtration and dried on the funnel to obtain 4-((6-bromoimidazo[1,2-a]pyridin-3-yl)methyl)morpholine (3.9 g). $^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$) δ 8.69 (d, $J = 1.7$ Hz, 1H), 7.54 (d, $J = 9.6$ Hz, 1H), 7.51 (s, 1H), 7.34 (dd, $J = 9.5, 1.7$ Hz, 1H), 3.81 (s, 2H), 3.64 – 3.39 (m, 3H), 2.43 – 2.26 (m, 3H). See U. S. Pat. App. Pub. no. 2005/0054701.

Example 94


[1294] 46-Bromo-N-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine-3-carboxamide can be prepared as shown in Scheme 41:




A stirring solution of 6-bromoimidazo[1,2-a]pyridine-3-carboxylic acid (0.91 g, 3.7 mmol), EDCI (1.08 g, 5.6 mmol), HOBt (0.76 g, 5.6 mmol) and 3,4,5-trimethoxyaniline (0.76 g, 4.1 mmol) in acetonitrile/DMF (8/3 mL) under argon was added *i*-Pr₂NEt (2.00 g, 2.6 ml), 15.4 mmol) drop wise for 5 min at room temperature. The resulting off-brown homogeneous reaction mixture was continued to stir at room temperature for 18h. Subsequently, the heterogeneous reaction mixture was diluted with water and the solid was collected by filtration. The solid was suction dried on funnel to obtain 6-bromo-N-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine-3-carboxamide (1.1 g) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.17 (s, 1H), 9.64 (s, 1H), 8.56 (d, *J* = 1.1 Hz, 1H), 7.75 (d, *J* = 9.7 Hz, 1H), 7.64 (dd, *J* = 9.5, 1.9 Hz, 1H), 7.15 (s, 2H), 3.78 (s, 6H), 3.63 (s, 3H).

[1295] Similarly, the following compounds can be prepared:

[1296] 6-Bromo-N-(1-methylpiperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide




[1297] 6-Bromo-N-(3-(2-oxopyrrolidin-1-yl)propyl)imidazo[1,2-a]pyridine-3-carboxamide



Example 95


[1298] 6-Bromoimidazo[1,2-a]pyridine-3-carboxylic acid can be prepared as shown in Scheme 42 or Scheme 43:



[1299] A stirring solution of 6-bromoimidazo[1,2-a]pyridine-3-carbonitrile [JMC 54(7), 2455-2466; 2011] (1.0 g), EtOH (10 mL) and aq. NaOH (1.0 g, 10 mL) was heated at 100 °C. After 12h, the reaction mixture was cooled and concentrated to dryness by rotary evaporator under

reduced pressure. Subsequently, the crude solid was diluted with water, cooled in ice-bath and acidified with conc. HCl till pH 4 while stirring. The resulting suspension was suction filtered and the solid was dried overnight. Subsequently, the collected solid was further dried over P₂O₅ under high vacuum to obtain 6-bromoimidazo[1,2-a]pyridine-3-carboxylic acid (0.91 g) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.27 (s, 1H), 9.36 (s, 1H), 8.24 (s, 1H), 7.77 (d, *J* = 9.5 Hz, 1H), 7.67 (d, *J* = 9.5, 1.7 Hz, 1H).


Scheme 43



[1300] Reaction mixture containing N¹-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide (6.5 g, 28.5 mmol), methyl 2-bromoacetate (5.6 g, 3.5 mL, 37.0 mmol) and NaHCO₃ (4.1 g, 48.8 mmol) in *i*-PrOH (60 mL) was heated at 90 °C under nitrogen. The heating was stopped after 12h and cooled the dense heterogeneous reaction mixture to room temperature. The reaction mixture was concentrated and diluted with water. The resultant slurry was collected by suction filtration and obtained methyl 6-bromoimidazo[1,2-a]pyridine-3-carboxylate (6.9 g) as a tan white solid upon drying. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.31 (d, *J* = 1.8 Hz, 1H), 8.31 (s, 1H), 7.80 (d, *J* = 9.5 Hz, 1H), 7.71 (dd, *J* = 9.5, 1.6 Hz, 1H), 3.88 (s, 4H). Ester hydrolysis was done by stirring a solution of methyl 6-bromoimidazo[1,2-a]pyridine-3-carboxylate (2.5 g), LiOH. H₂O (1.2 g) in THF/MeOH/H₂O (1/1/1, 75 mL) at room temperature. Reaction mixture was concentrated upon complete hydrolysis of ester to corresponding acid, diluted with water/ice and acidified with 2N. aq HCl until pH 6. The resulting solid was filtered, suction dried followed by drying under P₂O₅ under vacuum to obtain 6-bromoimidazo[1,2-a]pyridine-3-carboxylic acid (2.2 g) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.27 (s, 1H), 9.36 (s, 1H), 8.24 (s, 1H), 7.77 (d, *J* = 9.5 Hz, 1H), 7.67 (d, *J* = 9.5, 1.7 Hz, 1H).

Example 96


[1301] 6-Bromo-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine can be prepared as shown in Scheme 44:

Scheme 44

A reaction flask was charged with 6-bromo-3-iodoimidazo[1,2-a]pyridine (2.0 g, 6.2 mmol), (3,4,5-trimethoxyphenyl)boronic acid (1.44 g, 6.8 mmol), 2M. aq. Na₂CO₃ (8 mL, 16 mmol), 1,4-dioxane (50 mL) and a stir bar. The contents were degassed by vacuum and back filled with argon in three times while stirring. Subsequently, catalyst Pd(PPh₃)₄ (0.35 g, 0.30 mmol) was added to the reaction contents, repeated degassing cycles and heated at 90 °C for 12h. Reaction mixture was cooled and filtered the biphasic reaction mixture through Celite[®] and concentrated the filtrate. The crude solid residue was partitioned between CH₂Cl₂(150 mL)/water (50 mL). The organic layer was separated, dried over MgSO₄, filtered and concentrated. The crude concentrate (2.2 g) was subjected to purification by flash column chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g, 30-60% EtOAc/hexanes as an eluting solvent) to obtain 6-bromo-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine as a white solid (1.0 g).

Example 97

[1302] 1-(6-Bromoimidazo[1,2-a]pyridin-3-yl)ethan-1-one can be prepared as shown in Scheme 45:




(E)-N'-(5-Bromopyridin-2-yl)-N,N-dimethylformimidamide (2.0 g, 8.8 mmol), 1-chloropropan-2-one (1.2 mL, 1.4 g, 15 mmol), NaHCO₃ (1.3 g, 15.5 mmol) in 2-propanol (30 mL) were heated at 90 °C under nitrogen for 12h. The dark reaction mixture was cooled and the dense

heterogeneous suspension was diluted with water. The solid was collected by filtration, washed with water and dried to obtain 1.0 g of 1-(6-bromoimidazo[1,2-a]pyridin-3-yl)ethan-1-one. ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 9.62 (d, $J = 1.9$ Hz, 1H), 8.61 (s, 1H), 7.81 (d, $J = 9.5$ Hz, 1H), 7.75 (dd, $J = 9.5, 1.9$ Hz, 1H), 2.55 (s, 3H). See *Bioorg. Med. Chem. Lett.* 15(1), 403-412 (2007); Int'l Pat. App. Pub. no. 2009/158011.

Example 98


[1303] 7-Bromoimidazo[1,5-a]pyridine:



7-Bromoimidazo[1,5-a]pyridine can be prepared as described in Int'l Pat. App. Pub. no. 2005090304.

Example 99

[1304] 1-(6-Bromoimidazo[1,2-a]pyridin-3-yl)ethan-1-one can be prepared as shown in Scheme 46:




A reaction flask was charged with 1-bromo-3-(methyl- d_3)benzene (2.0 g, 11.5 mmol), bis(pinacolato)diboron (5.8 g, 23 mmol) and KOAc (2.25 g, 23 mmol), DMF (20 mL) and a stir bar. The contents were degassed by vacuum and back filled with argon three times while stirring. Subsequently, catalyst $\text{PdCl}_2(\text{dppf}) \cdot \text{CH}_2\text{Cl}_2$ (0.85 g, 1.15 mmol) was added to the reaction contents, repeated degassing cycles and heated at 100 °C for 12h. Reaction mixture was cooled and filtered the reaction mixture through Celite[®]. The filtrate cake was washed with EtOAc (30 mL) and the filtrate was partitioned between EtOAc (150 mL) / water (40 mL). Organic layer was separated and the aqueous layer was extracted with additional EtOAc. Combined organic layers were stirred over $\text{MgSO}_4/\text{Celite}^{\text{®}}/\text{Fluorosil}^{\text{®}}$ and filtered. The filtrate was concentrated and purified by flash column chromatography (CombiFlash[®] companion system[®] with RediSep[®] silica gel column 80 g, 10-20% EtOAc/hexanes as elutant) to obtain 4,4,5,5-tetramethyl-2-(3-

(methyl-*d*₃)phenyl)-1,3,2-dioxaborolane as a semi solid (2.85 g) and used in the boronate coupling with no further purification.

Example 100


[1305] Triazolopyrimidines can be prepared using the protocol of Scheme 47, described as in Huntsman, E and Balsells, J., Eur. J. Org. Chem. 2005, (17), 3761-3765:

Scheme 47




[1306] The following compounds were made:

[1307] 6-Bromo-5-methyl-[1,2,4]triazolo[1,5-a]pyridine




¹H NMR (300 MHz, DMSO-*d*₆) δ 8.52 (s, 1H), 7.83 (d, *J* = 9.4 Hz, 1H), 7.69 (d, *J* = 9.4 Hz, 1H), 2.84 (s, 3H).

[1308] 6-Bromo-7-methyl-[1,2,4]triazolo[1,5-a]pyridine



¹H NMR (300 MHz, DMSO-*d*₆) δ 9.36 (s, 1H), 8.44 (s, 1H), 7.86 (s, 1H), 2.45 (s, 3H).

[1309] 6-Bromo-8-fluoro-[1,2,4]triazolo[1,5-a]pyridine:




¹H NMR (300 MHz, DMSO-*d*₆) δ 9.32 (app dd, *J* = 1.5, 0.7 Hz, 1H), 8.59 (s, 1H), 7.98 (dd, *J* = 9.9, 1.5 Hz, 1H). ¹⁹F NMR (282 MHz, DMSO-*d*₆) δ -127.85 (d, *J* = 9.9 Hz).

Example 101


[1310] 6-Bromoimidazo[1,2-*b*]pyridazine-3-carbonitrile can be prepared as shown in Scheme 48:

Scheme 48



Example 102


[1311] (E)-N'-(6-Bromopyridazin-3-yl)-N,N-dimethylformimidamide



3-Amino-6-bromopyridazine (5.0 g, 28.7 mmol) was heated and stirred with dimethylformamide dimethylacetal (5.36 g, 6.0 mL, 45.0 mmol) under nitrogen at 110 °C for 3h. The brown homogeneous reaction mixture was cooled to room temperature. The resulting heterogeneous slurry was stirred in EtOAc/hexanes (1:1, 75 mL) and filtered. The filtered solid was suction dried to obtain apparently (E)-N'-(6-bromopyridazin-3-yl)-N,N-dimethylformimidamide (4.9 g) as a pale pink crystalline solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.45 (s, 1H), 7.64 (d, *J* = 9.1 Hz, 1H), 7.03 (d, *J* = 9.1 Hz, 1H), 3.11 (s, 3H), 3.00 (s, 3H).

Example 103


[1312] 6-Bromoimidazo[1,2-b]pyridazine-3-carbonitrile



(E)-N'-(6-Bromopyridazin-3-yl)-N,N-dimethylformimidamide (2.5 g, 10.9 mmol), bromoacetonitrile (3.92 g, 32.7 mmol) and NaHCO₃ (1.8 g, 21.8 mmol) in *i*-PrOH (15 mL) were heated at 75 °C for 8h while stirring the contents. Subsequently, the dark reaction mixture was diluted with water and the resulting solid was collected by filtration. The solid was purified by flash chromatography (Combiflash[®] companion system[®] with RediSep[®] silica gel column 40 g and 15-30-50% EtOAc/hexanes as an eluting solvent) to obtain 1.3 g of 6-bromoimidazo[1,2-b]pyridazine-3-carbonitrile. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.58 (s, 1H), 8.33 (d, *J* = 9.5 Hz, 1H), 7.77 (d, *J* = 9.5 Hz, 1H).

Example 104

[1313] 6-Chloro-[1,2,4]triazolo[1,5-b]pyridazine




(6-Chloro-[1,2,4]triazolo[1,5-b]pyridazine can be prepared as described in J. Het. Chem., 12(1), 107-110 (1975).


Example 105

[1314] Bromopyrido[2,3-d]pyrimidin-4-amine can prepared as shown in Scheme 49, and as described below:

Scheme 49




[1315] 6-Bromopyrido[2,3-d]pyrimidin-4(3H)-one



2-Amino-5-bromopyridin-3-carboxylic acid (2 g) and formamidine acetate (3.0 g) were heated at 120 °C in 2-methoxyethanol (15 ml) for 36 h under argon. The heterogeneous reaction mixture was diluted with water and filtered. The solid was suction dried to obtain 1.7 g of 6-bromopyrido[2,3-d]pyrimidin-4(3H)-one. ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.70 (s, 1H), 9.01 (d, *J* = 2.6 Hz, 1H), 8.59 (d, *J* = 2.6 Hz, 1H), 8.33 (s, 1H).


[1316] 6-Bromo-4-chloropyrido[2,3-d]pyrimidine:



6-Bromopyrido[2,3-d]pyrimidin-4(3H)-one (3.0g) and POCl₃ (15 mL) were heated at 130 °C under nitrogen for 3h. The homogeneous dark solution was concentrated under reduced pressure and diluted with EtOAc (150 mL). The heterogeneous brown slurry was poured onto mixture of


ice/aq. NaHCO₃ and allowed the mixture warm to room temperature. The heterogeneous brown mixture was further diluted with EtOAc (75 mL) and separated the organic layer. The organic layer was partitioned with aq. NaCl, separated, stirred with MgSO₄ and filtered through a pad of Celite[®] and silica gel. The pale yellow filtrate was concentrated and the crude solid was stirred in 50% EA/hexanes. 6-Bromo-4-chloropyrido[2,3-d]pyrimidine was obtained as a pale yellow crystalline solid (1.8 g, purity: 95%) upon filtration.

[1317] 6-Bromopyrido[2,3-d]pyrimidin-4-amine



6-Bromo-4-chloropyrido[2,3-d]pyrimidine (1.0 g) and 4% NH₃ in *i*-PrOH (25 mL) were stirred in a sealed tube at room temperature overnight. The pale brown heterogeneous slurry was concentrated, diluted with water and filtered. The brown solid thus collected was suction dried to obtain 6-bromopyrido[2,3-d]pyrimidin-4-amine (1.3 g, purity: 97%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.09 (d, *J* = 2.5 Hz, 1H), 9.01 (d, *J* = 2.5 Hz, 1H), 8.52 (s, 1H), 8.31 (br s, 2H).

Example 106



[1318] Starting ArCl (0.3 mmol), glycine *tert*-butyl ester (0.4 mmol), and dry THF (2.5 mL) were added into a 10 mL of microwave vial, Et₃N (0.25 mmol) was then added. The resulting mixture was heated at 60 °C overnight.

[1319] The mixture was then transferred to a 10 mL of round bottom flask and concentrated. The crude product was dissolved in dry CH₂Cl₂ (3 mL), followed by the addition of TFA (0.5 mL). After stirring at room temperature for 3 h, the volatiles were evaporated and the resulting mixture was subjected to HPLC purification to provide the corresponding compound.


LC/MS: rt (A or B)

[1320] Method A: Column: Luna 5μ C8 (100 X 4.6 mm), Flow rate 1.0 ml/min, Mobile phase: A: H₂O 0.05% TFA, B: CH₃CN 0.05% TFA

[1321] Method B: Column: Gemini 5 μ C18 (100 X 4.6 mm), Flow rate 1.5 ml/min, Mobile phase: A: H₂O 0.05% HCOOH, B: CH₃CN 0.05% HCOOH.


Example 107

[1322] 6-(2-(3-(benzyloxy)phenyl)pyridin-3-yl)quinazolin-4-amine




[1323] LCMS: rt 4.63 min (A), MS (m/e) 405 MH⁺.

[1324] 6-(2-(3-(benzyloxy)-5-methylphenyl)pyridin-3-yl)quinazolin-4-amine



[1325] LCMS: rt 4.85 min (A), MS (m/e) 419 MH⁺.

[1326] 3-(3-(4-aminoquinazolin-6-yl)pyridin-2-yl)phenol




[1327] LCMS: rt 2.16 min (A), MS (m/e) 315 MH⁺.

[1328] 6-(2-(3-chloro-2,4-difluorophenyl)pyridin-3-yl)quinazolin-4-amine-



[1329] LCMS: rt 4.68 min (A), MS (m/e) 369 MH⁺.


[1330] 3-(3-(4-aminoquinazolin-6-yl)pyridin-2-yl)phenyl dimethylcarbamate



[1331] LCMS: rt 3.68 min (A), MS (m/e) 386 MH⁺.


[1332] ¹H NMR (DMSO-d₆, 300 MHz): 8.71 (dd, J = 4.8, 1.8 Hz, 1H), 8.36 (s, 1H), 8.27 (d, J = 1.8 Hz, 1H), 7.94 (dd, J = 7.8, 1.8 Hz, 1H), 7.73 (brs, 2H), 7.54 (dd, J = 8.1, 1.8 Hz, 1H), 7.48 (d, J = 8.7 Hz, 1H), 7.35 (dd, J = 8.4, 1.8 Hz, 1H), 7.21 (m, 1H), 7.15 (m, 1H), 7.02-6.98 (m, 1H), 6.95-6.91 (m, 1H), 2.95 (s, 3H), 2.84 (s, 3H).

[1333] 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)-7-methylquinazolin-4-amine




[1334] LCMS: rt 2.96 min (B), MS (m/e) 365 MH⁺.

[1335] 6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)-7-methylquinazolin-4-amine



[1336] LCMS: rt 2.82 min (B), MS (m/e) 365 MH⁺.

[1337] 6-(2-(3-(difluoromethoxy)phenyl)pyridin-3-yl)quinazolin-4-amine



[1338] LCMS: rt 2.59 min (B), MS (m/e) 365 MH⁺.

[1339] ¹H NMR (CD₃OD, 300 MHz): 8.69 (dd, J = 4.8, 1.5 Hz, 1H), 8.41 (s, 1H), 8.17 (m, 1H), 8.02 (dd, J = 7.8, 1.5 Hz, 1H), 7.58 (dd, J = 7.8, 4.8 Hz, 1H), 7.55 (s, 1H), 7.48 (dd, J = 8.4, 1.8 Hz, 1H), 7.27 (m, 1H), 7.16-7.12 (m, 2H), 7.09-7.05 (m, 1H), 6.64 (t, J = 73.8 Hz, 1H).

[1340] 6-(2-(2,5-dimethylphenyl)pyridin-3-yl)quinazolin-4-amine



[1341] LCMS: rt 2.19 min (B), MS (m/e) 327 MH⁺.

[1342] 6-(2-(2-chloro-5-methylphenyl)pyridin-3-yl)quinazolin-4-amine




[1343] LCMS: rt 2.68 min (B), MS (m/e) 347 MH⁺.

[1344] ¹H NMR (CD₃OD, 300 MHz): 8.64 (dd, J = 4.8, 1.5 Hz, 1H), 8.38 (s, 1H), 8.14 (m, 1H), 8.03 (dd, J = 7.8, 1.5 Hz, 1H), 7.63 (dd, J = 7.8, 4.8 Hz, 1H), 7.49 (m, 2H), 7.27 (m, 1H), 7.14 (m, 2H), 2.31 (s, 3H).


[1345] 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)-8-methylquinazolin-4-amine

335



[1346] LCMS: rt 3.09 min (B), MS (m/e) 365 MH⁺.


[1347] 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-8-methylquinazolin-4-amine



[1348] LCMS: rt 2.67 min (B), MS (m/e) 345 MH⁺.


[1349] ¹H NMR (CD₃OD, 300 MHz): 8.62 (dd, J = 4.8, 1.5 Hz, 1H), 8.39 (s, 1H), 7.99 (dd, J = 7.8, 1.5 Hz, 1H), 7.95 (m, 1H), 7.55 (dd, J = 7.8, 4.8 Hz, 1H), 7.33 (m, 1H), 7.28 (m, 1H), 7.05 (m, 1H), 6.88 (m, 1H), 2.45 (s, 3H), 2.16 (s, 3H).

[1350] 6-(2-(4,5-difluoro-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine




[1351] LCMS: rt 2.58 min (B), MS (m/e) 349 MH⁺.

[1352] 6-(2-(5-fluoro-2,4-dimethylphenyl)pyridin-3-yl)quinazolin-4-amine




[1353] LCMS: rt 2.50 min (B), MS (m/e) 345 MH⁺.

[1354] 6-(2-(5-chloro-4-fluoro-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine



[1355] LCMS: rt 4.43 min (A), MS (m/e) 365 MH⁺.


[1356] 6-(2-(3-chloro-4-fluorophenyl)-5-methylpyridin-3-yl)quinazolin-4-amine



[1357] LCMS: rt 3.09 min (B), MS (m/e) 365 MH⁺.


[1358] ¹H NMR (CD₃OD, 300 MHz): 8.51 (dd, J = 4.8, 1.5 Hz, 1H), 8.41 (s, 1H), 8.17 (m, 1H), 7.83 (dd, J = 7.8, 1.5 Hz, 1H), 7.58 (m, 1H), 7.51 (dd, J = 7.8, 4.8 Hz, 1H), 7.48 (m, 1H), 7.13-7.04 (m, 2H), 2.48 (s, 3H).

[1359] 3-(3-(4-aminoquinazolin-6-yl)-5-methylpyridin-2-yl)phenol




[1360] LCMS: rt 1.72 min (B), MS (m/e) 329 MH⁺.

[1361] 6-(2-(3-chloro-4-fluorophenyl)-5-methoxypyridin-3-yl)quinazolin-4-amine



[1362] LCMS: rt 3.29 min (B), MS (m/e) 381 MH⁺.


[1363] 6-(2-(5-chloro-2-fluorophenyl)-5-methoxypyridin-3-yl)quinazolin-4-amine



[1364] LCMS: rt 3.18 min (B), MS (m/e) 381 MH⁺.


[1365] ¹H NMR (CD₃OD, 300 MHz): 8.41 (dd, J = 4.8, 1.5 Hz, 1H), 8.38 (s, 1H), 8.15 (m, 1H), 7.61 (dd, J = 7.8, 1.5 Hz, 1H), 7.56 (m, 1H), 7.51 (dd, J = 7.8, 4.8 Hz, 1H), 7.34 (m, 1H), 6.88 (m, 1H), 3.31 (s, 3H).

[1366] 3-(3-(4-aminoquinazolin-6-yl)-5-methoxypyridin-2-yl)phenol




[1367] LCMS: rt 2.16 min (B), MS (m/e) 345 MH⁺.

[1368] 6-(2-(2,3,5-trifluorophenyl)pyridin-3-yl)quinazolin-4-amine



[1369] LCMS: rt 2.63 min (B), MS (m/e) 353 MH⁺.


[1370] 6-(2-(2,5-dichloro-4-fluorophenyl)pyridin-3-yl)quinazolin-4-amine



[1371] LCMS: rt 3.06 min (B), MS (m/e) 386 MH⁺.


[1372] $^1\text{H NMR}$ (CD_3OD , 300 MHz): 8.69 (dd, $J = 4.8, 1.5$ Hz, 1H), 8.37 (s, 1H), 8.12 (m, 1H), 8.06 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.68 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.64 (s, 1H), 7.55 (m, 2H), 7.30-7.27 (m, 1H).

[1373] 5-(3-(4-aminoquinazolin-6-yl)pyridin-2-yl)benzene-1,3-diol




[1374] LCMS: rt 3.03 min (B), MS (m/e) 331 MH^+ .

[1375] 6-(2-(3-chloro-4-fluorophenyl)-5-fluoropyridin-3-yl)quinazolin-4-amine




[1376] LCMS: rt 3.36 min (B), MS (m/e) 369 MH^+ .

[1377] 6-(2-(5-chloro-2-fluorophenyl)-5-fluoropyridin-3-yl)quinazolin-4-amine




[1378] LCMS: rt 3.19 min (B), MS (m/e) 369 MH^+ .

[1379] 3-(3-(4-aminoquinazolin-6-yl)-5-fluoropyridin-2-yl)phenol



[1380] LCMS: rt 2.35 min (B), MS (m/e) 333 MH^+ .


[1381] 6-(2-(3-(difluoromethyl)-4-fluorophenyl)pyridin-3-yl)quinazolin-4-amine



[1382] LCMS: rt 2.69 min (B), MS (m/e) 367 MH⁺.


[1383] ¹H NMR (CD₃OD, 300 MHz): 8.70 (dd, J = 4.8, 1.5 Hz, 1H), 8.40 (s, 1H), 8.17 (m, 2H), 8.03 (dd, J = 7.8, 1.5 Hz, 1H), 7.59 (m, 2H), 7.54 (dd, J = 7.8, 4.8 Hz, 1H), 7.48 (m, 1H), 7.15-7.08 (m, 1H), 6.89 (t, J = 54.6 Hz, 1H).

[1384] 6-(2-(4-fluoro-2,5-dimethylphenyl)pyridin-3-yl)quinazolin-4-amine




[1385] LCMS: rt 2.16 min (B), MS (m/e) 345 MH⁺.

[1386] 6-(2-(2-fluorophenyl)pyridin-3-yl)quinazolin-4-amine



[1387] LCMS: rt 2.13 min (B), MS (m/e) 317 MH⁺.


[1388] 6-(2-(2-fluoro-5-methylphenyl)pyridin-3-yl)quinazolin-4-amine



[1389] LCMS: rt 2.46 min (B), MS (m/e) 331 MH⁺.


[1390] $^1\text{H NMR}$ (CD_3OD , 300 MHz): 8.69 (dd, $J = 4.8, 1.5$ Hz, 1H), 8.39 (s, 1H), 8.15 (m, 1H), 8.03 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.61 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.52 (m, 2H), 7.34-7.31 (m, 1H), 7.16 (m, 2H), 6.76 (m, 1H), 2.32 (s, 3H).

[1391] 3-(3-(4-aminoquinazolin-6-yl)pyridin-2-yl)-4-methylphenol



[1392] LCMS: rt 1.64 min (B), MS (m/e) 329 MH^+ .


[1393] 3-(3-(4-aminoquinazolin-6-yl)pyridin-2-yl)-4-fluorophenol



[1394] LCMS: rt 1.88 min (B), MS (m/e) 333 MH^+ .

[1395] $^1\text{H NMR}$ (CD_3OD , 300 MHz): 8.68 (dd, $J = 4.8, 1.5$ Hz, 1H), 8.43 (s, 1H), 8.19 (m, 2H), 8.03 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.61 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.55 (m, 1H), 6.89-6.86 (m, 1H), 6.74-6.71 (m, 2H).

[1396] 6-(2-(3-ethylphenyl)pyridin-3-yl)quinazolin-4-amine




[1397] LCMS: rt 2.39 min (B), MS (m/e) 327 MH^+ .

[1398] $^1\text{H NMR}$ (CD_3OD , 300 MHz): 8.66 (dd, $J = 4.8, 1.5$ Hz, 1H), 8.41 (s, 1H), 8.18 (m, 2H), 8.03 (dd, $J = 8.1, 1.5$ Hz, 1H), 7.55 (dd, $J = 8.1, 4.8$ Hz, 1H), 7.51 (s, 1H), 7.49 (dd, $J = 8.7, 1.5$ Hz, 1H), 7.19-7.10 (m, 3H), 2.49 (q, $J = 7.5$ Hz, 2H), 0.96 (t, $J = 7.5$ Hz, 3H).


[1399] 6-(2-(2-chloro-4-fluoro-5-methoxyphenyl)pyridin-3-yl)quinazolin-4-amine

341




[1400] LCMS: rt 2.72 min (B), MS (m/e) 381 MH⁺.

[1401] 6-(2-(2-chloro-5-(trifluoromethoxy)phenyl)pyridin-3-yl)quinazolin-4-amine



[1402] LCMS: rt 3.28 min (B), MS (m/e) 417 MH⁺.


[1403] 6-(2-(3-(difluoromethoxy)-4-fluorophenyl)pyridin-3-yl)quinazolin-4-amine



[1404] LCMS: rt 4.41 min (A), MS (m/e) 383 MH⁺.

[1405] ¹H NMR (CD₃OD, 300 MHz): 8.78 (dd, J = 4.8, 1.5 Hz, 1H), 8.68 (s, 1H), 8.37 (m, 1H), 8.13 (dd, J = 7.8, 1.5 Hz, 1H), 7.74 (dd, J = 8.7, 1.8 Hz, 2H), 7.73-7.67 (m, 1H), 7.32-7.19 (m, 3H), 6.71 (t, J = 72.9 Hz, 1H).


[1406] 6-(2-(2-chloro-5-methoxyphenyl)pyridin-3-yl)quinazolin-4-amine



[1407] LCMS: rt 4.03 min (A), MS (m/e) 363 MH⁺.

[1408] 6-(2-(2-chloro-4-fluoro-5-methylphenyl)pyridin-3-yl)quinazolin-4-amine


342



[1409] LCMS: rt 4.41 min (A), MS (m/e) 365 MH⁺.


[1410] ¹H NMR (CD₃OD, 300 MHz): 8.77 (dd, J = 4.8, 1.5 Hz, 1H), 8.66 (s, 1H), 8.37 (m, 1H), 8.16 (dd, J = 7.8, 1.5 Hz, 1H), 7.78(m, 1H), 7.73 (dd, J = 7.8, 4.8 Hz, 1H), 7.62 (m, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.05 (d, J = 9.6 Hz, 1H), 2.26 (s, 3H),

[1411] 5-(3-(4-aminoquinazolin-6-yl)pyridin-2-yl)-2,4-difluorophenol



[1412] LCMS: rt 3.46 min (A), MS (m/e) 351 MH⁺.


[1413] 6-(2-(2-fluoro-5-(trifluoromethoxy)phenyl)pyridin-3-yl)quinazolin-4-amine



[1414] LCMS: rt 5.06 min (A), MS (m/e) 401 MH⁺.

[1415] ¹H NMR (CD₃OD, 300 MHz): 8.80 (dd, J = 4.8, 1.5 Hz, 1H), 8.67 (s, 1H), 8.32 (m, 1H), 8.13 (dd, J = 7.8, 1.5 Hz, 1H), 7.81 (dd, J = 8.4, 1.8 Hz, 1H), 7.73 (dd, J = 8.1, 5.1 Hz, 1H), 7.69 (t, J = 8.4 Hz, 1H), 7.48 (m, 1H), 7.34 (m, 1H), 7.06 (t, J = 8.7 Hz, 1H).


[1416] 6-(2-(5-methoxy-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine



[1417] LCMS: rt 3.41 min (A), MS (m/e) 343 MH⁺.


[1418] 3-(3-(4-aminoquinazolin-6-yl)pyridin-2-yl)-4-chlorophenol

343




[1419] LCMS: rt 2.19 min (B), MS (m/e) 349 MH⁺.

[1420] 6-(2-(2-chloro-5-(difluoromethoxy)phenyl)pyridin-3-yl)quinazolin-4-amine




[1421] LCMS: rt 2.93 min (B), MS (m/e) 399 MH⁺.

[1422] 6-(2-(2-chloro-5-(difluoromethyl)phenyl)pyridin-3-yl)quinazolin-4-amine



[1423] LCMS: rt 2.83 min (B), MS (m/e) 383 MH⁺.

[1424] ¹H NMR (CD₃OD, 300 MHz): 8.71 (dd, J = 4.8, 1.5 Hz, 1H), 8.38 (s, 1H), 8.15 (m, 1H), 8.08 (dd, J = 7.8, 1.5 Hz, 1H), 7.70-7.64 (m, 2H), 7.52 (m, 3H), 7.43 (m, 1H), 6.78 (t, J = 56.1 Hz, 1H).




[1426] LCMS: rt 1.83 min (B), MS (m/e) 347 MH⁺.

[1427] 5-(3-(4-aminoquinazolin-6-yl)pyridin-2-yl)-4-chloro-2-fluorophenol




[1428] LCMS: rt 2.30 min (B), MS (m/e) 367 MH⁺.

[1429] 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-amine




[1430] LCMS: rt 3.76 min (A), MS (m/e) 331 MH⁺.

[1431] 6-(2-(4-fluoro-5-methoxy-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine



[1432] LCMS: rt 2.34 min (B), MS (m/e) 361 MH⁺.

[1433] 6-(2-(5-(difluoromethyl)-2-fluorophenyl)pyridin-3-yl)quinazolin-4-amine




[1434] LCMS: rt 2.64 min (B), MS (m/e) 367 MH⁺.

[1435] ¹H NMR (CD₃OD, 300 MHz): 8.72 (dd, J = 4.8, 1.5 Hz, 1H), 8.40 (s, 1H), 8.14 (m, 1H), 8.07 (dd, J = 7.8, 1.5 Hz, 1H), 7.75-7.73 (m, 1H), 7.65 (dd, J = 7.8, 4.8 Hz, 1H), 7.58-7.53 (m, 3H), 7.03 (m, 1H), 6.78 (t, J = 56.4 Hz, 1H).


[1436] 6-(2-(5-(difluoromethyl)-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine

345




[1437] LCMS: rt 2.56 min (B), MS (m/e) 363 MH⁺.

[1438] 6-(2-(5-(difluoromethyl)-4-fluoro-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine




[1439] LCMS: rt 2.71 min (B), MS (m/e) 381 MH⁺. ¹H NMR (CD₃OD, 300 MHz): 8.70 (dd, J = 4.8, 1.5 Hz, 1H), 8.39 (s, 1H), 8.13 (m, 1H), 8.05 (dd, J = 8.1, 1.8 Hz, 1H), 7.62 (dd, J = 7.8, 4.8 Hz, 1H), 7.52 (m, 1H), 7.47 (m, 1H), 7.39 (dd, J = 8.4, 1.8 Hz, 1H), 6.98 (m, 1H), 6.85 (t, J = 54.9 Hz, 1H), 2.00 (s, 3H).

[1440] 2-(((6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)amino)acetamide



[1441] LCMS: rt 2.26 min (B), MS (m/e) 388 MH⁺.


[1442] 2-(((6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)amino)propanamide



[1443] LCMS: rt 2.53 min (B), MS (m/e) 402 MH⁺.


[1444] methyl (6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)glycinate

346




[1445] LCMS: rt 2.66 min (B), MS (m/e) 403 MH⁺.

[1446] 3-((6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-yl)amino)propanamide




[1447] LCMS: rt 2.41 min (B), MS (m/e) 402 MH⁺.

[1448] 6-(2-(3-(oxetan-3-yloxy)phenyl)pyridin-3-yl)quinazolin-4-amine



[1449] LCMS: rt 2.16 min (B), MS (m/e) 371 MH⁺.


[1450] (6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)quinazolin-4-yl)glycine



[1451] LCMS: rt 3.05 min (B), MS (m/e) 409 MH⁺.

[1452] 6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)-N-(1-methyl-1H-pyrazol-3-yl)quinazolin-4-amine

347




[1453] LCMS: rt 3.76 min (B), MS (m/e) 431 MH⁺.

[1454] 6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)-N-(1H-pyrazol-4-yl)quinazolin-4-amine



[1455] LCMS: rt 3.20 min (B), MS (m/e) 417 MH⁺.


[1456] 6-(2-(5-(difluoromethyl)-3-fluoro-2-methylphenyl)pyridin-3-yl)quinazolin-4-amine



[1457] LCMS: rt 2.88 min (B), MS (m/e) 381 MH⁺.

[1458] ¹H NMR (CD₃OD, 300 MHz): 8.71 (dd, J = 4.8, 1.5 Hz, 1H), 8.38 (s, 1H), 8.13 (m, 1H), 8.09 (dd, J = 7.8, 1.5 Hz, 1H), 7.67 (dd, J = 8.4, 4.8 Hz, 1H), 7.51 (m, 1H), 7.43 (dd, J = 8.4, 1.8 Hz, 1H), 7.26 (s, 1H), 7.23 (m, 1H), 6.68 (t, J = 55.8 Hz, 1H), 1.90 (s, 3H).


[1459] 6-(2-(5-chloro-2,3-difluorophenyl)pyridin-3-yl)quinazolin-4-amine



[1460] LCMS: rt 2.76 min (A), MS (m/e) 369 MH⁺.

[1461] ¹H NMR (CD₃OD, 300 MHz): 8.73 (dd, J = 4.8, 1.5 Hz, 1H), 8.43 (s, 1H), 8.18 (m, 1H), 8.16 (dd, J = 7.8, 1.5 Hz, 1H), 8.09 (dd, J = 8.7, 1.5 Hz, 1H), 7.68 (dd, J = 7.8, 4.8 Hz, 1H), 7.61 (s, 1H), 7.41-7.36 (m, 2H).


[1462] 6-(2-(2,5-dichloro-3-fluorophenyl)pyridin-3-yl)quinazolin-4-amine



[1463] LCMS: rt 2.94 min (B), MS (m/e) 386 MH⁺.


[1464] ¹H NMR (CD₃OD, 300 MHz): 8.69 (dd, *J* = 4.8, 1.5 Hz, 1H), 8.41 (s, 1H), 8.17 (m, 1H), 8.13 (dd, *J* = 7.8, 1.8 Hz, 1H), 8.02 (dd, *J* = 8.4, 1.8 Hz, 1H), 7.66 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.61 (s, 1H), 7.19-7.13 (m, 1H), 7.03-6.99 (m, 1H).

[1465] 5-(2-(5-Chloro-2-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine




[1466] LCMS: rt 6.35 min (A), purity 97%, MS (m/e) 321 MH⁺.

[1467] 5-(2-(2,5-Dimethylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine



[1468] ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.84 (dd, *J* = 7.3, 0.9 Hz, 1H), 8.75 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.31 – 8.15 (m, 2H), 7.57 (dd, *J* = 7.9, 4.8 Hz, 1H), 7.06 (s, 2H), 6.97 (s, 1H), 6.73 (dd, *J* = 2.3, 0.8 Hz, 1H), 6.40 (d, *J* = 7.3 Hz, 1H), 2.18 (s, 3H), 1.89 (s, 3H). LCMS: rt 6.35 min (A), purity 97%, MS (m/e) 301 MH⁺.

[1469] 5-(2-(2-Chloro-5-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine




[1470] LCMS: rt 6.26 min (A), purity 99%, MS (m/e) 321 MH⁺.

[1471] 5-(2-(4,5-Difluoro-2-methylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine




[1472] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.94 (dd, $J = 7.3, 0.9$ Hz, 1H), 8.77 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.27 – 8.17 (app m, 2H), 7.62 (dd, $J = 7.9, 4.8$ Hz, 1H), 7.27 (ddd, $J = 11.5, 8.2, 2.8$ Hz, 2H), 6.70 (dd, $J = 2.4, 0.9$ Hz, 1H), 6.60 (d, $J = 7.3$ Hz, 1H), 1.88 (s, 3H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -139.59 (ddd, $J = 23.1, 11.9, 8.3$ Hz), -142.89 (ddd, $J = 23.2, 11.0, 8.5$ Hz). LCMS: rt 6.28 min (A), purity 98%, MS (m/e) 323 MH^+ .

[1473] 5-(2-(2,3,5-Trifluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine




[1474] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 9.08 (dd, $J = 7.3, 0.9$ Hz, 1H), 8.83 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.29 (dd, $J = 7.9, 1.7$ Hz, 1H), 8.22 (d, $J = 2.3$ Hz, 1H), 7.69 (dd, $J = 7.9, 4.8$ Hz, 1H), 7.64 – 7.51 (m, 1H), 7.34 – 7.22 (m, 1H), 6.97 (d, $J = 7.3$ Hz, 1H), 6.63 (dd, $J = 2.3, 0.9$ Hz, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -114.67 (dtd, $J = 18.1, 8.6, 3.6$ Hz), -134.41 (ddd, $J = 23.0, 11.1, 3.2$ Hz), -146.74 (ddt, $J = 21.3, 15.4, 5.7$ Hz). LCMS: rt 6.80 min (A), purity 95%, MS (m/e) 327 MH^+ .

[1475] 5-(2-(2,3,4,5-Tetrafluorophenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine




[1476] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 9.06 (dd, $J = 7.4, 0.9$ Hz, 1H), 8.83 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.30 (dd, $J = 7.9, 1.6$ Hz, 1H), 8.22 (d, $J = 2.4$ Hz, 1H), 7.70 (dd, $J = 7.9, 4.8$ Hz, 1H), 7.61 (dddd, $J = 11.0, 8.6, 6.3, 2.5$ Hz, 1H), 6.99 (d, $J = 7.3$ Hz, 1H), 6.65 (dd, $J = 2.4, 0.9$ Hz, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -139.46 (dt, $J = 22.8, 11.7$ Hz), -141.53 (dddd, $J = 22.3, 12.5, 6.2, 3.4$ Hz), -155.95 (tdd, $J = 22.5, 8.4, 3.4$ Hz), -156.81 (t, $J = 21.7$ Hz). LCMS: rt 7.28 min (A), purity 97%, MS (m/e) 345 MH^+ .

[1477] 6-(2-(2,3,4,5-Tetrafluorophenyl)pyridin-3-yl)benzo[d]thiazole




[1478] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 9.40 (s, 1H), 8.74 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.12 (dd, $J = 1.8, 0.6$ Hz, 1H), 8.03 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.99 (dd, $J = 8.5, 0.6$ Hz, 1H), 7.64 (dd, $J = 7.9, 4.8$ Hz, 1H), 7.52 (dddd, $J = 10.9, 8.4, 6.1, 2.5$ Hz, 1H), 7.29 (dd, $J = 8.5, 1.8$ Hz, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -139.52 (dt, $J = 22.7, 11.7$ Hz), -140.53 (dddd, $J = 22.3, 12.5, 6.2, 3.4$ Hz), -156.15 (tdd, $J = 21.9, 8.4, 3.4$ Hz), -156.62 (t, $J = 21.5$ Hz). LCMS: rt 7.95 min (A), purity 99%, MS (m/e) 361 MH^+ .

[1479] 6-(2-(2,3,5-Trifluorophenyl)pyridin-3-yl)benzo[d]thiazole




[1480] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 9.39 (s, 1H), 8.74 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.11 (d, $J = 1.8$ Hz, 1H), 8.02 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.98 (d, $J = 8.5$ Hz, 1H), 7.63 (dd, $J = 7.9, 4.8$ Hz, 1H), 7.50 (dddd, $J = 11.3, 9.0, 6.2, 3.2$ Hz, 1H), 7.28 (dd, $J = 8.5, 1.8$ Hz, 1H), 7.21 (dddd, $J = 7.9, 5.0, 3.1, 2.0$ Hz, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -114.81 (dtd, $J = 17.6, 8.6, 3.6$ Hz), -134.17 (ddd, $J = 23.0, 10.9, 3.2$ Hz), -145.38 (ddt, $J = 21.2, 15.1, 5.4$ Hz). LCMS: rt 7.43 min (A), purity 97%, MS (m/e) 343 MH^+ .

[1481] 6-(2-(5-Chloro-2-methylphenyl)pyridin-3-yl)benzo[d]thiazole




[1482] LCMS: rt 6.16 min (A), purity 98%, MS (m/e) 337 MH^+ .

[1483] 6-(2-(2,5-Dimethylphenyl)pyridin-3-yl)benzo[d]thiazole




[1484] ^1H NMR (300 MHz, DMSO- d_6) δ 9.34 (s, 1H), 8.66 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.00 (d, $J = 1.8$ Hz, 1H), 7.93 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.87 (dd, $J = 8.5, 0.6$ Hz, 1H), 7.51 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.19 (dd, $J = 8.5, 1.8$ Hz, 1H), 6.95 (q, $J = 1.5, 1.1$ Hz, 3H), 2.15 (s, 3H), 1.81 (s, 3H). LCMS: rt 5.33 min (A), purity 99%, MS (m/e) 317 MH^+ .

[1485] 6-(2-(2-Chloro-5-methylphenyl)pyridin-3-yl)benzo[d]thiazole




[1486] ^1H NMR (300 MHz, DMSO- d_6) δ 9.35 (s, 1H), 8.67 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.02 (d, $J = 1.8$ Hz, 1H), 7.95 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.89 (d, $J = 8.5$ Hz, 1H), 7.56 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.25 – 7.20 (m, 2H), 7.16 (d, $J = 8.2$ Hz, 1H), 7.10 (ddd, $J = 8.2, 2.1, 0.7$ Hz, 1H), 2.23 (s, 3H). LCMS: rt 6.25 min (A), purity 99%, MS (m/e) 337 MH^+ .

[1487] 6-(2-(4,5-Difluoro-2-methylphenyl)pyridin-3-yl)benzo[d]thiazole




[1488] LCMS: rt 6.18min (A), purity 99%, MS (m/e) 339 MH^+ .

[1489] 6-(2-(4-Fluoro-2,5-dimethylphenyl)pyridin-3-yl)benzo[d]thiazole




[1490] ^1H NMR (300 MHz, DMSO- d_6) δ 9.35 (s, 1H), 8.66 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.02 (d, $J = 1.6$ Hz, 1H), 7.94 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.90 (d, $J = 8.4$ Hz, 1H), 7.52 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.18 (dd, $J = 8.5, 1.8$ Hz, 1H), 7.05 (d, $J = 8.2$ Hz, 1H), 6.85 (d, $J = 10.9$ Hz, 1H), 2.08 (s, 3H), 1.81 (s, 3H). ^{19}F NMR (282 MHz, DMSO- d_6) δ -119.54 (t, $J = 9.6$ Hz). LCMS: rt 5.61 min (A), purity 99%, MS (m/e) 335 MH^+ .

[1491] 5-(2-(4-Fluoro-2,5-dimethylphenyl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine




[1492] LCMS: rt 5.73 min (A), purity 99%, MS (m/e) 319 MH⁺.

[1493] 6-(2-(4-Fluoro-2,5-dimethylphenyl)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carbonitrile




[1494] LCMS: rt 5.60 min (A), purity 99%, MS (m/e) 343 MH⁺.

[1495] 6-(2-(4-Fluoro-2,5-dimethylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine




[1496] LCMS: rt 4.88 min (A), purity 99%, MS (m/e) 319 MH⁺.

[1497] 7-(2-(4-Fluoro-2,5-dimethylphenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine




[1498] LCMS: rt 4.95 min (A), purity 98%, MS (m/e) 319 MH⁺.

[1499] 6-(2-(2-Chloro-4-fluoro-5-methylphenyl)pyridin-3-yl)benzo[d]thiazole




[1500] LCMS: rt 6.63 min (A), purity 97%, MS (m/e) 355 MH⁺.

[1501] 6-(2-(3-(Difluoromethyl)-4-fluorophenyl)pyridin-3-yl)benzo[d]thiazole




[1502] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 9.39 (s, 1H), 8.73 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.13 (d, $J = 1.7$ Hz, 1H), 8.02 – 7.95 (m, 2H), 7.67 (dd, $J = 6.9, 2.0$ Hz, 1H), 7.57 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.44 – 7.33 (m, 1H), 7.28 – 7.16 (m, 2H), 7.12 (t, $J = 54.2$ Hz, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -113.73 (dd, $J = 54.3, 4.6$ Hz), -119.33 (dt, $J = 11.2, 5.5$ Hz). LCMS: rt 6.35 min (A), purity 99%, MS (m/e) 357 MH^+ .

[1503] 6-(2-(2-Chloro-4-fluoro-5-methylphenyl)pyridin-3-yl)benzo[d]thiazole




[1504] LCMS: rt 6.65 min (A), purity 99%, MS (m/e) 355 MH^+ .

[1505] 6-(2-(2,5-Dichloro-4-fluorophenyl)pyridin-3-yl)benzo[d]thiazole




[1506] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 9.38 (s, 1H), 8.70 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.07 (d, $J = 1.8$ Hz, 1H), 7.99 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.96 (d, $J = 8.5$ Hz, 1H), 7.76 (d, $J = 8.0$ Hz, 1H), 7.61 (dd, $J = 8.2, 5.2$ Hz, 1H), 7.58 – 7.50 (m, 1H), 7.25 (dd, $J = 8.5, 1.8$ Hz, 1H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -114.24 (t, $J = 8.7$ Hz). LCMS: rt 7.85 min (A), purity 99%, MS (m/e) 376 MH^+ .

[1507] 6-(2-(Benzofuran-2-yl)pyridin-3-yl)benzo[d]thiazole




[1508] LCMS: rt 6.83 min (A), purity 96%, MS (m/e) 329 MH^+ .

[1509] 6-(2-(Benzofuran-5-yl)pyridin-3-yl)benzo[d]thiazole




[1510] $^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$) δ 9.36 (s, 1H), 8.69 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.12 (dd, $J = 1.8, 0.6$ Hz, 1H), 7.96 – 7.86 (m, 3H), 7.66 (dd, $J = 1.9, 0.7$ Hz, 1H), 7.49 (dd, $J = 7.7, 4.7$ Hz, 1H), 7.40 (dt, $J = 8.6, 0.8$ Hz, 1H), 7.21 (dd, $J = 8.4, 1.8$ Hz, 1H), 7.15 (dd, $J = 8.7, 1.9$ Hz, 1H), 6.86 (dd, $J = 2.2, 1.0$ Hz, 1H). LCMS: rt 5.12 min (A), purity 97%, MS (m/e) 329 MH^+ .

[1511] 6-(2-(Benzofuran-6-yl)pyridin-3-yl)benzo[d]thiazole




[1512] LCMS: rt 5.45 min (A), purity 95%, MS (m/e) 329 MH^+ .

[1513] 6-(2-(2,3-Dihydrobenzofuran-5-yl)pyridin-3-yl)benzo[d]thiazole



[1514] $^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$) δ 9.38 (s, 1H), 8.63 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.11 (dd, $J = 1.8, 0.6$ Hz, 1H), 7.96 (dd, $J = 8.4, 0.6$ Hz, 1H), 7.84 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.42 (dd, $J = 7.7, 4.7$ Hz, 1H), 7.32 (td, $J = 1.3, 0.7$ Hz, 1H), 7.24 (dd, $J = 8.4, 1.8$ Hz, 1H), 6.86 (dd, $J = 8.3, 2.0$ Hz, 1H), 6.51 (dd, $J = 8.3, 0.5$ Hz, 1H), 4.48 (t, $J = 8.8$ Hz, 2H), 3.06 (t, $J = 8.7$ Hz, 2H). LCMS: rt 4.81 min (A), purity 97%, MS (m/e) 331 MH^+ .


[1515] 6-(2-(2,3-Dihydrobenzofuran-7-yl)pyridin-3-yl)benzo[d]thiazole



[1516] LCMS: rt 4.90 min (A), purity 94%, MS (m/e) 329 MH^+ .


[1517] 2-(Benzofuran-2-yl)-3,4'-bipyridine

355




[1518] LCMS: rt 4.75 min (A), purity 96%, MS (m/e) 273 MH⁺.

[1519] 2-(Benzofuran-5-yl)-3,4'-bipyridine




[1520] LCMS: rt 3.71 min (A), purity 96%, MS (m/e) 273 MH⁺.

[1521] 2-(Benzofuran-7-yl)-3,4'-bipyridine




[1522] ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.78 (ddd, *J* = 4.8, 1.7, 0.6 Hz, 1H), 8.34 (ddd, *J* = 4.4, 1.7, 0.6 Hz, 2H), 7.99 (ddd, *J* = 7.8, 1.7, 0.6 Hz, 1H), 7.70 – 7.56 (m, 3H), 7.40 – 7.19 (m, 2H), 7.12 (ddd, *J* = 4.4, 1.6, 0.5 Hz, 2H), 6.84 (dd, *J* = 2.2, 0.6 Hz, 1H). LCMS: rt 3.93 min (A), purity 96%, MS (m/e) 273 MH⁺.

[1523] 2-(2,3-Dihydrobenzofuran-5-yl)-3,4'-bipyridine




[1524] LCMS: rt 3.18 min (A), purity 96%, MS (m/e) 275 MH⁺.

[1525] 2-(2,3-Dihydrobenzofuran-7-yl)-3,4'-bipyridine




[1526] LCMS: rt 3.45 min (A), purity 99%, MS (m/e) 275 MH⁺.

[1527] 6-(2-(Benzofuran-2-yl)pyridin-3-yl)quinazolin-4-amine




[1528] LCMS: rt 4.60 min (A), purity 99%, MS (m/e) 339 MH⁺.

[1529] 6-(2-(Benzofuran-5-yl)pyridin-3-yl)quinazolin-4-amine




[1530] ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.78 (br s, 2H), 8.81 (s, 1H), 8.58 – 8.51 (m, 2H), 8.00 – 7.94 (m, 2H), 7.68 (d, *J* = 1.8 Hz, 1H), 7.63 – 7.53 (m, 3H), 7.43 (d, *J* = 8.6 Hz, 1H), 7.15 (dd, *J* = 8.6, 1.8 Hz, 1H), 6.90 (dd, *J* = 2.2, 1.0 Hz, 1H). LCMS: rt 3.33 min (A), purity 99%, MS (m/e) 339 MH⁺.

[1531] 6-(2-(Benzofuran-7-yl)pyridin-3-yl)quinazolin-4-amine




[1532] ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.77 (br s, 2H), 8.81 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.76 (s, 1H), 8.51 (d, *J* = 1.5 Hz, 1H), 8.05 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.67 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.61 (dd, *J* = 9.1, 1.6 Hz, 2H), 7.53 (dd, *J* = 8.7, 1.7 Hz, 1H), 7.42 (d, *J* = 8.7 Hz, 1H), 7.35 (dd, *J* = 7.4, 0.9 Hz, 1H), 7.24 (t, *J* = 7.6 Hz, 1H), 6.80 (d, *J* = 2.2 Hz, 1H). LCMS: rt 3.58 min (A), purity 99%, MS (m/e) 339 MH⁺.

[1533] 6-(2-(2,3-Dihydrobenzofuran-5-yl)pyridin-3-yl)quinazolin-4-amine




[1534] LCMS: rt 2.83 min (A), purity 99%, MS (m/e) 341 MH⁺.

[1535] 6-(2-(2,3-Dihydrobenzofuran-7-yl)pyridin-3-yl)quinazolin-4-amine




[1536] LCMS: rt 2.90 min (A), purity 99%, MS (m/e) 341 MH⁺.

[1537] (E)-6-(2-Styrylpyridin-3-yl)benzo[d]thiazole




[1538] ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.46 (s, 1H), 8.65 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.26 (d, *J* = 1.8 Hz, 1H), 8.20 (d, *J* = 8.4 Hz, 1H), 7.82 (d, *J* = 15.7 Hz, 1H), 7.79 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.56 (dd, *J* = 8.4, 1.8 Hz, 1H), 7.46 – 7.37 (m, 3H), 7.36 – 7.23 (m, 3H), 7.12 (d, *J* = 15.7 Hz, 1H). LCMS: rt 5.90 min (A), purity 97%, MS (m/e) 315 MH⁺.

[1539] (E)-2-Styryl-3,4'-bipyridine




[1540] LCMS: rt 4.61 min (A), purity 97%, MS (m/e) 259 MH⁺.

[1541] (E)-6-(2-Styrylpyridin-3-yl)quinazolin-4-amine



[1542] ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.66 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.43 (s, 1H), 8.32 (d, *J* = 1.8 Hz, 1H), 7.90 – 7.73 (m, 6H), 7.49 – 7.37 (m, 3H), 7.37 – 7.20 (m, 3H), 7.13 (d, *J* = 15.7 Hz, 1H). LCMS: rt 4.00 min (A), purity 95%, MS (m/e) 325 MH⁺.


[1543] 6-(2-(3-((Trimethylsilyl)ethynyl)phenyl)pyridin-3-yl)quinazolin-4-amine



[1544] ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.71 (dd, *J* = 4.7, 1.6 Hz, 1H), 8.37 (s, 1H), 8.25 (d, *J* = 1.8 Hz, 1H), 7.95 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.74 (brs, 2H), 7.60 – 7.45 (m, 3H), 7.37 (dd,


$J = 8.6, 1.9$ Hz, 1H), 7.32 (dt, $J = 7.2, 1.7$ Hz, 1H), 7.21 – 7.07 (m, 2H), 0.17 (s, 9H). LCMS: rt 5.80 min (A), purity 95%, MS (m/e) 395 MH^+ .

[1545] 2-(3-((Trimethylsilyl)ethynyl)phenyl)-3,4'-bipyridine



[1546] LCMS: rt 6.43 min (A), purity 97%, MS (m/e) 329 MH^+ .

[1547] 6-(2-(3-(Trimethylsilyl)ethynyl)phenyl)pyridin-3-yl)benzo[d]thiazole




[1548] 1H NMR (300 MHz, $DMSO-d_6$) δ 9.38 (s, 1H), 8.70 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.10 (d, $J = 1.7$ Hz, 1H), 7.96 (d, $J = 8.4$ Hz, 1H), 7.92 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.52 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.48 (q, $J = 1.0$ Hz, 1H), 7.30 (ddd, $J = 6.1, 3.0, 1.7$ Hz, 1H), 7.24 (dd, $J = 8.4, 1.8$ Hz, 1H), 7.17 – 7.10 (m, 2H), 0.17 (s, 9H). LCMS: rt 7.98 min (A), purity 97%, MS (m/e) 385 MH^+ .

[1549] 3-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine



[1550] 1H NMR (300 MHz, $DMSO-d_6$) δ 8.69 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.27 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.08 – 8.02 (m, 2H), 8.00 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.90 (s, 1H), 7.73 (ddt, $J = 8.3, 6.6, 1.3$ Hz, 1H), 7.67 – 7.55 (m, 2H), 7.49 (ddd, $J = 7.7, 4.8, 0.6$ Hz, 1H), 7.35 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.33 – 7.27 (m, 1H), 7.15 – 7.01 (m, 2H), 6.80 (dd, $J = 9.7, 8.5$ Hz, 1H), 1.94 (d, $J = 1.9$ Hz, 3H). LCMS: rt 6.93 min (A), purity 97%, MS (m/e) 444 MH^+ .

[1551] 1-(Phenylsulfonyl)-3-(2-(*m*-tolyl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine




[1552] LCMS: rt 5.89 min (A), purity 96%, MS (m/e) 426 MH⁺.

[1553] 3-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine



[1554] Solid NaOH (50 mg, 1.25 mmol) was transferred to the stirring homogeneous solution of 3-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (150 mg, 0.34 mmol) and MeOH (4.0 mL). The vial was capped and heated at 90 °C with stirring. Progress of the reaction was monitored by silica gel TLC and LC/MS after 3h. The semi orange heterogeneous solution was concentrated, diluted with water (15 mL) and stirred at room temperature for 30 min. The heterogeneous suspension was suction filtered and dried. The crude off-white solid was purified by reverse phase preparative HPLC with TFA as a modifier. The product fractions were concentrated and neutralized with aq. NaHCO₃. The resulting white solid (78 mg, 75%) was collected by suction filtration and dried to obtain 3-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine. ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.80 (br s, 1H), 8.59 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.14 (dd, *J* = 4.7, 1.5 Hz, 1H), 7.89 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.47 – 7.34 (m, 4H), 7.10 (ddd, *J* = 7.7, 5.1, 2.3 Hz, 1H), 6.94 – 6.83 (m, 2H), 2.09 (s, 3H). ¹⁹F NMR (282 MHz, DMSO-*d*₆) δ -118.87 – -119.03 (m). LCMS: rt 4.23 min (A), purity 97%, MS (m/e) 304 MH⁺.


[1555] 3-(2-(*m*-Tolyl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine



[1556] 3-(2-(*m*-Tolyl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine was prepared analogous to the procedure described for 3-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine


from 1-(phenylsulfonyl)-3-(2-(*m*-tolyl)pyridin-3-yl)-1H-pyrrolo[2,3-*b*]pyridine. LCMS: rt 3.93 min (A), purity 97%, MS (m/e) 286 MH⁺.

[1557] 6-(2-(3-Ethynylphenyl)pyridin-3-yl)quinazolin-4-amine




[1558] 6-(2-(3-((Trimethylsilyl)ethynyl)phenyl)pyridin-3-yl)quinazolin-4-amine (100 mg, 0.253 mmol) and K₂CO₃ (70 mg, 0.50 mmol) in MeOH (4 mL) was stirred at room temperature. After 3h, the reaction mixture was concentrated to dryness upon complete proto-desilylation. The crude residue was partitioned between CH₂Cl₂/water. Organic layer was separated, dried over anhydrous Na₂SO₄, filtered and concentrated. The crude residue was purified by Combiflash[®] companion system[®] with RediSep[®] silica gel column (4 g) and 30-100% EtOAc/hexanes-100% EtOAc-3% 2M NH₃/MeOH in EtOAc as an eluting solvent gradient to obtain 6-(2-(3-ethynylphenyl)pyridin-3-yl)quinazolin-4-amine as a white solid (67 mg, 82%) after concentration of the product fractions. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.67 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.31 (s, 1H), 8.21 (d, *J* = 1.7 Hz, 1H), 7.89 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.69 (s, 2H), 7.50 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.44 (d, *J* = 6.6 Hz, 1H), 7.42 (s, 1H), 7.31 (ddd, *J* = 6.7, 3.5, 1.8 Hz, 2H), 7.18 – 7.12 (m, 2H), 4.05 (s, 1H). LCMS: rt 3.90 min (A), purity 97%, MS (m/e) 323 MH⁺.

[1559] 2-(3-Ethynylphenyl)-3,4'-bipyridine




[1560] 2-(3-Ethynylphenyl)-3,4'-bipyridine was prepared in the similar manner to 6-(2-(3-ethynylphenyl)pyridin-3-yl)quinazolin-4-amine from the corresponding 2-(3-((trimethylsilyl)ethynyl)phenyl)-3,4'-bipyridine. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.73 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.50 (dd, *J* = 4.4, 1.7 Hz, 2H), 7.90 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.54 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.44 – 7.37 (m, 2H), 7.31 – 7.24 (m, 2H), 7.20 (dd, *J* = 4.4, 1.7 Hz, 2H), 4.13 (s, 1H). LCMS: rt 4.18 min (A), purity 97%, MS (m/e) 257 MH⁺.

[1561] 6-(2-(3-Ethynylphenyl)pyridin-3-yl)benzo[d]thiazole




[1562] 6-(2-(3-Ethynylphenyl)pyridin-3-yl)benzo[d]thiazole was prepared in the similar manner to 6-(2-(3-ethynylphenyl)pyridin-3-yl)quinazolin-4-amine from the corresponding 6-(2-(3-(trimethylsilyl)ethynyl)phenyl)pyridin-3-yl)benzo[d]thiazole. ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 9.38 (s, 1H), 8.70 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.09 (dd, $J = 1.8, 0.5$ Hz, 1H), 7.96 (dd, $J = 8.4, 0.5$ Hz, 1H), 7.91 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.51 (dd, $J = 7.8, 4.7$ Hz, 1H), 7.46 (dt, $J = 1.6, 1.0$ Hz, 1H), 7.34 (ddd, $J = 5.4, 3.1, 1.7$ Hz, 1H), 7.25 (dd, $J = 8.4, 1.8$ Hz, 1H), 7.21 – 7.17 (m, 2H), 4.09 (s, 1H). LCMS: rt 5.83 min (A), purity 97%, MS (m/e) 313 MH^+ .

[1563] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine



[1564] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine was obtained analogous to the the preparation of 6-(3-chloro-4-fluorophenyl)pyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine by Suzuki-Miyura reaction of 6-(2-chloropyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine and 5-chloro-2-fluorophenylboronic acid. ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.86 – 8.78 (app m, 2H), 8.27 (dd, $J = 7.9, 1.7$ Hz, 1H), 8.22 (d, $J = 8.8$ Hz, 1H), 7.80 (d, $J = 8.8$ Hz, 1H), 7.72 – 7.61 (m, 2H), 7.45 (ddd, $J = 8.8, 4.4, 2.8$ Hz, 1H), 7.02 (dd, $J = 9.7, 8.9$ Hz, 1H), 4.09 (s, 3H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -119.02 (ddd, $J = 10.3, 6.5, 4.5$ Hz). LCMS: rt 4.93 min (A), purity 99%, MS (m/e) 367 MH^+ .


[1565] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one



[1566] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one was prepared by demethylation of 6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)-4-methoxypyrido[3,2-d]pyrimidine under acidic conditions analogous to the procedure for the preparation of 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one. ^1H NMR (300 MHz,

DMSO- d_6) δ 12.55 (s, 1H), 8.80 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.20 (dd, $J = 7.9, 1.7$ Hz, 1H), 8.13 (d, $J = 3.2$ Hz, 1H), 7.96 (d, $J = 8.6$ Hz, 1H), 7.71 – 7.60 (m, 2H), 7.56 (d, $J = 8.6$ Hz, 1H), 7.45 (ddd, $J = 8.8, 4.4, 2.8$ Hz, 1H), 7.06 (dd, $J = 9.7, 8.9$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6) δ -118.60 (ddd, $J = 10.1, 6.4, 4.5$ Hz). LCMS: rt 4.65 min (A), purity 99%, MS (m/e) 353 MH^+ .


[1567] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4-amine



[1568] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4-amine was prepared analogous to the procedure outlined in the preparation of 6-(2-(3-chloro-4-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4-amine from 6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4(3H)-one. ^1H NMR (300 MHz, DMSO- d_6) δ 8.80 (dd, $J = 4.6, 1.5$ Hz, 1H), 8.42 – 8.32 (app m, 2H), 7.99 (d, $J = 8.7$ Hz, 1H), 7.94 (s, 1H), 7.74 – 7.63 (m, 3H), 7.46 (ddd, $J = 8.8, 4.4, 2.8$ Hz, 1H), 7.26 (s, 1H), 7.07 (app t, $J = 9.4$ Hz, 1H). ^{19}F NMR (282 MHz, DMSO- d_6) δ -119.04 – -119.17 (m).


[1569] LCMS: rt 4.65 min (A), purity 99%, MS (m/e) 352 MH^+ .

[1570] **General procedure for the preparation of 6-(2-arylpyridin-3-yl)-N-substituted-quinazolin-4-amines**




[1571] 4-Chloro-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4-amine (70 mg, 0.2 mmol), corresponding RNH_2 (1.3 eq) and *i*-PrOH (2 mL) were added to a screw capped vial (20 ml) containing a stirbar. The vial was tightly capped and heated with stirring in a heating/stirring block for 6h. The semi heterogeneous reaction mixture was concentrated to dryness and purified by preparative HPLC on a reverse phase column with acetonitrile/water containing TFA as a modifier under solvent gradient conditions. The product fractions were concentrated, neutralized by aq. NaHCO_3 , and extracted into EtOAc. Organic layer was separated, dried over anhydrous Na_2SO_4 , polish filtered and concentrated. The concentrated samples were subjected to lyophilization to obtain the respective products as amorphous solids.

[1572] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-N-methylquinazolin-4-amine




[1573] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.74 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.44 (s, 2H), 8.31 (q, $J = 4.5$ Hz, 1H), 8.23 (d, $J = 1.8$ Hz, 1H), 8.00 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.63 (dd, $J = 7.9, 4.8$ Hz, 1H), 7.58 (dd, $J = 7.9, 4.8$ Hz, 1H), 7.47 (d, $J = 8.6$ Hz, 1H), 7.41 (ddd, $J = 8.8, 4.4, 2.8$ Hz, 1H), 7.35 (dd, $J = 8.6, 1.9$ Hz, 1H), 7.02 7.02 (app d, $J = 9.5$ Hz, 1H), 2.97 (d, $J = 4.5$ Hz, 3H). ^{19}F NMR (282 MHz, $\text{DMSO-}d_6$) δ -117.15 (ddd, $J = 10.1, 6.1, 4.3$ Hz). LCMS: rt 4.76 min (A), purity 97%, MS (m/e) 365 MH^+ .

[1574] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-N-(3-morpholinopropyl)quinazolin-4-amine




[1575] LCMS: rt 4.08 min (A), purity 97%, MS (m/e) 478 MH^+ .

[1576] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-N-(2-morpholinoethyl)quinazolin-4-amine



[1577] LCMS: rt 4.03 min (A), purity 97%, MS (m/e) 464 MH^+ .


[1578] N1-(6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)quinazolin-4-yl)-N-(3-(N,N-dimethylamino)propyl)quinazolin-4-amine



[1579] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.74 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.42 (s, 1H), 8.32 (t, $J = 5.4$ Hz, 1H), 8.23 (d, $J = 1.9$ Hz, 1H), 8.01 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.69 – 7.56 (m, 2H),


7.48 (d, $J = 8.6$ Hz, 1H), 7.45 – 7.34 (m, 2H), 7.02 (dd, $J = 9.6, 8.8$ Hz, 1H), 3.52 (q, $J = 6.7$ Hz, 2H), 2.44 (d, $J = 7.3$ Hz, 2H), 2.26 (s, 6H), 1.79 (p, $J = 7.1$ Hz, 2H). ^{19}F NMR (282 MHz, DMSO- d_6) δ -117.19 (app ddd, $J = 10.1, 5.8, 4.3$ Hz). LCMS: rt 4.03 min (A), purity 97%, MS (m/e) 436 MH^+ .

[1580] N1-(6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)quinazolin-4-yl)-N-(2-(N,N-dimethylamino)ethyl)quinazolin-4-amine




[1581] ^1H NMR (300 MHz, DMSO- d_6) δ 8.74 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.43 (s, 1H), 8.25 (d, $J = 1.8$ Hz, 1H), 8.22 (t, $J = 5.4$ Hz, 1H), 8.01 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.69 – 7.56 (m, 2H), 7.48 (d, $J = 8.6$ Hz, 1H), 7.53 – 7.33 (m, 2H), 7.02 (dd, $J = 9.6, 8.8$ Hz, 1H), 3.63 (q, $J = 6.4$ Hz, 2H), 2.59 (q, $J = 6.4$ Hz, 2H), 2.26 (s, 6H). ^{19}F NMR (282 MHz, DMSO- d_6) δ -117.19 (dt, $J = 9.9, 5.2$ Hz). LCMS: rt 3.96 min (A), purity 99%, MS (m/e) 422 MH^+ .

[1582] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)quinazolin-4-amine




[1583] LCMS: rt 3.95 min (A), purity 97%, MS (m/e) 477 MH^+ .

[1584] 6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)quinazolin-4-amine




[1585] LCMS: rt 3.90 min (A), purity 97%, MS (m/e) 492 MH^+ .

[1586] 1-(3-((6-(2-(5-Chloro-2-fluorophenyl)pyridin-3-yl)quinazolin-4-yl)amino)propyl)pyrrolidin-2-one




[1587] LCMS: rt 4.93 min (A), purity 99%, MS (m/e) 476 MH⁺.

[1588] Preparation of 4-chloro-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazoline




[1589] 6-(2-Chloropyridin-3-yl)-4-methoxyquinazoline




[1590] 2-Chloro-3-pyridineboronic acid (5.0 g, 31.5 mmol), 6-bromo-4-methoxyquinazoline (6.0 g, 25.1 mmol) and Pd(PPh₃)₄ (1.75 g, 1.51 mmol) were added into a 500 ml flask, followed by the addition of 2 N aqueous Na₂CO₃ (39 mL, 78 mmol) and 1,4-dioxane (120 mL). The resulting reaction mixture was heated at 95 °C under N₂ for 16 h. After cooling to room temperature, the reaction mixture was worked up with EtOAc and water. The organic layer was separated, dried over MgSO₄ and concentrated. The crude brown viscous syrup was stirred in hexanes-ethyl acetate (v/v: 13:1, 100 mL) and filtered to give 6-(2-chloropyridin-3-yl)-4-methoxyquinazoline (6.25 g, 91%) after suction drying the collected solid on the funnel. ¹H NMR (CD₃OD, 300 MHz): 8.82 (s, 1H), 8.46 (dd, J = 4.8, 1.8 Hz, 1H), 8.30 (d, J = 0.9 Hz, 1H), 8.04 (dd, J = 9.0, 1.8 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H), 7.52 (dd, J = 7.5, 1.8 Hz, 1H), 7.54 (m, 1H), 4.23 (s, 3H). MS (m/e) 272 MH⁺. Purity 94%.

[1591] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-methoxyquinazoline



[1592] 6-(2-Chloropyridin-3-yl)-4-methoxyquinazoline (6.25 g, 23.0 mmol), 4-fluoro-3-methylphenylboronic acid (4.4 g, 28.6 mmol) and $\text{PdCl}_2(\text{PPh}_3)_2$ (0.81 g, 1.2 mmol) were added into a 500 ml of flask, followed by the addition of 2 N aqueous Na_2CO_3 (35 mL, 70.0 mmol) and 1,4-dioxane (130 ml). The resulting reaction mixture was heated at 110 °C under N_2 for 16 h. After cooling to room temperature, the mixture was filtered via Celite, and worked up with EtOAc and water. The organic layer was separated, dried over MgSO_4 and concentrated. The crude pale yellow solid was stirred at room temperature in hexanes-ethyl acetate (v/v: 10:1, 110 ml) and filtered to provide 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)-4-methoxyquinazoline (5.7 g, 72%). $^1\text{H NMR}$ (CD_3OD , 300 MHz): 8.65 (dd, $J = 4.8, 1.8$ Hz, 1H), 8.15 (d, $J = 2.1$ Hz, 1H), 7.98-7.93 (m, 1H), 7.76 (d, $J = 8.7$ Hz, 1H), 7.59-7.49 (m, 3H), 7.26 (d, $J = 7.5$ Hz, 1H), 7.02 (m, 1H), 6.86 (m, 1H), 4.20 (s, 3H), 2.18 (s, 3H). MS (m/e) 346 MH^+ . Purity 95%.


[1593] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4(1H)-one



[1594] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)-4-methoxyquinazoline (5.7 g, 16.5 mmol) and anhydrous ethanol (55 mL) were added into a 250 mL flask, followed by the addition of conc. HCl (6 mL). The resulting reaction mixture was heated at 90 °C for 3 h. Reaction mixture was concentrated after cooling to room temperature. The solid was diluted with water (60 mL) and basified (pH = 10) the slow addition of saturated aqueous Na_2CO_3 solution. The resultant white solid was collected by suction filtration. The filter cake was washed with water (300 mL) and suction dried (12 h). The white solid was further dried under high vacuum over P_2O_5 to obtain 6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4(1H)-one (5.1 g, 93 %) and used in the next step with no further purification. $^1\text{H NMR}$ (CD_3OD , 300 MHz): 8.64 (dd, $J = 5.1, 1.8$ Hz, 1H), 8.11 (m, 1H), 8.09 (s, 1H), 7.98 (dd, $J = 7.8, 1.8$ Hz, 1H), 7.58-7.52 (m, 3H),


7.27 (dd, $J = 7.2, 2.1$ Hz, 1H), 7.04 (m, 1H), 6.88 (m, 1H), 2.17 (s, 3H). MS (m/e) 332 MH^+ . Purity 95%.

[1595] 4-Chloro-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazoline



[1596] 6-(2-(4-Fluoro-3-methylphenyl)pyridin-3-yl)quinazolin-4(1H)-one (5.0 g, 15 mmol) and $POCl_3$ (20 mL) were added into a 250 mL flask. The stirring heterogeneous mixture was heated at 110 °C under N_2 for 3 h. After cooling to room temperature, excess $POCl_3$ was evaporated. The residue was dissolved in dry CH_2Cl_2 and poured into a beaker containing a stirring mixture of ice water, saturated aqueous Na_2CO_3 and CH_2Cl_2 . Organic layer was separated from clear biphasic solution, dried over $MgSO_4$, filtered and concentrated. The resulting solid was loaded onto prewashed (2% NEt_3 in 2/1 Hexanes/ $EtOAc$) silica gel column and purified (30% -50% $EtOAc$ / in hexanes eluent gradient) to afford 4-chloro-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazoline as a white solid (4.75 g, 90%). 1H NMR ($CDCl_3$, 300 MHz): 9.06 (s, 1H), 8.80 (dd, $J = 4.8, 1.5$ Hz, 1H), 8.23 (d, $J = 2.1$ Hz, 1H), 7.93 (s, 1H), 7.90 (s, 1H), 7.65 (dd, $J = 9.0, 2.1$ Hz, 1H), 7.48 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.26 (dd, $J = 7.2, 2.1$ Hz, 1H), 6.97 (m, 1H), 6.80 (m, 1H), 2.21 (s, 3H). MS (m/e) 350 MH^+ . Purity 97%.


[1597] 4-Chloro-6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)quinazoline



[1598] 4-Chloro-6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)quinazoline was obtained in the similar manner to the preparation of 4-chloro-6-(2-(4-fluoro-3-methylphenyl)pyridin-3-yl)quinazoline from 6-(2-(5-chloro-2-fluorophenyl)pyridin-3-yl)quinazolin-4(3H)-one.


[1599] 1H NMR (300 MHz, $DMSO-d_6$) δ 9.08 (s, 1H), 8.79 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.13 (dd, $J = 7.9, 1.6$ Hz, 1H), 8.05-8.03 (m, 2H), 7.96 (dd, $J = 8.8, 1.9$ Hz, 1H), 7.73 – 7.61 (m, 2H), 7.44 (ddd, $J = 8.8, 4.4, 2.8$ Hz, 1H), 7.04 (app t, $J = 9.0$ Hz, 1H). ^{19}F NMR (282 MHz, $DMSO-d_6$) δ -117.93 (dt, $J = 10.3, 5.3$ Hz). LCMS: rt 7.98 min (A), purity 97%, MS (m/e) 370 MH^+ .

[1600] 3-(2-Chloropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine



[1601] ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 8.47 (dd, $J = 4.8, 1.9$ Hz, 1H), 8.43 (dd, $J = 4.7, 1.5$ Hz, 1H), 8.24 – 8.15 (m, 3H), 8.06 (dd, $J = 7.6, 1.9$ Hz, 1H), 7.93 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.77 – 7.59 (m, 3H), 7.54 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.33 (dd, $J = 8.0, 4.8$ Hz, 1H). LCMS: rt 8.00 min (A), purity 95%, MS (m/e) 370 MH^+ .

Example 108



Step 1:

[1602] 2-Chloro-3-pyridineboronic acid (16.5 g, 105 mmol), 6-bromo-4-methoxyquinazoline (20 g, 84 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (4.85 g, 4.2 mmol) were added into a 1 L of flask, followed by the addition of Na_2CO_3 (26.6 g, 250 mmol), 1,4- dioxane (350 mL) and water (110 mL). The resulting reaction mixture was heated at 100 °C under N_2 for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc (800 mL) and water (200 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (200 mL). The combined organic layer was dried over MgSO_4 and concentrated. The crude product was stirred with EtOAc (40 mL) and hexanes (500 mL) for 2 h at room temperature. The solid was filtered and

washed with hexanes (300 mL). The obtained product (20 g, 87%) was used for the next step without further purification (~95% purity by LC-MS)

Step 2:

[1603] KOAc (26.4 g, 269 mmol), bis(pinacolato)diboron (30 g, 116 mmol), 3-(difluoromethoxy)bromobenzene (20 g, 90 mmol) and PdCl₂(dppf) (7.3 g, 9 mmol) were suspended in dry 1,4-dioxane (280 ml) and heated at 100 °C under N₂ for 17 h. After cooling to room temperature, the mixture was diluted with EtOAc (600 mL) and water (200 mL). The mixture was then filtered via Celite, and washed with EtOAc (200 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (200 mL). The combined organic layer was dried over MgSO₄ and concentrated. The crude product was used for the next step without further purification.

[1604] To a 1 L flask with above crude product were added 6-(2-chloropyridin-3-yl)-4-methoxyquinazoline (18 g, 66 mmol), PdCl₂(PPh₃)₂ (2.3 g, 3.3 mmol), Na₂CO₃ (21 g, 198 mmol), 1,4-dioxane (240 mL) and water (80 mL). The resulting reaction mixture was heated at 105 °C under N₂ for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc (800 mL) and water (200 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (200 mL). The combined organic layer was dried over MgSO₄ and concentrated. The crude was purification by column (hexanes-ethyl acetate, 3:2 to 1:1) to afford the product as a white solid (16 g, 64%).

Step 3:

[1605] 6-(2-(3-(Difluoromethoxy)phenyl)pyridin-3-yl)-4-methoxyquinazoline (16 G, 42 mmol) was dissolved in 210 mL of EtOH, then conc HCl (20 mL) was added. The resulting reaction mixture was heated at 90 °C under N₂ for 3 h. After cooling to room temperature, the volatiles were evaporated. The residue was diluted with water (300 mL) and neutralized by the addition of sat. Na₂CO₃ solution. EtOAc (600 mL) was then added to dissolve the solid. The organic layer was separated, and the aqueous layer was extracted with EtOAc for three times (each with 300 mL). The combined organic layer was dried over MgSO₄ and concentrated. The obtained product (14 g, 90%) was used for the next step without further purification (~96% purity by LC-MS)

Step 4:

[1606] 6-(2-(3-(difluoromethoxy)phenyl)pyridin-3-yl)quinazolin-4(3H)-one (14 g, 38 mmol) was put into a 500 mL of flask, then POCl₃ (50 mL) was added. The resulting reaction mixture was heated at 110 °C under N₂ for 4 h. After cooling to room temperature, the volatiles were evaporated. The residue was dissolved in 100 mL of dry CH₂Cl₂, and poured into a 1 L of beaker including CH₂Cl₂ (~300 mL), sat Na₂CO₃ sol. (~200 mL) and ice (~200 g). After the temperature of the reaction mixture increased to room temperature, it was filtered via filter paper and washed with CH₂Cl₂ (~600 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ twice (each with 200 mL). The combined organic layers were dried over MgSO₄ and concentrated. The residue was rinsed with purification by column (hexanes/ethyl acetate = 2/1 to 1/1 including 2% Et₃N) to afford the product (12.5 g, 85%) which was used in the next step immediately.

Step 5:

[1607] Above chloro- intermediate (12.5 g, 33 mmol) was dissolved in 60 mL of dry THF, then 2 N NH₃ in IPA solution (120 mL) was added. The resulting reaction mixture was heated at 65 °C in pressure flask for 17 h. After cooling to room temperature, the volatiles were evaporated. Then water (100 mL) was added, followed by the addition of sat. Na₂CO₃ solution (30 mL). The white solid was filtered and washed with water (100 ml). The filtrate was extracted by EtOAc (each with 400 mL). The organic layer was dried over MgSO₄ and concentrated. The combined solid was stirred with EtOAc-MeOH (9:1, 100 mL) for 2 h at room temperature. The white solid was filtered and dried to provide the product (11.0 g, 92%) with the purity of 98%.

[1608] ¹H NMR (CD₃OD, 300 MHz) δ 8.71 (dd, *J* = 4.9, 1.7 Hz, 1H), 8.41 (s, 1H), 8.18 (dd, *J* = 1.9, 0.6 Hz, 1H), 8.06 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.66 – 7.56 (m, 2H), 7.51 (dd, *J* = 8.6, 1.9 Hz, 1H), 7.31 (t, *J* = 8.1 Hz, 1H), 7.21 – 7.14 (m, 2H), 7.13 – 7.09 (m, 1H), 6.67 (t, *J* = 73.8 Hz, 1H).

BIOLOGICAL EXAMPLE 1: AlphaScreen® SureFire® SMAD3 (p-Ser423/425) Assay

[1609] The p-SMAD-3 (Ser423/425) SureFire® assay has been designed to measure the phosphorylation of endogenous cellular p-SMAD-3 (Ser423/425) in cell lysates and is a system for the screening of both modulators of receptor activation (e.g. agonists and antagonists) as well as agents acting intracellularly, such as small molecule inhibitors of upstream events. The assay

will measure p-SMAD-3 (Ser423/425) activation by either cloned or endogenous receptors, and can be applied to primary cells.

P-SMAD-3 (Ser423/425) *SureFire*® Assay Protocols

[1610] Step A: Preparation of buffers

[1611] 1X Lysis buffer: 1ml of 5X Lysis buffer was diluted with 4ml of sterile water. After dilution, excess 1X Lysis buffer can be frozen and thawed up to 5 times without loss in activity.

[1612] Activation buffer: The buffer was warmed slowly to 37°C and gently mixed to re-suspend. Activation buffer can be stored at room temperature with no loss in activity.

[1613] Reaction buffer: The buffer was kept at 4 °C while in use.

[1614] AlphaScreen® Protein A IgG Kit: The kit was stored at 4 °C in the dark.

[1615] Reaction buffer + Activation buffer + AlphaScreen® Acceptor beads: Reaction buffer (40 parts), Activation Buffer (10 parts) and Acceptor beads (1 part) were mixed and the mixture was stored at room temperature and used the same day. Mixture was added to 384-well plates; excess mixture was discarded.

[1616] Dilution buffer + AlphaScreen® Donor beads: Dilution buffer (20 parts) and Donor beads (1 part) were mixed and the mixture was stored at room temperature and used the same day. Excess mixture was discarded.

[1617] Assay control samples: After reconstitution in 250 µl of water, lysates were at -20 °C in single use aliquots.

[1618] Step B: Preparation of samples and cells

[1619] 96-well Assay Protocol for 293FT and RMS13 adherent cells can be carried out manually or in high throughput with liquid handling robots.

[1620] The cells (80 µL of cells for 96 well plates) were plated in collagen coated tissue culture plates in RPMI or FreeStyle medium (Invitrogen) and incubated overnight. For manual analysis, 6 plates for GDF8, 6 plates for TGFβ, and optionally 6 plates for Alk5ca(ALK5 constitutively active) were used.

[1621] The compound dilution plates were prepared as follows: 12 µL of DMSO was transferred into first column of 96-well plate, and 16 µL of DMSO was transferred into columns 2-12 of the 96-well plate. 12 µL of compound solution was transferred into first column of the DMSO-containing 96-well plate. Three-fold dilution was performed up to column 10 of the DMSO-containing 96-well plate.

[1622] Step C: Treatment and analysis

[1623] The plate containing cells were treated with compounds for about 10 minutes, and then ligand was added. GDF8 or TGFb was added to plates to stimulate. 293FL cells were stimulated for 90 minutes at 37 °C; and RMS13 cells were stimulated for 60 minutes at 37 °C. The medium was then removed from the cells, and 1X Lysis Buffer (about 25 µL) was added and the plate was gently agitated on plate shaker for 5-10 minutes.

[1624] The lysate (5µL) was then placed into 384-well shallow plates avoiding the generation of bubbles. To this, the Reaction Buffer + Activation Buffer + AlphaScreen® Acceptor beadsmixture(5 µL) was added. The plate was sealed with adhesive cover and shielded from light (e.g., with metal foil), and agitated gently on plate shaker for 2 hours at room temperature.

[1625] Dilution buffer + AlphaScreen® Donor beads (2 µL) was then added, and the plate was intubated on the plate shaker for an additional 1½ hours. After completion, the plate was read on Synergy-4 or Enspire plate reader, using AlphaScreen® pSMAD3® settings.

[1626] Representative results for inhibition of GDF8 signaling are shown in **Table 2**(data = GDF pSMAD (MPC11) (µM)):

Cmpd #	Data
1	1.654
2	--*
3	1.296
4	----
5	----
6	18.65
7	23.11
8	5.349
9	5.135
10	0.5349
11	0.5945
12	18.89
13	----
14	----
15	0.0649

Cmpd #	Data
16	6.34
17	0.3358
18	0.1419
19	0.083
20	0.1037
21	1.917
22	1.414
23	2.245
24	0.6713
25	0.6123
26	0.8118
27	0.4527
28	1.754
29	1.446
30	3.704

Cmpd #	Data
31	1.899
32	2.796
33	5007
34	8.832
35	10.78
36	19.71
37	18.1
38	3.227
39	14.33
40	18.47
41	3.136
42	10.49
43	1.621
44	----
45	----

Cmpd #	Data
46	1.73
47	8.229
48	8.379
49	----
50	----
51	5.441
52	1.398
53	13.37
54	----
55	----
61	3.882
62	0.8036
63	0.1415
64	0.8396
65	2.238

Cmpd #	Data
66	1.784
67	1.807
68	0.1865
69	5005
70	5.703
71	7.012
72	5014
73	0.4969
74	----
75	3.468
76	1.815
77	3.65
78	0.3157
79	0.2636
80	6.333
81	----
82	----
83	--
84	--
85	--
86	--
87	--
88	--
89	2.551
90	2.612
91	3.028
92	--
93	4.835
94	--
95	--
96	--
97	--

Cmpd #	Data
98	10.34
99	0.8936
100	6.034
101	11.24
102	0.3408
103	--
104	--
105	--
106	--
107	--
108	--
109	17.19
110	--
111	--
112	0.2733
113	--
114	--
115	--
116	0.0326
117	0.1786
118	3.785
119	--
120	0.3635
121	5.348
122	4.037
123	--
124	0.5478
125	--
126	--
127	--
128	--
129	--

Cmpd #	Data
130	--
131	--
132	--
133	--
134	--
135	--
136	--
137	22.83
138	4.331
139	3.371
140	2.886
141	18.57
142	1.192
143	12.16
144	9.39
145	1.127
146	0.6209
147	--
148	--
149	0.6418
150	0.2085
151	0.678
152	0.0487
153	0.4504
154	1.306
155	0.2236
156	1.789
157	1.564
158	1.859
159	0.1304
160	0.0843
161	9.101

Cmpd #	Data
162	5.664
163	--
164	--
165	0.2646
166	0.1093
167	17.46
168	--
169	--
170	1.959
171	--
172	0.1874
173	1.827
174	1.176
175	0.1181
176	0.057
177	0.3629
178	0.187
179	0.3368
180	0.4224
181	0.5391
182	--
183	--
184	12.92
185	8.86
186	0.2996
187	0.2282
188	--
189	--
190	1.551
191	0.6629
192	0.3473
193	0.2432

Cmpd #	Data
194	0.1494
195	9.52
196	--
197	0.3588
198	0.44
199	1.164
200	0.2601
201	--
207	2.039
208	1.146
209	18.25
210	12.72
211	0.1979
212	18.39
213	4.437
214	2.642
215	15.67
216	0.7365
217	0.8413
218	0.4459
219	6.766
220	8.62
221	--
222	5.623
223	0.7071
224	0.6209
225	9.457
226	10.04
227	--
228	9.762
229	--
230	10.77

Cmpd #	Data
231	10.81
232	10.64
233	6.691
234	--
235	--
236	--
237	--
238	--
239	0.2662
240	7.454
241	4.056
242	--
243	11.89
244	0.7979
245	1.257
246	1.29
247	3.197
248	5007
249	8.832
250	10.46
251	17.81
252	12.65
253	12.38
254	0.3904
255	--
256	--
257	1.84
258	1.267
259	5007
260	--
261	--
262	--

Cmpd #	Data
263	--
264	9.152
265	8.122
266	4.535
267	6.757
268	14.41
269	1.383
270	--
271	4.444
272	3.401
273	9.786
274	14.77
275	2.948
276	--
277	1.671
278	2.226
279	--
280	--
281	1.304
282	19.38
283	17.72
284	--
285	--
286	11.96
287	3.03
288	--
289	--
290	--
291	1.231
292	1.739
293	5.541
294	--

Cmpd #	Data
295	--
296	--
297	2.26
298	0.9992
299	1.2
300	12.79
301	0.3451
302	0.7949
303	0.0947
304	0.0853
305	0.1751
306	0.1294
307	2.222
308	4.809
309	1.475
310	1.143
311	4.719
312	7.538
313	5009
314	5.345
315	0.7489
316	6.389
317	5.5
318	1.305
319	10.63
320	2.993
321	0.6792
322	0.2531
323	0.327
324	0.4612
325	0.1865
326	0.1983

Cmpd #	Data
327	0.3234
328	2.497
329	0.8032
330	0.4565
331	1.329
332	0.3115
333	0.3764
334	0.3727
335	0.306
336	0.7635
337	0.4792
338	0.1639
339	0.5903
340	0.4637
341	0.2595
342	0.1058
343	2.644
344	--
345	4.83
346	0.1933
347	1.493
348	1.303
349	1.009
350	0.3473
351	0.2151
352	0.3069
353	0.6888
354	1.27
355	--
356	0.9646
357	--
358	0.8629

Cmpd #	Data
359	0.5243
360	5.669
361	0.2296
362	0.1051
363	0.9033
364	0.3383
365	0.1653
366	0.2258
367	0.2799
368	0.1894
369	0.1933
370	0.4111
371	0.7368
372	0.3387
373	1.2
374	0.4949
375	0.1524
376	0.276
377	0.1724
378	0.5583
379	0.3954
380	18.51
381	2.607
382	14.8
383	16.74
384	7.792
385	2.557
386	2.004
387	1.279
388	0.5469
389	0.1871
390	0.5164

Cmpd #	Data
391	0.2278
392	0.1274
393	0.07
394	0.1191
395	0.9586
396	0.2083
397	9.407
398	3341
399	4.653
400	5.806
401	5.891
402	5000
403	1.666
404	1.029
405	10.69
406	2.794
407	2.467
408	0.6732
409	7.954
410	4.13
411	0.0725
412	--
413	--
414	3.334
415	11.8
416	4.858
417	--
418	--
419	--
420	--
421	1.401
422	1.275

Cmpd #	Data
423	0.6277
424	2.426
425	0.5369
426	--
427	--
428	--
429	0.3842
430	0.4748
431	0.3736
432	0.5131
433	0.2851
434	1.491
435	0.608
436	1.18
437	0.7391
438	0.9588
439	0.7381
440	1.863
441	1.156
442	0.3659
443	0.429
444	1.081
445	0.5146
446	0.3975
447	0.7534
448	0.1368
449	0.0686
450	0.1358
451	0.1151
452	0.2231
453	0.8161
454	0.9262

Cmpd #	Data
455	1.163
456	0.2988
457	5005
458	3333
459	11.48
460	0.1291
461	0.5511
462	18.41
463	0.2966
464	3.96
465	10.26
466	7.583
467	12.19
468	7.824
469	1.58
470	21.11
471	--
472	--
473	0.2925
474	0.4292
475	--
476	2.756
477	0.4919
478	6.604
479	--
480	1.213
481	1.285
482	1.698
483	0.8197
484	0.1606
485	--
486	--

Cmpd #	Data
487	--
488	--
489	--
490	6.51
491	9.218
492	3.729
493	0.9379
494	0.1069
495	0.2471
496	0.7833
497	9.222
498	1.197
499	6.521
500	--
501	0.3552
502	0.5629
503	4.816
504	4.96
505	--
506	1.832
507	3.365
508	--
509	0.2652
510	--
511	--
512	--
513	--
514	--
515	--
516	--
517	1.166
518	--

Cmpd #	Data
519	--
520	--
521	8.061
522	--
523	5006
524	5007
525	--
526	
527	0.1369
528	0.1751
529	0.3228
530	0.6247
531	11.23
532	17.67
533	6.118
534	18
535	0.5038
536	0.4043
537	0.1106
538	0.4739
539	0.6993
540	0.4264
541	0.2497
542	1.717
543	--
544	--
545	--
546	--
547	--
548	16.4
549	5.006
550	--

Cmpd #	Data
551	4.883
552	4.058
553	3.241
554	4.683
555	0.1564
556	0.3633
557	0.4389
558	0.1875
559	0.1616
560	2.477
561	10.96
562	9.784
563	5.199
564	18.35
565	0.406
566	0.342
567	0.2253
568	0.6745
569	5.414
570	5.903
571	7.312
572	--
573	1.214
574	0.8526
575	1.166
576	3.691
577	2.257
578	2.229
579	12.38
580	8.455
581	6.308
582	0.4936

Cmpd #	Data
583	0.5178
584	0.0962
585	0.5103
586	0.6169
587	0.3662
588	0.3164
589	1.223
590	0.5137
591	0.3331
592	0.2046
593	1.859
594	0.5704
595	1.159
596	0.2038
597	0.8369
598	2.046
599	3.883
600	0.1788
601	0.1409
602	0.0681
603	0.1093
604	8.522
605	7.936
606	1.439
607	0.7054
608	0.3258
609	0.3188
610	0.6479
611	0.1141
612	0.408
613	0.6236
614	5.558

Cmpd #	Data
615	2.129
616	2.185
617	10.8
618	1.12
619	0.5439
620	
621	3.926
622	3.63
623	6.867
624	0.1605
625	7.793
626	0.3457
627	1.255
628	1.707
629	0.1318
630	4.152
631	--
632	--
633	11.34
634	14.75
635	--
636	8.691
637	--
638	--
639	10.56
640	19.18
641	
642	
643	
644	
645	
646	

Cmpd #	Data
647	
648	
649	
650	
651	1.18
652	3.777
653	1.037
654	0.5532
655	0.2453
656	0.5499
657	3.488
658	1.501
659	2.007
660	2.243
661	1.842
662	9.637
663	8.093
664	1.382
665	2.36
666	3.973
667	0.2261
668	0.3134
669	0.4992
670	0.3666
671	--
672	0.2727
673	0.3747
674	0.2109
675	0.2268
676	0.2668
677	0.5621
678	2.472

Cmpd #	Data
679	10.82
680	2.133
681	0.2881
682	0.5389
683	0.2336
684	0.5928
685	0.1499
686	0.2054
687	0.1722
688	1.263
689	0.5163
690	0.4136
691	0.4468
692	0.4361
693	0.5073
694	0.7936
695	1.517
696	2.106
697	0.4147
698	0.145
699	2.301
700	0.1376
701	0.1671
702	0.8818
703	0.2081
704	0.2805
705	0.1217
706	0.2275
707	0.2215
708	0.2659
709	0.2523
710	1.218

Cmpd #	Data
711	9.278
712	4.057
713	10.2
714	5.662
715	2.03
716	5.026
717	0.2169
718	0.3141
719	0.4018
720	0.8217
721	0.4398
722	0.0639
723	0.1017
724	0.5366
725	0.4645
726	0.5654
727	0.8864
728	5.062
729	0.2864
730	0.5898
731	0.5061
732	0.2577
733	1.273
734	0.6942
735	0.6762
736	0.2507
737	0.2596
738	1.376
739	2.318
740	9.499
741	10.01
742	1.825

Cmpd #	Data
743	0.6383
744	0.9677
745	0.3663
746	0.5661
747	0.2844
748	0.4473
749	0.2982
750	--
751	--
752	--
753	--
754	--
755	--
756	0.3644
757	0.1274
758	0.4264
759	0.1747
760	0.2742
761	0.1312
762	1.188
763	0.5199
764	0.2751
765	0.096
766	0.1048
767	0.2267
768	0.3267
769	0.1533
770	1.309
771	1.107
772	4.949
773	8.48
774	--

Cmpd #	Data
775	3.961
776	--
777	--
778	--
779	0.7609
780	0.7298
781	5.864
782	0.3324
783	0.2309
784	0.1252
785	0.1103
786	0.3404
787	--
788	4.042
789	--
790	4.991
791	5.372
792	2.433
793	2.082
794	1.798
795	8.105
796	14
797	3.813
798	2.615
799	14.64
800	0.8792
801	--
802	5.828
803	2.262
804	10.11
805	0.9533
806	--

Cmpd #	Data
807	5008
808	1.537
809	4
810	5.784
811	2.924
812	2.142
813	2.43
814	--
815	0.9414
816	1.609
817	0.5839
818	0.0774
819	0.1192
820	3.062
821	2.161
822	0.1272
823	0.2137
824	--
825	--
826	--
827	--
828	--
829	--
830	--
831	--
832	--
833	--
834	--
835	--
836	5.937
837	4.861
838	--

Cmpd #	Data
839	--
840	8.142
841	7.644
842	17.37
843	0.0213
844	0.0324
845	0.0588
846	14.28
847	--
848	11.12
849	18.08
850	20.7
851	--
852	0.2074
853	0.8812
854	4.666
855	3.442
856	5.585
857	1.854
858	2.367
859	3.7
860	9.985
861	4.006
862	1.836
863	5.894
864	1.54
865	0.6077
866	0.2506
867	0.752
868	0.4041
869	0.6883
870	0.557

Cmpd #	Data
871	1.828
872	0.7755
873	1.193
874	6.466
875	12.41
876	2.374
877	--
878	10.22
879	1.477
880	0.8077
881	--
882	1.124
883	0.5124
884	0.9974
885	--
886	0.2526
887	1.746
888	4.054
889	1.519
890	1.296
891	0.6324
892	0.426
896	0.0936
897	--
898	0.7137
899	2.144
900	2.346
901	1.065
902	--
903	2.584
904	9.071
905	1.489

Cmpd #	Data
906	3.339
907	0.1635
908	--
909	--
910	0.0972
911	0.0939
912	0.112
913	0.6611
914	0.126
915	0.5578
916	0.1035
917	0.1804
918	0.2063
919	--
920	0.272
921	0.0706
922	--
923	--
924	--
925	--
926	--
927	--
928	--
929	--
930	--
931	--
932	--
933	--
934	0.4097
935	0.1918
936	0.2281
937	0.2072








Cmpd #	Data
938	0.2419
939	--
940	--
941	--
942	--
943	--
944	--
945	--
946	--
947	0.4288
948	0.9508
949	0.3754
950	0.129
951	0.5429
952	0.3911
953	0.6607
954	0.4381
955	0.2901
956	0.4211
957	--
958	--
959	--
960	1.685
961	0.129
962	0.622
963	0.1751
964	0.2315
965	5.188
966	--
967	1.44







#	Structure	Salt	Data
975		Parent	--
976		Parent	--
977		Parent	1.004
978		TFA	1.866
979		Parent	14.04
980		Formic Acid	3.726

#	Structure	Salt	Data
981		Formic Acid	9.336
982		Formic Acid	0.0411
983		Formic Acid	1.459
984		Formic Acid	0.4503
985		Formic Acid	2.18
986		Formic Acid	0.9563

#	Structure	Salt	Data
987		Formic Acid	7.995
988		Formic Acid	1.064
989		TFA	0.6918
990		Formic Acid	0.2846
991		Formic Acid	20.2
992		Formic Acid	1.863

#	Structure	Salt	Data
993		Formic Acid	0.486
994		Formic Acid	3.21
995		Formic Acid	5002
996		Formic Acid	4999
997		Formic Acid	--
998		Formic Acid	2.44

#	Structure	Salt	Data
999		Formic Acid	1.2
1000		Formic Acid	6.505
1001		Formic Acid	4999
1002		Formic Acid	1.422
1003		Formic Acid	7.272
1004		Formic Acid	0.2034
1005		Formic Acid	5.447

#	Structure	Salt	Data
1006		Formic Acid	0.735
1007		Formic Acid	0.2228
1008		Formic Acid	5.812
1009		Formic Acid	3.295
1010		TFA	0.5621
1011		TFA	3.329
1012		TFA	0.7279

#	Structure	Salt	Data
1013		TFA	1.046
1014		TFA	0.4164
1015		TFA	6.953
1016		TFA	2.771
1017		Formic Acid	2.08
1018		Formic Acid	0.7354
1019		Formic Acid	7.431

#	Structure	Salt	Data
1020		Formic Acid	4.771
1021		Parent	0.1745
1022		Formic Acid	13.65
1023		Formic Acid	0.0958
1024		Formic Acid	0.5772
1025		Formic Acid	0.9576
1026		Formic Acid	0.7367

#	Structure	Salt	Data
1027		Formic Acid	10.75
1028		Formic Acid	10.42
1029		Formic Acid	2.614
1030		Parent	1.135
1031		TFA	15.82
1032		Formic Acid	1.095
1033		Formic Acid	1.584

#	Structure	Salt	Data
1034		TFA	0.3418
1035		TFA	0.1613
1037		Parent	1.095
1038		Parent	0.5667
1039		Parent	0.0438
1040		Parent	0.1833
1041		Parent	1.127
1042		Parent	3.641

#	Structure	Salt	Data
1043		Parent	0.5296
1044		Parent	0.632
1045		Parent	4.543
1046		Parent	1.632
1047		Parent	3.551
1048		Parent	0.969
1049		Parent	0.671
1050		Parent	0.7151
1051		Parent	9.978

#	Structure	Salt	Data
1052		Parent	3.611
1053		Parent	0.3683
1054		Parent	0.7373
1055		Parent	0.129
1056		Parent	0.3003
1057		Parent	0.371
1058		Parent	0.1098
1059		Parent	0.4174
1060		Parent	3.758

#	Structure	Salt	Data
1061		Parent	0.4726
1062		Parent	8.697
1063		Parent	4.448
1064		Parent	0.8036
1065		Parent	2.526
1066		Parent	2.16
1067		Parent	0.5014
1068		Parent	3.306

#	Structure	Salt	Data
1069		Parent	3.199
1070		Parent	0.0611
1071		Parent	0.0924
1072		Parent	--
1073		Parent	0.4796
1074		Parent	0.9523
1075		Parent	3.008
1076		Parent	9.671

#	Structure	Salt	Data
1077		Parent	--
1078		Parent	--
1079		Parent	--
1080		Parent	--
1081		Parent	--
1082		Parent	--
1083		Parent	0.3094
1084		Parent	0.5318
1085		Parent	8.203


#	Structure	Salt	Data
1086		Parent	16.46
1087		Parent	--
1088		Parent	--
1089		Parent	--
1090		Parent	1.174
1091		Parent	--
1092		Parent	5.78
1093		Parent	0.2
1094		Parent	--
1095		Parent	0.1833

[1627] The notation "--" indicates that the compound was tested but did not have measurable activity in this assay.

[1628] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be incorporated within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated herein by reference for all purposes.

We claim:

1. A compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein

Cy^1 is phenyl optionally substituted with 1, 2, 3, or 4 moieties independently selected from halo; C_{1-3} alkyl optionally substituted with 1, 2, or 3 halo, ethynyl, or (trimethylsilyl)ethynyl; $-O-C_{1-3}$ alkyl optionally substituted with 1-3 halo; benzofuranyl; 2,3-dihydrobenzofuranyl; and phenylethenyl; or, when there is a single substituent on Cy^1 , the substituent is one of the foregoing substituents of the phenyl, $-O-(C_{0-3}alkyl)R^{IIIe}$, or $-C(O)N(R^x)_2$,

wherein R^{IIIe} is phenyl, heteroaryl or heterocycloalkyl and each R^x is independently H or C_{1-3} alkyl;

Cy^2 is pyrazolo[1,5-a]pyrimidinyl; benzo[d]thiazolyl; imidazo[1,2-a]pyridinyl optionally substituted with phenyl- $S(O)_2$; [1,2,4]triazolo[1,5-a]pyridinyl; pyridinyl; quinazolinyl; 1H-pyrrolo[2,3-b]pyridinyl; pyrido[3,2-d]pyrimidinyl optionally substituted with amino, methylamino, or methoxy; or pyrido[3,2-d]pyrimidin-4(3H)-one,

wherein the quinazolinyl is optionally substituted with 1 or 2 substituents independently selected from $-N(R^{IIIa})_2$; R^{IIIc} ; C_{1-3} alkyl optionally substituted with 1-3 halo; halo; methoxy; and $-N(H)(C_{1-3}alkyl)R^{IV}$

each R^{IIIa} is independently H; C_{1-6} alkyl optionally substituted with $-C(O)OH$, $-C(O)O(C_{1-3}alkyl)$, or $-CONH_2$; or heteroaryl optionally substituted with C_{1-3} alkyl;

R^{IIIc} is H or C_{1-3} alkyl optionally substituted with 1-3 halo;


R^{IV} is H, C_{1-3} alkyl, $-pyrrolidonyl$, 4-methylpiperziny, $-N(C_{1-2}alkyl)(C_{1-2}alkyl)$, or morpholinyl;

and

R^{IIIc} is H, halo, -OH, C_{1-3} alkyl optionally substituted with 1-3 halo, or -O-
 C_{1-3} alkyl optionally substituted with 1-3 halo

provided the compound is not one of compounds 1-974.

2. The compound according to claim 1 of formula (IIIa):



(IIIa)

or a pharmaceutically acceptable salt thereof, wherein

each R^{IIIa} is independently H; C_{1-6} alkyl optionally substituted with -C(O)OH, -C(O)O(C_{1-3} alkyl), or -CONH₂; or heteroaryl optionally substituted with C_{1-3} alkyl;

x is 0, 1, 2, or 3;

each R^{IIIb} is independently selected from halo, -OH, C_{1-3} alkyl optionally substituted with 1-3 halo, -O- C_{1-3} alkyl optionally substituted with 1-3 halo, or, when x is 1, R^{IIIb} also selected from -O-(C_{0-3} alkyl) R^{IIIe} and -C(O)N(R^x)₂

wherein R^{IIIe} is phenyl, heteroaryl, or heterocycloalkyl, and each

R^x is independently H or C_{1-3} alkyl;

R^{IIIc} is H, halo, -OH, C_{1-3} alkyl optionally substituted with 1-3 halo, or -O-
 C_{1-3} alkyl optionally substituted with 1-3 halo; and

R^{IIIc} is H or C_{1-3} alkyl optionally substituted with 1-3 halo,

provided the compound is not one of compounds 1-974.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein

a) both R^{IIIa} are H,

b) R^{IIIc} and R^{IIIc} are each H,

c) x is 1, 2, or 3 and each R^{IIIb} is independently selected from halo, methyl, methoxy, and hydroxy,

d) both R^{IIIa} are H and R^{IIIc} and R^{IIIc} are each H,

- e) both R^{IIIa} are H, R^{IIIc} and R^{IIIb} are each H, and x is 1, 2, or 3 and each R^{IIIb} is independently selected from halo, methyl, methoxy, -difluoromethyl, and hydroxy; or
- f) x is 1, 2, or 3 and at least one R^{IIIb} is difluoromethyl.

4. The compound according to claim 2 selected from

#	Structure
975	
976	
977	
978	

#	Structure
979	
980	
981	
982	
983	

#	Structure
984	
985	
986	
987	
988	

#	Structure
989	
990	
991	
992	
993	
994	

#	Structure
995	
996	
997	
998	
999	
1000	

#	Structure
1001	
1002	
1003	
1004	
1005	
1006	
1007	

#	Structure
1008	
1009	
1010	
1011	
1012	
1013	
1014	


#	Structure
1015	
1016	
1017	
1018	
1019	
1020	
1021	

#	Structure
1022	
1023	
1024	
1025	
1026	
1027	
1028	

#	Structure	#	Structure	#	Structure
1029		1032		1035	
1030		1033		and	
1031		1034		1036	

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 of formula (IVa):



(IVa)

or a pharmaceutically acceptable salt thereof, wherein

Cy¹ is phenyl optionally substituted with 1, 2, 3, or 4 moieties independently selected from halo, C₁₋₃alkyl optionally substituted with 1, 2, or 3 halo, ethynyl, and (trimethylsilyl)ethynyl, benzofuranyl, 2,3-dihydrobenzofuranyl, phenylethenyl, and

Cy² is pyrazolo[1,5-a]pyrimidinyl, benzo[d]thiazolyl, imidazo[1,2-a]pyridinyl optionally substituted with phenyl-S(O)₂-, [1,2,4]triazolo[1,5-a]pyridinyl, pyridinyl, quinazolinyl optionally substituted with halo, methoxy, and -N(H)(C₁₋₃alkyl)R^{IV}, 1H-pyrrolo[2,3-b]pyridinyl, pyrido[3,2-d]pyrimidinyl

optionally substituted with amino, methylamino, or methoxy, pyrido[3,2-d]pyrimidin-4(3H)-one,

wherein R^{IV} is H, C₁₋₃alkyl, -pyrrolidonyl, 4-methylpiperzinyl,

-N(C₁₋₂alkyl)(C₁₋₂alkyl), morpholinyl;

provided the compound is not one of compounds 1-974.

6. The compound according to claim 5, or pharmaceutically acceptable salt thereof, wherein

Cy¹ is phenyl optionally substituted with 1, 2, or 3 moieties independently selected from F, Cl, methyl, and -CF₂H;

Cy¹ is phenyl optionally substituted with (trimethylsilyl)ethynyl

Cy¹ is phenyl optionally substituted with ethynyl;

Cy¹ is benzofuranyl or 2,3-dihydrobenzofuranyl;

Cy² is quinazolin-6-yl optionally substituted with F, Cl, methoxy, amino, methylamino, or

Cy² is pyridin-4-yl or benzo[d]thiazol-6-yl.

7. The compound according to claim 5 that is a compound selected from

#	Structure
1037	
1038	
1039	
1040	
1041	

#	Structure
1042	
1043	
1044	
1045	

#	Structure
1046	
1047	
1048	
1049	
1050	

#	Structure
1051	
1052	
1053	
1054	
1055	
1056	
1057	
1058	
1059	

#	Structure
1060	
1061	
1062	
1063	
1064	
1065	
1066	
1067	

#	Structure
1068	
1069	
1070	
1071	
1072	
1073	
1074	
1075	
1076	


#	Structure
1077	
1078	
1079	
1080	
1081	
1082	
1083	
1084	

#	Structure
1085	
1086	
1087	
1088	
1089	
1090	
1091	
1092	
1093	

#	Structure
1094	
1095	
1096	
1097	
1098	
1099	
and	
1100	

or a pharmaceutically acceptable salt thereof.

8. A compound of formula,



or a pharmaceutically acceptable salt thereof, wherein

X is CH and each R^Z is independently -OH, -C₁₋₃alkyl optionally substituted with one or more halo, or C₁₋₃alkyloxy optionally substituted with one or more halo, or

X is N and each R^Z is independently halo, -OH, -C₁₋₃alkyl optionally substituted with one or more halo, or C₁₋₃alkyloxy optionally substituted with one or more halo, and

a is 1, 2, or 3,

provided the compound is not one of the following compounds:

411	451	452	456
462	478	480	484
	or		
495		964	

9. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt according to any one of claims 1-8 and a pharmaceutically acceptable carrier, excipient, or diluent.

10. A method of inhibiting GDF8 comprising contacting GDF8 with a compound according to any one of claims 1-8.
11. A method of treating a disease mediated by GDF8, the method comprising administering to a subject having a disease mediated by GDF8 a therapeutically effective amount of a compound according to any one of claims 1-8.
12. The method according to claim 11, wherein the disease is small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, pancreatic cancer, multiple myeloma, T-acute lymphoblastic leukemia or AML.
13. The method according to claim 11 or 12 further comprising administering a therapeutically effective amount of the compound to the subject in conjunction with another therapeutic cancer treatment of the subject for the cancerous cell type.
14. The method according to claim 13 wherein the other therapeutic treatment comprises administration of a therapeutically effective amount of one or more chemotherapeutic agents, wherein the one or more chemotherapeutic agents is selected from the group consisting of antimetabolites, alkylating agents, coordination compounds, platinum complexes, DNA cross-linking compounds, inhibitors of transcription enzymes, tyrosine kinase inhibitors, protein kinase inhibitors, topoisomerase inhibitors, DNA minor-groove binding compounds, vinca alkaloids, taxanes, antitumor antibiotics, hormones, aromatase inhibitors, enzymes, growth factor receptors antibodies, cytokines, cell surface markers antibodies, HDAC inhibitors, HSP 90 inhibitors, BCL-2 inhibitors, B-raf inhibitors, MEK inhibitors, mTOR inhibitors, proteasome inhibitors and monoclonal antibodies.
15. The method of claim 14 wherein the BCL-2 inhibitor is ABT-199.
16. The method according to claim 13 wherein the other therapeutic treatment comprises administration of a therapeutically effective amount of one or more chemotherapeutic agents, the one or more chemotherapeutic agents being independently selected from the group consisting of mechlorothamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, ethyleneimines, methylmelamines, procarbazine, dacarbazine, temozolomide, busulfan, carmustine, lomustine, methotrexate, fluorouracil, capecitabine,

cytarabine, gemcitabine, cytosine arabinoside, mecaptopurine, fludarabine, cladribine, thioguanine, azathioprine, vinblastine, vincristine, paclitaxel, docetaxel, colchicine, actinomycin D, daunorubicin, bleomycin, L-asparaginase, cisplatin, carboplatin, oxaliplatin, prednisone, dexamethasone, amino glutethimide, formestane, anastrozole, hydroxyprogesterone caproate, medroxyprogesterone, tamoxifen, amsacrine, mitoxantrone, topotecan, irinotecan, camptothecin, afatinib, axitinib, bosutinib, bortezomib, carfilzomib, cabozantinib, cediranib, crizotinib, dasatinib, dabrafenib, evorolimus, ibrutinib, LDK378, LGX818, MEK162, regorafenib, ruxolitinib, selumetinib, sorafenib, trametinib, vemurafenib, erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, nilotinib, palbociclib, pazopanib, pomatinib, semaxanib, sirolimus, sunitinib, temsirolimus, vatalanib, vandetanib, anti Her2 antibodies, interferon- α , interferon- γ , interleukin 2, GM-CSF, anti CTLA 4 antibodies, rituximab, anti CD33 antibodies, MGCD0103, vorinostat, 17-AAG, thalidomide, lenalidomide, rapamycin, CCI-779, doxorubicine, gemcitabine, melphalan, NPI052, gemtuzumab, alemtuzumab, cetuximab, ibritumomab tiuxetan, tositumomab, iodine-131 tositumomab, trastuzumab, ado-trastuzumab emtansine, obinutuzumab, bevacizumab, rituximab, and anti-TRAIL death receptor antibodies.

17. The method of claim 16 wherein the CTLA-4 antibody is ipilimumab.
18. The method of claim 13, wherein the the other cancer treatment comprises administration of a therapeutically effective amount of a checkpoint pathway inhibitor.
19. The method of claim 18 wherein the checkpoint pathway inhibitor is a PD-1 inhibitor, a PD-L1 inhibitor, an anti-LAG-3 agent, an anti-SLAMF7 agent, and anti-KIR agent, or an anti-CD137 agent.
20. The method of claim 19 wherein the checkpoint pathway inhibitor is nivolumab, lambrolizumab, pembrolizumab, MEDI-4736, MPDL3280A/RG7446, BMS-986016 (MDX-1408), elotuzumab (BMS-901608), lirilumab (BMS-986015), or urelumab (BMS-663513).
21. The method according to claim 13 wherein the cancer and other cancer treatment are selected from one of the following combinations:

Cancer	Drug or Treatment
Glioma	lomustine, temozolide and/or radiation
hepatocellular carcinoma	sorafenib, regorafenib
myelodysplastic syndromes	decitabine or azacytidine
pancreatic cancer	Gemcitabine
ovarian cancer, such as epithelial ovarian carcinoma	carboplatin, cisplatin, doxorubicin, gemcitabine, paclitaxel
breast cancer	Trastuzumab
basal and squamous skin carcinomas	5-fluorouracil, imiquimod, and/or photodynamic therapy (e.g. with 5-aminolevulinic acid),
head and neck carcinoma	bleomycin, cisplatin, cetuximab, docetaxel, fluorouracil, and/or methotrexate
triple negative breast cancer	Paclitaxel
and	
Prostate	abiraterone, and/or enzalutamide.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/024146

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C07D401/14 C07D401/04 C07D417/04 C07D417/14 C07D471/04
 C07D487/04 A61K31/4427 A61P35/00
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 C07D
 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ICHIDA JUSTIN K ET AL: "A Small-Molecule Inhibitor of Tgf-.beta. Signaling Replaces Sox2 in Reprogramming by Inducing Nanog", CELL STEM CELL, ELSEVIER, CELL PRESS, AMSTERDAM, NL, vol. 5, no. 5, 6 November 2009 (2009-11-06), pages 491-503, XP002564351, ISSN: 1934-5909, DOI: 10.1016/J.STEM.2009.09.012 E-616452, E-616451; figure 1 ----- -/--	1-21

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
--	--

Date of the actual completion of the international search 19 May 2015	Date of mailing of the international search report 01/06/2015
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Schuemacher, Anne
--	--

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/024146

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DOMBROSKI M A ET AL: "Benzimidazolone p38 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 14, no. 4, 23 February 2004 (2004-02-23), pages 919-923, XP002297425, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2003.12.023 figure 1; table 1; compound 12 -----	1-21
A	WO 2009/032653 A1 (SMITHKLINE BEECHAM CORP [US]; HEERDING DIRK A [US]; LIN HONG [US]; YAM) 12 March 2009 (2009-03-12) claims 1,8 -----	1-21
A	WO 2009/013335 A1 (NOVARTIS AG [CH]; LIZOS DIMITROS [CH]; WEILER SVEN [DE]; STIEFL NIKOLA) 29 January 2009 (2009-01-29) page 14, lines 6-7; claim 1; example 1; compounds 54-56 -----	1-21
X,P	WO 2014/055955 A1 (RIGEL PHARMACEUTICALS INC [US]) 10 April 2014 (2014-04-10) claims 1,20,26 -----	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2015/024146

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009032653	A1	12-03-2009	NONE
<hr style="border-top: 1px dashed black;"/>			
WO 2009013335	A1	29-01-2009	AT 522249 T 15-09-2011
		AU 2008280135 A1	29-01-2009
		BR PI0813625 A2	23-12-2014
		CA 2694261 A1	29-01-2009
		CN 101765442 A	30-06-2010
		CO 6290714 A2	20-06-2011
		CR 11207 A	12-02-2010
		EA 201000123 A1	30-08-2010
		EC SP109898 A	26-02-2010
		EP 2183027 A1	12-05-2010
		ES 2375425 T3	29-02-2012
		JP 5090528 B2	05-12-2012
		JP 2010534633 A	11-11-2010
		KR 20100034028 A	31-03-2010
		MA 31571 B1	02-08-2010
		PE 05062009 A1	28-05-2009
		SV 2010003463 A	13-04-2010
		TW 200911814 A	16-03-2009
		US 2010204235 A1	12-08-2010
		WO 2009013335 A1	29-01-2009
		ZA 201000079 A	29-09-2010
<hr style="border-top: 1px dashed black;"/>			
WO 2014055955	A1	10-04-2014	CA 2887203 A1 10-04-2014
		US 2014107073 A1	17-04-2014
		WO 2014055955 A1	10-04-2014
<hr style="border-top: 1px dashed black;"/>			